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Abstract 
In chemical biology and drug discovery, the development of novel methods for 
efficient synthesis of structurally distinct molecular scaffolds holds an immense importance. 
Gold catalyzed enyne cycloisomerizations are a powerful tool to access a wide range of 
complex molecules owing to the tunable nature of gold complexes with ligand and reaction 
conditions. A number of reactions have disclosed the role of substrates, ligands of gold(I) 
catalyst and the nucleophiles to afford a variety of products with intriguing molecular 
frameworks. The development of a ”ligand directed divergent scaffold synthesis” (LDS) 
approach that aims to create structurally distinct molecular scaffolds by means of a single 
mode of catalysis on common substrates is presented in this work. In this strategy, when 
oxindole derived 1,6-enynes were treated with different gold complexes, the fate of the 
common bicyclic gold carbene intermediates could be steered by ligand variations in gold(I) 
complexes, and selectively led to three structurally distinct scaffolds, the spirooxindoles, 
quinolones, and the df-oxindoles. Biological investigation of the resulting compound 
collection in cell-based assays revealed bioactive small molecules based on three different 
scaffolds displaying orthogonal modulation in the activities of the hedgehog signaling 
pathway, autophagy and cellular proliferation. 
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Zusammenfassung 
Die Entwicklung neuer Methoden zur effizienten Synthese strukturell verschiedener 
molekularer Gerüste ist von großer Wichtigkeit in der chemischen Biologie und der 
Entdeckung neuer Wirkstoffe. Die Gold katalysierte Enin-Cycloisomerisierung ist eine 
leistungsfähige Methode für den Zugang zu einer Vielzahl komplexer Moleküle, da die 
Natur der Goldkomplexe durch Änderung der Liganden und Reaktionsbedingungen 
einstellbar ist. Die genaue Erforschung der Substrate, Liganden des Gold(I)-Katalysators und 
der Nukleophile führt zu einer Vielfalt an Produkten mit interessanten molekularen 
Gerüsten. In dieser Arbeit wird die Entwicklung des Ansatzes einer divergierenden 
Gerüstsynthese, die durch Liganden dirigiert wird (engl. ligand directed divergent scaffold 
synthesis, LDS) präsentiert. Hierbei wird die Synthese strukturell verschiedener molekularer 
Gerüste durch nur einen Modus der Katalyse für gemeinsame Substrate angestrebt. Wenn die 
Oxindol-abgeleitete 1,6-Enine in der Gegenwart von Gold-Komplexen reagiert wurden, 
konnte der Reaktionsverlauf gängiger bicyclische Goldcarbenintermediate durch Variieren 
der Liganden des Gold(I)-Komplexes gesteuert werden. Als Resultat wurden selektiv zu drei 
verschiedener Gerüste erhalten: Spirooxindole, Chinolone und df-Oxindole. Die biologische 
Untersuchung der erhaltenen Substanzsammlung in Zell-basierten Experimenten ergab, dass 
die Moleküle, die auf drei verschiedenen Gerüsten basieren, die Aktivität des Hedgehog 
Signalwegs, Autophagie und Proliferation selektiv beeinflussen. 
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1  Introduction 
 Biologically active small molecules are the crucial elements that underpin research in 
drug discovery, medicinal chemistry, chemical biology, and allied fields. In ancient time, 
people managed to apply the extracts of plants or creatures for the treatment of wounds or 
diseases. For instance, salicylic acid had been utilized to get relief from the pain and fever, 
and was later acetylated to form the known pain killer, aspirin. With advances in 
technologies, structures of more complexed natural products (NPs) were elucidated and their 
intriguing biological activities were also realized. The penicillin antibiotic, isolated from the 
fungi, acts by inhibition of bacteria cell wall formation. The quinghau su, plant extract, was 
uncovered by YouYou Tu for the treatment of malaria.
[1]
 The dynemicin A contains the 
unique bridged enediyne and exhibits the excellent antitumor activity (Figure 1).
[2]
   
 
 
Figure 1. Representative natural products and derivatives. 
 
However, the isolation, structure elucidation, and total synthesis of NPs remain very 
challenging tasks which often provide only minute amounts of the complex NPs. Moreover, 
the development of high throughput screening (HTS) has puffed up the demand of small 
molecules for biological screenings and evaluations
[3]
, which are difficult to achieve via NP 
isolation or total synthesis. Therefore, pharmaceutical industry turned the attention to 
combinatorial chemistry to generate simple and relatively flat small molecules in a quick 
manner (around 3,300 compounds per one chemist month).
[4]
 However, these efforts 
delivered only limited success in drug discovery, i.e. two drugs, sorafenib (Nexavar) and 
ataluren (Translarna), were approved by FDA till 2014.
[5]
 In contrast to NPs, the molecules 
from combinatorial chemistry are endowed with less structural diversity, less number of 
chiral centers, and sp
3
 atoms, as well as the rigid molecular frameworks.
[6]
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In order to generate a compound collection with structurally diverse and 
three-dimensional small molecules in satisfactory quantity, synthetic chemistry community 
has proposed various approaches. Some library-synthesis designs aim at covering a broad 
range of chemical space that may interact with various protein targets. Synthesis approaches 
like diversity-oriented synthesis (DOS)
[7]
, branching cascade approach
[8]
, and complexity to 
diversity strategy (CtD)
[9]
 broadly fall in this category. On the other side, diverted total 
synthesis (DTS)
[10]
 and function-oriented synthesis (FOS)
[11]
 try to provide an alternative 
way to study the biological profiles of NP derivatives and thus remain focused around a 
particular scaffold.
[12]
  
Structural simplification of NPs can effectively reduce the molecular complexity, 
molecular weight, and the number of synthetic steps to make good amount of NP-related 
compounds.
[13]
 Previously mentioned antitumor NP, dynemicin A shows notable biological 
activities against many cancer cell lines with half-maximal lethal dose (LD50) in the 
picogram to nanogram per ml range. Wender’s group presented a truncated analog of 
dynemicin A that maintains the biological activities with satisfactory quantity for further 
studies.
[14]
 Not only the structural simplification but also functional group variation around a 
NP-scaffold can bequeath biological activity to a small molecule. By replacement of polyene 
side chain with ethyl ester and the installation of m-methoxy group to the phenyl ring, 
Gademann’s group reported a pyridine alkaloid analogue[15], which shares similar neurite 
outgrowth activity with the parent molecule, farinosone A
[16]. Waldmann’s group further 
modified the pyridone core with hydroxyl-n-hexyl chain and disclosed that MAP4K4 kinase 
is the target of this simplified NP analogue.
[17]
 Thus, structural simplification and functional 
group manipulations on the NP-core scaffolds may reveal the intriguing biological profiles 
and druggable cellular targets (Figure 2). 
Figure 2. Bioactivity maintenance by structural simplification and functional group 
variation. 
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1.1 Biology-oriented synthesis (BIOS) 
To rationalize the relationship between small molecules and their corresponding 
biological targets, the biology-oriented synthesis (BIOS) concept was proposed by 
Waldmann and co-workers. BIOS accommodates two complementary approaches, i.e. 
protein structure similarity clustering (PSSC) and structural classification of natural product 
(SCONP) with the extension to non-natural bioactive molecules. Based on this approach, 
synthetic chemist can identify the scaffolds for similar protein binding sites.
[18]
 
In nature, numerous NPs as secondary metabolites are generated to trigger biological 
responses for the physiologically important functions of an organism. Being synthesized by 
protein enzymes, they are inherently biologically relevant chemicals and therefore are 
suitable starting points to navigate the bio-relevant chemical space (Figure 3a). Importantly, 
the number of potential ligand-accommodating binding pockets is around 1315 according to 
the protein data bank (PDB).
[19]
 In such conserved binding sites, the functional diversity of 
proteins is driven by different peptide sequences or more precisely with the decoration of 
various amino acid side chains (Figure 3b). Therefore, the protein-ligand interaction is 
driven by the structural complementarity between a small molecule with suitable functional 
group decorations and a protein binding site with proper side chains of amino acids (Figure 
3c). On the other hand, the nature has also evolved to conserve the molecular scaffolds in 
NPs, such as alkaloids, terpenoides, and flavonoid, accompanied with the functional group 
driven structural diversity to interact with the high structural similarity of protein binding site 
to trigger a biological function, as shown in Figure 3d. The similar binding site subfolds of  
 
Figure 3. The structural conservation and diversity in protein-ligand interaction. 
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different protein were grouped and termed as protein structure similarity clustering (PSSC). 
Identification of a NP inhibitor of one of the proteins in this cluster would thus provide 
initial compound for optimization as inhibitor for other proteins in the same cluster.  
The dictionary of natural product (DNP) as database was explored in a chemiformatic 
analysis of NPs to identify the corresponding scaffolds by removing the functional group 
around NPs. Having an essential scaffold was followed by deconstruction of complex NP 
ring systems to single ring structures in stepwise manner to build up the tree-like diagram, 
SCONP scaffold tree (Figure 4). This NP tree diagram allows the logical exploration of 
NP-like chemical space. Within the NP tree, the larger scaffold is called “child” and the 
smaller scaffold is termed as “parent”. While starting from bioactive child scaffold to parent 
scaffold, the retention of bioactivity can be expected with the decreasing potency, which can 
be retrieved by the functional group variation.  
In a sense, the frequently presented scaffolds in NPs, known as the privileged ring 
system (PRS), could serve as the guiding segment for the biological relevant chemical space 
exploration and simplified small molecules with similar and/or unique biological activities 
can be identified. 
 
 
Figure 4. Graphic representation of SCNOP scaffold tree.  
Reproduced from ref
[20]
, copy right 2005 National Academy of Sciences. 
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1.2  Construction of diverse molecular frameworks  
 For the synthesis of biologically interesting small molecules, both natural and chemical 
approaches frequently utilize building block endowed with privileged ring system (PRS) and 
appropriately substituted reaction handles to generate more complicated and diverse 
molecular frameworks. 
 
1.2.1 Natural approach - divergent-scaffold formation via biosynthesis 
Generally, nature relies on primary simple building blocks to generate the structural 
complexity of NPs via sequential enzymatic-, degradative cascades, or rearrangement 
reactions. For instance, the essential amino acid L-tryptophan serves as the fundamental 
framework to assemble various NPs with distinctive scaffolds, like 
dimethoxy-fumitremorgic C, spirotryprostain B,
[21]
 indirubin,
[22]
  by multi-step as well as 
cascade transforamtions (Scheme 1a). Interestingly, structurally diverse terpenoids are 
generated from a common linear geranyl diphosphate precursor through monoterpene 
cyclases mediated cyclization reactions (Scheme 1b).
[23]
 This biosynthesis idea has in fact 
inspired several approaches to synthesize NPs
[24]
 or generate small molecule compound 
collections using common substrates
[8b]
. 
 
 
Scheme 1. a) L-Tryptophan derived NPs via multi-step biological cascades. b) Geranyl 
diphosphate derived NPs by monoterpene cyclases. 
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1.2.2 Chemical approach - diversity-oriented synthesis (DOS) 
 The diverse enzymatic proteins enable the nature to assemble various molecular 
frameworks in regio-, stereo-, or chemoselective manner under mild conditions. On the other 
hand, the chemical approaches may benefit from the tunable reactions that are subject to 
change with variations in solvents, temperatures, reagents, and additives, as well as catalysts 
to provide structurally distinct chemotypes. Schreiber et al. proposed the diversity-oriented 
synthesis (DOS) approach to prepare the small molecule compound collections with enriched 
functional, stereochemistry and scaffold diversity.
[7a, 25]
 The approach makes an extensive 
use of build/couple/pair strategy. In the build stage, the molecular segments are decorated 
with chemically orthogonal functionalities, which can be coupled with other segments to get 
the common intermediates supporting different chemical handles. For the final pairing stage, 
the diverse molecular frameworks can be formed by connecting the chemical handles 
orthogonally (Scheme 2a). The DOS approach has been further evolved into other related 
approaches, such as multidimensional DOS strategy to get higher degree of structurally 
diverse and complex small molecules
[26]
 and privileged substructure-based DOS (pDOS) as a 
strategy to construct diverse compound collection with high biological relevance
[27]
.  
 Based on pDOS, Park et al. synthesized a set of pyrimidine-based compound collection 
that represent one of the medicinally important classes that has been frequently presented in 
biological active small molecules, such as the EGFR tyrosine kinase inhibitor (1). Coupling 
of the two building segments, pyrimidine (2) and amine (3), led to the common intermediate 
4, which was ready for further divergent cyclization reactions. For example, A-B pair could 
lead to the polycyclic compound (6), the B-C pair could be cyclized to access the macrocycle 
8, and the closure of C-D points provided the bicyclic compound (10). The divergent pairing 
reactions were achieved within 2.2 steps on average to give 16 distinctive polyheterocycles. 
Moreover, by utilizing ELISA-based HTS, a tricycle compound (11) had been identified as a 
new class protein-protein interaction (PPI) inhibitor that could perturb the LRS-RagD 
interaction (Scheme 2b).
[28]   
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Scheme 2. a) Schematic representation of DOS approach. b) pDOS based approach to 
generate structurally diversed compound collection.  
 
Basically, DOS and related synthetic approaches can prepare a structurally diverse 
compound collection within 3-5 steps in a linear manner sharing some common 
intermediates, which are ideal to perform the initial biological screening. From substrate 
point of view, the precise selection of chemical handles is crucial to ensure that distinct 
pairing kind of reactions can work and afford different scaffolds. Besides that, the final 
divergent pairing steps should be robust enough to provide sufficient amount of final 
molecules for making a compound collection. Therefore, any new approach that can deliver 
diverse molecular scaffolds in a single step, under non-tedious and challenging reaction 
conditions and preferably using common substrates or intermediates would be highly useful 
and remains is in high demand.    
   
13 
 
1.3 Transition metal mediated divergent synthesis approaches 
Transition metal catalysis is a key scientific discipline in organic synthesis. Due to its 
robust nature and ability to reduce the potential energy of reactive intermediates, the 
foreseeable retrosynthetic disconnection, excellent chemo-/regio-/stereoselectivity in 
chemical transformations, transition metal catalysis is often the first resort for organic 
synthetic chemists to generate molecular complexity. Furthermore, molecular diversity can 
also be established by transition metal catalyzed reactions by employing variations in 
transition metals, ligands, solvents, additives, as well as reaction temperature.
[29]
 Among all 
these factors, the catalyst-controlled divergent approach has been well-known and developed, 
since most of the transition metal catalysts have their unique activation and catalysis 
pattern.
[30]
 Therefore proper selection of transition metal and design of reaction substrate 
could logically provide divergent scaffolds from the common substrate. For instance, Lam et 
al. applied Pd and Ru catalysts to perform selective C-H functionalizations on quinolone 
derived substrates (12) with acetylenes (13) to produce the sprio-quinolones (14) and 
fused-quinolones (15), respectively (Scheme 3).
[31]
 
 
 
Scheme 3. Catalyst-controlled divergent scaffold synthesis approach by Pd and Ru catalyst.  
 
In recent years, many examples for the ligand-directed divergent synthesis (LDS) 
approach have been unraveled by using various transition metal catalysts. This is certainly 
due to many developments in synthesis and commercial availability of different types of 
ligands.
[32]
 A large proportion of these reports utilized palladium and gold(I) catalyst with 
proper ligand selections to establish the synthesis of diverse scaffolds. For example, the 
furanocarboxamides (16) could either proceed by Heck type cyclization to give the 
spirooxindole (20) by palladium catalyst with PPh3 as ligand, or C-H functionalization to 
generate the fused quinolone (23) by palladium catalyst with P(o-OMePh)3 as the ligand 
through concerted metalation-deprotonation (CMD) process, as shown in Scheme 4.
[33]
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Scheme 4. Ligand-directed divergent scaffold synthesis approach by Pd catalyst.  
 
With distinctive catalytic properties, gold(I) catalyzed transformations behave 
differently from Pd catalysis and endows with tunable and versatile catalytic nature to 
support reactions like photoredox reaction
[34]
, cross couplings
[35]
, as well a series of gold(I) 
catalyzed enyne cycloisomerizations
[36]
, etc. that allow gold(I) catalyzed LDS to cover 
broader types of reactions and access broader chemical space. 
 
1.3.1 Gold(I) catalyzed transformations  
The gold(I) activated alkyne transformations have been extensively investigated 
among all of the gold catalyzed reactions, and widely applied in the synthesis of NPs and 
structurally complex molecules.
[37]
 A cationic gold(I) complex (24) acts as a unique 
carbophilic π-acid catalyst to react with acetylene (25) and generating linear 
-[AuL]+-alkyne intermediates (26, Scheme 5a).[38] Based on this intermediate (26), three 
types of gold (I) catalyzed reactions were identified and utilized as key transformations to 
generate structurally complex frameworks, i.e. oxidative formation of -oxo gold 
carbenes
[39]
, enyne cycloisomerizations
[36, 40]
, and acyloxy migrations
[41]
 (Scheme 5b, 5c, and 
5d). Generally, the -[AuL]+-alkynes (37, 31, or 36) are attacked by various nucleophiles 
(oxidants, olefin, carbonyl, etc.) to deliver trans-alkenyl-gold intermediates. When the 
nucleophile is an oxidant, such as N-oxides, sulfoxides, or nitrones, the oxidative -oxo gold 
carbene formation reaction takes place to from the trans-alkenyl-gold intermediates (28). 
15 
 
Subsequent elimination of leaving group provides the -oxo gold carbenes (29). However, 
the experimental and computational results had suggested that the nucleophilic insertion 
would stabilize the reactive gold carbenes (29) leading to the gold(I) carbenoids (30, Scheme 
5b).
[42]
 An olefin nucleophile can add to the gold(I) activated acetlyenes (31) via an endo-dig 
or exo-dig cyclization mode, generating the endocyclic gold carbenes (32) or exocyclic gold 
carbenes (34), respectively. Further skeletal rearrangement of 32 would offer gold(I) 
activated cyclobutenes (33). The exocyclic gold carbenes (34) can yield gold carbenes 35 
(Scheme 5c).
[40]
 Interestingly, the carbonly function might also act as the nucleophile and 
add to the gold activated acetylenes (36).
[43]
 In particular, the acyloxy group when present in 
the propargylic position, the carbonyl might follow a 1,2- or 1,3-shift of the acyl group 
assisted by gold(I) catalyst and via a 5-membered ring intermediates (37) or 6-membered 
ring intermediates (38) respectively. The 1,2-acyloxy shift will produce the gold carbenes 
(38) and 1,3-acyloxy shift will give the gold(I) activated allenes (40) as the reactive 
intermediates (Scheme 5d).
[41]
 The understanding of these transformations might be helpful 
for the logically design suitable substrate to discover the divergent reaction pathways.    
 
 
Scheme 5. a) Formation of 2-[AuL]+-alkyne intermediates. b) Oxidative formation of -oxo 
gold carbene. c) Gold(I) catalyzed enyne cycloisomerization. d) Gold(I) catalyzed 1,2- and 
1,3-acyloxy migration.   
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1.3.2 Oxidative formation of -oxo gold carbenes  
 In the presence of internal or external oxidants, such as nitrones, sulfoxides, or N-oxides, 
tandem addition and elimination sequence provides reactive -oxo gold carbene 
intermediates, which offer a variety of intriguing transformations. For example, treatment of 
the nitrone-tethered alkynes (41) with N-heterocyclic carbenes (NHC), such as IPr, or 
Johnphos gold(I) catalyst, followed the addition/elimination cascade reaction sequence to 
yield the -oxo gold carbene (42). This reactive intermediate (42) subsequently afforded the 
isoindole 44 as the product via the azomethine ylide intermediate (43, Scheme 6a).
[44]
 In 
2007, Trost’s and Zhang’s group independently revealed that the sulfoxide function could 
behave as an oxygen source to yield the -oxo gold carbene (46 or 49, Scheme 6b or 6c) that 
followed a Friedel-Crafts reaction (Scheme 6b)
[45]
 or pinacol type ring expansion  
 
 
Scheme 6. Gold(I) catalyzed -oxo gold carbene derived transformations.  
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reaction (Scheme 6c)
[46]
, respectively. With pinacol type ring expansion method, Chen et al. 
had applied it to build up the azepine scaffold (56) by utilizing the pyridine-N-oxide (53) as 
an oxidant.
[47]
 The alkynyl-dihydropyridine substrates (52) smoothly converted to gold 
carbene intermediates (54). The nitrogen lone pair of intermediates (54) triggered the 
addition to gold carbene moiety to form the cyclopropane intermediates (55), which relieved 
the ring-strain by ring-expansion-deauration to give the corresponding azepine products (56, 
Scheme 6d). It is worthwhile to mention here that Trost’s group also revealed that the 
sulfoxide group can proceed with the oxidation of gold carbene to generate carbonyl 
decorated products from the enyne cycloisomerization intermediate.
[48]
 The 1,6-enynes (57) 
under gold(I) catalysis followed a 5-exo-dig cyclization to give the exocyclic gold carbenes 
(58). The insertion of sulfoxide and elimination of thioether provided the exocyclic 
aldehydes (60) in high yield (Scheme 6e). The application of oxidant to gold activated 
acetylene could follow different cyclization modes, leading to different skeleton 
rearrangements, or integrate with cycloisomerizations to install an additional aldehyde 
functionality. These properties are beneficial to build up the intriguing molecular. 
 
1.3.3 1,6-Enyne cycloisomerizations  
Enyne cycloisomerization reactions present one of the most important and 
well-investigated chemical transformations in homogeneous gold(I) catalysis. In 2004, 
Fürstner, Toste, and Echavarren independently reported the gold(I) mediated enyne 
cyclo-isomerization to form carbo- and heterocyclic molecules (Scheme 7). In case of 
1,5-enyne with propargylic ester moiety (61), treatment with 2.0 mol% of Ph3PAuCl/AgSbF6 
led to a 1,2-acyl migration to form the gold carbene (62) that followed the insertion to olefin 
and gave the bicyclic[3.1.0] enol acetate (63). Under basic reaction conditions, the enol 
acetate was converted to the ketone 64 (Scheme 7a).
[49]
 Toste and co-workers treated 
1,5-enynes (65), which lacked the ester moiety, with a gold(I) catalyst (Scheme 7b). A 
5-endo-dig cyclization of 1,5-enynes (65) led to the endo-cyclic gold carbenes (66). A 
cascade of deprotonation and protodeauration provided the final bicyclo[3.1.0]hexenes (68) 
in 61-99% yield (Scheme 7b).
[50]
 Echavarren reported that 1,6-enynes with different tethers 
could follow two different cyclization pathways, 5-exo-dig and 6-endo-dig cyclization. For 
instance, the carbon-tethered 1,6-enynes (69) gave the single-cleavage products (72) via 
5-exo-dig cyclization and the nitrogen tethered 1,6-enyne (73) provided the mixture of 
bicyclic product 75 and single-cleavage product 77 via 6-exo-dig cyclization (Scheme 7c).
[51]
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Scheme 7. Gold(I) catalyzed enyne cycloisomerization.  
 
These reports further garnered great attention and highlighted the potential of the 
gold(I) catalyzed enyne cycloisomerization in organic synthesis. However, usage of further 
modified enynes as substartes in these reactions had identified a greater synthetic application 
of gold catalyzed enyne cycloisomerizations. For instance, having a quaternary carbon at the 
propargylic position would prohibit the deprotonation or 1,2-H shift mechanism in oxygen 
tethered 1,6-enynes (78, Scheme 8a). Therefore, a 1,2-alkyl migration dominated the 
transformation to generate the ring expansion products 79 in 15-98% yield (Scheme 8a).
[52]
 
Waldmann, Kumar and coworkers designed the 8-endo-dig cyclization in 1,7-enynes (80) to 
construct the benzoxocines (84). The inductive effect of phenolic ether moiety was thus 
cleverly used to achieve desired chemo- and regioselectivity of cyclization reactions. Under 
gold(I) catalytic reaction conditions, the endocyclic gold carbenes (81) were initially formed. 
Cyclopropane ring opening ensured the formation of benzylic cations (82) or oxocarbenium 
intermediates (83), which followed deprotonation and protodeauration to yield benzoxocines 
(84) in 29-75% yield (Scheme 8b).
[53]
   
The introduction of nucleophiles to the cycloisomerization reaction intermediates is 
helpful not only to understand the reaction mechanism but also to enhance the structural 
diversity of the ensuing products. In the absence of a nucleophile, the carbon-tethered  
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Scheme 8. Gold(I) catalyzed enyne cycloisomerization.  
 
1,6-enynes (69) afforded the dienes (72) as the product (Scheme 7c). However, addition of 
MeOH as nucleophile trapped the intermediates (70) by a 1,4-nucleophilic addition and led 
to the intermediates (85). The catalytic cycle was then closed by protodeauration to from the 
methylenecyclopentanes (86, Scheme 9a).
[54]
 Intriguingly, when oxygen-tethered 1,6-enyne 
(87) was exposed to indole as nucleophile under gold (I) catalytic conditions, an endocyclic 
gold carbene intermediate (88) was formed through a more complex mechanistic pathway. 
The C3-indole addition to cyclopropane led to form the gold carbene (89). An internal 
addition ethereal oxygen to gold carbene formed a highly starained oxinium cation 
intermediate (90). The ring-strain in 90 was released by elimination of cationic gold(I) to 
generate the vinyl ether (91). The keto-enol tautomerization transformed the enol ether to 
oxocarbenium intermediate (92), which served as electrophile for the C2-indole and thus a 
nucleophilic addition of indole provided the polycycles 93 as the final product (Scheme 
9b).
[55]
 Intrestingly, the variation of ligands in gold(I)-complex could further alter the pattern 
of nucleophilic additions between the nucleophilic 1,2- and 1,4-addition, as shown in 
Scheme 9c.
[55]
  
 In the presence of gold(I) catalyst, the bicyclic gold carbene intermediate (96, 97) was 
formed from N-tethered 1,6-enyne (94) via 5-exo-dig cyclization. The addition of the 
1,3-diketone nucleophile (95) was modulated by the ligand effect. Thus, the gold(I) catalyst 
with electron-deficient phosphite ligand (L1) presented strong electrophilicity that allowed  
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Scheme 9. Nucleophiles associated gold(I) catalyzed 1,6-enyne cyclitations.  
 
the 1,4-addition to become preferable. Hence, the nucleophilic 1,4-addition and 
protodeauration sequence took place to give the corresponding pyrrolidine (98) with a high 
selectivity of 98:99 = 95:5. In contrast, the electron-rich NHC ligand (IMes) enhanced the 
carbene property of gold carbene intermediate (97), which reversed the preference of 
selectivity in nucleophilic addition form 1,4-addition to 1,2-addition. Hence, the 1,2-addition 
product (99) was obtained in excellent yield and selectivity (Scheme 9c).  
 In gold(I) catalyzed enyne cycloisomerization, the mode of cyclizations and 
rearrangements are drastically influenced by several factors, including neighboring groups 
and heteroatoms in the enyne substrates, the presence of nucleophiles, as well as ligands in 
the cationic gold(I) complex. 
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1.3.4 Ligand effects in gold(I) catalyzed divergent reactions 
 In gold(I) catalyzed reactions, the proper utilization of different ligands can lead to 
formation of different products in varying selectivity and efficiency. The ligands can 
influence the reaction pathways owing to steric and/or electronic factors, and these factors 
cooperatively function to control the selectivity and efficiency of a gold(I) catalyzed 
reaction.
[56]
 From the electronic factor point of view, the relativistic effect in gold(I) 
complexes results in the contracted 6s orbital and expanded 5d orbital of gold(I) and 
influences the electronic nature of the gold complexes, which is attributed to the electronic 
nature of the ligands used in a gold complex. Therefore, the properties of cationic gold(I) 
catalyst, gold carbene or carbenoid, can be fine-tuned via judicious selection of ligands 
(Scheme 10).
[57]
 For example, NHC type ligands with strongly -donating and weakly 
-acidic character will be preferred for the carbene-like reactivity. On the other hand, 
phosphite as a strong electron-withdrawing ligand may be favored for the carbocationic 
reaction pathways (Scheme 10a). Besides the ligands effects, gold(I) catalyzed reactions may 
also depend on the structural properties of the substrates and the reaction conditions 
employed.
[57a]
  
By tuning the ligands, the impact of the electronic nature of gold(I) complexes was 
observed in gold(I) catalyzed divergent allene diyne cyclization reactions. When utilizing 
phosphite as the ligand of a gold(I) catalyst, the allene diyne (100) underwent the 
carbocationic reaction pathway throght the carbocationic intermediate (101). Subsequently, 
deauration took place to give the [4+2] cycloaddition product 103 in 89% yield. Using a 
bulky phosphine ligand, the cyclization mode was altered to [4+3] cycloaddition through 
gold carbene intermediate (105). A subsequent 1,2-H shift and protodeauration formed the 
bicyclic[5.3.0]dienes (106) in 89% yield and with excellent selectivity (Scheme 10b).
[58]
 
Intriguingly, replacing bulky phosphine, JohnPhos, with PPh3 led to a drop in the selectivity 
from 106:103 = 96:4 to 106:103 = 33:67 and with slight decrease in the reaction yield 
(103+106). The steric nature of the ligand also plays an important role in guiding product 
selectivity. As an example, the diene diynes (107) were prepared as substrate. By the 
treatment of gold(I) complexes with JohnPhos based ligands, the divergent bicyclic 
compounds were generated as the products (Scheme 11a). In such transformations, the 
common intermediates (110) were generated from the diene diyne substrates (107) via a gold 
catalyst assosciated 3-step cascade, 1,3-acyloxy migration to give the allenes, gold(I) 
assisted Nazarov type cyclization and protodeauration. When utilizing the JohnPhos as  
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Scheme 10. a) Electrophilicity tendency toward gold(I) catalyst with different ligands.
[59]
    
b) Gold(I) catalyzed divergent formal [4+3]/[4+2] cycloaddition with allenediene substrates.  
 
ligand, the 6-endo-dig cyclization took place to form the endocyclic gold carbene 
intermediates (111). On the other hand, the highly bulky ligand Me4tButylXphos modulated 
the cyclization mode to 5-exo-dig cyclization leading to exocyclic gold carbene 
inter-mediates (112) in order to release the steric repulsion between the ligand and the 
substrate. With the gold carbene intermediates (111, 112) in hand, a sequential 
rearrangement, deauration, and hydrolysis provided the corresponding bicyclic products 108 
and 109 respectively in good to excellent selectivity (Scheme 11a). However, in most of the 
cases, the steric and electronic nature of the ligand should both be considered to obtain the 
desired selectivity and yield of the divergent products. Recently, Echavarren et al. depicted 
the electrophilic tendency of the major type of gold(I) catalyst
[36]
 which can be further 
extended to the commercially available ligands for the assistance of reaction development 
and optimization (Scheme 11b). 
 Although the gold(I) catalyzed LDS approach seems to be robust, the preparation of 
small molecule collections by this approach is still difficult and challenging due to: 1) A 
large proportion of substrates are composed by the full carbon backbone with protected 
heteroatoms. The non-polar nature of the substrates and products renders the purification 
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Scheme 11. a) Ligand controlled formal [3+2]/[2+2] cycloaddition. b) Relative 
electrophilicity and steric bulkiness of representative gold(I) catalysts.
[36]
 
  
and isolation of products relatively difficult. 2) Often, due to the same molecular mass of the 
products as that of starting material, the structural determination of rearrangement products 
as well as their regio- and stereoisomers by NMR analyses is also challenging. 3) Generally, 
the substrates encounter severe restriction on the scope of transformations as not all 
functionals groups and modifications are tolerated in gold catalysis reactions. 4) In most of 
the cases, the gold(I) catalyzed LDS approaches provide no more than two distinctive 
products and the higher order of divergency is still challenging and demanding.  
These facts and challenges encouraged us to initiate this gold(I) catalyzed LDS 
approach to build up a molecule compound collection well represented by scaffold diversity 
and that can be used in cell based biological screenings to realize the potential of the ensuing 
products in medicinal and biological research.  
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2 Design and aim of the project  
Gold(I) catalyzed reactions have been reported with versatile transformations by 
modulating electronic and steric parameters in gold(I) complexes, and therefore gold(I) 
catalyzed reactions were selected to develop a unified approach to steer common enyne 
substrates into diverse and distinct molecular scaffolds. In this approach, reactive chemical 
handles would be an essential segment in substrate to guide different transformations leading 
to scaffold diversity as well as offering variations on the periphery of distinct scaffolds. The 
handles could be installed on a privileged ring system that allow the resulting scaffold with 
potential biological relevance. Moreover, the functional groups of the substrate can 
participate in further chemical manipulations to build up a compound library (Figure 5a). By 
treatment with a gold(I) catalyst, the chemical handles can be activated to form the 
common/divergent intermediate(s), as illustrated in Figure 5b. Subsequently, the 
isomerization reactions could convert the intermediate(s) to the divergent scaffolds by 
verifying the ligand properties in a gold(I) catalyst (Figure 5c). If the gold(I) catalyzed 
transformations were not successful, the chemical handle redesign might be helpful to alter 
the property of intermediate and provide the desired product-divergency. With the divergent 
catalytic transformations, a compound library with scaffold divergency could be prepared by 
verifying the sites for chemical manipulation (Figure 5d). Ultimately, the collection of 
structurally divergent small molecules could be utilized to explore the biological relevant 
chemical space and the molecular functions in biological system via bioactivity screening. 
 
 
Figure 5. Schematic representation of ligand directed divergent scaffold synthesis (LDS).  
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Although, the ligand associated gold(I) catalyzed divergent scaffold synthesis should 
allow to access structurally novel ring systems from a unified substrate class (Figure 6a). To 
ensure the biological relevance of the products, the substrates are generated based on a 
privileged ring system (Figure 6b). It was planned to use substrates with different functional 
groups so that the biological screenings later can display some sort of structure activity 
relationship (SAR). With these ideas, 1,6-enynes supporting an oxindole as privileged ring 
were selected as substrates for gold catalyzed divergent scaffold synthesis (Figure 6c). The 
assembly of substrates was performed in sequential steps, i.e. first alkylation of N-oxindole, 
followed by lithium acetylide addition to the ketone moiety of alkylated oxindole, and later 
allylic ether formation from propargyl alcohol to get the oxindole based 1,6-enyne 
substrates. Substituents on oxidole nitrogen and phenyl ring could establish diversity in the 
collections and the substituents on 1,6-enyne could influence the reaction pathway and might 
also help in generation of functional group variation around different scaffolds. The 
screenings of small molecule compound collection could be performed at Compound 
Management and Screening Center (COMAS), Dortmund for the primary screening for HH, 
Wnt, and Autophagy inhibition to sort out the bioactive molecules (Figure 6d).  
 
Figure 6. A combination of LDS approach with privileged ring system to generate small 
molecule collection for biological screening. 
26 
 
3 Results and discussion 
 The terminal alkynes in O-tethered 1,6-enynes predominately react via 5-exo-dig 
cyclizations to give the exo-gold carbene intermediates. But alkyl or aryl substituted alkynes 
prefer 6-endo-dig cyclization delivering endo-gold carbene intermediates in gold(I) mediated 
reactions.
[60]
 To develop a unified synthetic route, I chose the oxindole based 1,6-enynes 117 
as the substrates for scaffold diversity synthesis planning. A straightforward synthesis of 117 
was explored by utilizing isatin 112 as the starting material. After the protection of nitrogen, 
addition of lithium acetylide to the keto moiety of 113 gave the propargyl alcohol 114. While 
the R
3
 is TMS group (115), the terminal alkyne functionality of 116 could be produced via 
removal of the silyl group with K2CO3 in MeOH. The propargyl group with hydrogen, alkyl, 
or aryl substitutions could then undergo the O-allylation to provide the desire substrates 117 
(Scheme 12).   
 
 
Scheme 12. The general synthetic approach of oxindole based 1,6-enyne.  
 
In gold(I) catalyzed enyne cycloisomerizations, the protection of the nitrogen in 
substrates is important because the substrates bearing nonprotected nitrogen are often 
considered incompatible for the reactions. The nucleophilicity of nitrogen is stronger than 
olefin and may either lead to addition of nitrogen to the gold(I) activated acetylene, or the 
lone pair of the nitrogen can coordinate with the empty orbital of gold(I) catalyst itself 
resulting in the deactivation of the catalyst. Protection of nitrogen thus with aryl, sulfonyl, 
and carbonyl groups can be helpful. For instance, Fürstner et al. applied the carboxybenzyl 
(Cbz) as the nitrogen protecting group to complete the synthesis of the antidepressive drug 
candidate GSK1360707.
[65]
 Encouraged by some reported gold(I) catalyzed transformations 
of indole derivatives,
[66]
 I believed that the oxindole based 1,6-enyne can also prove 
interesting substrates of the gold(I) catalyzed reactions to yield structurally different 
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products. Besides the substrate, the mode of gold(I) catalyzed 1,6-enyne 
cyclo-isomerizations largely relies on the ligand around the cationic gold(I) complex, so a 
ligand screen is inevitable in the initial reaction screening process.
[61]
 Therefore, gold(I) 
catalysts with representative ligand decorations, i.e. strong -donating NHC ligand, 
moderate -donating JohnPhos ligand, and poor -donating phosphite ligand, were selected 
for uncovering the potential reaction pathways of enyne (117) substrates. The other factors, 
such as solvent
[63]
, counter anion
[62]
 of gold(I) catalyst, and temperature
[43c, 64]
, will also be 
considered during the condition screening process (Figure 7). 
  
  
Figure 7. Schematic representation for the initial screening process. 
 
 
  
28 
 
3.1 Gold(I) catalyzed cycloisomerizations of 1,6-enynes with a terminal acetylene  
 The initial screening for the divergent scaffold synthesis approach began with the 
terminal alkyne 118 as substrate (Table 1). By treatment of NHC gold(I) catalyst (I) or bulky 
phosphine gold(I) catalyst (II) to the 1,6-enyne (118) in DCM, the hydroxyl group adducts 
(119) were observed in all reactions along with unidentified side products (Table1, entry 
1-2). The selectivity was improved by utilizing the electrophilic phosphite gold(I) catalyst 
(III) and the diastereomeric hydroxyl adducts (119) were afforded in 57% with 1:1 
diastereomeric ratio (dr) and without generating any side product (entry 3). The hydroxyl 
group adduct (119) might come from the addition of trace amount of moisture to the reactive 
intermediate. In the presence of 4 Å molecular sieves (MS), no reaction happened, and the 
starting material remained unrected as the observed from crude NMR elucidation (entry 4). 
By employing the MeOH as nucleophile in the gold(I) catalyzed reaction, the methoxy 
adduct (120) was formed in a stereoselective manner. The structure was unambiguously 
determined by single-crystal X-ray analysis (see the experimental section). The less 
electrophilic gold(I) catalysts, I and II, gave good yield for 120 in 81% and 72%, 
respectively (entry 5-6). When most electrophilic gold(I) catalyst (III) was applied to the 
reaction, an excellent yield of 90% was obtained for 120 (entry 7). Inspired by the work from 
Toste’s group[48], the diphenyl sulfoxide (122) was used as the oxidative nucleophile to trap 
the gold carbene intermediate, which might provide the aldehyde (121) as the product. The 
newly generated aldehyde functionality can serve as the reactive handle for various 
late-stage functional group manipulations, such as reduction, reductive amination, 
nucleophilic addition, etc., which is beneficial for the further chemical biology studies. The 
desired aldehyde (121) was isolated in relative low yield and along with the hydroxyl group 
adduct (119) by treatment of a series of gold(I) catalysts (entry 8-10). In the presence of 4 Å 
MS, the conversion of aldehyde (121) was drastically improved to 52% yield by phosphite 
gold(I) catalyst III (entry 11). Using another oxidative nucleophile, the 8-methylquinoline 
N-oxide (123, entry 12) displayed similar reaction outcome to diphenyl sulfoxide (122, entry 
8) in the NHC gold(I) (I) catalyzed condition. On the other hand, the other gold(I) catalysts 
(II and V) did not give any product (entry 13-14).  
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Table 1. Catalysts and nucleophiles screening of gold(I) catalyzed 5-exo-dig cyclization. 
 
 
Entry [Au] Nu (eq) Product (Yield) Note 
1 I - - observed 119
[a]
 
2 II - - observed 119
[a]
 
3 III - 119 (57%) dr = 1:1 
4
[b]
 III - - -
[c]
 
5 I MeOH (20 eq) 120 (81%) - 
6 II MeOH (20 eq) 120 (72%) - 
7 III MeOH (20 eq) 120 (90%) - 
8 I 122 (1.1 eq) 121 (trace) observed 119  
9 II 122 (1.1 eq) 121 (16%) observed 119 
10 III 122 (1.1 eq) 121 (21%) observed 119   
11
[b]
 III 122 (1.1 eq) 121 (52%) - 
12
[d]
 I 123 (1.1 eq) 121 (trace) -
[a]
 
13
[d]
 II 123 (1.1 eq) - -
[c]
 
14
[d]
 III 123 (1.1 eq) - -
[c]
 
[a]
 Non-selective reaction.
 [b]
 Addition of 4 Å MS. 
[c] 
Starting material recovery. 
[d]
 Reaction 
was operated at 60 °C seal tube.  
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3.1.2 Reaction mechanism  
 Taking cognizance of the reported gold(I) catalyzed cycloisomerization reactions, I 
propose that cationic gold(I) catalyst activates the acetylene first. Nucleophilic addition of 
olefin concurrently takes place to form the vinyl gold (125) or exocyclic gold carbene 
intermediate (126), as shown in Scheme 13.
[48, 55]
 In the presence of trace amounts of 
moisture, water undergoes nucleophilic addition to the intermediate 125, which subsequently 
gives the hydroxylated adduct (119) via vinyl gold intermediate (127). By utilizing excess 
amount nucleophile, the 1,4-addition of nucleophile dominates the reaction causing the 
cyclopropane ring-opening in stereospecific manner. The protodeauration of intermediate 
128 closed the catalytic cycle to provide the spirooxindole (120) as the final product. 
Interestingly, the 1,2-addition of diphenyl sulfoxide to the gold carbene happened in a 
different manner and followed the Swern type oxidative elimination of thioether to form the 
aldehyde (121). 
 In the terminal alkyne substrate (118), the gold(I) catalyzed 5-exo-dig cyclization 
provides the exocyclic gold carbene intermediate (126) and the fate of this intermediate can 
be modulated by different types of nucleophiles to perform 1,2- or 1,4-nucleophilic addition 
leading to the spirooxindole 121 or 120, respectively.   
 
 
Scheme 13. Proposed reaction mechanism of gold(I) catalyzed spirooxindole formation.  
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3.2 Gold(I) catalyzed cycloisomerizations of oxindole based prenylated 1,6-enynes 
The prenylated 1,6-enyne (130) was synthesized for the investigation of gold(I) 
catalyzed cycloisomerization via 6-endo-dig cyclization. The initial study began with 
treatment of 5 mol% of Ph3PAu(BF4), generated in situ by mixing the Ph3PAuCl and AgBF4 
in DCM, to the 1,6-enyne substrate (130). In this case, no reaction occurred, and the starting 
material was fully recovered (Table 2, entry 1). The reactivity of the gold(I) catalyst was 
improved by replacing the AgBF4 by AgOTf. However, a substantial amount of starting 
material remained unreacted (entry 2). Complete conversion was observed by applying 10 
mol% of in situ prepared Ph3PAu(BF4) catalyst to the 1,6-enyne (130, Scheme 14 and Table 
2, entry 3). The spirooxindole (131) was isolated in 12% yield accompanied with the 
epi-spirooxindole (132) in 16% yield. The major product (133) in this reaction was obtained 
in 26% yield and was found to embody a novel scaffold, i.e. (E)-3-(dihydrofuran-2 
(3H)-ylidene)indolin-2-one (df-oxindole) with iso-propenyl and phenyl substitution in cis 
configuration. The trans-df-oxindole (134) was also isolated in 8% yield. Among df-oxindole 
products, the df-oxindole (135) bearing hydroxyl group at benzylic position was the 
unexpected product from the gold(I) catalyzed enyne cycloisomerization. All the relative 
configurations of spirooxindoles and df-oxindoles were corroborated by single crystal X-ray 
analysis of representative molecules (see experimental section). The Meyer-Schuster 
rearrangement product (136) was formed in 7% yield and the chemical structure was 
confirmed by comparing the 
1
H NMR
 
with reported reference.
[67]
  
 
 
Scheme 14. Proposed reaction mechanism of gold(I) catalyzed spirooxindole formation.  
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3.2.1 Reaction optimization towards df-oxindole scaffold 
 In order to realize the reaction conditions that can offer selective formation of intriguing 
and novel scaffolds from 1,6-enyne (130), further reaction condition screening and 
optimization was pursued as shown in Table 2. By switching the gold(I) to the higher 
oxidation state, gold(III) chloride, none of the cycloisomerization products was generated 
(entry 4). Therefore, further investigation was focused on gold(I) catalysts with different 
ligands. While the NHC gold(I) catalyst (I) provided no product under standard condition, 
increasing the concentration of substrate to 0.2 M led to the non-selective reaction (entry 
5-6). However, the steric bulkiness of phosphine (II) drastically enhanced the selectivity 
towards df-oxindole (134) that was formed in moderate yield (51%, entry 7). More steric 
bulkiness on phenyl ring (IIa) or the alkyl group (IIb) of phosphine ligand didn’t further 
influence the yield of 134 (entry 8-9). The product selectivity was again lost with 
electrophilic phosphite gold(I) catalyst (III), and df-oxindole (134), starting material (130) 
and spriooxindoles (131 and 132) were isolated in 17%, 40%, 13%, and 30% yield, 
respectively (entry 10).  
With the ideal gold(I) catalyst (II) in hand that afforded selectively the df-oxindole 
(134), the influence of solvents on the reaction was further investigated. With non-polar 
solvent, toluene, the yield of 134 decreased to 40% (entry 11). While using diethyl ether 
enhanced the yiled to 38%, tetrahydrofuran (THF) afforded excellent yield of 95% (entry 
12-13). With 1,4-dioxane as solvent, the moderate yield of 59% was obtained (entry 14). 
These results can be rationalized by the tendency of intermediate stabilization by the lone 
pair of oxygen. The more polar solvents were also examined, but the yield of 134 decreased 
to 38% in nitromethane (MeNO2) and there was no reaction using acetonitrile as solvent 
(entry 15-16). When dimethylformamide (DMF) was used as a polar protic solvent, no 
reaction occurred (entry 17). The reduction of catalyst loading from 5 mol% to 3 mol% also 
compromised the yield of 134 to 91% (entry 18). Therefore, the optimal condition was 
settled for 0.1 M of substrate (130) with 5 mol% of II in THF solvent for an overnight 
reaction to give df-oxindole (134) as product.  
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Table 2. Reaction optimization for the gold(I) catalyzed synthesis of df-oxindole. 
 
 
Entry [Au] (5 mol%) Solvent Yield (%) 
1 Ph3PAu(BF4) DCM -
[a]
 
2 Ph3PAu(OTf) DCM 15
[b]
 
3 Ph3PAu(OTf)
[c] 
DCM 19
[d]
 
4 AuCl3 DCM -
[a]
 
5 I DCM -
[a]
 
6 I
[d]
 DCM -
[e]
 
7 II DCM 51 
8 IIa DCM 49 
9 IIb DCM 40 
10 III DCM 17
[f]
 
11 II toluene 40 
12 II diethyl ether 38 
13 II THF 95 
14 II 1,4-dioxane 59 
15  II MeNO2 38 
16 II ACN -
[a]
 
17 II DMF -
[a]
 
18 II 
[g]
 THF 91 
[a] 
Starting material recovery.
 [b] 
Incomplete reaction. 
[c] 
10 mol% catalyst loading. 
[d] 
The 
complete compound isolations were shown in Scheme 14.
 [d] 
Concentration of SM is 0.2 M.
 [e] 
Non-selective reaction. 
[f] 
The compound 130 (40%) 131 (13%), and 132 (30%) were isolated. 
[f] 
3 mol% catalyst loading. Ad, adamantly. 
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3.2.2 Reaction scope  
 With the optimal reaction conditions in hand, the scope of the gold(I) catalyzed 
df-oxindole formation was studied by varying substitutions on the acetylenic moiety (R
1
) as 
well as on the aryl ring (R
2
) and the N-protecting group (R
3
) on the oxindole based 1,6-enyne 
(130). The results are summarized in Scheme 15. Substitutions on the acetylene (R
1
) with 
differently decorated phenyl ring with mono-methyl substitution on o-, m-, or p-position 
were well tolerated, giving the products (134b-d) in 69-83% yield. An aryl ring with other 
electron donating groups (EDGs), i.e. o-MeO-Ph or m,p-diMeO-Ph, could also provide the 
desired product in 46% (134e) or 56% (134f) yield. A variety of substrates with electron 
withdrawing groups (EWGs) on the phenyl ring were prepared to examine the scope of the 
reaction. The optimal catalytic condition nicely transformed them to the desired products in 
moderate to good yields (134g-k). As a representative example of heterocyclic substitution, 
the df-oxindole (134g) bearing thiophene moiety was also synthesized in 67% yield. It’s 
worthy to note that products bearing linear or branched alkyl chains at R
1
 position could also 
be prepared in 36% yield in each case, owing to the incomplete reaction (134m and 134n). 
Increasing the catalyst loading to 10 mol% improved the yield of 134m to 50%. Secondly, 
substitutions on the aryl moiety (R
2
) of oxindole were examined. The substrates with Me or 
OMe substitution at the 5-position of oxindole gave good yield for 134o and 134p in 76% or 
66%, respectively. However, the dimethyl-substituted analog (134q) was obtained in 
moderate yield (58%). Mono-halogenated oxindole substrates (F-, Cl-, or Br-) followed 
smooth conversion and the products (134r-t) were isolated in 62-69% yields. The oxindoles 
embodying strong EWG, such as trifluoromethoxyl or nitro group, were also tolerated in this 
transformation and provided good yields for df-oxindoles, 134u and 134v. In the end, a 
series of N-protecting groups (R
3
), for example benzyl (Bn), p-methoxy benzyl (PMB), 
methoxymethyl (MOM), and 2-(trimethylsilyl)ethoxymethyl (SEM) were installed on to the 
nitrogen to examine the reactivity of protected and unprotected (NH) substrates in this 
gold(I) catalyzed reaction. Most of the N-protected substrates provided excellent yields for 
the desired products (134w-y), but the SEM substrate seems to be incompatible with Lewis 
acidic conditions, affording the product 134z only isolated in 51% yield. In general, the 
substitutions on R
1
 to R
2
 of 1,6-enyne substrates were well tolerated and afforded the desired 
products in moderate to excellent yields (Scheme 15).  
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Scheme 15. Reaction scope of gold(I) catalyzed df-oxindole formation.  
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During the exploration of the reaction scope, the gem-dimethyl df-oxindole (138) was 
generated from 1,6-enyne substrate with iso-propenyl moiety (137) in 46% yield. In addition 
to offering an interesting substitution on the df-oxindole, this reaction also offers a hint for 
the mechanistic insights into gold(I) catalyzed df-oxindole formation (Scheme 16).    
 
 
Scheme 16. Gold(I) catalyzed df-oxindole 138 formation.  
 
3.2.3 Development of a removable N-protecting group for oxindole based 1,6-enyne 
cycloisomerization reaction 
 Having a NH group or a removable N-protecting group on the oxindole offers 
opportunities for further chemical manipulations in the compound collection synthesis of 
df-oxindoles. In this regard, the preparation of non-protected oxindole substrates were 
performed. Considering the substrate synthesis, the nitrogen has to be protected to avoid the 
over-allylation during the allyl ether formation step. Two factors were to be considered in the 
protecting group selection, first was the stability of protecting group during the synthesis 
sequence, and second is the condition for protecting group removal. With the available 
N-protected substrates in hand, the first attempt was the removal of N-MOM protection from 
1,6-enyne 130y, however the enyne moiety was sensitive to the acidic condition leading to 
the decomposition of substrate (Scheme 17a). The second trial was with employing 
tetra-n-butylammonium fluoride (TBAF) assisted SEM cleavage from 1,6-enyne 130z in 
DMF as solvent and at 100 °C, and the desired product (130aa) was obtained in 40% yield 
(Scheme 17b). The low yield of the product and the low reproducibility called for a more 
robust synthetic approach. The silyloxymethyl N-protection
[68]
 can be removed under 
relatively milder fluoride ion deprotection condition than SEM protection. A two-step 
approach was performed in gram scale synthesis of (tertbutyldimethylsiloxy)methyl 
protected isatin (143). In the presence of potassium carbonate, the isatin (139) was treated 
with paraformaldehyde to form the hemiaminal (140), which followed the conventional TBS 
protection condition to generate the desire substrate with corresponding N-protection (141). 
Previously developed 1,6-enyne synthesis approach was applied to form the desired substrate 
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(143) in excellent yield both in the alkynylation step and in the allylation step. The 
N-deprotection could be done by using TBAF to give the enenye 130aa in 66% yield 
(Scheme 17c). With the non-protected oxindole based 1,6-enyne (130aa), the gold(I) 
catalyzed synthesis of corresponding df-oxindole was performed. In the first attempt, it was 
proved that the purity of the enyne substrate is crucial for the transformation, i.e. trace 
amounts of TBAF may deactivate the gold(I) catalyst, resulting in recovering of the starting 
material. Gratefully, after another purification by silica gel column chromatography and 
removal of moisture by high vacuum, the pure 1,6-enyne (130aa) gave the expected product 
134aa in 72% yield under the optimized reacion condition (Scheme 17c). 
  
 
Scheme 17. Synthesis of non-protected oxindole based 1,6-enyne and gold(I) catalyzed 
non-protected df-oxindole formation.  
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3.2.4 Reaction mechanism  
 In prenylated 1,6-enyne substrate (130), gold(I) catalyzed cycloisomerization provides 
two diastereomeric spirooxindole (131, 132) as well as df-oxindole (133, 134, and 135), 
which come from the common 6-endo-dig cyclization mode (Scheme 18a). I assume that the 
formation of spirooxindoles (131, 132) occur by an initial 6-endo-dig cyclization of olefin to 
acetylene, activated by gold(I) catalyst to form cyclopropane gold carbene intermediate 
(144). Spontaneous formation of a stable tertiary carbocation by cyclopropane ring opening 
facilitates the deprotonation process to yield the i-propenyl moiety of sprio-oxindole (146), 
which undergoes protodeauration to yield the diastereomeric spriooxindoles (131, 132). 
Alternatively, the non-stereoselective protonation of spriooxindole (146) results in the 
formation of gold carbene intermediate (147), which is nucleophilically attacked by the 
spiroether to form a highly strained tetracyclic oxonium ion (148). The deauration closes the 
catalytic cycle with concomitant ring-opening to yield the diastereomeric df-oxindoles (133, 
134), as shown in Scheme 18b. It is notable that there are two steps determining the 
stereochemistry of the final product. One is the 6-endo-dig cyclization (130 to 144), which 
forms the diastereomeric centers at the cyclopropane ring and the spiro-carbon. 
Alternatively, the protonation process (146 to 147) generates the chiral center at the benzylic 
position resulting in the cis-, trans-isomer between two substitutions, i-propenyl and phenyl 
group, on the tetrahydrofuran ring. Increasing the steric bulk of the phosphine ligand can 
enhance the reaction selectivity, via creating stereospecific protonation environment. As 
presented in Scheme 18b, Johnphos gold(I) catalyst (II) catalyzed transformation shares a 
similar reaction pathway till the vinyl gold intermediate (146). At this stage, the steric 
repulsion between the i-propenyl moiety and the ligand of the gold(I) catalyst decisively 
offers the sterically less hindered face, which consequently blocks the originally more 
exposed protonation face (149). The stereoselective protonation determines the 
trans-orientation of i-propenyl and phenyl group, and further sequential cascade forms the 
df-oxindole (134).  
Similary, the 1,6-enyne (137) endowed with isopropenylacetylene followed the 
gold(I) mediated 6-endo-dig cyclization to form the conjugated vinyl gold intermediates 
(152). Unlike the protonation of vinyl gold intermediate (146) that take place at -position, 
the intermediate 152 protonates at the end of the conjugated system, i.e. the -positon, 
leading to the unique df-oxindole (138) by previously described oxygen migration sequence 
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(Scheme 18c). While formation of most of the products fits in this mechanistic proposal, the 
formation of df-oxindole (135) is still unclear and needs further investigation. 
 
Scheme 18. a) Gold(I) catalyzed cycloisomerization of prenylated 1,6-enyne (130). b) 
Proposed mechanism of gold(I) catalyzed df-oxindole and spirooxindole formation. c) 
Proposed mechanism of gold(I) catalyzed df-oxindole formation (138). 
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The bulky phosphine ligand can manipulate the stereochemistry course of the 
reaction to give the trans configuration of i-propenyl and phenyl substituents in df-oxindoles. 
Using an enantiopure enyne 154 thus would yield two diastereomeric gold carbene 
intermediates (155, 156) under the gold(I) catalyzed condition and each of the intermediates 
will subsequently deliver the corresponding df-oxindoles (157, 158). If the 6-endo-dig 
cyclization works in stereospecific manner, gold carbene intermediate (155 or 156) will form 
and give the corresponding product (157 or 158) as the enantiopure product, respect-tively. 
Alternatively, the non-stereospecific 6-endo-dig cyclization forms a mixture of gold carbene 
intermediates (155 and 156) which subsequently form a mixture of enantiomeric 
df-oxindoles (157 and 158) with reduced ee value (Scheme 19a). To unravel this 
information, an optically enriched substrate (130*) was prepared by Zn(OTf)2 catalyzed 
enantioselective alkylation.
[69]
 After the isolation of desired product (134*) of a JohnPhos 
gold(I) catalyzed reaction, chiral high-performance liquid chromatography (HPLC) analysis 
indicated a decrease of ee value from 73% to 36% ee. This partial racemization stands for the 
non-stereospecific 6-endo-dig cyclization (Scheme 19b).  
 
 
Scheme 19. a) Hypothesis of the stereoselectivity in gold(I) catalyzed df-oxindole formation. 
b) The experimental result of gold(I) catalyzed chirality transfer reaction. 
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To confirm the proposed reaction mechanism, the incorporation of CD3OD, as 
nucleophile and protonation source, to the gold(I) catalyzed 1,6-enyne transformation 
successfully provided the deuterated df-oxindole (159) in 12% yield with 40% of deuteration 
at benzylic position and the d-methoxyl adduct (160) in 47% yield with benzylic deuterium 
in 50% (Scheme 20). The addition of the d-methoxyl group hints at the formation of a stable 
tertiary carbocation or the electrophilic carbon of cyclopropane ring, and the deuteration on 
benzylic position. These results nicely agree with the proposed reaction mechanism.    
 
 
Scheme 20. The deuteration experiment for gold(I) mediated df-oxindole formation. 
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3.3 Gold(I) catalyzed cycloisomerizations of oxindole based crotylated 1,6-enynes 
 With the successful transformation of 1,6-enyne to df-oxindole, I envisaged that the 
cyclopropanyl gold carbene could be varied to other scaffolds. In the prenylated 1,6-enyne 
(130), the deprotonative cyclopropane ring opening (from 144 to 145) destabilized the key 
cyclopropanyl gold carbene intermediate and prohibited its potential to follow other reaction 
pathways (Scheme 21a). While 1,6-enyne (130) leads to 134 through the formation of a 
tertiary carbocation (145), the corresponding gold carbene 162 formed from crotylated 
1,6-enyne 161 might offer opportunities to form different scaffolds (164) and might be a 
subject to modulation under the influence of the reaction conditions like ligands, solvent and 
additives (Scheme 21b). Therefore, further investigations were performed by using enynes 
161. 
 
 
Scheme 21. Gold(I) catalyzed deprotonative cyclopropane ring opening a) in prenylated 
1,6-enyne (130) and b) crotylated 1,6-enyne (161). 
 
3.3.1 Reaction optimization towards crotylated 1,6-enyne 
 After the 4-step substrate synthesis of crotylated 1,6-enyne (161) with the E/Z isomer in 
3 to 1 ratio, the optimization of gold(I) mediated divergent synthesis began with the catalyst 
screening and is summarized in Table 3. By treatment of in situ prepared cationic gold(I) 
complex Ph3PAu(BF4) in DCM, the spirooxindole (165) was formed in 33% yield (entry 1). 
With 5 mol% of AuCl3 as the gold(III) catalyst, the cycloisomerization reaction provided the 
ring expansion product quinolone (166) in 23% yield, which did not improve with doubling 
the catalyst loading and resulted in complex product mixtures (entry 2-3). When the gold(I) 
catalyst with NHC as ligand (I) was applied for the transformation, the mixture of 
spirooxindole (165) and quinolone (166) was isolated as products in 43% and 7 % yield, 
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respectively (entry 4). Delightfully, the quinolone (166) could be selectively generated by 
utilizing the bulky phosphine as gold(I) ligand (II) in good yield. Fine tuning the steric factor 
of phosphine ligand revealed that the biphenyl ring of phosphine bearing 1,3,5-tri-iso-propyl 
groups (IIa) provided the highest yield of 67% as compared to others bulky phosphine 
ligands (entry 5-7). Interestingly, the epimer of quinolone (epi-166) was also isolated in the 
cat IIa catalyzed reaction in 20% yield, which would be the product from the Z-1,6-enyne 
(Z-161). Treatment of more electrophilic gold(I) catalyst with phosphite ligand (III) 
selectively gave the spirooxindole as the product in satisfactory yield (entry 8). The 
Z-1,6-enyne (Z-161) seemed to be inert in this catalytic condition, which was in 10% 
recovery.  
In the initial catalyst screening, two structurally distinct scaffolds, spirooxindole (165) 
and quinolone (166), were generated in a selective manner by bulky phosphine and 
electrophilic gold(I) catalysts, (IIa and III), respectively; and the screening of solvent and 
catalyst loading were followed up for the further improvements. However, no further 
improvement was observed during the whole process. For the bulky phosphine gold(I) 
catalyzed spirooxindole formation (IIa), the non-selective result was observed while using 
toluene as the solvent (entry 9). As the polar solvent, both of ACN and DMF diminished the 
power of catalysts to give the starting material recovery as the outcome (entry 10, 11) THF, 
as the optimal solvent for the df-oxindole formation, turned out to be incompatible in the 
condition and leading to the polymerization of THF (entry 12). When decreasing the catalyst 
loading from 5 mol% to 3 mol%, the yield of spirooxindole also dropped to 27%. On the 
other hand, by using toluene as solvent, the phosphite gold(I) catalyzed quinolone formation 
(III) could deliver the desired product thought in moderate yield (entry 14). When swiching 
the solvent to ACN or DMF, stating material was recovered due to the deactivation of 
catalyst by the polar solvent (entry 15 and 16). The THF was also proven to be not 
compatible as solvent to the gold(I) catalyzed condition that leading to the polymerization 
(entry 17). Reducing the catalyst loading to 3 mol% slightly decreased the yield of the 
quinolone formation (entry 18).  
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Table 3. Reaction optimization for gold(I) catalyzed divergent scaffold synthesis (I). 
 
Entry [Au] (5 mol%) Solvent 
Yield (%) 
165 166 epi-166 
1 Ph3PAu(BF4) DCM 33 - - 
2
 
AuCl3 DCM - 23 - 
3 AuCl3 DCM -
[a]
 
4
[b]
 I
 DCM 43 7 - 
5 II DCM - 57 - 
6 IIa DCM - 67 20 
7 IIb DCM - 43 - 
8
[c]
 III DCM 60 - - 
9 IIa toluene -
[a]
 
10 IIa ACN -
[d]
 
11 IIa DMF -
[d]
 
12 IIa THF -
[e]
 
13
[d]
 IIa DCM - 27 - 
14 III toluene 40 - - 
15 III ACN -
[d]
 
16 III DMF -
[d]
 
17
 
III THF -
[e]
 
18
[f]
 III DCM 58 - - 
[a] 
Non-selective reaction. 
[b] 
Starting material was in 26% recovery. 
[c] 
Z-161 was in 10% 
recovery.
 [d] 
Starting material recovery. 
[e] 
THF polymerized. 
[f] 
Catalyst loading: 3 mol%. 
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After identification of the optimal conditions for the formation of spirooxindoles (165, 
Table 3, entry 8) and quinolones (166, Table 3, entry 6), I envisioned that the cyclopropane 
moiety of the gold carbene intermediate could be opened up by nucleophilic addition, 
allowing the formation of df-oxindoles via O-migration, as shown in Table 4. In the presence 
of gold(I) catalyst (II), 20 equivalents (eq.) of MeOH were used as the nucleophile to trap 
the gold carbene intermediate. Since no reaction proceeded at room temperature, the reaction 
temperature was raised to 60 
o
C that also required switching the solvent from DCM to DCE. 
Indeed, he df-oxindole (167) was isolated in 62% yield, accompanied by the Mayer-Schuster 
rearrangement (M.-S. rear.) product (136) in 19% yield (entry 1-2). The replacement of 
catalyst from phosphine gold(I) catalyst (II) to NHC gold(I) catalyst (I) or phosphite gold(I) 
catalyst (III) didn’t provide a better yield of 167 (entry 3, or 4). After tuning the electronic 
property of the cationic gold(I) catalyst, the role of steric nature of the catalyst on reaction 
was investigated by tuning the bulky groups on the JohnPhos ligand, such as tBu to Ad or 
unsubstituted phenyl group to 1,3,5-tri-iso-propyl phenyl group. However, none of them 
gave higher yield than the initial trial (entry 5, 6).  
We assumeed that the exccess amount of MeOH influenced the formation of the M.-S. 
rearrangement product (136). Therefore, a series of reactions were set to see the effect of the 
amount of MeOH on the reaction outcome (entry 7-10). Decreasing the amount of MeOH led 
to corresponding decrease in the formation of 136. With only 1.0 eq. of MeOH, no more 136 
was formed. At the same time, the quinolone (166) started to form when the 3.0 eq or less 
MeOH was used. With 5 mol% of II in the presence of 10 eq. of MeOH, the reaction 
afforded the df-oxindole (4a) in 73% yield (entry 7). Lowering the catalyst loading to 3 
mol% also decreased the product yield (entries 11). The nucleophiles other than MeOH were 
also investigated, such as H2O, AcOH, and indole. In the case of H2O, a heterogeneous 
mixture was formed affording a mixture of 166, epi-166, and hydroxyl adduct 167OH in 
30%, 15%, and 23% yield, respectively (entry 12). The AcOH nucleophile gave the 
diasteromeric mixture of acetyl adduct 167OAc in 56% yield (entry 13). However, the indole 
molecule failed to serve as carbon nucleophile and did not form the expected adduct (entry 
14).
[55]
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Table 4. Reaction optimization for gold(I) catalyzed divergent scaffold synthesis (II). 
 
 
[a] 
Reaction was operated at rt. 
[b]
 Starting material recovery. 
[c] 
Catalyst loading: 3 mol%. 
 
  
Entry [Au] Solvent Nu (eq) 
Yield (%) 
167 166 epi-166 136 
1
[a]
 II DCM MeOH (20.0) no reaction 
2 II DCE MeOH (20.0) 62 - - 19 
3 I DCE MeOH (20.0) 27 - - 34 
4 III DCE MeOH (20.0) 20 - - - 
5 IIa DCE MeOH (20.0) 56 - - - 
6 IIb DCE MeOH (20.0) 50 - - - 
7 II DCE MeOH (10.0) 73 - - 18 
8 II DCE MeOH (3.0) 56 11 - 7 
9 II DCE MeOH (1.0) 43 32 - - 
10 II DCE MeOH (0.5) 30 24 - - 
11
[c]
 II DCE MeOH (10.0) 64 - - - 
12 II DCE H2O (20.0) 23 (167OH) 30 15 - 
13 II DCE AcOH (20.0) 56 (167OAc) 20 13 - 
14 II DCE indole (2.0) - 37 - 23 
47 
 
3.3.2 Reaction scope  
 The extensive reaction screening and optimization identified suitable conditions to 
selectively form spirooxinodle (165), quinolone (166), and df-oxindole (167), in satisfactory 
yield by merely changing the ligand of the gold(I) catalyst and applying the nucleophile to 
the reaction (Scheme 22). Based on these optimal conditions, I started to investigate the 
functional group tolerance for the diverse scaffold generating transformations. As I had 
already observed that the variation in the allyl moiety alters the scaffold formation, 
functional group variation was performed at the phenyl ring, aryl ring of the oxindole, and 
substituents on nitrogen for each scaffold generating gold(I) catalyzed reaction. 
 
Scheme 22. The optimal conditions for gold(I) catalyzed divergent scaffold synthesis. 
  
The investigation of the reaction scope began with the cationic gold(I) catalyzed 
spriooxindole formation (165). Substrates with electron rich phenyl ring at the alkynyl 
position (R
1
) provided moderate to good yield (59-66%) of spirooxindoles (165b-f, Scheme 
23). However, the 1,6-enynes with substituent at ortho-position of phenyl ring (165d, 165e) 
afforded either non-selective reaction reactions or low yield of spirooxindole. A similar 
phenomenon was observed for 1,6-enynes with o-Cl-Ph substitution (165i). This might be 
attributed to inhibition of the coordination of the bulky gold(I) catalyst to acetylene in the 
ortho-substituted enyne While the substrate bearing EWG p-F-Ph moiety (161g) was 
tolerable in the reaction, substrate (161h) with m-Cl-Ph gave a mixture of spirooxindole 
(165h, 31%), and quinolone (166h, 19%) along with starting material recovered (161h, 
12%). The p-Br-Ph substitution in 161j also resulted in low yield (28%, 165j). As a 
representative of heterocyclic ring systems, the thiophene substrate (161k) was prepared and 
subjected to the optimal reaction conditions, which provided the desired product 165k in 
45% yield. With further exploring the scope of the reaction, the substrates with i-propenyl  
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Scheme 23. The reaction scope for gold(I) catalyzed spriooxindole formation. 
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(161l), cyclopropane (161m), and n-propane (161n) groups were smoothly converted into 
the desired products in 25%, 75%, and 51% yield, respectively. I was pleased to see that the 
functional groups ranging from EDG to EWG and mono- or di-substituted oxindoles (R
2
) 
were well tolerated in the gold(I) catalyzed reaction conditions to give spirooxindoles in 
50-75% yield (165o-u). The reactions worked well for differently N-protected oxindole 
enynes to deliver spirooxindoles with four different nitrogen protecting groups (R
3
), Bn 
(165v), PMB (165w), MOM (165x), and SEM (165y), in 45%, 42%, 70% and 29%, 
respectively (Scheme 23).  
The reaction scope of quinolone (166) formation was performed by using bulky 
phosphine gold(I) catalyst (IIa). Based on the same set of substrates, the reaction scope was 
studied with substitution variation at R
1
 to R
3
. For R
1
 moiety, the phenyl substituted 
substrates with EDG or EWG at meta- or para-position gave moderate to good yield for the 
desired quinolones (166b-f). The ortho-substituted substrates failed to form the desired 
products and instead a complex mixture was formed in those reactions. Though the substrate 
with i-propenyl or alkyl group at R
1
 led to a complex mixture, the thiophenyl product (166g) 
was isolated in 59% yield. Again, the 1,6-enynes with substitutions at the aryl part of 
oxindole (R
2
) were converted to products (166h-n) in moderate yields (38-50%). As 
expected, the nitrogen with benzyl based protecting groups, such as Bn or PMB, provided 
the corresponding quinolones (166o or 166p) in 52% or 43% yield, respectively. Whereas, 
the protecting group endowed with hemiaminal, i.e. MOM or SEM, did not give any product. 
Thus, the functional group tolerance in quinolone synthesis is limited as compared to 
spirooxindoles (Scheme 24).      
With the assistance of alcohols, the scope of df-oxindole formation (167) was 
examined. For the two scaffolds discussed above, the substrate with ortho-substituted phenyl 
ring at R
1 
position suffered from the nonselective transformation. However, unlike the 
spirooxindoles and quinolones, all ortho-, meta-, or para-substitutions, decorated with EDG, 
or EWG, were generally well tolerated in the df-oxindole formation in the yields from 
30-86% (167b-k). However, the strong EWG, trifluoromenthyl group, at ortho-position did 
affect the yield, and the product 167k was obtained in only 30% yield. The heterocyclic 
substrate, thiophinyl 1,6-enyne (161l), however delivered the corresponding df-oxindole 
(167) in 77% yield. The df-oxindoles bearing EDG or EWG at R
2 
(166m-s) were formed in 
62-78% yield, and both Bn and PMB protected products (166t and u) were generated in 
good yields too. Switching the N-protecting group to MOM, the desired df-oxindole (166v) 
was isolated in 71% yield. Interestingly, the substrate with SEM protecting group didn’t 
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provide the corresponding df-oxindole, but the MOM protected df-oxindole (166v) was 
formed in 59% yield (Scheme 25). I proposed that the protecting group replacement 
happened in a 2-step cascade. Under the gold(I) catalysis conditions, oxygen of SEM 
protected oxindole (169) may coordinate with metal center, which subsequently triggers the 
elimination reaction giving the iminium (170) as the reactive intermediate. The excess 
amount of MeOH serves as the nucleophile to react with iminium and generate the MOM 
protected product (171, Scheme 26). When lesser nucleophilic EtOH was used, the 
df-oxindole 166w was formed in 76% yield (Scheme 25).  
 
 
Scheme 24. The reaction scope for gold(I) catalyzed quinolone formation. 
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Scheme 25. The reaction scope for gold(I) catalyzed df-oxindole formation. 
 
 
Scheme 26. The gold(I) catalyzed protecting group replacement reaction. 
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3.3.3 Scaffold diversity synthesis with 1,6-enynes supporting differently substituted 
olefins 
 It was observed that substituents on the allyl group were critical for accessing divergent 
rearrangements of 1,6-enyne cycloisomerizations intermediates in gold(I) catalyzed 
reactions. In this regard, the prenylated 1,6-enynes selectively gave the df-oxindoles as 
products and the crotylated 1,6-enynes generated three distinct scaffolds, spirooxindole, 
quinolone, and df-oxindole. Therefore, I was curious to know how the substitutions on allyl 
position might affect the reactivity of 1,6-enynes in gold(I) catalyzed cycloisomerization 
reactions. A series of 1,6-enynes with substituent variations (172a-g) were prepared to 
investigate the gold(I) catalyzed reactions and results are summarized in Table 5 (ligand 
effect) and 6 (nucleophile effect). 
 The investigation began with the ligand effect toward the 1,6-enyne with different allyl 
substitution (Table 5). Since the crotylated 1,6-enyne (172a) with E to Z isomeric ratio in 3:1 
could deliver spirooxindole and quinolone by switching the ligand in gold(I) catalyst (Table 
5, entry 1-3), I suspected that the reaction mechanism of E and Z isomer might differ. To 
investigate this hypothesis, the ethyl substituted E- and Z-1,6-enyne (172b and 172c) were 
synthesized and subjected for the catalyst screening. In the E-1,6-enyne system (172b), the 
quinolone (174b) was selectively generated by the bulky phosphine gold(I) catalyst (IIa) and 
spirooxindole formation could be achieved by applying NHC gold(I) catalyst (I) or 
phosphite gold(I) catalyst (III), as shown in entry 4-6. The more electrophilic gold(I) catalyst 
(III) gave spirooxindole (173b) in higher yield than the less electrophilic gold(I) catalyst (I) 
from 88% to 79% yield (entry 4-6). Interestingly, the Z-1,6-enyne (172c) was observed to be 
selective for the quinolone formation (174c) and the highest yield was afforded by the 
cationic gold(I) catalyst with phosphite ligand (III) in 63% yield (entry 7-9). On the basis of 
these experimental results, I can conclude that the E-1,6-enyne plays the major role for the 
spriooxindole and quinolone scaffold synthesis.  
If the sterically demanding functional group, such as phenyl group, was installed at 
R
2
, the NHC gold(I) catalyst (I) provided quinolone (174d) in 40% yield. For the other 
gold(I) catalysts (II and III), only a complex mixture was obtained after the treatment of 
catalyst to the substrate (entry 10-12). By treatment of bulky phosphine gold(I) catalyst (IIa), 
the allyl propargyl ether (172e) was converted to the corresponding quinolone (174e) in 56% 
yield (entry 14). With the same substrate, the cationic gold(I) catalyst with NHC ligand (I) or 
phosphite ligand (III) gave only starting material recovery or a complex mixture (entry 13, 
15). The gold(I) catalyst I could not catalyze the enyne cycloisomerization of the methallyl 
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substrate (172f), but the gold(I) catalyst with phosphine or bulky phosphite ligand (IIa and 
III) converted the methallyl 1,6-enyne (172f) to spriooxindole (173f) albeit in low yield. 
Changing solvent from DCM to Et2O could improve the yield from low to moderate (entry 
16-19). In case of prenylated 1,6-enynes (130), df-oxindole (134) was selectively generated 
by utilizing the bulky phosphine gold(I) catalyst (IIa), as shown in entry 21. More details for 
the df-oxindole formation of prenylated 1,6-enynes (130) were described in section 3.4.  
Since addition of a nucleophile to crotylated 1,6-enyne (172a) could facilitate the 
formation of df-oxindole (Table 6, entry 1) in the presence of bulky phosphine gold(I) 
catalyst (II), I also examined whether the same strategy could work on enynes with 
differently substituted olefin (172b-g, entry 2-7). The substrates with the substitution on R
2
 
position, i.e. Me, Et, or phenyl, followed the same transformation to give the df-oxindoles 
(175a, 175b, and 175f) as major product in good yield (entry 1, 2, and 4) along with M.-S. 
rear. product (136) that was formed in low yield. However, the M.-S. rear. product (136) was 
formed as the major product in 56% yield from the Z-1,6-enyne (172c) and the desired 
df-oxindole (175c) was isolated in 20% yield (entry 3). In case of allyl 1,6-enyne (172d) as 
substrate, no df-oxindole was observed and the M.-S. rear. product (136) was formed in 86% 
yield (entry 5). The methallyl 1,6-enyne (172e) resulted in a non-selective reaction reaction 
(entry 6). Finally, the prenylated 1,6-enynes (130) gave the corresponding methoxyl adduct 
(175g) in good yield with 23% of M.-S. rear. product (136). In general, the gold(I) catalyzed 
df-oxindole formation is tolerated by the 1,6-enyne substrates with substitution at R
2
 and R
3
 
position.  
The diphenyl sulfoxide (122) had been used as an oxidative nucleophile to trap the 
gold carbene intermediate, giving the carbonyl moiety.
[48]
 However, this reaction did not 
happen with 1,6-enyne (172b, entry 8). A stronger oxidative nucleophile i.e. N-oxide (123) 
delivered the ring expansion product (176b) bearing the quinolone core in 83% yield (entry 
9). In order to compare the nucleophilicity between N-oxide (123) and MeOH to provide 
4-ketoquinolone (176b) or df-oxindole (175b) respectively, I set up the competition reaction 
under the standard conditions in the presence of MeOH (10 eq) and N-oxide (123, 1.1 eq). 
Only quinolone (176b) was formed in 70% yield, which indicated that the N-oxide (123) is a 
stronger nucleophile than MeOH. Thus, the other 4-ketoquinolone derivative (176b) can be 
generated from oxindole derived 1,6-enyne by treatment of bulky phosphine gold(I) catalyst 
with N-oxide (123) as oxidative nucleophile. 
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Table 5. Reaction screening of 1,6-enynes with various gold(I) catalysts to establish  
diversity. 
 
 
 
Entry 172 
Substitutions 
[Au] 
Product (Yield %) 
R
1
 R
2
 R
3
 173 174 132 134 
1
[a,b]
 a
[c]
 H Me H I 43 7 - - 
2
[a]
 a
[c]
 H Me H IIa - 67 - - 
3
[a]
 a
[c]
 H Me H III 60 - - - 
4 b H Et H I 79 - - - 
5 b H Et H IIa - 40 - - 
6 b H Et H III 88 - - - 
7 c H H Et I - 58 - - 
6 c H H Et IIa - 37 - - 
9 c H H Et III - 63 - - 
10 d H Ph H I - 40 - - 
11 d H Ph H IIa -
[d]
 
12 d H Ph H III -
[d]
 
13 e H H H I -
[e]
 
14 e H H H IIa - 56 - - 
15 e H H H III -
[d]
 
16 f Me H H I  -
[e]
 
17 f Me H H IIa 37 - - - 
18
[f] 
f Me H H IIa 46 - - - 
19 f Me H H III 17 - - - 
20 g
[g]
 H Me Me I -
[e]
 
21 g
[g]
 H Me Me IIa - - - 51 
22
[h]
 g
[g]
 H Me Me III - - 33 17 
[a]
 E:Z = 3:1. 
[b]
 (Z)-172a was in 27% recovery.
 [c]
 Crotylated 1,6-enyne (161a). 
[d] 
Non-selective reaction.
 [e] 
Starting material recovery. 
[f]
 Solvent is diethylether.
 [g] 
Prenylated 
1,6-enyne (130a). 
[h]
 172g was in 30% recovery.  
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Table 6. Reaction screening of gold(I) catalyzed 1,6-enynes with various nucleophiles. 
 
 
 
[a]
 E:Z = 3:1. 
[b]
 Crotylated 1,6-enyne (161a). 
[c] 
Non-selective reaction. 
[d] 
Prenylated 
1,6-enyne (130a) 
 
 
  
Entry 172 
Substitutions 
Nu (eq) 
Product (Yield %) 
R
1
 R
2
 R
3
 174 175 136 176 
1
[a]
 a
[b]
  H Me H MeOH (10) - 73 18 - 
2 b H Et H MeOH (10) - 67 15 - 
3 c H H Et MeOH (10) - 20 67 - 
4 d H Ph H MeOH (10) - 56 8 - 
5 e H H H MeOH (10) - - 86 - 
6 f Me H H MeOH (10) -
[c]
 
7 g
[d]
 H Me Me MeOH (10) - 66 23 - 
8 b H Et H 122 (2) 60 - - - 
9 b H Et H 123 (1.1) - - - 83 
10 b H Et H MeOH (10)/123 (1.1) - - - 70 
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3.3.4 Reaction mechanisms  
 In the presence of gold(I) catalysts and with or without external nucleophiles, such as 
MeOH and N-oxide (123), the 1,6-enynes (172) can be converted into divergent products 
with unique quinolone (174, 176), spirooxindole (173) and methyleneoxindole (174, 134, 
and 136) scaffold (Scheme 27). Since the formation of spirooxindole (134) has discussed in 
the section 3.2.4, I will focus on the formation of quinolone (174, 176), spirooxindole (173), 
df-oxindole (174), and M.-S. product (136). 
 
Scheme 27. Gold(I) catalyzed divergent scaffold formation by allyl-substituents modulation. 
 
I believe that there are two distinctive modes of rearrangements leading to different 
sets of scaffolds. Addition of external nucleophile to gold(I) activated acetylene leads to the 
M.-S. product (136) and 4-ketoquinolone (176), as shown in Scheme 28a. On the other hand, 
a gold(I) catalyzed enyne cycloisomeritzation via 6-endo-dig cyclization forms endocyclic 
gold carbene intermediates (178), which led to the formation of quinolones (174), 
spirooxindoles (173), or df-oxindoles (174) as products (Scheme 28b). 
For the synthesis of spirooxindole (173), the migration of cyclopropane ring in 178 
firstly generates the carbocationic intermediates (179), which spontaneously rearrange to the 
final spirooxindoles (173), as indicated in Scheme 28b (magenta arrows). In the gold carbene 
intermediates (178), the steric interaction between substrate and bulky gold(I) catalyst is 
relieved by the pinacol type acyl group migration, which consequently delivers the oxonium 
intermediates (180). The deauration reaction closes the catalytic cycle by forming the 
quinolones (174) as the final product (Scheme 28b, blue arrows).
[52]
 In the prenylated 
substrate, the cyclopropane opening of bicyclic gold carbene intermediates  
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Scheme 28. Proposed reaction mechanism of gold(I) catalyzed divergent scaffold synthesis. 
 
(178) undergoes an O-migration cascade to form df-oxindoles (174) as the products (Scheme 
17). Alternatively, the nucleophilic 1,4-addition/protonation sequence on 178 finally gives 
the monocyclic gold carbene intermediates (182), which can further undergo the O-migration 
cascade ultimately delivering the df-oxindoles (174, (Scheme 28b, turquoise arrows).
[55]
 The 
M.-S. product (136) is often observed as the side product or sometime even as the major 
product from the nucleophilic addition based df-oxindole formation. The addition of MeOH 
to gold(I) activated acetylenes (184) form the vinyl gold 185, which can be stabilized by the 
gem-diaurate intermediate (191)
[70]
 and proceed the elimination of alcohol and keto-enol 
tautomerization giving conjugated ketone (136), as depicted in Scheme 28a, cond 5.
[71]
 As 
the oxidative nucleophile (123) is applied, the vinyl gold complex 188 is formed and 
simultaneously eliminates the 8-methylquinoline (Z). Subsequently, the phenyl group 
migration associated ring expansion and dearuation take place to form the 4-ketoquinolone 
(176, Scheme 28a, cond. 4).     
 
  
58 
 
3.3.5 Gold catalyzed cycloisomerization of enantioenriched enynes 
In order to explore stereoselective cycloisomerization of enantioenriched enyne 
substrates that may lead to similar enantioenriched diverse scaffolds, chiral 1,6-enyne (192*) 
was employed as the model substrate. The chiral 1,6-enyne (192*) may result in 
diastereomeric (dia) gold carbene intermediates (193* and dia-193*) via gold(I) mediated 
6-endo-dig cyclization. While the spirooxindole (194*) does not generate any new 
stereogenic center, the enantiomeric ratio for spirooxindole formation should be maintained 
after the reaction (Scheme 29a, cond. 1). In contrast, the quinolone formation keeps all the 
stereogenic centers form the cyclopropane ring except the one from the spiro-carbon, and 
may deliver 195* from 193* and the enantiomer (ent) of 195* from dia-193*. In the 
stereospecific 6-endo-dig cyclization, only one of the gold carbene intermediate will form, 
which lead to the corresponding quinolone. Under such circumstances, retention of the 
enantiomeric ratio should be observed. On the other hand, if the cyclization proceeds in 
stereoselective manner, both gold carbene intermediates (193*, dia-193*) will be generated, 
leading to the quinolone 195* and ent-195* (Scheme 29a, cond. 2). Since the 
1,4-nucleophilic addition and protonation of df-oxindole (196) are stereospecific, the chiral 
induction of 6-endo-dig cyclization can be determined in the same manner as for the 
quinolone formation (Scheme 29a, cond. 3).  
Thus, an optically enriched substrate (172*, 36% ee) was synthesized to perform the 
investigation.
[69]
 As expected, the ee value of spirooxindole (173*) was found to be the same 
as that of the starting material, i.e. 36%. Both quinolone (174*) and df-oxindole (175*) were 
formed, and the reduction of ee value from 36% to 30% and 14% respectively was also 
observed. Therefore, it can be concluded that the 6-endo-dig cyclizations in the gold(I) 
catalyzed quinolone and df-oxindole formation was underwent a non-stereospecific 
cyclization via the mixture of 193* and dia-193* as the intemedates (Scheme 29b). 
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Scheme 29. a) Hypothesis of the stereoselectivity in gold(I) catalyzed divergent scaffold 
synthesis. b) The experimental results of gold(I) catalyzed chirality induction reactions.  
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3.4 Gold(I) catalyzed camphorquinone based 1,6-enyne cycloisomerization  
Incorporation of the oxindole moiety in the enyne allowed to build scaffold diversity 
by variation of the ligands around the gold(I) complexes. In order to expand this idea to 
further intriguing scaffolds, I planned to introduce another natural product based 
ring-system. Camphor is a terpenoid that has been widely applied in medicinal and industrial 
applications.  
The unique bicyclic [2.2.1] core structure distinguishes itself from the oxindole that I 
had successfully used in ligand directed scaffold diversity synthesis. Therefore, I selected the 
camphor derivative, camphorquinone, as starting material to prepare the enyne substrate. A 
similar preparation sequence, i.e. lithium phenylacetylide addition to ketone (197) and 
O-crotylation to the newly generated alcohol, was employed to give the camphor based 
1,6-enynes (198, 199, E:Z = 3:1) in 41% and 26% respectively (Scheme 30a). The strong 
electrophilic phosphite gold(I) catalyst (III), sterically demanding phosphine gold(I) catalyst 
(IIa) and MeOH nucleophile accompanying phosphine gold(I) catalyst (II) were chosen as 
conditions for the initial screening to identify the formation of different scaffolds. 
Interestingly, the gold(I) catalyzed reactions toward the camphor based 1,6-enynes (198, 
199) selectively provided the ring expansion bicyclo[3.2.1]octenones (201, 203) as products, 
via 6-endo-dig gold carbene intermediates (200, 202). Treatment of camphor based 
1,6-enynes (198) with 5 mol% of phosphite gold(I) catalyst (III) formed the scaffold 201 in 
56% yield, For the other conditions, an increase of catalyst loading and of reaction 
temperature were mandatory for achieving full conversion, but they afforded 201 in 
comparatively lower yields (Scheme 30b). The 1,6-enyne substrate (199) was found to be 
inert to the phosphite gold(I) catalyst (III) at room temperature presumably due to the steric 
hindrance. The elevation of reaction temperature and catalyst loading to 10 mol% nicely 
overcame the energy barrier and desired ring expansion product (203) was formed in 63% 
yield (Scheme 30b). The stereochemistry of bicyclic [3.2.1] products (201 and 203) was 
carefully determined by 2D NMR analysis, COSY, HSQC, HMBC, and NOESY.  
From a mechanistic point of view, the bicyclic [3.2.1] system formation (201, 203) 
shares the similar reaction mechanism to quinolone formation (166) via the acyl group 
migration of gold carbene intermediates (200, 202). Intriguingly, the 6-endo-dig cyclizations 
in camphor based 1,6-enynes occur in stereospecific manner to give the enaotiomeric pure 
diastereomers exclusively, which is different from the stereoselective 6-endo-dig cyclization 
in oxindole based 1,6 enynes. 
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Scheme 30. a) Synthesis of camphor based 1,6-enynes (198, 199). b) Cationic gold(I) 
catalyzed of bicyclo[3.2.1]octenone formation (200, 201). 
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3.5 Biological activity of the small molecule compound collection 
  In the previous section, the gold(I) catalyzed oxindole based 1,6-enyne 
cyclo-isomerizations are described to generate divergent products with distinctive core 
structures, i.e. quinolone, spirooxindole, and methyleneoxindole. These core structures cover 
a broad range of NPs, bioactive molecules, and drugs with intriguing mode of functions in 
biological systems. For the quinolone scaffold, orixalone D as NP was isolated from the 
stems of Orixa japonica
[72]
, and euodenine A was isolated from the leaves of Euodia 
asteridula and disclosed as an agonist of the human TLR4 receptor with 3.9 M half 
maximal effective concentration (EC50), which was further improved to 0.39 M by the 
replacement of methyl group to cyclopentantyl group
[73]
. The spirooxindole with the 
tetrahydropyran ring frequently present as the bioactive small molecules, ex. the inhibitor of 
human ion channel Nav1.7
[74]
 or the agonist of CB2 receptor
[75]
. The methylene-oxindole 
scaffold have been widely investigated for the protein-ligand interaction, dihydrobenzofuran 
fused methyleneoxindole is the inhibitor of tyrosine kinase
[76]
 and the derivative, sunitinib, is 
utilizing the receptor tyrosine kinase inhibitory property for the treatment of gastrointestinal 
stromal tumors and advanced renal cell carcinoma
[77]
 (Figure 8). Therefore, it was 
investigated whether the scaffold divergency in the compound collection could result in 
selective bioactivity by utilizing the cell-based screening. 
 The following cell-based screens and data analysis were performed by Compound 
Management and Screening Center (COMAS) in Dortmund, and the biological validation 
experiments were carried out by Dr. Sumersing Patil, a doctoral researcher in Department of 
Chemical Biology at the Max Plank Institute of Molecular Physiology, Dortmund, Germany.  
 
 
 
Figure 8. Representative NPs, bioactive and drug molecules with quinolone, spirooxindole 
or methyleneoxindole scaffold. 
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3.5.1 Cell-based screening of the small molecule compound collection (performed by 
COMAS) 
 The small molecule compound collection was prepared form oxindole based prenylated 
and crotylated 1,6-enynes (130, and 161), leading to three distinctive molecular frameworks, 
df-oxindole, quinolone, and spirooxindole. In total, ca. 60 compounds were tested at 
COMAS in Dortmund for the cell-based screening of biological activities. The cell-based 
screening of these compounds revealed inhibition of the Hedgehog (HH) and Wnt signaling 
pathways, autophagy, and HeLa cell proliferation, as shown in Table 7.  
For the primary screening of HH signaling pathway modulators, the osteogenesis 
assay was performed. C3H/10T1/2 cells were stimulated with SMO agonist, purmorphamine, 
to activate the HH pathway. As a result, C3H/10T1/2 cells differentiate into osteoblast 
producing alkaline phosphatase (ALP). To determine the levels of ALP, CDP-star reagent 
was used, which generated luminescence upon conversion by ALP.
[78]
 In this assay, 
df-oxindoles exhibited selective inhibition of HH signaling pathway. Besides, df-oxindoles 
(134w, 134x) had been identified as the most potent molecules for osteogenesis inhibition 
with half-maximal inhibitory concentration (IC50) in 2.75 and 3.13 µM, respectively. As 
another important signaling cascade, Wnt signaling plays a vital role in cell proliferation, 
migration, polarity, etc. The irregular activation of Wnt has been linked to development 
various types of cancers.
[79]
 The screening of Wnt signaling was performed by using the 
HEK293 reporter cell line, which co-transfected with the human Frizzled-1 receptor and the 
TOPFLASH-driven luciferase reporter gene.
[80]
 The quinolone class of molecules presented 
the dose-dependent inhibition to the Wnt signaling, for instance the quinolone 166p 
displayed the lowest IC50 value (4.2 µM) in this class. Screening of autophagy modulators 
resulted in identification of df-oxindole and quinolone compound collections as inhibitors of 
autophagy with low micromolar concentration. The most potent molecule in the screening is 
quinolone 166l, which inhibited autophagy with IC50 = 4.8 µM. In order to characterize the 
cell proliferation, the IncuCyte ZOOM was applied for collecting time-lapse imaging of cell 
confluency. With the strategy in hand, the small molecule collections were subjected for 
screening and the spriooxindole 165h reduced the proliferation of HeLa cells with IC50 = 
15.4 µM. 
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Table 7. Initial small molecule biological screening for HH, Wnt, and autophagy. 
 
Data are mean values of three independent experiments (n = 3) ± s.d. (standard deviation),  
n.a. (no activity). 
 
 
 
Compound 
Inhibition of HH 
signaling IC50 [µM] 
Inhibition of Wnt 
signaling IC50 [µM] 
Inhibition of 
Autophagy IC50 [µM] 
165a  n.a n.a n.a 
165b (R
1
 = p-MePh) n.a n.a n.a 
165g (R
1
 = p-FPh) n.a n.a n.a 
165h (R
1
 = m-ClPh) n.a n.a n.a 
165k (R
1
 = 3-thiophene) n.a n.a n.a 
165p (R
2
 = 6-OMe) n.a n.a n.a 
165r (R
2
 = 6-F) n.a n.a n.a 
165s (R
2
 = 6-Cl) n.a n.a n.a 
165t (R
2
 = 7-Br) n.a n.a n.a 
165u (R
2
 = 6-OCF3) n.a n.a n.a 
165v (R
3
 = Bn) n.a n.a n.a 
165w (R
3
 = PMB) n.a n.a n.a 
166a n.a 12 (1.32) n.a 
166e (R
1
 = m-ClPh) n.a n.a 5.61 (0.25) 
166g (R
1
 = 3-thiophene) n.a n.a n.a 
166j (R
2
 = 6-OMe) n.a 17 (4.03) n.a 
166k (R
2
 = 6-F) n.a n.a n.a 
166l (R
2
 = 6-Cl) n.a n.a 4.81 (0.25) 
166m (R
2
 = 7-Br) n.a n.a n.a 
166n (R
2
 = 6-OCF3) n.a 8.6 (2.32) n.a 
166o (R
3
 = Bn) 9.6 (2.98) n.a n.a 
166p (R
3
 = PMB) n.a 4.2 (1.35) n.a 
167a n.a n.a n.a 
167f (R
1
 = p-FPh) n.a n.a n.a 
167i (R
1
 = m-ClPh) n.a n.a n.a 
167j (R
1
 = p-BrPh) 6.8 (1.89) n.a n.a 
167l (R
1
 = 3-thiophene)  n.a n.a n.a 
167n (R
2
 = 6,8-diMe) n.a n.a 8.33 (0.11) 
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Compound 
Inhibition of HH 
signaling IC50 [µM] 
Inhibition of Wnt 
signaling IC50 [µM] 
Inhibition of 
Autophagy IC50 [µM] 
167o (R
2
 = 6-OMe) 6.26 (2.56) n.a n.a 
167p (R
2
 = 6-F) n.a n.a n.a 
167q (R
2
 = 6-Cl) n.a n.a 6.88 (0.36) 
167r (R
2
 = 7-Br) n.a n.a n.a 
167s (R
2
 = 6-OCF3) n.a n.a n.a 
167t (R
3
 = Bn) n.a n.a n.a 
167u (R
3
 = PMB) n.a n.a n.a 
134a 5.26 (1.25) n.a 8.92 (0.74) 
134c (R
1
 = m-MePh) n.a n.a n.a 
134d (R
1
 = p-MePh) n.a n.a n.a 
134e (R
1
 = o-OMePh) 6.96 (2.66) 17.03 (6.22) n.a 
134f (R
1
 = m,p-diOMePh) n.a n.a n.a 
134g (R
1
 = p-FPh) n.a n.a n.a 
134l (R
1
 = 3-thiophene) n.a n.a n.a 
134m (R
1
 = n-propyl) n.a n.a n.a 
134n (R
1
 = i-pentyl) n.a n.a n.a 
134o (R
2
 = 6-Me) n.a n.a n.a 
134p (R
2
 = 6-OMe) n.a n.a n.a 
134r (R
2
 = 7-Br) n.a n.a n.a 
134s (R
2
 = 6-F) 6.53 (0.56) 13.65 (3.89) 6.71 (0.79) 
134u (R
2
 = 6-OCF3) n.a n.a n.a 
134v (R
2
 = 6-NO2) n.a n.a n.a 
134t (R
2
 = 6-Cl) n.a n.a 6.47 (0.60) 
134w (R
3
 = Bn) 2.75 (0.62) n.a n.a 
134x (R
3
 = PMB) 3.13 (1.02) n.a n.a 
134y (R
3
 = MOM) 9.56 (3.32) n.a n.a 
134z (R
3
 = SEM) 6.33 (0.65) n.a n.a 
134aa (R
3
 = H) n.a n.a n.a 
 
Figure 16. The most active compounds in each biological screening. 
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3.5.2 Hedgehog Signaling Pathway  
 Among all the biological screening outcomes, the biological mode of action of the 
synthesized small molecules (134w and 134x) for HH signaling pathway modulation was 
investigated. After the genetic mutation studies of fruit fly Drosophila melanogaster in 1980, 
hedgehog (HH)-gene had been identified as the key factor to regulate the embryonic 
development, i.e. the mutation of HH in embryonic cell results in the coat of larvae covering 
with spines. The hedgehog-like phenotype of larvae allowed the gene to be termed as 
HH-gene.
[81]
 A decade later, three mammalian paralogous genes, Sonic HH, Indian HH, and 
Desert HH, had also been discovered to share similar biological behaviors with the HH gene 
from fruit fly.
[82]
 In the development of embryonic cell, they regulate the cell differentiation, 
proliferation, and tissue polarity. In the absence of HH ligand, their membrane bound 
receptor Patched (PTCH) localizes in the cilia, and inhibits the trafficking of 
seven-transmembrane protein smoothened (SMO) to the cilia. In the absence of active SMO 
in the cilia, GLI is phosphorylated by PKA, CK1 and GSK3 beta. The phosphorylated GLI is 
proteolytical processed into GLI repressor form (GLI
R
), which suppress the expression of 
HH target genes (Figure 9a). When the HH binding with PTCH, the lysosomal degradation 
of PTCH takes place and SMO translocate to cilia to initiate the signaling cascade. After the 
localization of active form of GLI (GLI
A
) to the nucleus, it starts to turn on the HH target 
genes, such as Patch1, Gli1 (Figure 9b).
[83]
 
 The dysregulated HH signaling pathway will continuously turn on the HH target gene, 
resulting as the trigger of various human cancers, such as basal cell carcinoma (BCC), 
medulloblastoma, etc. When the PTCH losses the original function by the mutation, the 
SMO constitutively activate the HH target genes as ligand-independent HH activation. 
Alternatively, the over express of HH ligand will activate PTCH and lead to 
ligand-dependent HH activation. By targeting the improper activation of HH signaling, two 
small molecule drugs, vismodegib (GDC0449)
[84]
 and sonidegib (LDE225)
[85]
, were 
developed as the SMO inhibitor for the treatment of BCC (Scheme 10). However, due to the 
recently discovered  mutation of SMO led to resistance to vismodegib
[86]
 Therefore, small 
molecule inhibitors of HH signaling that act via different mode of action in demand.  
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Figure 9. The schematic representation of HH signaling pathway. a) HH signaling pathway 
without HH ligand. b) HH signaling pathway with HH ligand. Reprinted from ref 
[83a]
, copy 
right 2013 Springer Nature, Inc (license number: 4270991022617).  
 
  
Figure 10. The chemical structure of SMO inhibitors, vismodegib and sonidegib.  
 
3.5.3 Target Identification for the Hedgehog Signaling Inhibitor (performed by S. P.)
  
 The df-oxindoles (134w, 134x) displayed potent inhibitory activity of the HH signaling 
pathway in a cell-based osteogenesis assay (Figure 11a). To confirm and determine the HH 
inhibitory activity of df-oxindoles (134w, 134x), orthogonal assays, such as Gli reporter gene 
assay and HH target gene expression by quantitative polymerase chain reaction (qPCR), 
were performed. In the Gli reporter gene assay, the NIH-3T3 cell clones Shh-Light2 cells, 
which are stably transfected with Gli-luciferase and Renilla luciferase reporter plasmids were 
used.
[87]
 The Shh-Light2 cells were treated with purmorphamine and various concentrations 
of compounds. Firefly luciferase was measured as a result of different concentration of 134w 
and 134x. Dose dependent inhibition of firefly luciferase led to IC50 values 1.7 µM for 134w 
and 0.8 µM for 134x (Figure 11b). Additionally, Ptch1 and Gli1 gene expression were 
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monitored in C3H/10T1/2 cells as results of compound treatment.
[88]
 First, HH signaling was 
activated by treatment with purmorphamine followed by compound treatment. 
Dose-dependent suppression of the Ptch1 and Gli1 was observed when different 
concentration of 134w and 134x were applied (Figure 11c, d).   
 
 
 
 
Figure 11. a) The structure of 134w, 134x, and Purmorphamine. b) 134w and 134x inhibit 
Gli-dependent reporter gene expression. c) 134w and 134x inhibit the Hh target gene Ptch1. 
d) 134w and 134x inhibit the Hh target gene Gli1. 
 
Since SMO frequently serves as the HH signaling pathway inhibition target for small 
molecules, such as vismodegib and sonidegib, the boron-dipyrromethene 
(BODIPY)-cyclopamine displacement assay were performed in HEK-293T cells transiently 
transfected with SMO-expressing construct. The BODIPY-cyclopamine binds to cells 
expressing SMO thus providing green fluorescence. Vismodegib, a known SMO inhibitor, 
can replace the BODIPY-cyclopamine from the SMO binding site, which reduce of 
fluorescence signal.  Upon treatment with 134w and 134x, the green fluorescence was 
suppressed certifying the competition between BODIPY-cyclopamine to 134w, 134x (Figure 
12a). Additionally, the translocation of SMO to primary cilium had been prooved to be vital 
for triggering the singling cascade.
[88]
 The co-localization experiments were performed to 
investigate the SMO trafficking to cilium. The SMO agonist, purmorphamine, activates the 
translocation of SMO to the primary cilium, therefore the co-localization of SMO (red) on 
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the cilia (green) is observed. In contrast, the SMO antagonist, vismodegib, prohibited the 
translocation mechanism and the SMO inhibitor 134w and 134x share the similar property to 
vismodegib (Scheme 12b). In this stage, it was concluded that df-oxindole 134w and 134x 
are the HH signaling pathway inhibitor by binding to SMO and preventing the SMO 
trafficking to primary cilia.  
 
 
Figure 12. a) The competition experiment of 134w, 134x to BODIPY-cyclopamine from 
SMO. BODIPY-cyclopamine (green), nuclei (blue, staining with 4’,6-diamidino-2- 
phenylindole, DAPI) b) Visualization experiment for SMO trafficking to primary cilium. 
nuclei (blue, staining with DAPI), Smo (red), cilia (green, acetylated tublin) c) The structure 
of 134w, 134x. d) The structure of BODIPY-cyclopamine, Purmorphamine, and 
Vismodegib. 
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4 Summary  
 The work presented in this thesis focuses on and explores the potential of cationic 
gold(I) catalyzed oxindole derived 1,6-enyne transformations to build structurally distinct 
molecular scaffolds, which could be used to build structurally rich compound collections for 
the exploration of chemical space. The selection of the oxindole fragment was inspired by its 
prevalence in numerous natural and synthetic bioactive molecules and the enyne segment 
had been shown to give cycloisomerization products under transition metal catalysis. The 
oxindole based 1,6-enynes (130 and 161) were prepared in up to 4 steps and then subjected 
to gold(I) catalyzed scaffold transformations. The common gold carbene intermediates (204) 
were generated from the crotylated 1,6-enynes (161) and further rearranged into three 
structurally distinct scaffolds, i.e. spirooxindoles (165, magenta arrow), quinolones (166, 
blue arrows), and df-oxindoles (134, turquoise arrow) by single cleavage rearrangement, acyl 
migration, and O-migration, respectively. The steric and electronic factors of ligands in 
cationic gold(I) catalysts played subtle roles in these transformations to deliver high 
selectivity and satisfactory yields of desired products which were used for further biological 
studies. A small compound collection based on different scaffolds generated via gold(I) 
catalyzed transformations, was subjected to cell-based screening. Interestingly, each 
compound class could deliver bioorthogonally active small molecule, i.e. one of the 
spirooxindoles (165) reduced the proliferation of HeLa cells, a quinolone (166) inhibited the 
Wnt signaling pathway, and one of the df-oxindoles (134) suppressed the HH signaling 
pathway. As the representative example, df-oxindoles (134w, 134x) were further investigated 
to find their biological target and mode of function and were found to prevent the 
translocation of Smo to primary cilia, which ultimately inhibits HH signaling (Scheme 31a). 
Thus, a ”ligand directed divergent scaffold synthesis” (LDS) approach was successfully 
developed to access novel and biologically relevant chemical space and to deliver bioactive 
small molecules. 
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Scheme 31. a) Gold(I) catalyzed ligand directed divergent scaffold synthesis (LDS). b) The 
steric and electronic properties of gold(I) catalysts. 
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5 Experimental section 
5.1 General information 
All commercially obtained chemicals and reagents were used without further purification. 
Dry dichloromethane (DCM), 1,2-dicholoroethane (DCE), tetrahydrofuran (THF), 
dimethylformamide (DMF), and diethyl ether (Et2O) were used the Solvent Purification 
System M-BRAUN Glovebox Technology SPS-800 or purchased from Arcos Organics. All 
reactions were performed in flame dried glassware with dry solvent under argon atmosphere. 
Analytical thin-layer chromatography (TLC) was performed on Merck silica gel aluminum 
plates with F-254 indicator. Compounds were visualized by irradiation with UV light. 
Column chromatography was performed by using silica gel Merck 60 (particle size 
0.040-0.063 mm). 
1
H NMR and 
13
C NMR were recorded on a Bruker DPX300 (300 MHz), 
Bruker DRX400 (400 MHz), Bruker DRX500 (500MHz), Bruker DRX600 (600 MHz) and 
Varian INOVA500 (500 MHz) at 300 K using CDCl3 as solvent. chemical shifts of spectra 
were expressed in parts per million (ppm, δ) and calibrated relative to residual proton and 
carbon signals in deuterated NMR solvent (CDCl3: δ = 7.26 ppm for 
1
H NMR and δ = 77.16 
ppm for 
13
C NMR). Multiplicities are indicated as following: (s = singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet), and coupling constants (J) are represented in Hertz (Hz). 
High resolution mass spectra (HRMS) were recorded on a LTQ Orbitrap mass spectrometer 
coupled to an Acceka HPLC-System (HPLC column: Hypersyl GOLD, 50 mm x 1 mm, 
particle size 1.9 μm, ionization method: electron spray ionization). The enantiomeric excess 
(ee) was measured by HPLC analysis on the machine Agilent 1100. Optical rotations were 
measured in a Schmidt + Haensch Polartronic HH8 polarimeter. The substrates of 
1-methylisatin [2058-74-4] and 1-benzyl-1H-indole-2,3-dione [1217-89-6] were directly 
purchased from Sigma-Aldrich for later studies. The substrate of 1,6-enynes with the 
substituent of (E)-crotyl group were prepared from crotyl bromide [29576-14-5] with a small 
amount of inseparable (Z)-isomer. Inseparable (Z)-isomers were proceeded through the 
1,6-enyne synthesizes and following gold catalyzed cycloisomerization reactions. The ratio 
of (E,Z)-isomers in 1,6-enynes were determined by 
1
H-NMR, and the yield of gold catalyzed 
cycloisomerizations were calculated on the basis of (E,Z)-mixture. The recrystallizations 
were performed from DCM and petroleum ether. 
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5.2 Synthesis of gold(I) catalysts 
The gold complexes (I
[55]
, 
 
II [866641-66-9]
[89]
, IIa [1140531-94-7]
[89]
, IIb
[90]
 and III
[58, 90]
) 
were either purchased from Sigma-Aldrich or synthesized as following procedures : 
 
5.2.I Synthesis of gold(l) catalyst (I)  
 
To a solution of the 1,3-dimesitylimidazolium chloride (S1, 1.0 mmol) in dry DCM was added 
Ag2O (0.5 mmol). The suspension became clear after stirring for 3 h at 23 °C. A solution of 
Au(Me2S)Cl (1.0 mmol) in dry DCM was added dropwise, the reaction mixture was then 
stirred for another 4 h, the solution was filtered through Celite®, and the solvent was partially 
evaporated. Addition of hexane resulted in the precipitation of gold(l) complex (S2). A 
solution of S2 (0.1 mmol) and 2,4,6-trimethoxybenzonitrile (0.1 mmol) in dry DCM was 
added over solid AgSbF6 (0.1 mmol) and stirred for 5 min. The mixture was filtered (HPLC 
Teflon filter) and the solid residue washed with DCM twice. The gold complex precipitated 
from the filtrate upon addition of Et2O. Filtration and air-drying furnished a bright white solid 
(I). 
 
5.2.2 Synthesis of gold(l) catalysts (II, IIa, and IIb)  
 
At 0 °C, to the orange solution of sodium tetrachloroaurate dihydrate (1.0 mmol) in water was 
slowly added 2,2’-thiodiethanol (3.0 mmol) with 45 min stirring. The corresponded phosphine 
ligand (S3, 1.0 mmol) was added to the mixture and a white precipitate was formed during the 
process. After stirring for 20 min, the solid was filtered off, washed with MeOH, and dried in 
vacuo to provide the Au(L)Cl (S4) . 
At 0 °C, to a solution of S4 (0.5 mmol) in dry DCM was added dry MeCN (1.0 mmol), 
followed by the addition of AgSbF6 (0.5 mmol). The reaction mixture was stirred at room 
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temperature overnight, the crude product was filtered through a pad of Celite®, and the 
solvent was again filtered through a syringe filter to give a clear solution. After the evaporation 
of solvent, the white solid was obtained as the desired cationic gold(l) complex (II, IIa, or 
IIb). 
 
5.2.3 Synthesis of gold(l) catalyst (III)  
 
At 0 °C, to a solution of Au(Me2S)Cl (1 mmol) in dry DCM was slowly added a solution of 
tris(2,4-di-tert-butylphenyl) phosphite (S5, 1.05 mmol) in dry DCM and the resulting 
reaction mixture was allowed to warm to room temperature. The reaction was monitored by 
the consumption of the ligand through TLC. After the reaction was complete, the mixture 
was filtered through a syringe filter and concentrated to provide the desired Au(l)Cl complex 
(S6).  
At 0 °C, to a solution of S6 (1.00 mmol) and PhCN (1.1 mmol) in dry DCM was added 
AgSbF6 (1.00 mmol). A white precipitate appeared immediately and the reaction mixture was 
further stirred at room temperature overnight. The resulting reaction mixture was filtered 
through a pad of Celite®, and the solvent was again filtered through a syringe filter to give a 
clear solution. After the evaporation of solvent and drying in vacuo, the white solid was 
obtained as the desired cationic gold(l) complex (III). 
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5.3 Preparation of starting material^ 
 
 
 
General procedure A (N-alkylation) 
To a solution of a isatin analog (112, 10 mmol) in DMF (30 ml) at 0 °C was added NaH 60% 
wt (12 mmol) in one portion and the mixture was stirred at the same temperature for 1 h. To 
the resulting mixture was added dropwise the respective alkyl halide (13 mmol). The mixture 
was warmed to room temperature and stirred overnight. The reaction was quenched with 
NH4Cl(sat) and diluted with EtOAc (100 ml). After extraction, the organic layer was washed 
with H2O (300 ml) three times and once with brine, dried over MgSO4(s), filtered, and 
concentrated under reduced pressure to provide the crude product. The product was purified 
by flash column chromatography (petroleum ether/EtOAc mixture as eluents,) to afford the 
desired product (113). 
 
General procedure B (lithium acetylide addition) 
At -78
 
°C, to a solution of acetylene (2.4 mmol) in THF (30 ml) was slowly added 2.5 M 
nBuLi in hexanes (2.3 mmol) and the mixture was stirred for 1 h at the same temperature. 
The N-protected isatin analog (113, 2 mmol) was then added to the reaction mixture in one 
portion. Afterwards, the resulting mixture was slowly warmed to room temperature and 
stirred overnight. The reaction was quenched with NH4Cl(sat) and extracted with EtOAc (30 
ml) three times. The combined organic layers were washed with brine and dried over 
MgSO4(s). After concentration under reduced pressure, the crude product was purified by 
flash column chromatography (EtOAc/petroleum ether or DCM/EtOAc mixture as eluents,) 
to afford the desired product (114 or 115). 
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General procedure C (desilylation) 
To a soultion of TMS acetylene (2.0 mmol) in MeOH (5 ml) at room temperature was added 
K2CO3 (373 mg, 2.7 mmol) in one portion. The resulting suspension mixture was stirred for 
2 h and then quenched with NH4Cl(sat). The mixture was extracted with EtOAc for three 
times, and the combined organic phases were dried over MgSO4, filtered and concentrated 
under reduced pressure. The crude product (116) was subjected to next step without further 
purification. 
 
General procedure D (allylation) 
To a solution of the propargyl alcohol (114 or 116, 0.5 mmol) in DMF (5 ml) at 0 °C was 
added NaH 60% wt (0.55 mmol) in one portion and the mixture was stirred at same 
temperature for 1 h. To the resulting mixture was added dropwise the respective allylic 
halide (0.6 mmol). The mixture was warmed to room temperature and stirred overnight. The 
reaction was quenched with NH4Cl(sat) and diluted with EtOAc (50 ml). After extraction, the 
organic layer was washed with H2O (50 ml) three times and once with brine, dried over 
MgSO4(s), filtered, and concentrated under reduced pressure to provide the crude product. 
The product was purified by flash column chromatography (petroleum ether/EtOAc mixture 
as eluents,) to afford the desired product (117). 
 
1,5-dimethylindoline-2,3-dione (112a) was prepared according to the general procedure A, 
by using 5-methylindoline-2,3-dione (150 mg, 0.93 mmol) and 
iodomethane. After silica gel column chromatography with 
EtOAc/petroleum ether = 1/2 (Rf = 0.30) as eluents, the desired product 
was obtained in 89% yield (145 mg, 0.83 mmol) as a red solid. The analytical data were 
identical to literature data.
[91]
 
1
H NMR (500 MHz, CDCl3) δ 7.41 (s, 1H), 7.40 (d, J = 8.0 
Hz, 1H), 6.78 (d, J = 8.0 Hz, 1H), 3.23 (s, 3H), 2.34 (s, 3H). 
 
 5-methoxy-1-methylindoline-2,3-dione (112b) was prepared according to the general 
procedure A, by using 5-methoxyindoline-2,3-dione (1074 mg, 6.06 mmol) 
and iodomethane. After silica gel column chromatography with 
EtOAc/petroleum ether = 1/2 (Rf = 0.23) as eluents, the desired product 
was obtained in 89% yield (1026 mg, 5.37 mmol) as a black solid. The analytical data were 
identical to literature data.
[92]
 
1
H NMR (400 MHz, CDCl3) δ 7.13 (dd, J = 8.5, 2.7 Hz, 1H), 
7.09 (d, J = 2.7 Hz, 1H), 6.79 (d, J = 8.5 Hz, 1H), 3.78 (s, 3H), 3.19 (s, 3H). 
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1,5,7-trimethylindoline-2,3-dione (112c) was prepared according to the general procedure 
A, by using 5,7-dimethylindoline-2,3-dione (1000 mg, 5.71 mmol) and 
iodomethane. After silica gel column chromatography with EtOAc/DCM = 
1/2 (Rf = 0.3) as eluents, the desired product was obtained in 72% yield 
(781 mg, 4.13 mmol) as a dark red solid. 
1
H NMR (500 MHz, CDCl3) δ 7.25 (s, 1H), 7.13 
(s, 1H), 3.48 (s, 3H), 2.51 (s, 3H), 2.27 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 184.15, 
159.49, 146.92, 142.83, 133.72, 123.83, 121.71, 118.76, 29.78, 20.47, 18.79. HRMS (ESI): 
Calcd for (M + H)
+
 [C11H12O2N]
+
: 190.0863, found: 190.0869. 
 
5-fluoro-1-methylindoline-2,3-dione (112d) was prepared according to the general 
procedure A, by using 5-fluoroindoline-2,3-dione (1001 mg, 6.06 mmol) and 
iodomethane. After silica gel column chromatography with 
EtOAc/petroleum ether = 1/2 (Rf = 0.3) as eluents, the desired product was 
obtained in 87% yield (945 mg, 5.27 mmol) as a dark red solid. The analytical data were 
identical to literature data.
[91]
 
1
H NMR (400 MHz, CDCl3) δ 7.39 – 7.25 (m, 2H), 6.89 (dd, J 
= 8.5, 3.6 Hz, 1H), 3.26 (s, 3H). 
 
5-chloro-1-methylindoline-2,3-dione (112e) was prepared according to the general 
procedure A, by using 5-chloroindoline-2,3-dione (1100 mg, 6.06 mmol) and 
iodomethane. After silica gel column chromatography with 
EtOAc/petroleum ether = 1/2 (Rf = 0.33) as eluents, the desired product was 
obtained in 96% yield (1142 mg, 5.84 mmol) as a red solid. The analytical data were 
identical to literature data.
[91]
 
1
H NMR (400 MHz, CDCl3) δ 7.55 (dd, J = 8.3, 2.2 Hz, 1H), 
7.52 (d, J = 2.2 Hz, 1H), 6.86 (d, J = 8.3 Hz, 1H), 3.23 (s, 3H). 
 
6-bromo-1-methylindoline-2,3-dione (112f) was prepared according to the general 
procedure A, by using 6-bromoindoline-2,3-dione (1370 mg, 6.06 mmol) 
and iodomethane. After silica gel column chromatography with 
EtOAc/petroleum ether = 1/2 (Rf = 0.65) as eluents, the desired product was 
obtained in 80% yield (1162 mg, 4.84 mmol) as an orange solid. The analytical data were 
identical to literature data.
[92]
 
1
H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 8.0 Hz, 1H), 7.30 
(dd, J = 8.0, 1.5 Hz, 1H), 7.10 (d, J = 1.5 Hz, 1H), 3.26 (s, 3H). 
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1-methyl-5-nitroindoline-2,3-dione (112g) was prepared according to the general procedure 
A, by using 5-nitroindoline-2,3-dione (800 mg, 4.16 mmol) and 
iodomethane. After silica gel column chromatography with 
EtOAc/petroleum ether = 1/2 (Rf = 0.13) as eluents, the desired product 
was obtained in 99% yield (849 mg, 4.12 mmol) as a brown solid. The analytical data were 
identical to literature data.
[93] 1
H NMR (500 MHz, CDCl3) δ 8.56 (dd, J = 8.7, 2.3 Hz, 1H), 
8.48 (d, J = 2.3 Hz, 1H), 7.05 (d, J = 8.7 Hz, 1H), 3.36 (s, 3H). 
 
1-methyl-5-(trifluoromethoxy)indoline-2,3-dione (112h) was prepared according to the 
general procedure A, by using 5-(trifluoromethoxy)indoline-2,3-dione (420 
mg, 1.82 mmol) and iodomethane. After silica gel column chromatography 
with EtOAc/petroleum ether = 1/2 (Rf = 0.35) as eluents, the desired 
product was obtained in 94% yield (418 mg, 1.71 mmol) as a red solid. 
1
H NMR (400 MHz, 
CDCl3) δ 7.56 – 7.38 (m, 2H), 6.95 (d, J = 8.3 Hz, 1H), 3.26 (s, 3H). 
13
C NMR (101 MHz, 
CDCl3) δ 182.5, 158.0, 149.9, 145.4, 145.4, 131.3, 120.5 (q, J = 258.2 Hz), 118.5, 118.0, 
111.2, 26.5. HRMS (ESI): Calcd for (M + H)
+
 [C10H7O3NF3]
+
: 246.0373, found: 246.0379. 
  
1-(4-methoxybenzyl)indoline-2,3-dione (112i) was prepared according to the general 
procedure A, by using indoline-2,3-dione (2.000 g, 13.59 mmol) and 
4-methoxybenzyl chloride. After silica gel column chromatography with 
EtOAc/petroleum ether = 1/2 (Rf = 0.53) as eluents, the desired product was 
obtained in 95% yield (3.452 g, 12.91 mmol) as an orange solid. The analytical data were 
identical to literature data.
[94]
 
1
H NMR (400 MHz, CDCl3) δ 7.60 (dd, J = 7.6, 0.8 Hz, 1H), 
7.48 (td, J = 7.6, 1.3 Hz, 1H), 7.31-7.22 (m, 2H), 7.08 (t, J = 7.6 Hz, 1H), 6.89 – 6.85 (m, 
2H), 6.80 (d, J = 8.0 Hz, 1H), 4.87 (s, 2H), 3.79 (s, 3H). 
 
1-(methoxymethyl)indoline-2,3-dione (112j) was prepared according to the general 
procedure A, by using indoline-2,3-dione (2.000 g, 13.95 mmol) and 
chloromethyl methyl ether. After silica gel column chromatography with 
EtOAc/petroleum ether = 1/2 (Rf = 0.51) as eluents, the desired product was 
obtained in 64% yield (1.662 g, 8.69 mmol) as an orange solid. The analytical data were 
identical to the literature data.
[95] 1
H NMR (500 MHz, CDCl3) δ 7.65 (d, J = 7.7 Hz, 1H), 
7.62 (td, J = 7.7, 1.2 Hz, 1H), 7.18 (t, J = 7.7 Hz, 1H), 7.12 (d, J = 7.7 Hz, 1H), 5.16 (s, 2H), 
3.38 (s, 3H). 
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1-((2-(trimethylsilyl)ethoxy)methyl)indoline-2,3-dione (112k) was prepared according to 
the general procedure A, by using indoline-2,3-dione (2.000 g, 13.59 mmol) 
and 2-(trimethylsilyl)ethoxymethyl chloride. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/2 (Rf = 0.79) as eluents, 
the desired product was obtained in 97% yield (3.640 g, 13.12 mmol) as an orange solid. The 
analytical data were identical to the literature data.
[96]
 
1
H NMR (500 MHz, CDCl3) δ 7.69 – 
7.60 (m, 2H), 7.18 (td, J = 7.6, 0.7 Hz, 1H), 7.14 (d, J = 8.2 Hz, 1H), 5.18 (s, 2H), 3.60 (dd, 
J = 8.3, 7.8 Hz, 2H), 0.93 (dd, J = 8.3, 7.8 Hz, 2H), -0.02 (s, 9H). 
 
 
1-(((tert-butyldimethylsilyl)oxy)methyl)indoline-2,3-dione (141) was prepared by 
following procedure. A solution of isatin (139, 2.5 g, 17.0 mmol) in dry 
THF (125 ml) was added paraformaldehyde (15.3 g, 0.17 mol) and 
K2CO3(s) (2.3 g, 17.0 mmol). The heterogeneous mixture was stirred at 
room temperature till the indication of full convertion by TLC analysis with 
EtOAc/petroleum ether = 1/2 (Rf = 0.18) as eluents. The mixture was filtered through a shout 
pad of celite to remove the insoluable residues. NH4Cl(sat.) was added to the filtrate and the 
resulting mixture was extracted with EtOAc for three times, and the combined organic 
phases were washed with water, dried over MgSO4, filtered and concentrated under reduced 
pressure. The crude product (140) was obtained in 77% yield (2.328 g, 13.1 mmol) and 
subjected to next step without further purification. At 0 °C, to the solution of alcohol (140, 
2.328 g, 13.1 mmol) in dry DCM (100 ml) was added imidazole (1.047 g, 15.8 mmol) and 
TBSCl (2.179 g, 14.5 mmol). The resulting mixture was stirred at room temperature for 1 h 
and quenched with NH4Cl(sat.). The organic layer was dried over anhydrous MgSO4, filtered, 
and concentrated under reduced pressure. The residue was purified by silica gel column 
chromatography with DCM/petroleum ether = 2/1 (Rf = 0.45) as eluents and the desired 
product was obtained in 87% yield (3.323 g, 11.4 mmol) as a pale yellow solid. mp: 72 °C  
1
H NMR (500 MHz, CDCl3) δ 7.65 – 7.60 (m, 1H), 7.16 (t, J = 7.6 Hz, 1H), 7.13 (d, J = 7.9 
Hz, 1H), 5.34 (s, 1H), 0.87 (s, 5H), 0.12 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 183.42, 
157.38, 150.50, 138.64, 125.49, 124.21, 117.59, 111.89, 64.75, 25.72, 18.14, -5.14. HRMS 
(ESI): Calcd for (M + H)
+
 [C15H22O3NSi]
+
: 292.1364, found: 292.1365. 
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3-hydroxy-1-methyl-3-((trimethylsilyl)ethynyl)indolin-2-one (115) was prepared 
according to the general procedure B, by using 1-methylisatin (1.172 g, 
7.27 mmol) and trimethylsilylacetylene. After silica gel column 
chromatography with EtOAc/DCM = 1/15 (Rf = 0.32) as eluents, the 
desired product was obtained in 69% yield (1.307 g, 5.04 mmol) as a pale yellow solid. The 
analytical data were identical to the literature data.
[97]
 
1
H NMR (300 MHz, CDCl3) δ 7.53 (d, 
J = 7.6 Hz, 1H), 7.34 (t, J = 7.6 Hz, 1H), 7.12 (t, J = 7.6 Hz, 1H), 6.82 (d, J = 7.6 Hz, 1H), 
4.08 (s, 1H), 3.18 (s, 3H), 0.13 (s, 9H). 
 
3-hydroxy-1-methyl-3-(phenylethynyl)indolin-2-one (114a) was prepared according to the 
general procedure B, by using 1-methylisatin (139, 1.000 g, 6.21 
mmol) and phenylacetylene. After silica gel column chromatography 
with EtOAc/petroleum ether = 1/2 (Rf = 0.32) as eluents, the desired 
product was obtained in 81% yield (1.326 g, 5.04 mmol) as a pale yellow solid. The 
analytical data were identical to the literature data.
[98]
 
1
H NMR (500 MHz, CDCl3) δ 7.61 
(dd, J = 7.6, 0.7 Hz, 1H), 7.46 – 7.40 (m, 2H), 7.38 (td, J = 7.6, 1.2 Hz, 1H), 7.34 – 7.21 (m, 
3H), 7.16 (td, J = 7.6, 0.7 Hz, 1H), 6.85 (d, J = 7.6 Hz, 1H), 3.86 (s, 1H), 3.23 (s, 3H). 
 
3-hydroxy-1-methyl-3-(o-tolylethynyl)indolin-2-one (114b) was prepared according to the 
general procedure B, by using 1-methylisatin (139, 300 mg, 1.86 
mmol) and 2-ethynyltoluene. After silica gel column chromatography 
with EtOAc/DCM = 1/10 (Rf = 0.35) as eluents, the desired product 
was obtained in 88% yield (454 mg, 1.64 mmol) as a white solid. mp: 163 °C 
1
H NMR (500 
MHz, CDCl3) δ 7.61 (dd, J = 7.6, 0.7 Hz, 1H), 7.42 – 7.34 (m, 2H), 7.24 – 7.19 (m, 1H), 
7.19 – 7.14 (m, 2H), 7.09 (t, J = 7.6 Hz, 1H), 6.87 (d, J = 7.6 Hz, 1H), 3.63 (s, 1H), 3.25 (s, 
3H), 2.39 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 174.29, 143.08, 141.06, 132.42, 130.45, 
129.44, 129.39, 129.02, 125.49, 124.71, 123.83, 121.54, 108.93, 89.61, 85.37, 69.77, 26.70, 
20.65. HRMS (ESI): Calcd for (M + H)
+
 [C18H16O2N]
+
: 278.1176, found: 278.1176. 
 
3-hydroxy-1-methyl-3-(m-tolylethynyl)indolin-2-one (114c) was prepared according to the 
general procedure B, by using 1-methylisatin (139, 300 mg, 1.86 
mmol) and 3-ethynyltoluene. After silica gel column chromatography 
with EtOAc/DCM = 1/15 (Rf = 0.32) as eluents, the desired product 
was obtained in 90% yield (466 mg, 1.68 mmol) as a pale yellow solid. mp: 161 °C 
1
H 
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NMR (500 MHz, CDCl3) δ 7.61 (d, J = 7.6 Hz, 1H), 7.37 (t, J = 7.6 Hz, 1H), 7.28 – 7.21 (m, 
2H), 7.20 – 7.08 (m, 3H), 6.85 (d, J = 7.6 Hz, 1H), 3.84 (s, 1H), 3.23 (d, J = 0.9 Hz, 3H), 
2.27 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 174.10, 143.21, 138.04, 132.78, 130.59, 
130.00, 129.25, 129.12, 128.23, 124.85, 123.86, 121.55, 108.96, 86.69, 85.29, 69.69, 26.77, 
21.24. HRMS (ESI): Calcd for (M + Na)
+
 [C18H15O2NNa]
+
: 300.0995, found: 300.1004. 
 
3-hydroxy-1-methyl-3-(p-tolylethynyl)indolin-2-one (114d) was prepared according to the 
general procedure B, by using 1-methylisatin (139, 500 mg, 3.10 
mmol) and 4-ethynyltoluene. After silica gel column 
chromatography with EtOAc/DCM = 1/15 (Rf = 0.34) as eluents, the 
desired product was obtained in 88% yield (755 mg, 2.72 mmol) as a yellow solid The 
analytical data were identical to the literature data.
[98]
 
1
H NMR (500 MHz, CDCl3) δ 7.61 (d, 
J = 7.6 Hz, 1H), 7.37 (t, J = 7.6 Hz, 1H), 7.32 (d, J = 8.0 Hz, 2H), 7.15 (t, J = 7.6 Hz, 1H), 
7.06 (d, J = 8.0 Hz, 2H), 6.84 (d, J = 7.6 Hz, 1H), 3.82 (s, 1H), 3.23 (s, 3H), 2.32 (s, 3H). 
 
3-hydroxy-3-((2-methoxyphenyl)ethynyl)-1-methylindolin-2-one (114e) was prepared 
according to the general procedure B, by using 1-methylisatin (139, 
300 mg, 1.86 mmol) and 2-ethynylanisole. After silica gel column 
chromatography with EtOAc/DCM = 1/10 (Rf = 0.24) as eluents, the 
desired product was obtained in 92% yield (503 mg, 1.71 mmol) as a white solid. The 
analytical data were identical to the literature data.
[98]
 
1
H NMR (500 MHz, CDCl3) δ 7.62 
(dd, J = 7.6, 0.8 Hz, 1H), 7.40 – 7.33 (m, 2H), 7.29 (ddd, J = 8.0, 7.6, 1.7 Hz, 1H), 7.15 (td, J 
= 8.0, 0.8 Hz, 1H), 6.90 – 6.81 (m, 3H), 3.85 (s, 3H), 3.24 (s, 3H). 
 
3-hydroxy-3-((4-methoxyphenyl)ethynyl)-1-methylindolin-2-one (114f) was prepared 
according to the general procedure B, by using 1-methylisatin (139, 
300 mg, 1.86 mmol) and 4-ethynylanisole. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/2 (Rf = 0.33) as 
eluents, the desired product was obtained in 90% yield (491 mg, 1.67 mmol) as a pale yellow 
solid. The analytical data were identical to the literature data.
[99] 1H NMR (600 MHz, 
Chloroform-d) δ 7.61 (d, J = 7.8 Hz, 1H), 7.39 (td, J = 7.8, 1.1 Hz, 1H), 7.19 (t, J = 7.8 Hz, 
1H), 7.17 (t, J = 7.8 Hz, 1H), 7.04 (d, J = 7.8 Hz, 1H), 6.98 – 6.94 (m, 1H), 6.91 – 6.85 (m, 
2H), 3.77 (s, 3H), 3.25 (s, 3H). 
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3-((3,4-dimethoxyphenyl)ethynyl)-3-hydroxy-1-methylindolin-2-one (114g) was prepared 
according to the general procedure B, by using 1-methylisatin (139, 
100 mg, 0.62 mmol) and 3,4-dimethoxyphenyl acetylene. After 
silica gel column chromatography with EtOAc/DCM = 1/6 (Rf = 
0.35) as eluents, the desired product was obtained in 90% yield (180 mg, 0.56 mmol) as a 
pale yellow solid. mp: 160 °C 
1
H NMR (500 MHz, CDCl3) δ 7.58 (dd, J = 7., 0.6 Hz, 1H), 
7.28 (td, J = 7.6, 1.1 Hz, 1H), 7.09 (td, J = 7.6, 0.6 Hz, 1H), 6.96 (dd, J = 8.3, 1.8 Hz, 1H), 
6.87 (d, J = 1.8 Hz, 1H), 6.74 (d, J = 7.6 Hz, 1H), 6.63 (d, J = 8.3 Hz, 1H), 5.12 (s, 1H), 3.77 
(s, 3H), 3.68 (s, 3H), 3.12 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 174.32, 149.79, 148.32, 
142.76, 130.17, 129.39, 125.44, 124.52, 123.61, 114.62, 113.74, 110.71, 108.75, 86.27, 
84.24, 69.53, 55.71, 26.49. HRMS (ESI): Calcd for (M + Na)
+
 [C19H17O4NNa]
+
: 346.1050, 
found: 346.1055. 
 
3-((4-fluorophenyl)ethynyl)-3-hydroxy-1-methylindolin-2-one (114h) was prepared 
according to the general procedure B, by using 1-methylisatin (139, 
288 mg, 1.79 mmol) and 1-ethynyl-4-fluorobenzene. After silica gel 
column chromatography with EtOAc/petroleum ether = 1/2 (Rf = 
0.32) as eluents, the desired product was obtained in 84% yield (422 mg, 1.50 mmol) as a 
white solid. mp: 159 °C 
1
H NMR (500 MHz, CDCl3) δ 7.60 (d, J = 7.6 Hz, 1H), 7.45 – 7.34 
(m, 3H), 7.16 (t, J = 7.6 Hz, 1H), 6.96 (t, J = 8.7 Hz, 2H), 6.86 (d, J = 7.6 Hz, 1H), 3.80 (s, 
1H), 3.24 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 174.07, 163.01 (d, J = 250.6 Hz), 143.17, 
134.21 (d, J = 8.6 Hz), 130.66, 129.00, 124.83, 123.93, 117.86 (d, J = 3.5 Hz), 115.68 (d, J = 
22.2 Hz), 109.02, 85.46 (d, J = 1.5 Hz), 85.39, 69.64, 26.79. HRMS (ESI): Calcd for (M + 
H)
+
 [C17H13O2NF]
+
: 282.0925, found: 282.0924. 
 
3-((2,4-difluorophenyl)ethynyl)-3-hydroxy-1-methylindolin-2-one (114i) was prepared 
according to the general procedure B, by using 1-methylisatin (139, 
329 mg, 2.04 mmol) and 1-ethynyl-2,4-difluorobenzene. After silica 
gel column chromatography with EtOAc/petroleum ether = 1/2 (Rf = 
0.33) as eluents, the desired product was obtained in 90% yield (547 mg, 1.83 mmol) as a 
white solid. mp: 159 °C 
1
H NMR (300 MHz, CDCl3) δ 7.61 (d, J = 7.4 Hz, 1H), 7.42 – 7.31 
(m, 2H), 7.16 (t, J = 7.5 Hz, 1H), 6.85 (d, J = 7.8 Hz, 1H), 6.78 (t, J = 8.7 Hz, 2H), 4.18 (s, 
1H), 3.23 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 173.86, 165.06 (dd, J = 21.5, 11.7 Hz), 
161.69 (d, J = 31.0 Hz), 143.16, 134.97 (dd, J = 9.8, 2.5 Hz), 130.75, 128.72, 124.92, 
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124.01, 111.66 (dd, J = 22.0, 3.8 Hz), 109.05, 106.78 (d, J = 15.7 Hz), 104.35 (t, J = 25.5 
Hz), 90.49, 78.93, 69.66, 26.81. HRMS (ESI): Calcd for (M + Na)
+
 [C17H11O2NF2Na]
+
: 
322.0650, found: 322.0655. 
 
3-((2-chlorophenyl)ethynyl)-3-hydroxy-1-methylindolin-2-one (114j) was prepared 
according to the general procedure B, by using 1-methylisatin (139, 
300 mg, 1.86 mmol) and 1-chloro-2-ethynylbenzene. After silica gel 
column chromatography with EtOAc/DCM = 1/10 (Rf = 0.5) as 
eluents, the desired product was obtained in 93% yield (513 mg, 1.72 mmol) as a red solid. 
mp: 165 °C 
1
H NMR (500 MHz, CDCl3) δ 7.63 (d, J = 7.6 Hz, 1H), 7.47 (dd, J = 7.6, 1.6 
Hz, 1H), 7.43 – 7.33 (m, 2H), 7.31 – 7.22 (m, 1H), 7.22 – 7.13 (m, 2H), 6.87 (d, J = 7.6 Hz, 
1H), 3.47 (s, 1H), 3.25 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 173.87, 143.19, 136.65, 
133.86, 130.65, 130.10, 129.32, 128.90, 126.44, 125.00, 123.92, 121.80, 108.98, 90.75, 
83.13, 69.73, 26.79. HRMS (ESI): Calcd for (M + Na)
+
 [C17H12O2NClNa]
+
: 320.0449, 
found: 320.0449. 
 
3-((3-chlorophenyl)ethynyl)-3-hydroxy-1-methylindolin-2-one (114k) was prepared 
according to the general procedure B, by using 1-methylisatin (139, 
337 mg, 2.09 mmol) and 3-chloro-1-ethynylbenzene. After silica gel 
column chromatography with EtOAc/petroleum ether = 1/2 (Rf = 
0.38) as eluents, the desired product was obtained in 79% yield (489 mg, 1.64 mmol) as a 
pale yellow solid. mp: 148 °C 
1
H NMR (500 MHz, CDCl3) δ 7.60 (dd, J = 7.6, 0.8 Hz, 1H), 
7.44 – 7.41 (m, 1H), 7.39 (td, J = 7.6, 1.2 Hz, 1H), 7.34 – 7.27 (m, 2H), 7.19 (t, J = 7.6 Hz, 
1H), 7.17 (td, J = 7.6, 0.8 Hz, 1H), 6.87 (d, J = 7.6 Hz, 1H), 3.86 (s, 1H), 3.24 (s, 3H). 
13
C 
NMR (126 MHz, CDCl3) δ 173.88, 143.23, 134.25, 132.06, 130.80, 130.29, 129.61, 129.44, 
128.77, 124.89, 123.99, 123.48, 109.08, 86.88, 84.95, 69.62, 26.82. HRMS (ESI): Calcd for 
(M + H)
+
 [C17H13O2NCl]
+
: 298.0629, found: 298.0634. 
 
3-((4-bromophenyl)ethynyl)-3-hydroxy-1-methylindolin-2-one (114l) was prepared 
according to the general procedure B, by using 1-methylisatin (139, 
300 mg, 1.86 mmol) and 1-bromo-4-ethynylbenzene. After silica gel 
column chromatography with EtOAc/DCM = 1/15 (Rf = 0.31) as 
eluents, the desired product was obtained in 85% yield (543 mg, 1.59 mmol) as a pale yellow 
solid. The analytical data were identical to the literature data.
[98]
 
1
H NMR (300 MHz, 
84 
 
CDCl3) δ 7.63 (d, J = 7.4 Hz, 1H), 7.48 – 7.35 (m, 3H), 7.32 – 7.24 (m, 2H), 7.18 (t, J = 7.7 
Hz, 1H), 6.86 (d, J = 7.7 Hz, 1H), 4.42 (s, 1H), 3.24 (s, 3H). 
 
3-hydroxy-1-methyl-3-((2-(trifluoromethyl)phenyl)ethynyl)indolin-2-one (114m) was 
prepared according to the general procedure B, by using 
1-methylisatin (139, 271 mg, 1.68 mmol) and 
1-ethynyl-2-(trifluoromethyl)benzene. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/2 (Rf = 0.32) as eluents, the desired 
product was obtained in 78% yield (432 mg, 1.30 mmol) as a pale yellow solid. The 
analytical data were identical to the literature data.
[98]
 
1
H NMR (500 MHz, CDCl3) δ 7.66 – 
7.54 (m, 3H), 7.49 – 7.34 (m, 3H), 7.17 (td, J = 7.6, 0.8 Hz, 1H), 6.86 (d, J = 7.6 Hz, 1H), 
3.71 (s, 1H), 3.24 (s, 3H).  
 
3-hydroxy-1-methyl-3-(thiophen-3-ylethynyl)indolin-2-one (114n) was prepared 
according to the general procedure B, by using 1-methylisatin (139, 
292 mg, 1.81 mmol) and 3-ethynylthiophene. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/10 (Rf = 0.38) as 
eluents, the desired product was obtained in 87% yield (426 mg, 1.58 mmol) as a brown 
solid. mp: 201 °C 
1
H NMR (500 MHz, CDCl3) δ 7.60 (d, J = 7.6 Hz, 1H), 7.48 (d, J = 2.9 
Hz, 1H), 7.38 (t, J = 7.6 Hz, 1H), 7.22 (dd, J = 5.0, 2.9 Hz, 1H), 7.16 (t, J = 7.6 Hz, 1H), 
7.09 (d, J = 5.0 Hz, 1H), 6.86 (d, J = 7.6 Hz, 1H), 3.58 (s, 1H), 3.24 (s, 3H). 
13
C NMR (126 
MHz, CDCl3) δ 173.95, 143.24, 130.68, 130.51, 130.10, 128.92, 125.48, 124.87, 123.89, 
120.82, 109.00, 85.28, 81.77, 69.71, 26.80. HRMS (ESI): Calcd for (M + H)
+
 
[C15H12O2NS]
+
: 270.0583, found: 270.0591. 
 
3-hydroxy-1-methyl-3-(3-methylbut-3-en-1-yn-1-yl)indolin-2-one (114o) was prepared 
according to the general procedure B, by using 1-methylisatin (139, 522 
mg, 3.24 mmol) and 2-methyl-1-buten-3-yne. After silica gel column 
chromatography with EtOAc/DCM = 1/15 (Rf = 0.32) as eluents, the 
desired product was obtained in 88% yield (645 mg, 2.84 mmol) as a yellow solid. 
1
H NMR 
(300 MHz, CDCl3) δ 7.54 (d, J = 7.6 Hz, 1H), 7.33 (t, J = 7.6 Hz, 1H), 7.11 (t, J = 7.6 Hz, 
1H), 6.81 (d, J = 7.6 Hz, 1H), 5.31 (s, 1H), 5.22 (s, 1H), 4.67 (s, 1H), 3.18 (s, 3H), 1.81 (s, 
3H). 
13
C NMR (75 MHz, CDCl3) δ 174.23, 142.88, 130.33, 129.21, 125.66, 124.64, 123.80, 
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123.74, 108.84, 87.28, 84.55, 69.40, 26.61, 23.00. HRMS (ESI): Calcd for (M + H)
+
 
[C14H14O2N]
+
: 228.1019, found: 228.1027. 
 
3-(cyclopropylethynyl)-3-hydroxy-1-methylindolin-2-one (114p) was prepared according 
to the general procedure B, by using 1-methylisatin (139, 522 mg, 3.24 
mmol) and cyclopropylacetylene. After silica gel column 
chromatography with EtOAc/DCM = 1/15 (Rf = 0.33) as eluents, the 
desired product was obtained in 99% yield (729 mg, 3.21 mmol) as a yellow solid. mp: 180 
°C 
1
H NMR (300 MHz, CDCl3) δ 7.50 (d, J = 7.6 Hz, 1H), 7.33 (t, J = 7.6 Hz, 1H), 7.11 (t, 
J = 7.6 Hz, 1H), 6.82 (d, J = 7.6 Hz, 1H), 3.73 (s, 1H), 3.19 (s, 3H), 1.33 – 1.15 (m, 1H), 
0.86 – 0.59 (m, 4H). 13C NMR (75 MHz, CDCl3) δ 174.32, 143.03, 130.33, 129.40, 124.55, 
123.73, 108.82, 91.00, 72.08, 69.25, 26.66, 8.57, 8.53, -0.31. HRMS (ESI): Calcd for (M + 
H)
+
 [C14H14O2N]
+
: 228.1019, found: 228.1022. 
 
3-hydroxy-1-methyl-3-(pent-1-yn-1-yl)indolin-2-one (114q) was prepared according to the 
general procedure B, by using 1-methylisatin (139, 1.000 g, 6.21 
mmol) and 1-pentyne. After silica gel column chromatography with 
EtOAc/petroleum ether = 1/2 (Rf = 0.26) as eluents, the desired 
product was obtained in 72% yield (1.021 g, 4.45 mmol) as a brown solid. mp: 122 °C 
1
H 
NMR (300 MHz, CDCl3) δ 7.52 (dd, J = 7.6, 0.8 Hz, 1H), 7.35 (td, J = 7.6, 1.3 Hz, 1H), 
7.13 (td, J = 7.6, 0.8 Hz, 1H), 6.83 (d, J = 7.6 Hz, 1H), 3.21 (s, 3H), 2.18 (t, J = 7.1 Hz, 2H), 
1.51 (qt, J = 7.4, 7.1 Hz, 2H), 0.93 (t, J = 7.4 Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ 174.42, 
143.12, 130.41, 129.42, 124.58, 123.78, 108.87, 88.03, 77.36, 69.30, 26.69, 21.80, 20.93, 
13.57. HRMS (ESI): Calcd for (M + H)
+
 [C14H16O2N]
+
: 230.1176, found: 230.1184. 
 
3-hydroxy-1-methyl-3-(5-methylhex-1-yn-1-yl)indolin-2-one (114r) was prepared 
according to the general procedure B, by using 1-methylisatin (139, 
200 mg, 1.24 mmol) and 5-methyl-1-hexyne. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/2 (Rf = 0.44) as 
eluents, the desired product was obtained in 51% yield (162 mg, 0.63 mmol) as a brown 
solid. mp: 100 °C 
1
H NMR (300 MHz, CDCl3) δ 7.51 (dd, J = 7.6, 0.8 Hz, 1H), 7.32 (td, J = 
7.6, 1.3 Hz, 1H), 7.11 (td, J = 7.6, 0.8 Hz, 1H), 6.81 (d, J = 7.6 Hz, 1H), 4.12 (s, 1H), 3.18 
(s, 3H), 2.18 (t, J = 7.4 Hz, 2H), 1.66 - 1.50 (m, 1H), 1.36 (td, J = 7.4, 7.4 Hz, 2H), 0.82 (dd, 
J = 6.6, 0.9 Hz, 6H). 
13
C NMR (75 MHz, CDCl3) δ 174.58, 142.96, 130.24, 129.59, 124.51, 
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123.71, 108.78, 88.07, 77.36, 69.25, 37.16, 27.32, 26.61, 22.16, 16.95. HRMS (ESI): Calcd 
for (M + Na)
+
 [C16H19O2NNa]
+
: 280.1308, found: 280.1314. 
 
3-hydroxy-1,5-dimethyl-3-(phenylethynyl)indolin-2-one (114s) was prepared according to 
the general procedure B, by using 112a (88 mg, 0.50 mmol) and 
phenylacetylene. After silica gel column chromatography with 
EtOAc/petroleum ether = 1/2 (Rf = 0.29) as eluents, the desired 
product was obtained in 88% yield (122 mg, 0.44 mmol) as a brown solid. mp: 189 °C 
1
H 
NMR (500 MHz, CDCl3) δ 7.49 – 7.40 (m, 3H), 7.37 – 7.22 (m, 3H), 7.17 (dd, J = 7.9, 0.8 
Hz, 1H), 6.74 (d, J = 7.9 Hz, 1H), 3.73 (s, 1H), 3.22 (s, 3H), 2.37 (s, 3H). 
13
C NMR (126 
MHz, CDCl3) δ 173.96, 140.84, 133.63, 132.21, 130.88, 129.09, 128.92, 128.34, 125.59, 
121.82, 108.75, 86.41, 85.80, 69.79, 26.81, 21.20. HRMS (ESI): Calcd for (M + H)
+
 
[C18H16O2N]
+
: 278.1176, found: 278.1177. 
 
3-hydroxy-5-methoxy-1-methyl-3-(phenylethynyl)indolin-2-one (114t) was prepared 
according to the general procedure B, by using 112b (585 mg, 3.06 
mmol) and phenylacetylene. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/2 (Rf = 0.25) as 
eluents, the desired product was obtained in 82% yield (734 mg, 2.50 mmol) as a brown 
solid. mp: 157 °C 
1
H NMR (500 MHz, CDCl3) δ 7.41 (d, J = 7.1 Hz, 2H), 7.37 – 7.18 (m, 
4H), 6.89 (dd, J = 8.5, 2.5 Hz, 1H), 6.74 (d, J = 8.5 Hz, 1H), 4.41 (s, 1H), 3.82 (s, 3H), 3.19 
(s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 173.96, 156.92, 136.44, 132.18, 130.21, 129.03, 
128.28, 121.78, 115.49, 111.56, 109.52, 86.46, 85.76, 70.00, 56.04, 26.82. HRMS (ESI): 
Calcd for (M + H)
+
 [C18H16O3N]
 +
: 294.1125, found: 294.1126. 
 
3-hydroxy-1,5,7-trimethyl-3-(phenylethynyl)indolin-2-one (114u) was prepared 
according to the general procedure B, by using 112c (400 mg, 2.11 
mmol) and phenylacetylene. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/2 (Rf = 0.32) as 
eluents, the desired product was obtained in 64% yield (393 mg, 1.35 mmol) as a brown 
solid. mp: 172 °C 
1
H NMR (500 MHz, CDCl3) δ 7.43 (d, J = 8.0 Hz, 2H), 7.35 – 7.20 (m, 
4H), 6.90 (s, 1H), 3.59 (s, 1H), 3.48 (s, 3H), 2.51 (s, 3H), 2.31 (s, 3H). 
13
C NMR (126 MHz, 
CDCl3) δ 174.64, 138.38, 134.78, 133.49, 132.19, 129.61, 129.03, 128.31, 123.51, 121.90, 
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120.36, 86.29, 86.09, 69.30, 30.18, 20.86, 18.89.HRMS (ESI): Calcd for (M + H)
+
 
[C19H18O2N]
+
: 292.1332, found: 292.1336. 
 
5-fluoro-3-hydroxy-1-methyl-3-(phenylethynyl)indolin-2-one (114v) was prepared 
according to the general procedure B, by using 112d (400 mg, 2.23 
mmol) and phenylacetylene. After silica gel column 
chromatography with EtOAc/petroleum ether = 2/3 (Rf = 0.34) as 
eluents, the desired product was obtained in 55% yield (345 mg, 1.23mmol) as a brown 
solid. The analytical data were identical to the literature data.
[98]
 
1
H NMR (500 MHz, 
CDCl3) δ 7.44 (d, J = 7.4 Hz, 2H), 7.39 (dd, J = 7.2, 1.9 Hz, 1H), 7.37 – 7.26 (m, 3H), 7.09 
(td, J = 8.7, 2.0 Hz, 1H), 6.79 (dd, J = 8.4, 3.7 Hz, 1H), 4.43 (s, 1H), 3.24 (s, 3H). 
 
5-chloro-3-hydroxy-1-methyl-3-(phenylethynyl)indolin-2-one (114w) was prepared 
according to the general procedure B, by using 112e (400 mg, 2.04 
mmol) and phenylacetylene. After silica gel column chromatography 
with EtOAc/petroleum ether = 1/2 (Rf = 0.53) as eluents, the desired 
product was obtained in 94% yield (574 mg, 1.93 mmol) as a brown solid. The analytical 
data were identical to the literature data.
[98]
 
1
H NMR (500 MHz, CDCl3) δ 7.59 (d, J = 2.0 
Hz, 1H), 7.47 – 7.39 (m, 2H), 7.36 – 7.29 (m, 2H), 7.29 – 7.22 (m, 2H), 6.76 (dd, J = 8.3, 2.1 
Hz, 1H), 4.15 (s, 1H), 3.21 (d, J = 1.9 Hz, 3H). 
 
6-bromo-3-hydroxy-1-methyl-3-(phenylethynyl)indolin-2-one (114x) was prepared 
according to the general procedure B, by using 112f (400 mg, 1.67 
mmol) and phenylacetylene. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/2 (Rf = 0.46) as 
eluents, the desired product was obtained in % yield (492 mg, 1.44 mmol) as a pale yellow 
solid. mp: 177 °C 
1
H NMR (500 MHz, CDCl3) δ 7.46 (d, J = 7.9 Hz, 2H), 7.44 – 7.38 (m, 
4H), 7.34 – 7.23 (m, 9H), 7.00 (d, J = 1.6 Hz, 2H), 3.89 (s, 2H), 3.21 (s, 6H). 13C NMR (126 
MHz, CDCl3) δ 174.03, 144.39, 132.16, 129.22, 128.35, 128.05, 126.71, 126.13, 124.28, 
121.51, 112.56, 86.78, 85.04, 69.29, 26.88. HRMS (ESI): Calcd for (M + Na)
+
 
[C17H12O2NBrNa]
+
: 363.9944, found: 363.9951. 
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3-hydroxy-1-methyl-5-nitro-3-(phenylethynyl)indolin-2-one (114y) was prepared 
according to the general procedure B, by using 112g (400 mg, 1.94 
mmol) and phenylacetylene. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/2 (Rf = 0.22) as 
eluents, the desired product was obtained in 58% yield (346 mg, 1.12 mmol) as a brown 
solid. mp: 176 °C 
1
H NMR (400 MHz, CDCl3) δ 8.48 (d, J = 2.3 Hz, 1H), 8.33 (dd, J = 8.7, 
2.3 Hz, 1H), 7.47 – 7.38 (m, 2H), 7.36 – 7.21 (m, 3H), 6.94 (d, J = 8.7 Hz, 1H), 4.50 (s, 1H), 
3.29 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 174.24, 148.57, 144.41, 132.25, 129.89, 
129.59, 128.46, 127.46, 121.02, 120.96, 108.79, 87.77, 84.00, 68.98, 27.23. HRMS (ESI): 
Calcd for (M + H)
+
 [C17H13O4N2]
+
: 309.0870, found: 309.0868. 
 
3-hydroxy-1-methyl-3-(phenylethynyl)-5-(trifluoromethoxy)indolin-2-one (114z) was 
prepared according to the general procedure B, by using 112h (500 
mg, 2.04 mmol) and phenylacetylene. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/2 (Rf = 0.33) as 
eluents, the desired product was obtained in 68% yield (485 mg, 1.40 mmol) as a yellow 
solid. mp: 130 °C 
1
H NMR (500 MHz, CDCl3) δ 7.50 (s, 1H), 7.43 (d, J = 7.0 Hz, 2H), 7.33 
- 7.24 (m, 4H), 6.84 (d, J = 8.5 Hz, 1H), 3.90 (s, 1H), 3.24 (s, 3H). 
13
C NMR (126 MHz, 
CDCl3) δ 173.93, 145.65, 141.80, 132.24, 130.39, 129.38, 128.42, 123.66, 121.39, 120.66 (d, 
J = 257.0 Hz), 118.91, 109.59, 87.18, 84.79, 69.54, 26.96. HRMS (ESI): Calcd for (M + H)
+
 
[C18H13O3NF3]
+
: 348.0842, found: 348.0848. 
 
1-benzyl-3-hydroxy-3-(phenylethynyl)indolin-2-one (114aa) was prepared according to 
the general procedure B, by using 1-benzyl-1H-indole-2,3-dione (500 
mg, 2.11 mmol) and phenylacetylene. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/2 (Rf = 0.29) as 
eluents, the desired product was obtained in 71% yield (511 mg, 1.51 mmol) as a white solid. 
The analytical data were identical to the literature data.
[98]
 
1
H NMR (500 MHz, CDCl3) δ 
7.62 (d, J = 7.4 Hz, 1H), 7.46 (d, J = 7.0 Hz, 2H), 7.37 – 7.20 (m, 11H), 7.12 (t, J = 7.4 Hz, 
1H), 6.73 (d, J = 7.4 Hz, 1H), 4.94 (s, 2H), 3.58 (s, 1H). 
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3-hydroxy-1-(4-methoxybenzyl)-3-(phenylethynyl)indolin-2-one (114ab) was prepared 
according to the general procedure B, by using 112i (134 mg, 0.50 
mmol) and phenylacetylene. After silica gel column chromatography 
with EtOAc/petroleum ether = 1/2 (Rf = 0.39) as eluents, the desired 
product was obtained in 38% yield (70 mg, 0.19 mmol) as a pale yellow solid. mp: 228 °C 
1
H NMR (500 MHz, DMSO) δ 7.52 (dd, J = 7.6, 0.7 Hz, 1H), 7.47 – 7.34 (m, 4H), 7.34 – 
7.24 (m, 4H), 7.10 (td, J = 7.6, 0.7 Hz, 1H), 6.98 (d, J = 7.6 Hz, 1H), 6.90 (d, J = 8.7 Hz, 
2H), 4.87 (d, J = 15.5 Hz, 1H), 4.82 (d, J = 15.5 Hz, 1H), 3.71 (s, 3H). 
13
C NMR (126 MHz, 
DMSO) δ 173.14, 158.65, 141.50, 131.49, 130.27, 129.88, 129.17, 128.73, 128.65, 127.80, 
124.22, 123.11, 121.17, 114.07, 109.81, 87.58, 84.41, 68.81, 55.04, 42.25. HRMS (ESI): 
Calcd for (M + H)
+
 [C24H20O3N]
+
: 370.1438, found: 370.1452. 
 
3-hydroxy-1-(methoxymethyl)-3-(phenylethynyl)indolin-2-one (114ac) was prepared 
according to the general procedure B, by using 112j (200 mg, 1.05 
mmol) and phenylacetylene. After silica gel column chromatography 
with EtOAc/petroleum ether = 1/3 (Rf = 0.37) as eluents, the desired 
product was obtained in 73% yield (224 mg, 0.76 mmol) as a brown solid. mp: 158 °C 
1
H 
NMR (300 MHz, CDCl3) δ 7.62 (dd, J = 7.6, 0.8 Hz, 1H), 7.44 – 7.37 (m, 2H), 7.34 (dd, J = 
7.6, 1.3 Hz, 1H), 7.31 – 7.22 (m, 3H), 7.17 (td, J = 7.6, 0.8 Hz, 1H), 7.05 (d, J = 7.6 Hz, 1H), 
5.15 (d, J = 11.0 Hz, 1H), 5.11 (d, J = 11.0 Hz, 1H), 4.22 (s, 1H), 3.33 (s, 3H). 
13
C NMR (75 
MHz, CDCl3) δ 174.85, 141.36, 132.16, 130.72, 129.18, 128.68, 128.35, 124.99, 124.37, 
121.62, 110.51, 86.84, 85.44, 71.97, 69.93, 56.52. HRMS (ESI): Calcd for (M + Na)
+
 
[C18H15O3NNa]
+
: 316.0944, found: 316.0950. 
 
3-hydroxy-3-(phenylethynyl)-1-((2-(trimethylsilyl)ethoxy)methyl)indolin-2-one (114ad) 
was prepared according to the general procedure B, by using 112k 
(100 mg, 0.36 mmol) and phenylacetylene. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/5 (Rf = 0.44) as 
eluents, the desired product was obtained in 52% yield (71 mg, 0.19 mmol) as a brown solid. 
mp: 97 °C 
1
H NMR (300 MHz, CDCl3) δ 7.62 (dd, J = 7.6, 0.9 Hz, 1H), 7.47 – 7.23 (m, 
6H), 7.19 (td, J = 7.6, 0.9 Hz, 1H), 7.09 (d, J = 7.6 Hz, 1H), 5.21 (d, J = 11.1 Hz, 1H), 5.15 
(d, J = 11.1 Hz, 1H), 3.69 – 3.56 (m, 2H), 1.69 (s, 1H), 0.99 – 0.87 (m, 2H), -0.05 (s, 9H). 
13
C NMR (75 MHz, CDCl3) δ 174.44, 141.65, 132.19, 130.74, 129.22, 128.56, 128.38, 
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124.93, 124.25, 121.64, 110.64, 86.83, 85.46, 70.04, 69.95, 66.42, 17.85, -1.34. HRMS 
(ESI): Calcd for (M + Na)
+
 [C22H25O3NSiNa]
+
: 402.1496, found: 402.1508. 
 
1-(((tert-butyldimethylsilyl)oxy)methyl)-3-hydroxy-3-(phenylethynyl)indolin-2-one 
(114ae) was prepared according to the general procedure B, by using 
141 (102 mg, 0.35 mmol) and phenylacetylene. After silica gel 
column chromatography with EtOAc/petroleum ether = 1/7 (Rf = 
0.38) as eluents, the desired product was obtained in 91% yield (125 mg, 0.32 mmol) as a 
yellow oil . 
1
H NMR (500 MHz, CDCl3) δ 7.61 (d, J = 7.5 Hz, 1H), 7.45 – 7.40 (m, 2H), 
7.38 (t, J = 7.8 Hz, 1H), 7.34 – 7.26 (m, 3H), 7.18 (t, J = 7.6 Hz, 1H), 7.11 (d, J = 7.9 Hz, 
1H), 5.39 (d, J = 10.2 Hz, 1H), 5.28 (d, J = 10.2 Hz, 1H), 3.70 (s, 1H), 0.86 (s, 9H), 0.12 (d, 
J = 1.3 Hz, 6H). 
13
C NMR (126 MHz, CDCl3) δ 173.14, 141.64, 132.13, 130.64, 129.13, 
128.55, 128.35, 124.82, 124.08, 121.69, 110.77, 86.77, 85.39, 70.02, 65.26, 25.76, 18.08, 
-5.09, -5.15. HRMS (ESI): Calcd for (M + Na)
+
 [C23H27O3NNaSi]
+
: 416.1652, found: 
416.1650. 
 
3-hydroxy-1-methyl-3-((trimethylsilyl)ethynyl)indolin-2-one (116) was prepared 
according to the general procedure C, by using 115 (500 mg, 1.93 mmol) 
as the starting material. Due to the poor solubility and high purity, the 
crude product was obtained as a brown solid in 94% yield (339 mg, 1.81 
mmol) and subjected to next step without further purification. 
1
H NMR (500 MHz, 
DMSO-d6) δ 7.41 (d, J = 7.7 Hz, 1H), 7.37 (td, J = 7.7, 1.1 Hz, 1H), 7.10 (td, J = 7.7, 1.1 Hz, 
1H), 7.05 (s, 1H), 7.03 (d, J = 7.7 Hz, 1H), 3.62 (s, 1H), 3.12 (s, 3H). 
13
C NMR (126 MHz, 
DMSO) δ 172.76, 142.58, 130.10, 130.03, 123.94, 123.05, 109.18, 81.95, 76.32, 68.17, 
26.24. HRMS (ESI): Calcd for (M + H)
+
 [C11H10O2N]
+
: 188.0706, found: 188.0705. 
 
3-(cinnamyloxy)-3-ethynyl-1-methylindolin-2-one (118) was prepared according to the 
general procedure D, by using 116 (225 mg, 1.20 mmol) and cinnamyl 
bromide. After silica gel column chromatography with EtOAc/petroleum 
ether = 1/5 (Rf = 0.35) as eluents, the desired product was obtained in 51% 
yield (186 mg, 0.61 mmol) as a pale yellow solid. mp: 99 °C 
1
H NMR 
(500 MHz, CDCl3) δ 7.53 (d, J = 7.2 Hz, 1H), 7.38 (td, J = 7.8, 1.2 Hz, 1H), 7.36 – 7.33 (m, 
2H), 7.29 (t, J = 7.5 Hz, 2H), 7.22 (t, J = 7.2 Hz, 1H), 7.15 (td, J = 7.6, 0.8 Hz, 1H), 6.83 (d, 
J = 7.8 Hz, 1H), 6.56 (d, J = 15.9 Hz, 1H), 6.30 (dt, J = 15.9, 6.3 Hz, 1H), 4.60 (ddd, J = 
91 
 
11.6, 6.3, 1.3 Hz, 1H), 4.50 (ddd, J = 11.6, 6.3, 1.3 Hz, 1H), 3.17 (s, 3H), 2.71 (s, 1H). 
13
C 
NMR (126 MHz, CDCl3) δ 171.42, 143.31, 136.56, 133.29, 130.86, 128.53, 127.80, 127.18, 
126.60, 125.10, 125.02, 123.59, 108.90, 78.43, 76.50, 73.54, 66.77, 26.52. HRMS (ESI): 
Calcd for (M + Na)
+
 [C20H17O2NNa]
+
: 326.1152, found: 326.1152. 
 
1-methyl-3-((3-methylbut-2-en-1-yl)oxy)-3-(phenylethynyl)indolin-2-one (130a) was 
prepared according to the general procedure D, by using 114a (79 mg, 
0.30 mmol) and 3,3-dimethylallyl bromide. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/7 (Rf = 0.32) as 
eluents, the desired product was obtained in 93% yield (92 mg, 0.28 
mmol) as a brown oil. 
1
H NMR (400 MHz, CDCl3) δ 7.55 (d, J = 7.6 Hz, 1H), 7.46 (d, J = 
6.3 Hz, 2H), 7.36 (t, J = 7.6 Hz, 1H), 7.30 - 7.26 (m, 3H), 7.13 (t, J = 7.6 Hz, 1H), 6.84 (d, J 
= 7.6 Hz, 1H), 5.39 (t, J = 7.1 Hz, 1H), 4.42 (dd, J = 10.4, 7.1 Hz, 1H), 4.35 (dd, J = 10.4, 
7.1 Hz, 1H), 3.23 (s, 3H), 1.72 (s, 3H), 1.64 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 172.08, 
143.41, 138.39, 132.26, 130.54, 129.04, 128.32, 128.27, 125.13, 123.56, 121.98, 120.51, 
108.76, 87.80, 83.98, 74.26, 62.51, 26.60, 25.97, 18.22. HRMS (ESI): Calcd for (M + H)
+
 
[C22H22O2N]
+
: 332.1645, found: 332.1645 
 
1-methyl-3-((3-methylbut-2-en-1-yl)oxy)-3-(o-tolylethynyl)indolin-2-one (130b) was 
prepared according to the general procedure D, by using 114b (50 mg, 
0.18 mmol) and 3,3-dimethylallyl bromide. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/7 (Rf = 0.48) as 
eluents, the desired product was obtained in 64% yield (40 mg, 0.12 
mmol) as an orange oil. 
1
H NMR (500 MHz, CDCl3) δ 7.55 (ddd, J = 7.4, 1.2, 0.5 Hz, 1H), 
7.43 (dd, J = 7.7, 1.3 Hz, 1H), 7.35 (td, J = 7.8, 1.3 Hz, 1H), 7.21 (td, J = 7.5, 1.4 Hz, 1H), 
7.20 – 7.14 (m, 1H), 7.16 – 7.06 (m, 2H), 6.83 (d, J = 7.8 Hz, 1H), 5.45 – 5.34 (m, 1H), 4.51 
(dd, J = 10.6, 7.2 Hz, 1H), 4.42 (dd, J = 10.6, 7.1 Hz, 1H), 3.22 (s, 3H), 2.41 (s, 3H), 1.71 (s, 
3H), 1.65 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 172.09, 143.35, 141.09, 138.29, 132.52, 
130.47, 129.51, 129.07, 128.51, 125.57, 125.01, 123.50, 121.72, 120.56, 108.74, 87.75, 
86.94, 74.28, 62.54, 26.55, 25.95, 20.82, 18.22. HRMS (ESI): Calcd for (M + Na)
+
 
[C23H23O2NNa]
+
: 368.1621, found: 368.1621. 
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1-methyl-3-((3-methylbut-2-en-1-yl)oxy)-3-(m-tolylethynyl)indolin-2-one (130c) was 
prepared according to the general procedure D, by using 114c (131 
mg, 0.47 mmol) and 3,3-dimethylallyl bromide. After silica gel 
column chromatography with EtOAc/petroleum ether = 1/7 (Rf = 
0.29) as eluents, the desired product was obtained in 78% yield (127 
mg, 0.37 mmol) as a brown oil.
 1
H NMR (500 MHz, CDCl3) δ 7.68 (dd, J = 7.6, 0.6 Hz, 
1H), 7.48 (td, J = 7.6, 0.5 Hz, 1H), 7.46 – 7.37 (m, 2H), 7.30 (t, J = 7.6 Hz, 1H), 7.28 – 7.23 
(m, 2H), 6.96 (d, J = 7.6 Hz, 1H), 5.52 (t, J = 7.4 Hz, 1H), 4.57 (dd, J = 10.5, 7.4 Hz, 1H), 
4.50 (dd, J = 10.5, 7.4 Hz, 1H), 3.35 (s, 3H), 2.42 (s, 3H), 1.85 (s, 3H), 1.78 (s, 3H). 
13
C 
NMR (126 MHz, CDCl3) δ 172.12, 143.39, 138.33, 138.02, 132.85, 130.50, 129.93, 129.30, 
128.36, 128.22, 125.11, 123.54, 121.76, 120.56, 108.73, 88.06, 83.58, 74.25, 62.50, 26.57, 
25.97, 21.25, 18.22. HRMS (ESI): Calcd for (M + Na)
+
 [C23H23O2NNa]
+
: 368.1621, found: 
368.1623. 
 
1-methyl-3-((3-methylbut-2-en-1-yl)oxy)-3-(p-tolylethynyl)indolin-2-one (130d) was 
prepared according to the general procedure D, by using 114d (100 
mg, 0.36 mmol) and 3,3-dimethylallyl bromide. After silica gel 
column chromatography with EtOAc/petroleum ether = 1/7 (Rf = 
0.33) as eluents, the desired product was obtained in 90% yield (112 
mg, 0.32 mmol) as a brown oil. 
1
H NMR (500 MHz, CDCl3) δ 7.55 (d, J = 7.5 Hz, 1H), 7.40 
– 7.30 (m, 3H), 7.12 (t, J = 7.5 Hz, 1H), 7.08 (d, J = 7.7 Hz, 2H), 6.81 (d, J = 7.5 Hz, 1H), 
5.39 (t, J = 6.5 Hz, 1H), 4.42 (dd, J = 8.0, 6.5 Hz, 1H), 4.36 (dd, J = 8.0, 6.5 Hz, 1H), 3.21 
(s, 3H), 2.31 (s, 3H), 1.71 (s, 3H), 1.64 (s, 3H).
 13
C NMR (126 MHz, CDCl3) δ 172.05, 
143.30, 139.16, 138.13, 132.06, 130.40, 129.00, 128.28, 124.99, 123.42, 120.52, 118.82, 
108.66, 87.95, 83.25, 74.22, 62.37, 26.45, 25.86, 21.53, 18.12. HRMS (ESI): Calcd for (M + 
H)
+
 [C23H24O2N]
+
: 346.1802, found: 346.1804. 
 
3-((2-methoxyphenyl)ethynyl)-1-methyl-3-((3-methylbut-2-en-1-yl)oxy)indolin-2-one 
(130e) was prepared according to the general procedure D, by using 
114e (100 mg, 0.34 mmol) and 3,3-dimethylallyl bromide. After silica 
gel column chromatography with EtOAc/petroleum ether = 1/7 (Rf = 
0.16) as eluents, the desired product was obtained in 61% yield (75 
mg, 0.21 mmol) as a brown oil. 
1
H NMR (500 MHz, CDCl3) δ 7.57 (d, J = 7.6 Hz, 1H), 7.40 
(dd, J = 7.6, 1.5 Hz, 1H), 7.33 (td, J = 7.6, 0.5 Hz, 1H), 7.31 – 7.26 (m, 1H), 7.11 (t, J = 7.6 
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Hz, 1H), 6.90 – 6.78 (m, 3H), 5.41 (t, J = 7.3 Hz, 1H), 4.55 (dd, J = 10.4, 7.3 Hz, 1H), 4.48 
(dd, J = 10.4, 7.3 Hz, 1H), 3.83 (s, 3H), 3.21 (s, 3H), 1.72 (s, 3H), 1.67 (s, 3H). 
13
C NMR 
(126 MHz, CDCl3) δ 172.10, 160.79, 143.41, 138.14, 133.99, 130.47, 130.39, 128.61, 
125.23, 123.43, 120.74, 120.36, 111.35, 110.86, 108.64, 87.64, 84.76, 74.33, 62.49, 55.87, 
26.53, 25.97, 18.20. HRMS (ESI): Calcd for (M + Na)
+
 [C23H24O3NNa]
+
: 384.1570, found: 
384.1574. 
 
3-((3,4-dimethoxyphenyl)ethynyl)-1-methyl-3-((3-methylbut-2-en-1-yl)oxy)indolin-2-on
e (130f) was prepared according to the general procedure D, by 
using 114g (223 mg, 0.69 mmol) and 3,3-dimethylallyl bromide. 
After silica gel column chromatography with EtOAc/petroleum 
ether = 1/1 (Rf = 0.59) as eluents, the desired product was obtained 
in 94% yield (256 mg, 0.64 mmol) as a brown oil. 
1
H NMR (400 MHz, CDCl3) δ 7.54 (dd, J 
= 7.4, 0.6 Hz, 1H), 7.33 (td, J = 7.8, 1.1 Hz, 1H), 7.11 (t, J = 7.5 Hz, 1H), 7.05 (dd, J = 8.3, 
1.8 Hz, 1H), 6.94 (d, J = 1.8 Hz, 1H), 6.81 (d, J = 7.8 Hz, 1H), 6.74 (d, J = 8.4 Hz, 1H), 5.37 
(t, J = 7.2 Hz, 1H), 4.42 – 4.32 (m, 1H), 4.32 – 4.23 (m, 1H), 3.83 (s, 3H), 3.81 (s, 3H), 3.20 
(s, 3H), 1.69 (s, 3H), 1.61 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 172.05, 149.92, 148.42, 
143.23, 138.28, 130.41, 128.04, 125.66, 124.95, 123.44, 120.33, 114.66, 113.87, 110.75, 
108.68, 87.72, 82.36, 74.22, 62.25, 55.92, 55.85, 26.47, 25.87, 18.10. HRMS (ESI): Calcd 
for (M + Na)
+
 [C24H25O4NNa]
+
: 414.1676, found: 414.1688. 
 
3-((4-fluorophenyl)ethynyl)-1-methyl-3-((3-methylbut-2-en-1-yl)oxy)indolin-2-one 
(130g) was prepared according to the general procedure D, by using 
114h (100 mg, 0.36 mmol) and 3,3-dimethylallyl bromide. After 
silica gel column chromatography with EtOAc/petroleum ether = 1/7 
(Rf = 0.37) as eluents, the desired product was obtained in 74% yield 
(92 mg, 0.26 mmol) as a brown oil. 
1
H NMR (500 MHz, CDCl3) δ 7.54 (dd, J = 7.6, 0.8 Hz, 
1H), 7.48 – 7.40 (m, 2H), 7.36 (td, J = 7.6, 0.8 Hz, 1H), 7.13 (td, J = 7.6, 0.8 Hz, 1H), 6.97 
(t, J = 8.8 Hz, 2H), 6.84 (d, J = 7.6 Hz, 1H), 5.41 – 5.35 (m, 1H), 4.37 (dd, J = 10.5, 7.3 Hz, 
1H), 4.31 (dd, J = 10.5, 7.1 Hz, 1H), 3.22 (s, 3H), 1.71 (s, 3H), 1.63 (s, 3H). 
13
C NMR (126 
MHz, CDCl3) δ 171.99, 162.97 (d, J = 250.5 Hz), 143.39, 138.45, 134.24 (d, J = 8.5 Hz), 
130.60, 128.05, 125.07, 123.58, 120.40, 118.03 (d, J = 3.5 Hz), 115.66 (d, J = 22.1 Hz), 
108.80, 86.61, 83.81, 74.23, 62.47, 26.59, 25.95, 18.19. HRMS (ESI): Calcd for (M + Na)
+
 
[C22H20O2NFNa]
+
: 372.1370, found: 372.1376. 
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3-((2,4-difluorophenyl)ethynyl)-1-methyl-3-((3-methylbut-2-en-1-yl)oxy)indolin-2-one 
(130h) was prepared according to the general procedure D, by using 
114i (50 mg, 0.17 mmol) and 3,3-dimethylallyl bromide. After silica 
gel column chromatography with EtOAc/petroleum ether = 1/7 (Rf = 
0.33) as eluents, the desired product was obtained in 98% yield (60 
mg, 0.16 mmol) as a pale yellow solid. mp: 57 °C 
1
H NMR (500 MHz, CDCl3) δ 7.54 (d, J 
= 7.4 Hz, 1H), 7.47 – 7.39 (m, 1H), 7.35 (td, J = 7.8, 1.2 Hz, 1H), 7.12 (td, J = 7.6, 0.8 Hz, 
1H), 6.86 – 6.75 (m, 3H), 5.43 – 5.33 (m, 1H), 4.45 (dd, J = 10.2, 7.6 Hz, 1H), 4.37 (dd, J = 
10.4, 7.3 Hz, 1H), 3.21 (s, 3H), 1.71 (s, 3H), 1.64 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 
171.69, 164.43 (dd, J = 53.1, 11.8 Hz), 162.41 (dd, J = 50.5, 11.8 Hz), 143.38, 138.47, 
134.85 (dd, J = 9.8, 2.3 Hz), 130.65, 127.89, 125.15, 123.57, 120.36, 111.62 (dd, J = 22.0, 
3.7 Hz), 108.78, 107.00 (dd, J = 15.8, 3.9 Hz), 104.35 (d, J = 25.2 Hz), 88.94, 80.26, 74.17, 
62.56, 26.55, 25.91, 18.13. HRMS (ESI): Calcd for (M + H)
+
 [C22H20O2NF2]
+
: 368.1457, 
found: 368.1465. 
 
3-((2-chlorophenyl)ethynyl)-1-methyl-3-((3-methylbut-2-en-1-yl)oxy)indolin-2-one 
(130i) was prepared according to the general procedure D, by using 
114j (50 mg, 0.17 mmol) and 3,3-dimethylallyl bromide. After silica 
gel column chromatography with EtOAc/petroleum ether = 1/7 (Rf = 
0.37) as eluents, the desired product was obtained in 81% yield (50 
mg, 0.14 mmol) as a yellow solid. mp: 70 °C 
1
H NMR (500 MHz, CDCl3) δ 7.60 – 7.54 (m, 
1H), 7.48 (dd, J = 7.7, 1.7 Hz, 1H), 7.40 – 7.32 (m, 2H), 7.24 (dd, J = 8.0, 1.7 Hz, 1H), 7.17 
(td, J = 7.6, 1.2 Hz, 1H), 7.13 (td, J = 7.6, 1.0 Hz, 1H), 6.83 (d, J = 7.8 Hz, 1H), 5.46 – 5.34 
(m, 1H), 4.56 (dd, J = 10.6, 7.2 Hz, 1H), 4.47 (dd, J = 10.5, 7.2 Hz, 1H), 3.22 (s, 3H), 1.71 
(s, 3H), 1.66 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 171.77, 143.37, 138.43, 136.71, 
133.82, 130.59, 130.06, 129.34, 128.14, 126.46, 125.31, 123.54, 121.99, 120.48, 108.76, 
88.99, 84.67, 74.19, 62.71, 26.58, 25.96, 18.24. HRMS (ESI): Calcd for (M + Na)
+
 
[C22H20O2NClNa]
+
: 388.1075, found: 388.1076. 
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3-((3-chlorophenyl)ethynyl)-1-methyl-3-((3-methylbut-2-en-1-yl)oxy)indolin-2-one 
(130j) was prepared according to the general procedure D, by using 
114k (50 mg, 0.17 mmol) and 3,3-dimethylallyl bromide. After silica 
gel column chromatography with EtOAc/petroleum ether = 1/5 (Rf = 
0.33) as eluents, the desired product was obtained in 37% yield (23 
mg, 0.06 mmol) as a brown solid. 
1
H NMR (500 MHz, CDCl3) δ 7.54 (d, J = 7.4 Hz, 1H), 
7.44 (s, 1H), 7.41 – 7.26 (m, 3H), 7.21 (t, J = 7.9 Hz, 1H), 7.14 (t, J = 7.5 Hz, 1H), 6.84 (d, J 
= 7.8 Hz, 1H), 5.38 (t, J = 7.3 Hz, 1H), 4.39 (t, J = 10.2, 7.3 Hz, 1H), 4.32 (dd, J = 10.2, 7.3 
Hz, 1H), 3.23 (s, 3H), 1.72 (s, 3H), 1.64 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 171.84, 
143.41, 138.55, 134.21, 132.09, 130.70, 130.34, 129.60, 129.36, 127.91, 125.12, 123.66, 
123.63, 120.37, 108.84, 86.17, 85.33, 74.18, 62.57, 26.62, 25.96, 18.22. HRMS (ESI): Calcd 
for (M + H)
+
 [C22H21O2N
37
Cl]
+
: 368.1226, found: 368.1231. 
 
3-((4-bromophenyl)ethynyl)-1-methyl-3-((3-methylbut-2-en-1-yl)oxy)indolin-2-one 
(130k) was prepared according to the general procedure D, by using 
114l (57 mg, 0.17 mmol) and 3,3-dimethylallyl bromide. After silica 
gel column chromatography with EtOAc/petroleum ether = 1/7 (Rf 
= 0.38) as eluents, the desired product was obtained in 75% yield 
(51 mg, 0.12 mmol) as a yellow solid. 
1
H NMR (500 MHz, CDCl3) δ 7.54 (d, J = 7.6 Hz, 
1H), 7.41 (d, J = 8.6 Hz, 2H), 7.36 (t, J = 7.6 Hz, 1H), 7.31 (d, J = 8.6 Hz, 2H), 7.13 (t, J = 
7.6 Hz, 1H), 6.83 (d, J = 7.6 Hz, 1H), 5.45 – 5.32 (m, 1H), 4.37 (dd, J = 10.7, 7.1 Hz, 1H), 
4.30 (dd, J = 10.7, 7.1 Hz, 1H), 3.22 (s, 3H), 1.71 (s, 3H), 1.63 (s, 3H). 
13
C NMR (126 MHz, 
CDCl3) δ 171.83, 143.38, 138.46, 133.62, 131.61, 130.63, 127.87, 125.07, 123.58, 123.42, 
120.88, 120.35, 108.80, 86.50, 85.24, 74.22, 62.48, 26.58, 25.92, 18.17. HRMS (ESI): Calcd 
for (M + H)
+
 [C22H21O2NBr]
+
: 410.0750, found: 410.0759. 
 
 
1-methyl-3-((3-methylbut-2-en-1-yl)oxy)-3-(thiophen-3-ylethynyl)indolin-2-one (130l) 
was prepared according to the general procedure D, by using 114n (50 
mg, 0.19 mmol) and 3,3-dimethylallyl bromide. After silica gel 
column chromatography with EtOAc/petroleum ether = 1/6 (Rf = 0.43) 
as eluents, the desired product was obtained in 83% yield (52 mg, 0.15 
mmol) as a brown oil. 
1
H NMR (500 MHz, CDCl3) δ 7.54 (d, J = 7.6 Hz, 1H), 7.52 – 7.47 
(m, 1H), 7.36 (td, J = 7.6, 1.1 Hz, 1H), 7.22 (dd, J = 5.0, 3.0 Hz, 1H), 7.17 – 7.07 (m, 2H), 
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6.83 (d, J = 7.6 Hz, 1H), 5.38 (t, J = 7.3 Hz, 1H), 4.39 (dd, J = 10.4, 7.3 Hz, 1H), 4.32 (dd, J 
= 10.4, 7.3 Hz, 1H), 3.22 (s, 3H), 1.71 (s, 3H), 1.63 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 
172.05, 143.40, 138.39, 130.55, 130.42, 130.20, 128.16, 125.37, 125.13, 123.56, 121.05, 
120.49, 108.77, 83.66, 82.95, 74.31, 62.50, 26.60, 25.97, 18.22. HRMS (ESI): Calcd for (M 
+ Na)
+
 [C20H19O2NSNa]
+
: 360.1029, found: 360.1045. 
 
1-methyl-3-((3-methylbut-2-en-1-yl)oxy)-3-(pent-1-yn-1-yl)indolin-2-one (130m) was 
prepared according to the general procedure D, by using 114q (48 
mg, 0.21 mmol) and 3,3-dimethylallyl bromide. After silica gel 
column chromatography with EtOAc/petroleum ether = 1/2 (Rf = 
0.80) as eluents, the desired product was obtained in 99% yield (61 
mg, 0.21 mmol) as a yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.46 (dd, J = 7.6, 0.8 Hz, 
1H), 7.31 (td, J = 7.6, 1.2 Hz, 1H), 7.09 (td, J = 7.6, 0.8 Hz, 1H), 6.79 (d, J = 7.6 Hz, 1H), 
5.34 (t, J = 7.2 Hz, 1H), 4.31 (dd, J = 10.5, 7.2 Hz, 1H), 4.25 (dd, J = 10.5, 7.2 Hz, 1H), 3.18 
(s, 3H), 2.22 (td, J = 7.2, 1.9 Hz, 2H), 1.69 (s, 3H), 1.61 (s, 3H),1.53 (qt, J = 7.2, 7.2 Hz, 
2H), 0.95 (t, J = 7.2 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 172.43, 143.30, 138.01, 
130.24, 128.69, 124.84, 123.39, 120.61, 108.59, 89.21, 75.19, 73.90, 62.16, 26.45, 25.92, 
21.87, 21.05, 18.13, 13.60. HRMS (ESI): Calcd for (M + H)
+
 [C19H24O2N]
+
: 298.1802, 
found: 298.1807. 
 
1-methyl-3-((3-methylbut-2-en-1-yl)oxy)-3-(5-methylhex-1-yn-1-yl)indolin-2-one (130n) 
was prepared according to the general procedure D, by using 114r 
(64 mg, 0.25 mmol) and 3,3-dimethylallyl bromide. After silica gel 
column chromatography with EtOAc/petroleum ether = 1/2 (Rf = 
0.8) as eluents, the desired product was obtained in 86% yield (70 
mg, 0.22 mmol) as a yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.45 (dd, J = 7.4, 0.7 Hz, 
1H), 7.31 (td, J = 7.8, 1.2 Hz, 1H), 7.09 (td, J = 7.6, 0.8 Hz, 1H), 6.79 (d, J = 7.8 Hz, 1H), 
5.40 – 5.30 (m, 1H), 4.31 (dd, J = 10.5, 7.3 Hz, 1H), 4.24 (dd, J = 10.5, 7.1 Hz, 1H), 3.18 (s, 
3H), 2.24 (td, J = 7.4, 1.6 Hz, 2H), 1.69 (s, 3H), 1.67 – 1.61 (m, 1H), 1.61 (s, 3H), 1.41 (td, J 
= 7.4, 7.4 Hz, 2H), 0.86 (d, J = 2.3 Hz, 3H), 0.85 (d, J = 2.3 Hz, 3H). 
13
C NMR (126 MHz, 
CDCl3) δ 172.42, 143.29, 137.98, 130.23, 128.68, 124.84, 123.38, 120.62, 108.58, 89.47, 
74.84, 73.90, 62.15, 37.33, 27.44, 26.45, 25.91, 22.22, 18.13, 17.12. HRMS (ESI): Calcd for 
(M + Na)
+
 [C21H27O2NNa]
+
: 348.1934, found: 348.1949. 
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1,5-dimethyl-3-((3-methylbut-2-en-1-yl)oxy)-3-(phenylethynyl)indolin-2-one (130o) was 
prepared according to the general procedure D, by using 114s (44 
mg, 0.16 mmol) and 3,3-dimethylallyl bromide. After silica gel 
column chromatography with EtOAc/petroleum ether = 1/4 (Rf = 
0.59) as eluents, the desired product was obtained in 82% yield (45 
mg, 0.13 mmol) as a brown oil. 
1
H NMR (300 MHz, CDCl3) δ 7.50 – 7.39 (m, 2H), 7.33 (s, 
1H), 7.29 – 7.18 (m, 3H), 7.11 (d, J = 7.9 Hz, 1H), 6.68 (d, J = 7.9 Hz, 1H), 5.36 (t, J = 7.2 
Hz, 1H), 4.41 (d, J = 10.5, 7.2 Hz, 1H), 4.31 (d, J = 10.5, 7.2 Hz, 1H), 3.16 (s, 3H), 2.32 (s, 
3H), 1.68 (s, 3H), 1.62 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 171.99, 140.92, 138.34, 
133.22, 132.20, 130.74, 128.97, 128.28, 128.13, 125.78, 121.96, 120.51, 108.49, 87.70, 
84.06, 74.30, 62.41, 26.56, 25.96, 21.17, 18.19. HRMS (ESI): Calcd for (M + Na)
+
 
[C23H23O2NNa]
+
: 368.1621, found: 368.1637. 
 
5-methoxy-1-methyl-3-((3-methylbut-2-en-1-yl)oxy)-3-(phenylethynyl)indolin-2-one 
(130p) was prepared according to the general procedure D, by using 
114t (97 mg, 0.33 mmol) and 3,3-dimethylallyl bromide. After 
silica gel column chromatography with EtOAc/petroleum ether = 
1/4 (Rf = 0.35) as eluents, the desired product was obtained in 74% 
yield (89 mg, 0.25 mmol) as a brown oil. 
1
H NMR (300 MHz, CDCl3) δ 7.51 – 7.37 (m, 
2H), 7.31 – 7.19 (m, 3H), 7.14 (d, J = 2.5 Hz, 1H), 6.85 (dd, J = 8.5, 2.5 Hz, 1H), 6.71 (d, J 
= 8.5 Hz, 1H), 5.37 (t, J = 7.5 Hz, 1H), 4.37 (dd, J = 10.5, 7.5 Hz, 1H), 4.30 (dd, J = 10.5, 
7.5 Hz, 1H), 3.77 (s, 3H), 3.16 (s, 3H), 1.68 (s, 3H), 1.62 (s, 3H). 
13
C NMR (75 MHz, 
CDCl3) δ 171.65, 156.56, 138.31, 136.55, 132.07, 129.01, 128.92, 128.18, 121.72, 120.27, 
115.10, 111.78, 109.16, 87.63, 83.85, 74.42, 62.32, 55.85, 26.49, 25.82, 18.08. HRMS 
(ESI): Calcd for (M + H)
+
 [C23H24O3N]
+
: 362.1750, found: 362.1760. 
 
1,5,7-trimethyl-3-((3-methylbut-2-en-1-yl)oxy)-3-(phenylethynyl)indolin-2-one (130q) 
was prepared according to the general procedure D, by using 114u 
(50 mg, 0.17 mmol) and 3,3-dimethylallyl bromide. After silica gel 
column chromatography with EtOAc/petroleum ether = 1/5 (Rf = 
0.38) as eluents, the desired product was obtained in 73% yield (45 
mg, 0.13 mmol) as an orange solid. mp: 69 °C 
1
H NMR (500 MHz, CDCl3) δ 7.52 – 7.42 
(m, 2H), 7.34 – 7.24 (m, 3H), 7.21 (s, 1H), 6.88 (s, 1H), 5.45 – 5.34 (m, 1H), 4.42 (dd, J = 
10.6, 7.3 Hz, 1H), 4.35 (dd, J = 10.6, 7.1 Hz, 1H), 3.47 (s, 3H), 2.51 (s, 3H), 2.30 (s, 3H), 
98 
 
1.72 (s, 3H), 1.66 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 172.67, 138.50, 138.09, 134.66, 
133.06, 132.20, 128.90, 128.26, 123.74, 122.10, 120.69, 120.01, 87.62, 84.42, 73.80, 62.35, 
29.91, 25.95, 20.84, 18.91, 18.20. HRMS (ESI): Calcd for (M + Na)
+
 [C24H25O2NNa]
+
: 
382.1778, found: 382.1791. 
 
6-bromo-1-methyl-3-((3-methylbut-2-en-1-yl)oxy)-3-(phenylethynyl)indolin-2-one 
(130r) was prepared according to the general procedure D, by using 
114x (117 mg, 0.34 mmol) and 3,3-dimethylallyl bromide. After 
silica gel column chromatography with EtOAc/petroleum ether = 
1/4 (Rf = 0.91) as eluents, the desired product was obtained in 46% 
yield (65 mg, 0.16 mmol) as a brown oil. 
1
H NMR (300 MHz, CDCl3) δ 7.45 – 7.38 (m, 
2H), 7.36 (d, J = 7.9 Hz, 1H), 7.31 – 7.18 (m, 4H), 6.94 (d, J = 1.6 Hz, 1H), 5.33 (t, J = 7.2 
Hz, 1H), 4.39 (dd, J = 10.2, 7.2 Hz, 1H), 4.30 (dd, J = 10.2, 7.2 Hz, 1H), 3.16 (s, 3H), 1.67 
(s, 3H), 1.60 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 171.81, 144.60, 138.74, 132.20, 129.19, 
128.35, 127.13, 126.35, 124.26, 121.63, 120.19, 112.31, 88.18, 83.19, 73.74, 62.54, 29.80, 
26.67, 25.96, 18.21. HRMS (ESI): Calcd for (M + Na)
+
 [C22H20O2NBrNa]
+
: 432.0570, 
found: 432.0571. 
 
5-fluoro-1-methyl-3-((3-methylbut-2-en-1-yl)oxy)-3-(phenylethynyl)indolin-2-one (130s) 
was prepared according to the general procedure D, by using 114v 
(40 mg, 0.14 mmol) and 3,3-dimethylallyl bromide. After silica gel 
column chromatography with EtOAc/petroleum ether = 1/4 (Rf = 
0.45) as eluents, the desired product was obtained in 99% yield (49 
mg, 0.14 mmol) as a yellow oil. 
1
H NMR (300 MHz, CDCl3) δ 7.56 – 7.36 (m, 2H), 7.33 – 
7.17 (m, 4H), 7.02 (td, J = 8.6, 2.6 Hz, 1H), 6.72 (dd, J = 8.6, 4.0 Hz, 1H), 5.34 (t, J = 7.4 
Hz, 1H), 4.42 (dd, J = 10.3, 7.4 Hz, 1H), 4.34 (dd, J = 10.3, 7.4 Hz, 1H), 3.17 (s, 3H), 1.68 
(s, 3H), 1.62 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 171.78, 159.68 (d, J = 242.5 Hz), 139.24 
(d, J = 2.0 Hz), 138.77, 132.22, 129.67 (d, J = 7.9 Hz), 129.21, 128.35, 121.60, 120.19, 
116.78 (d, J = 23.6 Hz), 113.18 (d, J = 25.1), 88.29, 83.22, 77.36, 74.12, 62.59, 26.67, 25.94, 
18.19. HRMS (ESI): Calcd for (M + Na)
+
 [C22H20O2NFNa]
+
: 372.1370, found: 372.1375. 
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5-chloro-1-methyl-3-((3-methylbut-2-en-1-yl)oxy)-3-(phenylethynyl)indolin-2-one (130t) 
was prepared according to the general procedure D, by using 114w 
(37 mg, 0.12 mmol) and 3,3-dimethylallyl bromide. After silica gel 
column chromatography with EtOAc/petroleum ether = 1/4 (Rf = 
0.49) as eluents, the desired product was obtained in 99% yield (45 
mg, 0.12 mmol) as a yellow oil. 
1
H NMR (300 MHz, CDCl3) δ 7.53 (d, J = 2.1 Hz, 1H), 
7.50 – 7.43 (m, 2H), 7.38 – 7.20 (m, 4H), 6.76 (d, J = 8.3 Hz, 1H), 5.39 (t, J = 7.2 Hz, 1H), 
4.48 (dd, J = 10.3, 7.3 Hz, 1H), 4.41 (dd, J = 10.3, 7.3 Hz, 1H), 3.21 (s, 3H), 1.73 (s, 3H), 
1.67 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 171.60, 141.82, 138.85, 132.23, 130.39, 129.80, 
129.25, 128.91, 128.37, 125.55, 121.57, 120.17, 109.75, 88.47, 83.06, 73.92, 62.63, 26.66, 
25.96, 18.22. HRMS (ESI): Calcd for (M + Na)
+
 [C22H20O2NClNa]
+
: 388.1075, found: 
388.1087. 
 
1-methyl-3-((3-methylbut-2-en-1-yl)oxy)-3-(phenylethynyl)-5-(trifluoromethoxy) 
indolin-2-one (130u) was prepared according to the general 
procedure D, by using 114z (102 mg, 0.29 mmol) and 
3,3-dimethylallyl bromide. After silica gel column chromatography 
with EtOAc/petroleum ether = 1/4 (Rf = 0.57) as eluents, the 
desired product was obtained in 59% yield (72 mg, 0.17 mmol) as a brown oil. 
1
H NMR 
(300 MHz, CDCl3) δ 7.54 – 7.36 (m, 3H), 7.34 – 7.14 (m, 4H), 6.80 (d, J = 8.5 Hz, 1H), 5.36 
(t, J = 7.3 Hz, 1H), 4.44 (dd, J = 10.1, 7.3 Hz, 1H), 4.36 (dd, J = 10.1, 7.3 Hz, 1H), 3.19 (s, 
3H), 1.69 (s, 3H), 1.62 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 171.83, 145.33 (d, J = 1.9 Hz), 
141.94, 138.96, 132.24, 129.66, 129.30, 128.39, 123.60, 121.51, 120.62 (q, J = 257.1 Hz), 
120.09, 119.07, 88.55, 82.93, 73.95, 62.67, 29.80, 26.70, 25.94, 18.13. HRMS (ESI): Calcd 
for (M + Na)
+
 [C23H20O3NF3Na]
+
: 438.1288, found: 438.11289. 
 
1-methyl-3-((3-methylbut-2-en-1-yl)oxy)-5-nitro-3-(phenylethynyl)indolin-2-one (130v) 
was prepared according to the general procedure D, by using 114y 
(40 mg, 0.13 mmol) and 3,3-dimethylallyl bromide. After silica gel 
column chromatography with EtOAc/petroleum ether = 1/4 (Rf = 
0.26) as eluents, the desired product was obtained in 90% yield (44 
mg, 0.12 mmol) as a yellow oil. 
1
H NMR (300 MHz, CDCl3) δ 8.43 (d, J = 2.3 Hz, 1H), 
8.33 (dd, J = 8.6, 2.3 Hz, 1H), 7.59 – 7.44 (m, 2H), 7.42 – 7.28 (m, 3H), 6.93 (d, J = 8.7 Hz, 
1H), 5.39 (t, J = 7.2 Hz, 1H), 4.59 (dd, J = 10.4, 7.5 Hz, 1H), 4.51 (dd, J = 10.4, 7.2 Hz, 1H), 
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3.29 (s, 3H), 1.74 (s, 3H), 1.70 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 172.07, 148.73, 
144.10, 139.36, 132.28, 129.55, 129.35, 128.48, 127.44, 121.08, 119.88, 108.52, 89.44, 
81.97, 73.21, 62.93, 29.80, 26.98, 25.98, 18.26. HRMS (ESI): Calcd for (M + H)
+
 
[C22H21O4N2]
+
: 377.1496, found: 377.1501. 
 
1-benzyl-3-((3-methylbut-2-en-1-yl)oxy)-3-(phenylethynyl)indolin-2-one (130w) was 
prepared according to the general procedure D, by using 114aa (47 
mg, 0.14 mmol) and 3,3-dimethylallyl bromide. After silica gel 
column chromatography with EtOAc/petroleum ether = 1/4 (Rf = 
0.69) as eluents, the desired product was obtained in 90% yield (51 
mg, 0.13 mmol) as a brown oil. 
1
H NMR (300 MHz, CDCl3) δ 7.57 (d, J = 6.6 Hz, 1H), 7.53 
– 7.44 (m, 2H), 7.38 – 7.17 (m, 9H), 7.10 (t, J = 7.6 Hz, 1H), 6.71 (d, J = 7.6 Hz, 1H), 5.44 
(t, J = 7.5 Hz, 1H), 4.96 (d, J = 15.8 Hz, 1H), 4.90 (d, J = 15.8 Hz, 1H), 4.46 (dd, J = 10.4, 
7.5 Hz, 1H), 4.40 (dd, J = 10.4, 7.5 Hz, 1H), 1.74 (s, 3H), 1.68 (s, 3H). 
13
C NMR (75 MHz, 
CDCl3) δ 172.18, 142.41, 138.58, 135.38, 132.23, 130.40, 129.05, 128.94, 128.32, 128.21, 
127.82, 127.30, 125.14, 123.59, 121.91, 120.40, 109.79, 87.89, 83.94, 74.30, 62.44, 44.02, 
25.96, 18.20. HRMS (ESI): Calcd for (M + Na)
+
 [C28H25O2NNa]
+
: 430.1778, found: 
430.1792. 
 
1-(4-methoxybenzyl)-3-((3-methylbut-2-en-1-yl)oxy)-3-(phenylethynyl)indolin-2-one 
(130x) was prepared according to the general procedure D, by using 
114ab (50 mg, 0.14 mmol) and 3,3-dimethylallyl bromide. After silica 
gel column chromatography with EtOAc/petroleum ether = 1/4 (Rf = 
0.60) as eluents, the desired product was obtained in 90% yield (53 
mg, 0.12 mmol) as a transparent oil. 
1
H NMR (300 MHz, CDCl3) δ 7.57 (dd, J = 7.4, 0.8 Hz, 
1H), 7.53 – 7.45 (m, 2H), 7.41 – 7.19 (m, 6H), 7.10 (t, J = 7.4 Hz, 1H), 6.85 (d, J = 8.7 Hz, 
2H), 6.74 (d, J = 7.8 Hz, 1H), 5.44 (t, J = 7.6 Hz, 1H), 4.90 (d, J = 15.5 Hz, 1H), 4.84 (d, J = 
15.5 Hz, 1H), 4.44 (dd, J = 10.4, 7.6 Hz, 1H), 4.39 (dd, J = 10.4, 7.6 Hz, 1H), 3.77 (s, 3H), 
1.75 (s, 3H), 1.68 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 172.12, 159.23, 142.45, 138.52, 
132.23, 130.37, 129.03, 128.74, 128.31, 128.22, 127.44, 125.11, 123.52, 121.93, 120.42, 
114.31, 109.81, 87.81, 84.00, 74.31, 62.40, 55.33, 43.53, 25.95, 18.20. HRMS (ESI): Calcd 
for (M + Na)
+
 [C29H27O3NNa]
+
: 460.1883, found: 460.1878. 
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1-(methoxymethyl)-3-((3-methylbut-2-en-1-yl)oxy)-3-(phenylethynyl)indolin-2-one 
(130y) was prepared according to the general procedure D, by using 
114ac (191 mg, 0.65 mmol) and 3,3-dimethylallyl bromide. After 
silica gel column chromatography with EtOAc/petroleum ether = 1/5 
(Rf = 0.75) as eluents, the desired product was obtained in 89% yield 
(210 mg, 0.58 mmol) as a yellow oil. 
1
H NMR (300 MHz, CDCl3) δ 7.58 (dd, J = 7.5, 0.8 
Hz, 1H), 7.50 – 7.42 (m, 2H), 7.36 (td, J = 7.8, 1.3 Hz, 1H), 7.32 – 7.27 (m, 4H), 7.17 (td, J 
= 7.6, 0.9 Hz, 1H), 7.04 (d, J = 7.8 Hz, 1H), 5.41 (t, J = 7.7 Hz, 1H), 5.14 (s, 2H), 4.43 (dd, J 
= 10.4, 7.7 Hz, 1H), 4.35 (dd, J = 10.5, 7.7 Hz, 1H), 3.37 (s, 3H), 1.72 (s, 3H), 1.65 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 172.53, 141.53, 138.55, 132.13, 130.59, 129.06, 128.28, 
127.72, 125.17, 124.00, 121.74, 120.26, 110.20, 88.07, 83.71, 74.45, 71.73, 62.41, 56.41, 
25.88, 18.11. HRMS (ESI): Calcd for (M + Na)
+
 [C23H23O3NNa]
+
: 384.1570, found: 
384.1585. 
 
3-((3-methylbut-2-en-1-yl)oxy)-3-(phenylethynyl)-1-((2-(trimethylsilyl)ethoxy)methyl)  
indolin-2-one (130z) was prepared according to the general procedure 
D, by using 114ad (57 mg, 0.15 mmol) and 3,3-dimethylallyl 
bromide. After silica gel column chromatography with 
EtOAc/petroleum ether = 1/7 (Rf = 0.63) as eluents, the desired 
product was obtained in 76% yield (51 mg, 0.11 mmol) as a brown oil. 
1
H NMR (500 MHz, 
CDCl3) δ 7.57 (d, J = 7.5 Hz, 1H), 7.48 – 7.42 (m, 2H), 7.36 (td, J = 7.8, 1.2 Hz, 1H), 7.34 – 
7.26 (m, 3H), 7.16 (td, J = 7.6, 0.9 Hz, 1H), 7.07 (d, J = 7.8 Hz, 1H), 5.45 – 5.32 (m, 1H), 
5.19 (d, J = 11.1 Hz, 1H), 5.16 (d, J = 11.1 Hz, 1H), 4.42 – 4.35 (m, 1H), 4.35 – 4.29 (m, 
1H), 3.62 (d, J = 7.9 Hz, 1H), 3.60 (d, J = 7.8 Hz, 1H), 1.72 (s, 3H), 1.64 (s, 3H), 0.96 – 0.89 
(m, 2H), -0.05 (s, 9H). 
13
C NMR (75 MHz, CDCl3) δ 172.45, 141.78, 138.57, 132.23, 
130.59, 129.07, 128.31, 127.81, 125.17, 123.97, 121.87, 120.33, 110.38, 88.02, 83.83, 74.54, 
69.81, 66.30, 62.44, 25.95, 18.19, 17.85, -1.37. HRMS (ESI): Calcd for (M + Na)
+
 
[C27H33O3NSiNa]
+
: 470.2122, found: 470.2137. 
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1-methyl-3-((3-methylbut-2-en-1-yl)oxy)-3-(3-methylbut-3-en-1-yn-1-yl)indolin-2-one 
(137) was prepared according to the general procedure D, by using 
114o (63 mg, 0.28 mmol) and 3,3-dimethylallyl bromide. After silica 
gel column chromatography with DCM/petroleum ether = 1/2 (Rf = 
0.25) as eluents, the desired product was obtained in 80% yield (145 
mg, 0.31 mmol) as a yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.48 
(d, J = 7.6 Hz, 1H), 7.34 (td, J = 7.6, 1.0 Hz, 1H), 7.11 (t, J = 7.6 Hz, 1H), 6.81 (d, J = 7.6 
Hz, 1H), 5.42 – 5.32 (m, 2H), 5.27 (s, 1H), 4.35 (dd, J = 10.4, 7.4 Hz, 1H), 4.27 (dd, J = 
10.4, 7.3 Hz, 1H), 3.20 (s, 3H), 1.87 (s, 3H), 1.70 (s, 3H), 1.62 (s, 3H). 
13
C NMR (126 MHz, 
CDCl3) δ 172.06, 143.36, 138.31, 130.47, 128.25, 125.87, 125.07, 123.89, 123.51, 120.50, 
108.70, 88.94, 82.82, 74.11, 62.37, 26.55, 25.96, 23.23, 18.18. HRMS (ESI): Calcd for (M + 
Na)
+
 [C19H21O2NNa]
+
: 318.1465, found: 318.1468. 
 
1-(((tert-butyldimethylsilyl)oxy)methyl)-3-((3-methylbut-2-en-1-yl)oxy)-3-(phenyl 
ethynyl) indolin-2-one (137) was prepared according to the general 
procedure D, by using 114ae (154 mg, 0.39 mmol) and 
3,3-dimethylallyl bromide. After silica gel column chromatography 
with EtOAc/petroleum ether = 1/7 (Rf = 0.32) as eluents, the desired 
product was obtained in 67% yield (55 mg, 0.19 mmol) as a yellow oil. 
1
H NMR (500 MHz, 
CDCl3) δ 7.55 (d, J = 7.6 Hz, 1H), 7.48 – 7.42 (m, 2H), 7.36 (td, J = 7.6, 1.3 Hz, 1H), 7.33 – 
7.26 (m, 3H), 7.15 (td, J = 7.6, 0.8 Hz, 1H), 7.08 (d, J = 7.6 Hz, 1H), 5.42 – 5.36 (m, 2H), 
5.28 (d, J = 10.1 Hz, 1H), 4.50 – 4.30 (m, 2H), 1.72 (s, 3H), 1.65 (s, 3H), 0.86 (s, 9H), 0.14 
(s, 3H), 0.11 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 171.24, 141.80, 138.56, 132.19, 
130.52, 129.04, 128.33, 127.90, 125.09, 123.84, 121.94, 120.39, 110.50, 88.12, 83.74, 74.55, 
65.01, 62.43, 26.01, 25.77, 18.22, 18.09, -5.04, -5.16. HRMS (ESI): Calcd for (M + H)
+
 
[C28H36O3NSi]
+
: 462.2459, found: 462.2458. 
 
3-((3-methylbut-2-en-1-yl)oxy)-3-(phenylethynyl)indolin-2-one (130aa) was prepared by 
following procedure. TBAF (1.0 M in THF, 0.8 ml, 0.8 mmol) was 
added to a solution of 130z (120 mg, 0.27 mmol) in DMF (5 ml). 
After 1 h stirring at 100 °C, the reaction mixture was cooled, and then 
diluted with water and ethyl acetate. The aqueous phase was extracted 
twice with ethyl acetate. The combined organic phases were washed with 1N HCl(aq) and 
NaHCO3(sat), dried over MgSO4(s) and concentrated to give the crude product. After silica gel 
103 
 
column chromatography with EtOAc/petroleum ether = 1/4 (Rf = 0.21) as eluents, the 
desired product was obtained in 40% yield (34 mg, 0.11 mmol) as a brown oil.  
Alternatively, TBAF (1.0 M in THF, 0.1 ml, 0.1 mmol) was added to a solution of 143 (11 
mg, 0.02 mmol) in THF (2 ml) at 0 °C. After stirring for 3 h at rt, the reaction mixture was 
added NH4Cl(sat), extracted with EtOAc for three times The combined organic phases were 
washed with H2O, dried over MgSO4(s) and concentrated under reduce pressure to give the 
crude product. After silica gel column chromatography with EtOAc/petroleum ether = 1/4 
(Rf = 0.21) as eluents, the desired product was obtained in 66% yield (5 mg, 0.05 mmol) as a 
brown oil. 
1
H NMR (500 MHz, CDCl3) δ 8.94 (s, 1H), 7.54 (d, J = 7.6 Hz, 1H), 7.46 (dd, J 
= 8.1, 1.5 Hz, 2H), 7.35 – 7.24 (m, 4H), 7.11 (td, J = 7.6, 0.8 Hz, 1H), 6.95 (d, J = 7.6 Hz, 
1H), 5.41 (t, J = 7.2 Hz, 1H), 4.37 (dd, J = 10.2, 7.2 Hz, 1H), 4.31 (dd, J = 10.5, 7.2 Hz, 1H), 
1.72 (s, 3H), 1.64 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 174.49, 140.66, 138.59, 132.25, 
130.59, 129.07, 128.57, 128.32, 125.46, 123.55, 121.90, 120.38, 110.88, 87.88, 83.81, 74.78, 
62.48, 25.93, 18.19. HRMS (ESI): Calcd for (M + Na)
+
 [C21H19O2NNa]
+
: 340.1308, found: 
340.1322. 
 
(E)-3-(but-2-en-1-yloxy)-1-methyl-3-(phenylethynyl)indolin-2-one (161a) was prepared 
according to the general procedure D, by using 114a (582 mg, 2.21 
mmol) and crotyl bromide. After silica gel column chromatography 
with EtOAc/petroleum ether = 1/7 (Rf = 0.34) as eluents, the desired 
product was obtained in 91% yield (640 mg, 2.02 mmol, 82% 
(E)-isomer) as a pale yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.55 (d, J = 7.4 Hz, 1H, E 
and Z), 7.46 (dd, J = 8.0, 1.6 Hz, 2H, E and Z), 7.35 (td, J = 7.6, 0.8 Hz, 1H, E and Z), 7.32 – 
7.22 (m, 3H, E and Z), 7.13 (td, J = 7.6, 0.8 Hz, 1H, E and Z), 6.82 (d, J = 7.6 Hz, 1H, E and 
Z), 5.80 – 5.69 (m, 1H, E and Z), 5.68 – 5.58 (m, 1H, E and Z), 4.53 (dd, J = 10.7, 6.0 Hz, 
1H, Z), 4.47 (dd, J = 10.7, 6.0 Hz, 1H, Z), 4.39 (dd, J = 10.7, 6.3 Hz, 4H, E), 4.31 (dd, J = 
10.7, 6.3 Hz, 1H, E), 3.21 (s, 3H, Z), 3.21 (s, 3H, E), 1.68 (dd, J = 6.3, 1.0 Hz, 3H, E), 1.64 
(d, J = 5.3 Hz, 3H, Z). HRMS (ESI): Calcd for (M + Na)
+
 [C21H19O2NNa]
+
: 340.1308, 
found: 340.1319. 
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(E)-3-(but-2-en-1-yloxy)-1-methyl-3-(o-tolylethynyl)indolin-2-one (161b) was prepared 
according to the general procedure D, by using 114b (120 mg, 0.43 
mmol) and crotyl bromide. After silica gel column chromatography 
with EtOAc/petroleum ether = 1/7 (Rf = 0.47) as eluents, the desired 
product was obtained in 86% yield (124 mg, 0.37 mmol, 79% 
(E)-isomer) as a pale yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.58 – 7.52 (m, 1H, E and 
Z), 7.42 (dd, J = 7.8, 1.2 Hz, 1H, E and Z), 7.35 (td, J = 7.8, 1.2 Hz, 1H, E and Z), 7.24 – 
7.07 (m, 4H, E and Z), 6.83 (d, J = 7.8 Hz, 1H, E and Z), 5.78 – 5.70 (m, 1H, E and Z), 5.70 
– 5.59 (m, 1H, E and Z), 4.62 – 4.59 (m, 1H, Z), 4.55 – 4.51 (m, 1H, Z), 4.50 – 4.42 (m, 1H, 
E), 4.42 – 4.33 (m, 1H, E), 3.22 (s, 3H, Z), 3.21 (s, 3H, E), 2.42 (s, 3H, Z), 2.42 (s, 3H, E), 
1.69 – 1.66 (m, 3H, E), 1.66 – 1.63 (m, 3H, Z). HRMS (ESI): Calcd for (M + Na)+ 
[C22H21O2NNa]
+
: 354.1465, found: 354.1465. 
 
(E)-3-(but-2-en-1-yloxy)-1-methyl-3-(m-tolylethynyl)indolin-2-one (161c) was prepared 
according to the general procedure D, by using 114c (150 mg, 0.54 
mmol) and crotyl bromide. After silica gel column chromatography 
with EtOAc/petroleum ether = 1/7 (Rf = 0.30) as eluents, the desired 
product was obtained in 76% yield (137 mg, 0.41 mmol, 84% 
(E)-isomer) as a pale yellow oil. 
1
H NMR (600 MHz, CDCl3) δ 7.55 (dd, J = 7.6, 1.3 Hz, 
1H, E and Z), 7.36 (td, J = 7.6, 1.3 Hz, 1H, E and Z), 7.29 (s, 1H, E and Z), 7.29 – 7.24 (m, 
1H, E and Z), 7.17 (t, J = 7.6 Hz, 1H, E and Z), 7.16 – 7.10 (m, 2H, E and Z), 6.83 (d, J = 7.8 
Hz, 1H, E and Z), 5.76 – 5.70 (m, 1H, E and Z), 5.68 – 5.59 (m, 1H, E and Z), 4.55 – 4.50 
(m, 1H, Z), 4.49 – 4.44 (m, 1H, Z), 4.41 – 4.36 (m, 1H, E), 4.34 – 4.28 (m, 1H, E), 3.23 (s, 
3H, Z), 3.22 (s, 3H, E), 2.29 (s, 3H, E and Z), 1.68 (dd, J = 6.4, 1.3 Hz, 3H, E), 1.66 – 1.61 
(m, 1H, Z). HRMS (ESI): Calcd for (M + Na)
+
 [C22H21O2NNa]
+
: 354.1465, found: 
354.1480. 
 
(E)-3-(but-2-en-1-yloxy)-1-methyl-3-(p-tolylethynyl)indolin-2-one (161c) was prepared 
according to the general procedure D, by using 114d (180 mg, 0.65 
mmol) and crotyl bromide. After silica gel column chromatography 
with EtOAc/petroleum ether = 1/7 (Rf = 0.30) as eluents, the desired 
product was obtained in 57% yield (122 mg, 0.37 mmol, 77% 
(E)-isomer) as a brown oil. 
1
H NMR (500 MHz, CDCl3) δ 7.55 (d, J = 7.6 Hz, 1H, E and Z), 
7.35 (d, J = 8.0 Hz, 3H, E and Z), 7.12 (t, J = 7.6 Hz, 1H, E and Z), 7.08 (d, J = 8.0 Hz, 2H, 
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E and Z), 6.82 (d, J = 7.6 Hz, 1H, E and Z), 5.77 – 5.68 (m, 1H, E and Z), 5.68 – 5.58 (m, 
1H, E and Z), 4.52 (dd, J = 10.6, 5.8 Hz, 1H, Z), 4.47 (dd, J = 10.6, 5.8 Hz, 1H, Z), 4.38 (dd, 
J = 10.3, 6.6 Hz, 1H, E), 4.31 (dd, J = 10.3, 6.6 Hz, 1H, E), 3.21 (s, 3H, Z), 3.20 (s, 3H, E), 
2.32 (s, 3H, E and Z), 1.67 (d, J = 6.2 Hz, 3H, E), 1.64 (d, J = 5.7 Hz, 3H, Z). HRMS (ESI): 
Calcd for (M + Na)
+
 [C22H21O2NNa]
+
: 354.1465, found: 354.1479. 
 
(E)-3-(but-2-en-1-yloxy)-3-((2-methoxyphenyl)ethynyl)-1-methylindolin-2-one (161d) 
was prepared according to the general procedure D, by using 114e (120 
mg, 0.41 mmol) and crotyl bromide. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/7 (Rf = 0.37) as 
eluents, the desired product was obtained in 94% yield (134 mg, 0.39 
mmol, 81% (E)-isomer) as a yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.56 (d, J = 7.4 Hz, 
1H, E and Z), 7.40 (dd, J = 7.6, 1.3 Hz, 1H, E and Z), 7.34 (td, J = 7.8, 1.3 Hz, 1H, E and Z), 
7.30 – 7.25 (m, 1H, E and Z), 7.11 (td, J = 7.6, 1.3 Hz, 1H, E and Z), 6.90 – 6.78 (m, 3H, E 
and Z), 5.78 – 5.71 (m, 1H, E and Z), 5.71 – 5.62 (m, 1H, E and Z), 4.68 – 4.62 (m, 1H, Z), 
4.62 – 4.56 (m, 1H, Z), 4.52 – 4.47 (m, 1H, E), 4.46 – 4.40 (m, 1H, E), 3.82 (s, 3H, E and Z), 
3.20 (s, 3H, Z), 3.20 (s, 3H, E), 1.71 – 1.65 (m, 3H, E and Z). HRMS (ESI): Calcd for (M + 
Na)
+
 [C22H21O3NNa]
+
: 370.1414, found: 370.1414. 
 
(E)-3-(but-2-en-1-yloxy)-3-((4-methoxyphenyl)ethynyl)-1-methylindolin-2-one (161e) 
was prepared according to the general procedure D, by using 114f 
(150 mg, 0.51 mmol) and crotyl bromide. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/7 (Rf = 0.20) as 
eluents, the desired product was obtained in 94% yield (134 mg, 
0.39 mmol, 82% (E)-isomer) as a yellow oil. 
1
H NMR (600 MHz, CDCl3) δ 7.55 (d, J = 6.6 
Hz, 1H, E and Z), 7.36 (td, J = 7.8, 1.3 Hz, 1H, E and Z), 7.18 (t, J = 8.0 Hz, 1H, E and Z), 
7.13 (td, J = 7.5, 1.0 Hz, 1H, E and Z), 7.05 (d, J = 7.5 Hz, 1H, E and Z), 7.00 – 6.96 (m, 1H, 
E and Z), 6.90 – 6.81 (m, 2H, E and Z), 5.77 – 5.68 (m, 1H, E and Z), 5.68 – 5. 59 (m, 1H, E 
and Z), 4.50 (dd, J = 11.2, 6.5 Hz, 1H, Z), 4.44 (dd, J = 11.2, 6.5 Hz, 1H, Z), 4.36 (dd, J = 
10.7, 6.4 Hz, 1H, E), 4.28 (dd, J = 10.7, 6.4 Hz, 1H, E), 3.76 (s, 3H, E and Z), 3.23 (s, 3H, 
Z), 3.22 (s, 3H, E), 1.67 (dd, J = 6.4, 1.3 Hz, 3H, E), 1.63 (d, J = 6.3 Hz, 1H, Z). HRMS 
(ESI): Calcd for (M + Na)
+
 [C22H21O3NNa]
+
: 370.1414, found: 370.1427. 
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(E)-3-(but-2-en-1-yloxy)-3-((4-fluorophenyl)ethynyl)-1-methylindolin-2-one (161f) was 
prepared according to the general procedure D, by using 114h (234 
mg, 0.70 mmol) and crotyl bromide. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/5 (Rf = 0.32) as 
eluents, the desired product was obtained in 98% yield (234 mg, 
0.70 mmol, 78% (E)-isomer) as a brown oil. 
1
H NMR (500 MHz, CDCl3) δ 7.54 (d, J = 7.5 
Hz, 1H, E and Z), 7.51 – 7.39 (m, 2H, E and Z), 7.37 (td, J = 7.5, 0.8 Hz, 1H, E and Z), 7.14 
(t, J = 7.5 Hz, 1H, E and Z), 6.98 (t, J = 8.7 Hz, 2H, E and Z), 6.84 (d, J = 7.5 Hz, 1H, E and 
Z), 5.78 – 5.68 (m, 1H, E and Z), 5.67 – 5.57 (m, 1H, E and Z), 4.47 (dd, J = 11.0, 6.5 Hz, 
1H, Z), 4.42 (dd, J = 10.9, 6.6 Hz, 1H, Z), 4.34 (dd, J = 10.5, 6.5 Hz, 1H, E), 4.26 (dd, J = 
10.5, 6.4 Hz, 1H, E), 3.23 (s, 3H, Z), 3.23 (s, 3H, E), 1.67 (d, J = 6.3 Hz, 3H, E), 1.63 (d, J = 
6.1 Hz, 3H, Z). HRMS (ESI): Calcd for (M + Na)
+
 [C21H18O2NFNa]
+
: 358.1214, found: 
358.1229. 
 
(E)-3-(but-2-en-1-yloxy)-3-((2,4-difluorophenyl)ethynyl)-1-methylindolin-2-one (161g) 
was prepared according to the general procedure D, by using 114i 
(215 mg, 0.72 mmol) and crotyl bromide. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/7 (Rf = 0.32) as 
eluents, the desired product was obtained in 23% yield (58 mg, 0.16 
mmol, 78% (E)-isomer) as a light yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.54 (d, J = 7.3 
Hz, 1H, E and Z), 7.45 – 7.40 (m, 1H, E and Z), 7.36 (t, J = 7.8 Hz, 1H, E and Z), 7.13 (t, J = 
7.5 Hz, 1H, E and Z), 6.86 – 6.75 (m, 3H, E and Z), 5.76 – 5.67 (m, 1H, E and Z), 5.67 – 
5.59 (m, 1H, E and Z), 4.54 (dd, J = 11.0, 6.4 Hz, 1H, Z), 4.47 (dd, J = 11.1, 6.4 Hz, 1H, Z), 
4.40 (dd, J = 10.6, 6.5 Hz, 1H, E), 4.32 (dd, J = 10.6, 6.4 Hz, 1H, E), 3.22 (s, 3H, Z), 3.21 (s, 
3H, E), 1.67 (d, J = 6.3 Hz, 3H, E), 1.63 (d, J = 6.4 Hz, 3H, Z). HRMS (ESI): Calcd for (M 
+ H)
+
 [C21H18O2NF2]
+
: 354.1300, found: 354.1306. 
 
(E)-3-(but-2-en-1-yloxy)-3-((3-chlorophenyl)ethynyl)-1-methylindolin-2-one (161h) was 
prepared according to the general procedure D, by using 114k (200 
mg, 0.67 mmol) and crotyl bromide. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/5 (Rf = 0.30) as 
eluents, the desired product was obtained in 94% yield (223 mg, 0.63 
mmol, 80% (E)-isomer) as a brown oil. 
1
H NMR (500 MHz, CDCl3) δ 7.53 (d, J = 6.6 Hz, 
1H, E and Z), 7.45 (s, 1H, E and Z), 7.37 (td, J = 7.8, 1.2 Hz, 1H, E and Z), 7.34 (d, J = 7.7 
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Hz, 1H, E and Z), 7.30 (d, J = 8.1 Hz, 1H, E and Z), 7.22 (t, J = 7.9 Hz, 1H, E and Z), 7.14 
(td, J = 7.6, 0.8 Hz, 1H, E and Z), 6.84 (d, J = 7.8 Hz, 1H, E and Z), 5.77 – 5.70 (m, 1H, E 
and Z), 5.70 – 5.59 (m, 1H, E and Z), 4.49 (dd, J = 11.1, 6.7 Hz, 1H, Z), 4.42 (dd, J = 11.1, 
6.6 Hz, 1H, Z), 4.35 (dd, J = 10.6, 6.4 Hz, 1H, E), 4.27 (dd, J = 10.6, 6.4 Hz, 1H, E), 3.24 (s, 
3H, Z), 3.23 (s, 3H, E), 1.68 (dd, J = 6.3, 1.0 Hz, 3H, E), 1.63 (d, J = 6.2 Hz, 1H, Z). HRMS 
(ESI): Calcd for (M + Na)
+
 [C21H18O2NClNa]
+
: 374.0918, found: 370.0934. 
 
(E)-3-(but-2-en-1-yloxy)-3-((2-chlorophenyl)ethynyl)-1-methylindolin-2-one (161i) was 
prepared according to the general procedure D, by using 114j (129 mg, 
0.67 mmol) and crotyl bromide. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/7 (Rf = 0.36) as 
eluents, the desired product was obtained in 86% yield (131 mg, 0.37 
mmol, 78% (E)-isomer) as a yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.57 (dd, J = 7.5, 1.3 
Hz, 1H, E and Z), 7.47 (dd, J = 7.6, 1.7 Hz, 1H, E and Z), 7.40 – 7.31 (m, 2H, E and Z), 7.28 
– 7.21 (m, 1H, E and Z), 7.17 (td, J = 7.5, 1.3 Hz, 1H, E and Z), 7.12 (td, J = 7.6, 1.0 Hz, 1H, 
E and Z), 6.82 (d, J = 7.8 Hz, 1H, E and Z), 5.79 – 5.70 (m, 1H, E and Z), 5.70 – 5.59 (m, 
1H, E and Z), 4.68 – 4.61 (m, 1H, Z), 4.60 – 4.54 (m, 1H, Z), 4.53 – 4.47 (m, 1H, E), 4.44 – 
4.38 (m, 1H, E), 3.21 (s, 3H, Z), 3.21 (s, 3H, E), 1.67 (dd, J = 6.3, 1.3 Hz, 3H, E), 1.66 – 
1.62 (m, 3H, Z). HRMS (ESI): Calcd for (M + Na)
+
 [C21H18O2NClNa]
+
: 374.0918, found: 
375.0919. 
 
(E)-3-((4-bromophenyl)ethynyl)-3-(but-2-en-1-yloxy)-1-methylindolin-2-one (161j) was 
prepared according to the general procedure D, by using 114l (130 
mg, 0.38 mmol) and crotyl bromide. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/7 (Rf = 0.35) as 
eluents, the desired product was obtained in 66% yield (100 mg, 
0.25 mmol, 76% (E)-isomer) as a brown oil. 
1
H NMR (600 MHz, CDCl3) δ 7.53 (d, J = 7.8 
Hz, 1H, E and Z), 7.42 (d, J = 8.6 Hz, 2H, E and Z), 7.37 (td, J = 7.8, 1.2 Hz, 1H, E and Z), 
7.31 (d, J = 8.6 Hz, 2H, E and Z), 7.14 (td, J = 7.8, 0.9 Hz, 1H, E and Z), 6.84 (d, J = 7.8 Hz, 
1H, E and Z), 5.76 – 5.67 (m, 1H, E and Z), 5.67 – 5.57 (m, 1H, E and Z), 4.45 (dd, J = 11.0, 
6.7 Hz, 1H, Z), 4.40 (dd, J = 11.0, 6.7 Hz, 1H, Z), 4.32 (dd, J = 10.6, 6.5 Hz, 1H, E), 4.24 
(dd, J = 10.6, 6.5 Hz, 1H, E), 3.23 (s, 3H, Z), 3.22 (s, 3H, E), 1.67 (dd, J = 6.4, 1.2 Hz, 3H, 
E), 1.62 (dd, J = 6.7, 1.3 Hz, 3H, Z). HRMS (ESI): Calcd for (M + Na)
+
 [C21H18O2NBrNa]
+
: 
418.0413, found: 418.0421. 
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(E)-3-(but-2-en-1-yloxy)-1-methyl-3-((2-(trifluoromethyl)phenyl)ethynyl)indolin-2-one 
(161k) was prepared according to the general procedure D, by using 
114m (200 mg, 0.60 mmol) and crotyl bromide. After silica gel 
column chromatography with EtOAc/petroleum ether = 1/4 (Rf = 0.33) 
as eluents, the desired product was obtained in 81% yield (188 mg, 
0.49 mmol, 72% (E)-isomer) as a pale yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.67 – 7.59 
(m, 2H, E and Z), 7.54 (d, J = 7.3 Hz, 1H, E and Z), 7.47 (t, J = 7.5 Hz, 1H, E and Z), 7.42 (t, 
J = 7.7 Hz, 1H, E and Z), 7.39 – 7.33 (m, 1H, E and Z), 7.13 (t, J = 8.0 Hz, 1H, E and Z), 
6.83 (d, J = 7.7 Hz, 1H, E and Z), 5.80 – 5.69 (m, 1H, E and Z), 5.69 – 5.58 (m, 1H, E and 
Z), 4.64 (dd, J = 11.1, 6.5 Hz, 1H, Z), 4.56 – 4.46 (m, 1H, E and Z), 4.37 (dd, J = 10.6, 6.4 
Hz, 1H, E), 3.23 (s, 3H, Z), 3.22 (s, 3H, E), 1.68 (dd, J = 6.3, 1.4 Hz, 3H, E), 1.65 (d, J = 6.0 
Hz, 3H, Z). HRMS (ESI): Calcd for (M + H)
+
 [C22H19O2NF3]
+
: 386.1362, found: 386.1373. 
 
(E)-3-(but-2-en-1-yloxy)-1-methyl-3-(thiophen-3-ylethynyl)indolin-2-one (161l) was 
prepared according to the general procedure D, by using 114n (200 
mg, 0.74 mmol) and crotyl bromide. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/6 (Rf = 0.31) as 
eluents, the desired product was obtained in 88% yield (211 mg, 0.65 
mmol, 83% (E)-isomer) as a yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.53 (d, J = 7.6 Hz, 
1H, E and Z), 7.50 (dd, J = 3.0, 0.9 Hz, 1H, E nd Z), 7.36 (td, J = 7.6, 1.2 Hz, 1H, E nd Z), 
7.22 (dd, J = 5.0, 3.0 Hz, 1H, E nd Z), 7.16 – 7.09 (m, 2H, E nd Z), 6.83 (d, J = 7.6 Hz, 1H, 
E nd Z), 5.77 – 5.67 (m, 1H, E nd Z), 5.67 – 5.57 (m, 1H, E nd Z), 4.48 (dd, J = 11.2, 6.3 Hz, 
1H, Z), 4.42 (dd, J = 11.2, 6.3 Hz, 1H, Z), 4.35 (dd, J = 10.7, 6.3 Hz, 1H, E), 4.27 (dd, J = 
10.7, 6.3 Hz, 1H, E), 3.22 (s, 3H, Z), 3.21 (s, 3H, E), 1.67 (dd, J = 6.3, 1.1 Hz, 3H, E), 1.63 
(dd, J = 5.9, 0.5 Hz, 1H, Z). HRMS (ESI): Calcd for (M + Na)
+
 [C19H17O2NSNa]
+
: 
346.0872, found: 346.0882. 
 
(E)-3-(but-2-en-1-yloxy)-1-methyl-3-(3-methylbut-3-en-1-yn-1-yl)indolin-2-one (161m) 
was prepared according to the general procedure D, by using 114o (184 
mg, 0.81 mmol) and crotyl bromide. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/7 (Rf = 0.50) as 
eluents, the desired product was obtained in 86% yield (197 mg, 0.70 
mmol, 79% (E)-isomer) as a yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.47 (d, J = 7.3 Hz, 
1H, E and Z), 7.33 (t, J = 7.3 Hz, 1H, E and Z), 7.10 (t, J = 7.3 Hz, 1H, E and Z), 6.80 (d, J = 
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7.3 Hz, 1H, E and Z), 5.79 – 5.64 (m, 1H, E and Z), 5.64 – 5.54 (m, 1H, E and Z), 5.35 (s, 
1H, E and Z), 5.26 (s, 1H, E and Z), 4.43 (dd, J = 11.1, 6.5 Hz, 1H, Z), 4.37 (dd, J = 11.1, 6.4 
Hz, 1H, Z), 4.29 (dd, J = 10.5, 6.4 Hz, 1H, E), 4.21 (dd, J = 10.5, 6.6 Hz, 1H, E), 3.19 (s, 3H, 
Z), 3.18 (s, 3H, E), 1.86 (s, 3H, E and Z), 1.65 (d, J = 6.2 Hz, 3H, E), 1.61 (d, J = 6.2 Hz, 3H, 
Z). HRMS (ESI): Calcd for (M + Na)
+
 [C18H19O2NNa]
+
: 304.1308, found: 304.1309. 
 
(E)-3-(but-2-en-1-yloxy)-3-(cyclopropylethynyl)-1-methylindolin-2-one (161n) was 
prepared according to the general procedure D, by using 114p (185 mg, 
0.81 mmol) and crotyl bromide. After silica gel column chromatography 
with EtOAc/petroleum ether = 1/7 (Rf = 0.31) as eluents, the desired 
product was obtained in 87% yield (200 mg, 0.71 mmol, 78% 
(E)-isomer) as a yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.44 (d, J = 7.8 Hz, 1H, E and Z), 
7.32 (t, J = 7.6 Hz, 1H, E and Z), 7.09 (t, J = 7.6 Hz, 1H, E and Z), 6.79 (d, J = 7.6 Hz, 1H, E 
and Z), 5.76 – 5.62 (m, 1H, E and Z), 5.62 – 5.51 (m, 1H, E and Z), 4.36 (dd, J = 10.9, 6.5 
Hz, 1H, Z), 4.31 (dd, J = 10.9, 6.9 Hz, 1H, Z), 4.22 (dd, J = 10.6, 6.5 Hz, 1H, E), 4.15 (dd, J 
= 10.6, 6.5 Hz, 1H, E), 3.19 (s, 3H, Z), 3.18 (s, 3H, E), 1.66 (d, J = 6.2 Hz, 3H, E), 1.60 (d, J 
= 6.4 Hz, 3H, Z), 1.41 – 1.19 (m, 1H, E and Z), 0.80 – 0.66 (m, 4H, E and Z). HRMS (ESI): 
Calcd for (M + H)
+
 [C18H19O2N]
+
: 282.1416, found: 282.1418. 
 
(E)-3-(but-2-en-1-yloxy)-1-methyl-3-(pent-1-yn-1-yl)indolin-2-one (161o) was prepared 
according to the general procedure D, by using 114q (200 mg, 0.87 
mmol) and crotyl bromide. After silica gel column chromatography 
with EtOAc/petroleum ether = 1/8 (Rf = 0.33) as eluents, the desired 
product was obtained in 97% yield (239 mg, 0.84 mmol, 81% 
(E)-isomer) as a yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.45 (d, J 
= 7.5 Hz, 1H, E and Z), 7.32 (td, J = 7.5, 1.3 Hz, 1H, E and Z), 7.09 (t, J = 7.5 Hz, 1H, E and 
Z), 6.79 (d, J = 7.5 Hz, 1H, E and Z), 5.73 – 5.62 (m, 1H, E and Z), 5.63 – 5.52 (m, 1H, E 
and Z), 4.41 (dd, J = 11.1, 6.6 Hz, 1H, Z), 4.35 (dd, J = 11.1, 6.6 Hz, 1H, Z), 4.27 (dd, J = 
10.6, 6.4 Hz, 1H, E), 4.20 (dd, J = 10.6, 6.4 Hz, 1H, E), 3.18 (s, 3H, Z), 3.18 (s, 3H, E), 2.21 
(td, J = 7.0, 1.5 Hz, 2H, E and Z), 1.65 (d, J = 6.3 Hz, 3H, E), 1.60 (d, J = 6.2 Hz, 1H, Z), 
1.57 – 1.46 (m, 2H, E and Z), 0.95 (t, J = 7.3 Hz, 3H, E and Z). HRMS (ESI): Calcd for (M 
+ Na)
+
 [C18H21O2NNa]
+
: 306.1465, found: 346.1472. 
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(E)-3-(but-2-en-1-yloxy)-1,5-dimethyl-3-(phenylethynyl)indolin-2-one (161p) was 
prepared according to the general procedure D, by using 114s (200 
mg, 0.72 mmol) and crotyl bromide. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/5 (Rf = 0.35) as 
eluents, the desired product was obtained in 85% yield (204 mg, 
0.62 mmol, 80% (E)-isomer) as a brown oil. 
1
H NMR (500 MHz, CDCl3) δ 7.47 (dd, J = 
7.9, 1.7 Hz, 2H, E and Z), 7.36 (s, 1H, E and Z), 7.33 – 7.24 (m, 3H, E and Z), 7.15 (d, J = 
7.9 Hz, 1H, E and Z), 6.72 (d, J = 7.9 Hz, 1H, E and Z), 5.79 – 5.68 (m, 1H, E and Z), 5.68 – 
5.57 (m, 1H, E and Z), 4.53 (dd, J = 11.2, 6.0 Hz, 1H, Z), 4.48 (dd, J = 11.3, 5.9 Hz, 1H, Z), 
4.39 (dd, J = 10.7, 6.4 Hz, 1H, E), 4.32 (dd, J = 10.7, 6.4 Hz, 1H, E), 3.21 (s, 3H, Z), 3.20 (s, 
3H, E), 2.36 (s, 3H, E and Z), 1.68 (dd, J = 6.4, 1.4 Hz, 3H, E), 1.65 (d, J = 5.8 Hz, 1H, Z). 
HRMS (ESI): Calcd for (M + H)
+
 [C22H22O2N]
+
: 332.1645, found: 332.1653. 
 
(E)-3-(but-2-en-1-yloxy)-5-methoxy-1-methyl-3-(phenylethynyl)indolin-2-one (161q) 
was prepared according to the general procedure D, by using 114t 
(200 mg, 0.68 mmol) and crotyl bromide. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/5 (Rf = 0.33) as 
eluents, the desired product was obtained in 92% yield (218 mg, 
0.63 mmol, 83% (E)-isomer) as a brown oil. 
1
H NMR (500 MHz, CDCl3) δ 7.46 (d, J = 6.6 
Hz, 2H, E and Z), 7.38 – 7.23 (m, 3H, E and Z), 7.17 (d, J = 2.5 Hz, 1H, E and Z), 6.88 (dd, J 
= 8.5, 2.5 Hz, 1H, E and Z), 6.74 (d, J = 8.5 Hz, 1H, E and Z), 5.78 – 5.68 (m, 1H), 5.69 – 
5.59 (m, 1H), 4.50 (dd, J = 11.3, 6.0 Hz, 1H, Z), 4.45 (dd, J = 11.3, 6.0 Hz, 1H, Z), 4.36 (dd, 
J = 10.7, 6.4 Hz, 1H, E), 4.29 (dd, J = 10.7, 6.4 Hz, 1H, E), 3.81 (s, 3H, E and Z), 3.20 (s, 
3H, Z), 3.19 (s, 3H, E), 1.68 (dd, J = 6.3, 1.0 Hz, 3H, E), 1.64 (d, J = 5.4 Hz, 3H, Z). HRMS 
(ESI): Calcd for (M + Na)
+
 [C22H21O3NNa]
+
: 370.1414, found: 370.1427. 
 
(E)-3-(but-2-en-1-yloxy)-1,5,7-trimethyl-3-(phenylethynyl)indolin-2-one (161r) was 
prepared according to the general procedure D, by using 114u (200 
mg, 0.69 mmol) and crotyl bromide. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/5 (Rf = 0.38) as 
eluents, the desired product was obtained in 95% yield (225 mg, 
0.65 mmol, 80% (E)-isomer) as a brown oil. 
1
H NMR (500 MHz, CDCl3) δ 7.49 (d, J = 6.5 
Hz, 2H, E and Z), 7.35 – 7.30 (m, 3H, E and Z), 7.23 (s, 1H, E and Z), 6.91 (s, 1H, E and Z), 
5.81 – 5.70 (m, 1H, E and Z), 5.70 – 5.60 (m, 1H, E and Z), 4.53 (dd, J = 11.3, 6.1 Hz, 1H, 
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Z), 4.49 (dd, J = 11.3, 6.1 Hz, 1H, Z), 4.33 (dd, J = 10.7, 6.4 Hz, 1H, E), 3.51 (s, 3H), 3.50 
(s, 3H), 2.54 (s, 3H), 2.33 (s, 3H), 1.71 (d, J = 6.3 Hz, 3H), 1.68 (d, J = 6.1 Hz, 3H). HRMS 
(ESI): Calcd for (M + Na)
+
 [C23H23O2NNa]
+
: 368.1621, found: 368.1632. 
 
(E)-3-(but-2-en-1-yloxy)-5-fluoro-1-methyl-3-(phenylethynyl)indolin-2-one (161s) was 
prepared according to the general procedure D, by using 114v (200 
mg, 0.71 mmol) and crotyl bromide. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/6 (Rf = 0.34) as 
eluents, the desired product was obtained in 81% yield (194 mg, 
0.58 mmol, 77% (E)-isomer) as a yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.46 (d, J = 6.6 
Hz, 2H, E and Z), 7.41 – 7.23 (m, 4H, E and Z), 7.06 (td, J = 8.7, 2.6 Hz, 1H, E and Z), 6.76 
(dd, J = 8.7, 3.9 Hz, 1H, E and Z), 5.81 – 5.70 (m, 1H, E and Z), 5.70 – 5.56 (m, 1H, E and 
Z), 4.55 (dd, J = 11.0, 6.7 Hz, 1H, Z), 4.49 (dd, J = 11.0, 6.7 Hz, 1H, Z), 4.41 (dd, J = 10.7, 
6.4 Hz, 1H, E), 4.34 (dd, J = 10.7, 6.4 Hz, 1H, E), 3.21 (s, 3H, Z), 3.21 (s, 3H, E), 1.69 (dd, J 
= 6.4, 1.1 Hz, 3H, E), 1.66 (d, J = 6.7 Hz, 1H, Z). HRMS (ESI): Calcd for (M + Na)
+
 
[C21H18O2NFNa]
+
: 358.1214, found: 358.1228. 
 
(E)-3-(but-2-en-1-yloxy)-5-chloro-1-methyl-3-(phenylethynyl)indolin-2-one (161t) was 
prepared according to the general procedure D, by using 114w (200 
mg, 0.67 mmol) and crotyl bromide. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/6 (Rf = 0.34) as 
eluents, the desired product was obtained in 80% yield (190 mg, 
0.54 mmol, 77% (E)-isomer) as a brown oil. 
1
H NMR (500 MHz, CDCl3) δ 7.52 (d, J = 2.1 
Hz, 1H, E and Z), 7.47 (d, J = 6.7 Hz, 2H, E and Z), 7.36 – 7.25 (m, 4H, E and Z), 6.76 (d, J 
= 8.3 Hz, 1H, E and Z), 5.80 – 5.67 (m, 1H, E and Z), 5.67 – 5.55 (m, 1H, E and Z), 4.57 (dd, 
J = 11.0, 6.8 Hz, 1H, Z), 4.51 (dd, J = 11.0, 6.8 Hz, 1H, Z), 4.43 (dd, J = 10.6, 6.5 Hz, 1H, 
E), 4.35 (dd, J = 10.6, 6.5 Hz, 1H, E), 3.21 (d, J = 3.6 Hz, 3H, Z), 3.20 (s, 3H, E), 1.69 (dd, J 
= 6.4, 0.9 Hz, 3H, E), 1.67 (d, J = 6.7 Hz, 3H, Z). HRMS (ESI): Calcd for (M + Na)
+
 
[C21H18O2NClNa]
+
: 374.0918, found: 374.0932. 
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(E)-6-bromo-3-(but-2-en-1-yloxy)-1-methyl-3-(phenylethynyl)indolin-2-one (161u) was 
prepared according to the general procedure D, by using 114x (200 
mg, 0.58 mmol) and crotyl bromide. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/8 (Rf = 0.37) as 
eluents, the desired product was obtained in 93% yield (220 mg, 
0.56 mmol, 76% (E)-isomer) as a yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.45 (d, J = 6.7 
Hz, 2H, E and Z), 7.43 – 7.38 (m, 1H, E and Z), 7.36 – 7.25 (m, 4H, E and Z), 6.99 (d, J = 
1.6 Hz, 1H, E and Z), 5.79 – 5.67 (m, 1H, E and Z), 5.66 – 5.56 (m, 1H, E and Z), 4.53 (dd, J 
= 11.0, 6.7 Hz, 1H, Z), 4.47 (dd, J = 11.0, 6.7 Hz, 1H, Z), 4.39 (dd, J = 10.7, 6.5 Hz, 1H, E), 
4.31 (dd, J = 10.7, 6.5 Hz, 1H, E), 3.21 (s, 3H, Z), 3.20 (s, 3H, E), 1.68 (dd, J = 6.4, 1.2 Hz, 
3H, E), 1.65 (d, J = 6.7 Hz, 3H, Z). HRMS (ESI): Calcd for (M + Na)
+
 [C21H18O2NBrNa]
+
: 
418.0413, found: 418.0430. 
 
(E)-3-(but-2-en-1-yloxy)-1-methyl-3-(phenylethynyl)-5-(trifluoromethoxy)indolin-2-one 
(161v) was prepared according to the general procedure D, by 
using 114z (200 mg, 0.58 mmol) and crotyl bromide. After silica 
gel column chromatography with EtOAc/petroleum ether = 1/5 (Rf 
= 0.29) as eluents, the desired product was obtained in 80% yield 
(202 mg, 0.50 mmol, 80% (E)-isomer) as a pale yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 
7.47 (d, J = 6.7 Hz, 2H, E and Z), 7.44 (d, J = 1.5 Hz, 1H, E and Z), 7.37 – 7.28 (m, 3H, E 
and Z), 7.24 (d, J = 8.5 Hz, 1H, E and Z), 6.82 (d, J = 8.5 Hz, 1H, E and Z), 5.80 – 5.68 (m, 
1H, E and Z), 5.67 – 5.59 (m, 1H, E and Z), 4.57 (dd, J = 11.0, 6.7 Hz, 1H, Z), 4.50 (dd, J = 
11.0, 6.7 Hz, 1H, Z), 4.43 (dd, J = 10.7, 6.5 Hz, 1H, E), 4.36 (dd, J = 10.7, 6.5 Hz, 1H, E), 
3.24 (s, 3H, Z), 3.23 (s, 3H, E), 1.69 (dd, J = 6.4, 1.1 Hz, 3H, E), 1.65 (d, J = 6.7 Hz, 3H, Z). 
HRMS (ESI): Calcd for (M + Na)
+
 [C22H18O3NF3Na]
+
: 424.1131, found: 424.1142. 
 
(E)-1-benzyl-3-(but-2-en-1-yloxy)-3-(phenylethynyl)indolin-2-one (161w) was prepared 
according to the general procedure D, by using 114aa (200 mg, 0.59 
mmol) and crotyl bromide. After silica gel column chromatography 
with EtOAc/petroleum ether = 1/8 (Rf = 0.33) as eluents, the desired 
product was obtained in 90% yield (195 mg, 0.60 mmol, 76% 
(E)-isomer) as a brown oil. 
1
H NMR (500 MHz, CDCl3) δ 7.57 (d, J = 7.1 Hz, 1H, E and Z), 
7.49 (d, J = 6.5 Hz, 2H, E and Z), 7.46 – 7.17 (m, 9H, E and Z), 7.10 (t, J = 7.5 Hz, 1H, E 
and Z), 6.71 (d, J = 7.5 Hz, 1H, E and Z), 5.84 – 5.71 (m, 1H, E and Z), 5.71 – 5.62 (m, 1H, 
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E and Z), 4.93 (s, 2H, E and Z), 4.56 (dd, J = 10.5, 5.0 Hz, 1H, Z), 4.51 (dd, J = 10.5, 5.0 Hz, 
1H, Z), 4.43 (dd, J = 10.6, 6.4 Hz, 1H, E), 4.37 (dd, J = 10.6, 6.4 Hz, 1H, E), 1.70 (d, J = 6.2 
Hz, 3H, E), 1.66 (d, J = 5.1 Hz, 3H, Z).HRMS (ESI): Calcd for (M + Na)
+
 [C27H23O2NNa]
+
: 
416.1621, found: 416.1637. 
 
(E)-3-(but-2-en-1-yloxy)-1-(4-methoxybenzyl)-3-(phenylethynyl)indolin-2-one (161x) 
was prepared according to the general procedure D, by using 114ab 
(96 mg, 0.26 mmol) and crotyl bromide. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/6 (Rf = 0.38) as 
eluents, the desired product was obtained in 87% yield (96 mg, 0.23 
mmol, 73% (E)-isomer) as a yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.55 (d, J = 7.5 Hz, 
1H, E and Z), 7.48 (d, J = 6.5 Hz, 2H, E and Z), 7.36 – 7.19 (m, 6H, E and Z), 7.09 (t, J = 7.5 
Hz, 1H, E and Z), 6.85 (d, J = 8.6 Hz, 2H, E and Z), 6.73 (d, J = 7.5 Hz, 1H, E and Z), 5.80 – 
5.70 (m, 1H, E and Z), 5.70 – 5.60 (m, 1H, E and Z), 4.87 (s, 2H, E and Z), 4.52 (dd, J = 
10.4, 5.5 Hz, 1H, Z), 4.48 (dd, J = 10.3, 5.5 Hz, 1H, Z), 4.39 (dd, J = 10.7, 6.4 Hz, 1H, E), 
4.34 (dd, J = 10.7, 6.4 Hz, 1H, E), 3.77 (s, 3H, E and Z), 1.69 (d, J = 6.3 Hz, 3H, E), 1.65 (d, 
J = 5.4 Hz, 3H, Z). HRMS (ESI): Calcd for (M + Na)
+
 [C28H25O3NNa]
+
: 446.1727, found: 
446.1737. 
 
(E)-3-(but-2-en-1-yloxy)-1-(methoxymethyl)-3-(phenylethynyl)indolin-2-one (161y) was 
prepared according to the general procedure D, by using 114ac (150 
mg, 0.51 mmol) and crotyl bromide. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/4 (Rf = 0.35) as 
eluents, the desired product was obtained in 51% yield (90 mg, 0.26 
mmol, 77% (E)-isomer) as a yellow oil. 
1
H NMR (600 MHz, CDCl3) δ 7.58 (dd, J = 7.4, 1.3 
Hz, 1H, E and Z), 7.46 (dd, J = 8.3, 1.5 Hz, 2H, E and Z), 7.37 (td, J = 7.7, 1.3 Hz, 1H, E and 
Z), 7.36 – 7.26 (m, 3H, E and Z), 7.17 (td, J = 7.6, 1.0 Hz, 1H, E and Z), 7.05 (d, J = 7.8 Hz, 
1H, E and Z), 5.78 – 5.69 (m, 1H, E and Z), 5.68 – 5.59 (m, 1H, E and Z), 5.18 – 5.11 (m, 
2H, E and Z), 4.51 (dd, J = 11.1, 6.7 Hz, 1H, Z), 4.46 (dd, J = 11.1, 6.6 Hz, 1H, Z), 4.36 (dd, 
J = 10.6, 6.5 Hz, 1H, E), 4.31 (dd, J = 10.6, 6.5 Hz, 1H, E), 3.37 (s, 3H, Ek), 1.68 (d, J = 6.4 
Hz, 3H, E) 1.64 (d, J = 6.1 Hz, 3H, Z). HRMS (ESI): Calcd for (M + Na)
+
 [C22H21O3NNa]
+
: 
370.1414, found: 370.1424. 
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(E)-3-(but-2-en-1-yloxy)-3-(phenylethynyl)-1-((2-(trimethylsilyl)ethoxy)methyl) 
indolin-2-one (161z) was prepared according to the general procedure 
D, by using 114ad (168 mg, 0.44 mmol) and crotyl bromide. After 
silica gel column chromatography with DCM/petroleum ether = 1/2 (Rf 
= 0.50) as eluents, the desired product was obtained in 47% yield (90 
mg, 0.21 mmol, 82% (E)-isomer) as a yellow oil. 
1
H NMR (600 MHz, CDCl3) δ 7.57 (d, J = 
6.7 Hz, 1H, E and Z), 7.45 (dd, J = 8.3, 1.4 Hz, 2H, E and Z), 7.36 (td, J = 7.8, 1.2 Hz, 1H, E 
and Z), 7.34 – 7.26 (m, 3H, E and Z), 7.16 (td, J = 7.5, 1.0 Hz, 1H, E and Z), 7.07 (d, J = 7.8 
Hz, 1H, E and Z), 5.78 – 5.68 (m, 1H, E and Z), 5.68 – 5.59 (m, 1H, E and Z), 5.21 – 5.14 
(m, 2H, E and Z), 4.48 (dd, J = 11.0, 6.7 Hz, 1H, Z), 4.44 (dd, J = 11.0, 6.5 Hz, 1H, Z), 4.34 
(dd, J = 10.6, 6.4 Hz, 1H, E), 4.29 (dd, J = 10.6, 6.4 Hz, 1H, E), 3.64 – 3.57 (m, 2H, E and 
Z), 1.68 (d, J = 6.4 Hz, 3H, E), 1.64 (d, J = 6.5 Hz, 3H, Z), 0.93 (dd, J = 9.2, 7.3 Hz, 2H, E 
and Z), -0.05 (s, 9H, E and Z). HRMS (ESI): Calcd for (M + Na)
+
 [C26H31O3NNaSi]
+
: 
456.1965, found: 456.1977. 
 
(E)-1-methyl-3-(pent-2-en-1-yloxy)-3-(phenylethynyl)indolin-2-one (172b) was prepared 
according to the general procedure, by using 114a (500 mg, 1.90 mmol) 
and (E)-1-bromo-2-pentene [1576-96-1]. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/7 (Rf = 0.58) as eluents, 
the desired product was obtained in 47% yield (295 mg, 0.89 mmol) as a 
brown oil. 
1
H NMR (500 MHz, CDCl3) δ 7.55 (dd, J = 7.5, 0.8 Hz, 1H), 7.48 – 7.42 (m, 
2H), 7.34 (td, J = 7.8, 1.3 Hz, 1H), 7.30 – 7.23 (m, 3H), 7.12 (td, J = 7.6, 1.0 Hz, 1H), 6.81 
(d, J = 7.8 Hz, 1H), 5.75 (dt, J = 15.4, 6.2 Hz, 1H), 5.61 (dt, J = 15.3, 6.4 Hz, 1H), 4.40 (ddd, 
J = 10.7, 6.4, 1.1 Hz, 1H), 4.32 (ddd, J = 10.7, 6.4, 1.1 Hz, 1H), 3.18 (s, 3H), 2.09 – 1.95 (m, 
2H), 0.96 (t, J = 7.5 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 171.75, 143.18, 136.97, 
132.04, 130.45, 128.93, 128.17, 127.91, 124.93, 124.67, 123.37, 121.69, 108.67, 87.69, 
83.78, 74.13, 66.75, 26.38, 25.24, 13.07. HRMS (ESI): Calcd for (M + Na)
+
 
[C22H21O2NNa]
+
: 354.1465, found: 354.1459.  
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(Z)-pent-2-en-1-yl methanesulfonate (S8)
[100]
  
To a solution of cis-2-penten-1-ol (S7, 0.29 ml, 2.90 mmol) and trimethylamine (0.81 ml, 
5.80 mmol) in dry THF (3 ml) was added methanesulfonyl chloride (0.27 mL, 3.48 mmol) at 
0 °C. The mixture was stirred for 1 h, and then poured into ether. The organic layer was 
washed with 1.0% HCl(aq), brine, and NaHCO3(sat.), dried over MgSO4(s) and evaporated to 
give mesylate (S8, 377 mg, 79%) as a light yellow oil. Due to the unstability, the product 
subjected to the further transformation without purification. 
 
(Z)-1-methyl-3-(pent-2-en-1-yloxy)-3-(phenylethynyl)indolin-2-one (172c) was prepared 
according to the general procedure D, by using 114a (500 mg, 1.90 mmol) 
and mesylate S8. After silica gel column chromatography with 
EtOAc/petroleum ether = 1/7 (Rf = 0.33) as eluents, the desired product 
was obtained in 50% yield (313 mg, 0.94 mmol) as a pale yellow oil. 
1
H 
NMR (500 MHz, CDCl3) δ 7.55 (dd, J = 7.4, 0.8 Hz, 1H), 7.48 – 7.41 (m, 2H), 7.33 (td, J = 
7.8, 1.3 Hz, 1H), 7.29 – 7.23 (m, 3H), 7.12 (td, J = 7.6, 1.0 Hz, 1H), 6.80 (d, J = 7.8 Hz, 1H), 
5.61 – 5.53 (m, 2H), 4.53 (dd, J = 11.0, 5.5 Hz, 1H), 4.48 (dd, J = 11.0, 5.5 Hz, 1H), 3.17 (s, 
3H), 2.12 – 2.00 (m, 2H), 0.94 (t, J = 7.6 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 171.63, 
143.08, 135.76, 131.91, 130.40, 128.87, 128.11, 127.84, 124.78, 124.65, 123.29, 121.58, 
108.62, 87.65, 83.72, 74.08, 61.33, 26.25, 20.83, 14.04. . HRMS (ESI): Calcd for (M + Na)
+
 
[C22H21O2NNa]
+
: 354.1465, found: 354.1462.  
 
3-(cinnamyloxy)-1-methyl-3-(phenylethynyl)indolin-2-one (172d) was prepared according 
to the general procedure D, by using 114a (200 mg, 0.76 mmol) and 
cinnamyl bromide [4392-24-9]. After silica gel column chromatography 
with EtOAc/petroleum ether = 1/7 (Rf = 0.65) as eluents, the desired 
product was obtained in 88% yield (320 mg, 1.01 mmol) as a pale yellow 
oil. 
1
H NMR (500 MHz, CDCl3) δ 7.63 (d, J = 7.4 Hz, 1H), 7.51 (dd, J = 7.9, 1.4 Hz, 2H), 
7.43 – 7.27 (m, 8H), 7.23 (t, J = 7.3 Hz, 1H), 7.18 (t, J = 7.6 Hz, 1H), 6.84 (d, J = 7.8 Hz, 
1H), 6.61 (d, J = 15.9 Hz, 1H), 6.38 (dt, J = 15.9, 6.3 Hz, 1H), 4.69 (ddd, J = 11.7, 6.3, 0.9 
Hz, 1H), 4.59 (ddd, J = 11.7, 6.3, 0.8 Hz, 1H), 3.19 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 
171.77, 143.18, 136.52, 133.13, 132.09, 130.61, 129.04, 128.46, 128.23, 127.70, 127.65, 
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126.52, 125.28, 124.98, 123.47, 121.56, 108.82, 87.92, 83.59, 74.19, 66.68, 26.41. HRMS 
(ESI): Calcd for (M + Na)
+
 [C26H21O2NNa]
+
: 402.1465, found: 402.1458. 
 
3-(allyloxy)-1-methyl-3-(phenylethynyl)indolin-2-one (172e) was prepared according to 
the general procedure D, by using 114a (200 mg, 0.76 mmol) and allyl 
bromide [106-95-6]. After silica gel column chromatography with 
EtOAc/petroleum ether = 1/7 (Rf = 0.63) as eluents, the desired product 
was obtained in 84% yield (194 mg, 0.64 mmol) as a pale yellow oil. 
1
H 
NMR (500 MHz, CDCl3) δ 7.56 (d, J = 7.4 Hz, 1H), 7.50 – 7.43 (m, 2H), 7.36 (td, J = 7.8, 
1.1 Hz, 1H), 7.33 – 7.24 (m, 3H), 7.14 (t, J = 7.6 Hz, 1H), 6.83 (d, J = 7.8 Hz, 1H), 6.05 – 
5.93 (m, 1H), 5.31 (dd, J = 17.2, 1.5 Hz, 1H), 5.17 (dd, J = 10.4, 1.5 Hz, 1H), 4.49 (dd, J = 
11.8, 5.8 Hz, 1H), 4.42 (dd, J = 11.8, 5.8 Hz, 1H), 3.20 (s, 3H). 
13
C NMR (126 MHz, 
CDCl3) δ 171.68, 143.16, 134.14, 132.07, 130.58, 129.03, 128.23, 127.77, 124.95, 123.46, 
121.57, 117.59, 108.77, 87.86, 83.50, 74.15, 66.84, 26.42. HRMS (ESI): Calcd for (M + 
Na)
+
 [C20H17O2NNa]
+
: 326.1152, found: 326.1146. 
 
1-methyl-3-((2-methylallyl)oxy)-3-(phenylethynyl)indolin-2-one (172f) was prepared 
according to the general procedure D, by using 114a (300 mg, 1.14 
mmol) and methallyl bromide [1458-98-6]. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/7 (Rf = 0.65) as eluents, 
the desired product was obtained in 88% yield (320 mg, 1.01 mmol) as a 
pale yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.56 (d, J = 7.3 Hz, 1H), 7.46 (dd, J = 7.9, 
1.4 Hz, 2H), 7.36 (td, J = 7.8, 1.0 Hz, 1H), 7.33 – 7.25 (m, 3H), 7.14 (t, J = 7.5 Hz, 1H), 6.83 
(d, J = 7.8 Hz, 1H), 5.02 (s, 1H), 4.89 (s, 1H), 4.36 (s, 2H), 3.20 (s, 3H), 1.80 (s, 3H). 
13
C 
NMR (126 MHz, CDCl3) δ 171.70, 143.18, 141.75, 132.08, 130.54, 129.02, 128.25, 128.00, 
124.92, 123.46, 121.67, 112.59, 108.73, 87.81, 83.66, 74.24, 69.52, 26.42, 19.81. HRMS 
(ESI): Calcd for (M + Na)
+
 [C21H19O2NNa]
+
: 340.1308, found: 340.1301. 
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5.4 Synthesis of gold(I) catalyzed cycloisomerization products 
5.4.1  Gold(I) catalyzed 5-exo-dig cycloisomerizations 
 
 
 
To the solution of 1,6-enyne (118, 10 mg, 0.03 mmol) in DCM was added cat III (1.9 mg, 
1.65 µmol) and the corresponding additive under Ar(g) atmosphere. After stirring for 
overnight, the reaction mixture was passed through a short pad of silica gel (Et2O as the 
eluent). The resulting solution was concentrated under reduced pressure, followed by silica 
gel column chromatography (EtOAc/petroleum ether as eluents) to obtain the desired 
product. 
 
4-(hydroxy(phenyl)methyl)-1'-methyl-3-methylene-4,5-dihydro-3H-spiro[furan-2,3'-ind
olin ]-2'-one (119, epi-119) were prepared according to 
the general procedure without additive. After silica gel 
column chromatography with EtOAc/petroleum ether = 
1/2 as eluents, the desired products (119, epi-119) were 
obtained in 57% yield (6 mg, 0.02 mmol, 119:epi-119 = 1:1) as a pale yellow oil. 
1
H NMR 
(500 MHz, CDCl3) δ 7.29 – 7.26 (m, 1H), 7.12 (dd, J = 7.5, 1.3 Hz, 1H), 7.05 – 6.99 (m, 
3H), 6.99 – 6.94 (m, 3H), 6.75 (d, J = 7.8 Hz, 1H), 4.93 (d, J = 9.4 Hz, 1H), 4.89 (dd, J = 
8.8, 6.5 Hz, 1H), 4.58 (dd, J = 8.8, 7.2 Hz, 1H), 4.28 (d, J = 2.2 Hz, 1H), 3.98 (d, J = 2.0 Hz, 
1H), 3.50 – 3.42 (m, 1H), 3.14 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 176.38, 148.68, 
144.64, 140.70, 130.05, 129.92, 128.62, 127.29, 126.98, 124.81, 123.11, 111.65, 108.02, 
85.88, 83.79, 72.25, 51.53, 26.19. HRMS (ESI): Calcd for (M + H)
+
 [C20H20O3N]
+
: 
322.1438, found: 322.1439. 
1
H NMR (500 MHz, CDCl3) δ 7.42 – 7.35 (m, 2H), 7.35 – 7.29 
(m, 3H), 7.26 – 7.21 (m, 1H), 7.10 (dd, J = 7.5, 1.3 Hz, 1H), 6.99 (td, J = 7.6, 1.3 Hz, 1H), 
6.71 (d, J = 7.8 Hz, 1H), 4.60 – 4.45 (m, 3H), 4.21 (d, J = 2.3 Hz, 1H), 3.89 (d, J = 2.3 Hz, 
1H), 3.50 – 3.42 (m, 1H), 3.06 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 176.39, 148.78, 
144.47, 139.29, 130.22, 129.85, 128.84, 128.41, 128.35, 124.67, 123.11, 111.36, 107.96, 
85.85, 78.95, 72.90, 50.57, 26.15. HRMS (ESI): Calcd for (M + H)
+
 [C20H20O3N]
+
: 
322.1438, found: 322.1439. 
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4-(methoxy(phenyl)methyl)-1'-methyl-3-methylene-4,5-dihydro-3H-spiro[furan-2,3'-ind
olin-2'-one (120) was prepared according to the general procedure 
with MeOH (27 L, 0.66 mol) as the additive. After silica gel column 
chromatography with EtOAc/petroleum ether = 1/5 (Rf = 0.43) as 
eluents, the desired product was obtained in 90% yield (10 mg, 0.03 
mmol) as a pale yellow oil. The recrystallization was performed from DCM and petroleum 
ether. mp: 191 °C (decomposed) 
1
H NMR (500 MHz, CDCl3) δ 7.38 (d, J = 6.8 Hz, 2H), 
7.33 (t, J = 7.3 Hz, 2H), 7.32 – 7.25 (m, 3H), 7.14 (dd, J = 7.4, 1.0 Hz, 1H), 7.02 (td, J = 7.6, 
0.7 Hz, 1H), 6.78 (d, J = 7.8 Hz, 1H), 4.73 (dd, J = 9.0, 4.8 Hz, 1H), 4.66 (d, J = 10.2 Hz, 
1H), 4.49 (dd, J = 9.0, 6.9 Hz, 1H), 4.30 (d, J = 1.7 Hz, 1H), 3.93 (d, J = 1.7 Hz, 1H), 3.34 – 
3.24 (m, 1H), 3.24 (s, 3H), 3.17 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 176.53, 148.55, 
144.65, 140.05, 130.33, 130.11, 128.60, 128.17, 128.02, 125.00, 123.43, 112.75, 108.25, 
85.98, 84.35, 72.65, 56.72, 52.01, 26.36. HRMS (ESI): Calcd for (M + H)
+
 [C21H22O3N]
+
: 
326.1594, found: 326.1595. 
 
1'-methyl-2'-oxo-6-phenyl-3-oxaspiro[bicyclo[3.1.0]hexane-2,3'-indoline]-1-carb 
aldehyde (121) was prepared according to the general procedure with 
diphenyl sulfoxide (15 mg, 0.07 mmol) and 4 Å MS (10 mg) as the 
additive. After silica gel column chromatography with 
EtOAc/petroleum ether = 1/5 (Rf = 0.15) as eluents, the desired product 
was obtained in 52% yield (5.5 mg, 17 mol) as a pale yellow oil. The recrystallization was 
performed from DCM and petroleum ether. mp: 185 °C (decomposed) 
1
H NMR (500 MHz, 
CDCl3) δ 8.76 (s, 1H), 7.40 – 7.32 (m, 3H), 7.31 (t, J = 7.7 Hz, 2H), 7.24 (t, J = 7.5 Hz, 1H), 
7.14 (dd, J = 7.5, 1.2 Hz, 1H), 7.04 (t, J = 7.5 Hz, 1H), 6.91 (d, J = 7.8 Hz, 1H), 4.45 (dd, J = 
8.9, 3.2 Hz, 1H), 4.36 (d, J = 8.9 Hz, 1H), 4.11 (d, J = 6.3 Hz, 1H), 3.38 (dd, J = 6.3, 3.2 Hz, 
1H), 3.29 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 195.28, 173.24, 143.70, 133.25, 130.27, 
129.16, 128.92, 128.71, 127.52, 123.31, 123.17, 108.85, 80.48, 69.28, 52.66, 33.55, 30.36, 
26.75. HRMS (ESI): Calcd for (M + H)
+
 [C20H18O3N]
+
: 320.1281, found: 320.1281. 
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5.4.2  Gold(I) catalyzed 6-endo-dig cycloisomerizations of prenylated 1,6-enyne 
(130) 
 
 
Under Ar(g) atmosphere, a mixture of PPh3AuCl (12 mg, 25 mol) and AgOTf (6 mg, 25 
mol) was added dry DCM (1 ml) and stirred at room temperature for 10 min. After cooling 
to 0 °C, a solution of 130 (150 mg, 0.45 mmol) in dry DCM (1.5 ml) was added to the gold 
catalyst solution. After gradually warming to room temperature, the resulting mixture was 
keep stirring till the TLC analysis indicated no starting material remaining. The crude 
product was passed through a short pad of silica gel (Et2O as the eluent). The resulting 
solution was concentrated under reduced pressure, followed by silica gel column 
chromatography (EtOAc/petroleum ether as eluents) to obtain the corresponding products.  
 
1-methyl-4'-phenyl-5'-(prop-1-en-2-yl)-5',6'-dihydrospiro[indoline-3,2'-pyran]-2-one 
(131) was obtained in 12% yield (18 mg, 0.05 mmol) as a pale yellow oil. 
The recrystallization was performed from DCM and petroleum ether. mp: 
124 °C 
1
H NMR (500 MHz, CDCl3) δ 7.39 (d, J = 6.9 Hz, 2H), 7.36 – 7.23 
(m, 5H), 7.04 (td, J = 7.6, 1.0 Hz, 1H), 6.84 (d, J = 7.6 Hz, 1H), 5.86 (d, J = 
1.5 Hz, 1H), 5.11 (s, 1H), 4.96 (s, 1H), 4.56 (dd, J = 11.5, 5.3 Hz, 1H), 4.19 
(dd, J = 11.5, 5.3 Hz, 1H), 3.69 (t, J = 5.3 Hz, 1H), 3.22 (s, 3H). 
13
C NMR (126 MHz, 
CDCl3) δ 175.13, 143.62, 143.45, 140.90, 139.57, 130.26, 130.14, 128.36, 127.79, 126.10, 
124.91, 123.17, 122.61, 115.82, 108.59, 77.75, 65.56, 43.94, 26.41, 20.40. HRMS (ESI): 
Calcd for (M + Na)
+
 [C22H21O2NNa]
+
: 354.1465, found: 354.1474. 
 
1-methyl-4'-phenyl-5'-(prop-1-en-2-yl)-5',6'-dihydrospiro[indoline-3,2'-pyran]-2-one 
(epi-132) was obtained in 16% yield (24 mg, 0.07 mmol) as a pale yellow 
oil. The recrystallization was performed from DCM and petroleum ether. 
mp: 150 °C 
1
H NMR (500 MHz, CDCl3) δ 7.43 – 7.22 (m, 7H), 7.08 (t, J 
= 7.1 Hz, 1H), 6.84 (dd, J = 8.2, 0.5 Hz, 1H), 5.96 (s, 1H), 5.05 (dd, J = 
11.4, 3.4 Hz, 1H), 5.03 (s, 1H), 5.01 (s, 1H), 4.05 (dd, J = 11.4, 0.9 Hz, 
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1H), 3.32 (d, J = 3.4 Hz, 1H), 3.19 (s, 3H), 1.97 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 
175.92, 144.82, 143.86, 139.78, 139.05, 130.27, 129.61, 128.46, 127.99, 125.91, 125.02, 
123.38, 122.20, 114.46, 108.59, 77.73, 65.42, 43.56, 26.31, 22.31. HRMS (ESI): Calcd for 
(M + Na)
+
 [C22H21O2NNa]
+
: 354.1465, found: 402.1457. 
 
(E)-1-methyl-3-(3-phenyl-4-(prop-1-en-2-yl)dihydrofuran-2(3H)-ylidene)indolin-2-one 
(epi-133) was obtained in 26% yield (39 mg, 0.12 mmol) as a pale 
yellow oil. The recrystallization was performed from DCM and 
petroleum ether. mp: 188 °C 
1
H NMR (500 MHz, CDCl3) δ 7.80 (d, J = 
7.4 Hz, 1H), 7.29 – 7.25 (m, 2H), 7.26 – 7.16 (m, 4H), 7.08 (t, J = 7.2 
Hz, 1H), 6.81 (d, J = 7.7 Hz, 1H), 5.31 (d, J = 7.8 Hz, 1H), 4.75 (s, 1H), 
4.71 (d, J = 3.3 Hz, 2H), 4.69 (s, 1H), 4.50 (s, 1H), 3.44 – 3.35 (m, 1H), 3.19 (s, 3H), 1.61 (s, 
3H). 
13
C NMR (176 MHz, CDCl3) δ 173.18, 167.93, 140.54, 138.90, 136.59, 128.66, 
128.26, 126.99, 126.18, 122.51, 122.39, 121.50, 113.49, 107.11, 101.23, 72.83, 51.07, 49.15, 
25.76, 22.84. HRMS (ESI): Calcd for (M + H)
+
 [C22H22O2N]
+
: 332.1645, found: 332.1645. 
 
(E)-1-methyl-3-(3-phenyl-4-(prop-1-en-2-yl)dihydrofuran-2(3H)-ylidene)indolin-2-one 
(134) was obtained in 8% yield (12 mg, 0.04 mmol) as a brown oil. The 
recrystallization was performed from DCM and petroleum ether. mp: 178 
°C 
1
H NMR (500 MHz, CDCl3) δ 7.79 (d, J = 7.4 Hz, 1H), 7.36 – 7.13 
(m, 6H), 7.06 (t, J = 7.6 Hz, 1H), 6.78 (d, J = 7.8 Hz, 1H), 5.15 (s, 1H), 
4.83 (s, 1H), 4.81 (s, 1H), 4.69 (dd, J = 9.4, 6.1 Hz, 1H), 4.56 (d, J = 9.4 
Hz, 1H), 3.16 (s, 3H), 2.97 (d, J = 6.1 Hz, 1H), 1.80 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 
171.96, 168.05, 144.82, 140.85, 140.70, 129.00, 127.05, 127.03, 126.30, 122.69, 122.56, 
121.59, 111.65, 107.23, 101.76, 75.39, 53.84, 53.46, 25.89, 20.77. HRMS (ESI): Calcd for 
(M + H)
+
 [C22H22O2N]
+
: 332.1645, found: 332.1660. 
 
(E)-3-(3-hydroxy-3-phenyl-4-(prop-1-en-2-yl)dihydrofuran-2(3H)-ylidene)-1-methyl 
indolin-2-one (135) was obtained in 5% yield (8 mg, 0.02 mmol) as a 
pale yellow oil. The recrystallization was performed from DCM and 
petroleum ether. mp: 205 °C 
1
H NMR (500 MHz, CDCl3) δ 7.81 (d, J = 
7.5 Hz, 1H), 7.43 – 7.34 (m, 2H), 7.34 – 7.18 (m, 5H), 7.11 (td, J = 7.6, 
0.9 Hz, 1H), 6.82 (d, J = 7.7 Hz, 1H), 4.80 (dd, J = 9.2, 7.9 Hz, 1H), 4.74 
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(s, 1H), 4.60 (dd, J = 12.2, 9.2 Hz, 1H), 4.47 (s, 1H), 3.61 (dd, J = 12.2, 7.9 Hz, 1H), 3.16 (s, 
3H), 1.53 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 178.53, 169.36, 140.65, 139.67, 138.15, 
128.11, 128.01, 126.58, 125.65, 122.82, 122.78, 122.38, 114.52, 107.80, 101.71, 85.35, 
74.45, 56.12, 26.15, 22.68. HRMS (ESI): Calcd for (M + H)
+
 [C22H22O3N]
+
: 348.1594, 
found: 348.1594. 
 
(E)-1-methyl-3-(2-oxo-2-phenylethylidene)indolin-2-one (136)
[101]
 was obtained in 7% 
yield (8 mg, 0.03 mmol) as a red oil. 
1
H NMR (500 MHz, CDCl3) δ 8.32 (d, J 
= 7.7 Hz, 1H), 8.11 (d, J = 7.5 Hz, 2H), 7.89 (s, 1H), 7.63 (t, J = 7.5 Hz, 1H), 
7.53 (t, J = 7.5 Hz, 2H), 7.37 (td, J = 7.7, 0.9 Hz, 1H), 7.03 (t, J = 7.7 Hz, 1H), 
6.81 (d, J = 7.7 Hz, 1H), 3.27 (s, 3H). 
 
5.4.3 Gold(I) catalyzed O-migration reaction of prenylated 1,6-enynes (130) 
 
To a THF (0.6 ml) solution of the 1,6-enyne (130, 0.1 mmol) was added a solution of cat II 
(3.9 mg, 5 µmol) in THF (0.4 ml). After warming to room temperature, the reaction mixture 
was stirred overnight and TLC showed full conversion of the starting material. The reaction 
mixture was passed through a short pad of silica gel (Et2O as the eluent). The resulting 
solution was concentrated under reduced pressure, followed by silica gel column 
chromatography (EtOAc/petroleum ether as eluents) to obtain the desired product. 
 
(E)-1-methyl-3-(3-phenyl-4-(prop-1-en-2-yl)dihydrofuran-2(3H)-ylidene)indolin-2-one 
(134a) was prepared according to the general procedure for the gold 
catalyzed O-migration reaction, by using 130a (49 mg, 0.15 mmol) as the 
starting material. After the purification done by silica gel column 
chromatography with EtOAc/petroleum ether = 1/7 (Rf = 0.26) as eluents, 
the desired product was obtained in 95% yield (47 mg, 0.14 mmol) as a brown oil. The 
recrystallization was performed from DCM and petroleum ether. mp: 178 °C 
1
H NMR (500 
MHz, CDCl3) δ 7.79 (d, J = 7.4 Hz, 1H), 7.36 – 7.13 (m, 6H), 7.06 (t, J = 7.6 Hz, 1H), 6.78 
(d, J = 7.8 Hz, 1H), 5.15 (s, 1H), 4.83 (s, 1H), 4.81 (s, 1H), 4.69 (dd, J = 9.4, 6.1 Hz, 1H), 
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4.56 (d, J = 9.4 Hz, 1H), 3.16 (s, 3H), 2.97 (d, J = 6.1 Hz, 1H), 1.80 (s, 3H). 
13
C NMR (126 
MHz, CDCl3) δ 171.96, 168.05, 144.82, 140.85, 140.70, 129.00, 127.05, 127.03, 126.30, 
122.69, 122.56, 121.59, 111.65, 107.23, 101.76, 75.39, 53.84, 53.46, 25.89, 20.77. HRMS 
(ESI): Calcd for (M + H)
+
 [C22H22O2N]
+
: 332.1645, found: 332.1660. 
 
(E)-1-methyl-3-(4-(prop-1-en-2-yl)-3-(o-tolyl)dihydrofuran-2(3H)-ylidene)indolin-2-one 
(134b) was prepared according to the general procedure for the gold 
catalyzed O-migration reaction, by using 130b (29 mg, 0.08 mmol) as 
the starting material. After the purification done by silica gel column 
chromatography with EtOAc/petroleum ether = 1/7 (Rf = 0.33) as 
eluents, the desired product was obtained in 69% yield (20 mg, 0.06 
mmol) as a yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.82 (d, J = 7.5 Hz, 1H), 7.24 (d, J = 
7.5 Hz, 1H), 7.21 (td, J = 7.5, 1.3 Hz, 1H), 7.13 (td, J = 7.5, 1.3 Hz, 1H), 7.08 (td, J = 7.5, 
1.0 Hz, 1H), 7.03 (t, J = 7.5 Hz, 1H), 6.87 (dd, J = 7.5, 1.0 Hz, 1H), 6.81 (d, J = 7.5 Hz, 1H), 
5.31 (s, 1H), 4.88 (s, 1H), 4.83 (t, J = 1.5 Hz, 1H), 4.69 (dd, J = 9.4, 6.0 Hz, 1H), 4.53 (dd, J 
= 9.4, 0.9 Hz, 1H), 3.17 (s, 3H), 2.87 (d, J = 6.0 Hz, 1H), 2.55 (s, 3H), 1.79 (dd, J = 1.3, 0.9 
Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 172.91, 168.02, 145.08, 140.49, 138.99, 136.19, 
130.83, 126.99, 126.13, 126.11, 125.76, 124.92, 122.61, 122.36, 121.47, 112.08, 107.11, 
75.37, 52.32, 50.53, 25.77, 20.20, 20.15. HRMS (ESI): Calcd for (M + H)
+
 [C23H24O2N]
+
: 
346.1802, found: 346.1801. 
 
(E)-1-methyl-3-(4-(prop-1-en-2-yl)-3-(m-tolyl)dihydrofuran-2(3H)-ylidene)indolin-2-on
e (134c) was prepared according to the general procedure for the gold 
catalyzed O-migration reaction, by using 130c (18 mg, 0.05 mmol) as 
the starting material. After the purification done by silica gel column 
chromatography with EtOAc/petroleum ether = 1/7 (Rf = 0.25) as 
eluents, the desired product was obtained in 77% yield (14 mg, 0.04 mmol) as a yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.80 (d, J = 7.5 Hz, 1H), 7.24 – 7.15 (m, 2H), 7.11 – 7.00 (m, 
4H), 6.80 (d, J = 7.7 Hz, 1H), 5.12 (s, 1H), 4.83 (s, 1H), 4.81 (s, J = 1.2 Hz, 1H), 4.69 (dd, J 
= 9.4, 6.0 Hz, 1H), 4.55 (dd, J = 9.4, 0.8 Hz, 1H), 3.18 (s, 3H), 2.96 (d, J = 6.0 Hz, 1H), 2.32 
(s, 3H), 1.80 (s, 3H).
 13
C NMR (126 MHz, CDCl3) δ 172.10, 168.11, 144.91, 140.75, 140.71, 
138.62, 128.85, 127.93, 127.67, 126.26, 124.04, 122.77, 122.57, 121.57, 111.58, 107.23, 
101.75, 75.35, 53.80, 53.56, 25.92, 21.70, 20.82. HRMS (ESI): Calcd for (M + H)
+
 
[C23H24O2N]
+
: 346.1802, found: 346.1815. 
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(E)-1-methyl-3-(4-(prop-1-en-2-yl)-3-(p-tolyl)dihydrofuran-2(3H)-ylidene)indolin-2-one 
(134d) was prepared according to the general procedure for the gold 
catalyzed O-migration reaction, by using 130d (37 mg, 0.11 mmol) as 
the starting material. After the purification done by silica gel column 
chromatography with EtOAc/petroleum ether = 1/7 (Rf = 0.25) as 
eluents, the desired product was obtained in 83% yield (31 mg, 0.09 mmol) as a yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.79 (d, J = 7.6 Hz, 1H), 7.19 (td, J = 7.6, 1.2 Hz, 1H), 7.15 
(d, J = 8.1 Hz, 2H), 7.11 (d, J = 8.1 Hz, 2H), 7.06 (td, J = 7.6, 1.2 Hz, 1H), 6.80 (d, J = 7.6 
Hz, 1H), 5.10 (s, 1H), 4.81 (s, 1H), 4.80 (s, 1H), 4.69 (dd, J = 9.4, 6.0 Hz, 1H), 4.55 (dd, J = 
9.4, 1.1 Hz, 1H), 3.17 (s, 3H), 2.96 (d, J = 6.0 Hz, 1H), 2.29 (s, 3H), 1.79 (s, 3H). 
13
C NMR 
(126 MHz, CDCl3) δ 172.26, 168.06, 144.90, 140.67, 137.85, 136.62, 129.69, 126.89, 
126.22, 122.74, 122.52, 121.55, 111.54, 107.20, 101.62, 75.43, 53.54, 53.52, 25.89, 21.18, 
20.77. HRMS (ESI): Calcd for (M + H)
+
 [C23H24O2N]
+
: 346.1802, found: 346.1804. 
 
(E)-3-(3-(2-methoxyphenyl)-4-(prop-1-en-2-yl)dihydrofuran-2(3H)-ylidene)-1- 
methylindolin-2-one (134e) was prepared according to the general 
procedure for the gold catalyzed O-migration reaction, by using 130e 
(60 mg, 0.17 mmol) as the starting material. After the purification done 
by silica gel column chromatography with EtOAc/petroleum ether = 
1/4 (Rf = 0.31) as eluents, the desired product was obtained in 46% 
yield (28 mg, 0.08 mmol) as a brown oil. 
1
H NMR (500 MHz, CDCl3) δ 7.82 (d, J = 7.5 Hz, 
1H), 7.25 – 7.17 (m, 2H), 7.08 (td, J = 7.5, 0.9 Hz, 1H), 6.96 – 6.90 (m, 2H), 6.80 (d, J = 7.5 
Hz, 2H), 5.36 (s, 1H), 4.83 (s, 1H), 4.80 (s, 1H), 4.62 – 4.54 (m, 2H), 3.93 (s, 3H), 3.17 (s, 
3H), 2.92 – 2.83 (m, 1H), 1.87 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 172.63, 168.06, 
157.02, 145.33, 140.64, 128.82, 128.36, 126.56, 126.11, 122.82, 122.46, 121.52, 120.50, 
110.96, 110.83, 107.15, 101.90, 75.44, 55.57, 51.73, 49.24, 25.86, 21.24. HRMS (ESI): 
Calcd for (M + H)
+
 [C23H24O3N]
+
: 362.1751, found: 362.1757. 
 
(E)-3-(3-(3,4-dimethoxyphenyl)-4-(prop-1-en-2-yl)dihydrofuran-2(3H)-ylidene)-1- 
methylindolin-2-one (134f) was prepared according to the general 
procedure for the gold catalyzed O-migration reaction, by using 130f 
(41 mg, 0.10 mmol) as the starting material. After the purification 
done by silica gel column chromatography with EtOAc/petroleum 
124 
 
ether = 1/1 (Rf = 0.55) as eluents, the desired product was obtained in 56% yield (23 mg, 
0.06 mmol) as a brown oil. 
1
H NMR (500 MHz, CDCl3) δ 7.79 (d, J = 7.6 Hz, 1H), 7.20 (t, J 
= 7.6 Hz, 1H), 7.07 (t, J = 7.6 Hz, 1H), 6.83 (s, 1H), 6.81 (d, J = 7.6 Hz, 1H), 6.79 – 6.71 (m, 
2H), 5.11 (s, 1H), 4.83 (s, 1H), 4.81 (s, 1H), 4.70 (dd, J = 9.4, 6.0 Hz, 1H), 4.55 (d, J = 9.4 
Hz, 1H), 3.87 (s, 3H), 3.82 (s, 3H), 3.19 (s, 3H), 2.97 (d, J = 6.0 Hz, 1H), 1.80 (s, 3H). 
13
C 
NMR (126 MHz, CDCl3) δ 172.07, 168.10, 149.38, 148.20, 144.83, 140.67, 133.41, 126.28, 
122.71, 122.56, 121.58, 118.65, 111.63, 111.48, 110.83, 107.24, 101.72, 75.48, 56.09, 55.98, 
53.56, 53.37, 25.91, 20.80. HRMS (ESI): Calcd for (M + H)
+
 [C24H26O4N]
+
: 392.1856, 
found: 392.1846. 
 
(E)-3-(3-(4-fluorophenyl)-4-(prop-1-en-2-yl)dihydrofuran-2(3H)-ylidene)-1-methyl 
indolin-2-one (134g) was prepared according to the general procedure 
for the gold catalyzed O-migration reaction, by using 130g (31 mg, 0.09 
mmol) as the starting material. After the purification done by silica gel 
column chromatography with EtOAc/petroleum ether = 1/7 (Rf = 0.33) 
as eluents, the desired product was obtained in 78% yield (24 mg, 0.07 mmol) as a yellow 
oil. 
1
H NMR (500 MHz, CDCl3) δ 7.79 (d, J = 7.6 Hz, 1H), 7.25 – 7.18 (m, 3H), 7.07 (t, J = 
7.6 Hz, 1H), 7.00 (d, J = 8.6 Hz, 1H), 6.98 (d, J = 8.6 Hz, 1H), 6.81 (d, J = 7.6 Hz, 1H), 5.12 
(s, 1H), 4.86 – 4.80 (m, 2H), 4.68 (dd, J = 9.5, 6.0 Hz, 1H), 4.57 (dd, J = 9.5, 1.0 Hz, 1H), 
3.18 (s, 3H), 2.96 (d, J = 6.0 Hz, 1H), 1.80 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 171.61, 
168.02, 161.86 (d, J = 245.4 Hz), 144.58, 140.72, 136.63 (d, J = 3.4 Hz), 128.60 (d, J = 8.0 
Hz), 126.45, 122.62, 122.55, 121.67, 115.85 (d, J = 21.5 Hz), 111.84, 107.32, 101.83, 75.36, 
53.48, 53.07, 25.91, 20.72. HRMS (ESI): Calcd for (M + H)
+
 [C22H21O2NF]
+
: 350.1551, 
found: 350.1554. 
 
(E)-3-(3-(2,4-difluorophenyl)-4-(prop-1-en-2-yl)dihydrofuran-2(3H)-ylidene)-1- 
methylindolin-2-one (134h) was prepared according to the general 
procedure for the gold catalyzed O-migration reaction, by using 130h 
(35 mg, 0.10 mmol) as the starting material. After the purification done 
by silica gel column chromatography with EtOAc/petroleum ether = 1/4 
(Rf = 0.40) as eluents, the desired product was obtained in 73% yield (26 mg, 0.07 mmol) 
pale yellow solid. mp: 151 °C 
1
H NMR (500 MHz, CDCl3) δ 7.79 (d, J = 7.5 Hz, 1H), 7.22 
(td, J = 7.5, 1.2 Hz, 1H), 7.08 (td, J = 7.5, 0.9 Hz, 1H), 7.01 (td, J = 8.6, 6.4 Hz, 1H), 6.90 – 
6.83 (m, 1H), 6.81 (d, J = 7.5 Hz, 1H), 6.74 (td, J = 8.0, 1.6 Hz, 1H), 5.25 (s, 1H), 4.88 – 
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4.80 (m, 2H), 4.66 – 4.55 (m, 2H), 3.18 (s, 3H), 2.95 (d, J = 4.4 Hz, 1H), 1.84 (s, 3H). 13C 
NMR (151 MHz, CDCl3) δ 170.33, 167.92, 162.16 (dd, J = 236.2, 12.8 Hz), 160.69 (dd, J = 
249.8, 12.1 Hz), 144.24, 140.82, 128.37 (dd, J = 9.6, 5.3 Hz), 126.61, 123.88 (dd, J = 15.0, 
3.9 Hz), 122.68, 122.37, 121.72, 111.84, 111.27 (dd, J = 21.2, 3.7 Hz), 107.38, 104.54 (t, J = 
25.6 Hz), 102.16, 75.48, 52.21, 47.63 (d, J = 2.5 Hz), 25.92, 20.85. HRMS (ESI): Calcd for 
(M + Na)
+
 [C22H19O2NF2Na]
+
: 390.1276, found: 350.1289. 
 
(E)-3-(3-(2-chlorophenyl)-4-(prop-1-en-2-yl)dihydrofuran-2(3H)-ylidene)-1-methyl 
indolin-2-one (134i) was prepared according to the general procedure 
for the gold catalyzed O-migration reaction, by using 130i (30 mg, 0.08 
mmol) as the starting material. After the purification done by silica gel 
column chromatography with EtOAc/petroleum ether = 1/5 (Rf = 0.33) 
as eluents, the desired product was obtained in 83% yield (25 mg, 0.07 mmol) as a yellow 
oil. 
1
H NMR (500 MHz, CDCl3) δ 7.81 (d, J = 7.5 Hz, 1H), 7.45 (dd, J = 7.7, 1.3 Hz, 1H), 
7.22 (td, J = 7.7, 1.3 Hz, 1H), 7.18 (td, J = 7.7, 1.7 Hz, 1H), 7.14 – 7.05 (m, 2H), 6.99 (dd, J 
= 7.7, 1.7 Hz, 1H), 6.81 (d, J = 7.7 Hz, 1H), 5.50 (s, 1H), 4.90 (s, 1H), 4.89 – 4.82 (m, 1H), 
4.60 (dd, J = 9.3, 5.6 Hz, 1H), 4.56 (dd, J = 9.3, 1.2 Hz, 1H), 3.18 (s, 3H), 2.97 (d, J = 5.6 
Hz, 1H), 1.87 – 1.82 (m, 3H). 13C NMR (151 MHz, CDCl3) δ 171.14, 167.97, 144.58, 
140.83, 138.12, 134.27, 130.29, 128.47, 127.05, 126.97, 126.52, 122.61, 122.48, 121.66, 
112.26, 107.34, 101.96, 75.39, 51.79, 51.39, 25.92, 20.98. HRMS (ESI): Calcd for (M + H)
+
 
[C22H21O2NCl]
+
: 366.1255, found: 366.1258. 
 
(E)-3-(3-(3-chlorophenyl)-4-(prop-1-en-2-yl)dihydrofuran-2(3H)-ylidene)-1-methyl 
indolin-2-one (134j) was prepared according to the general procedure 
for the gold catalyzed O-migration reaction, by using 130j (26 mg, 0.07 
mmol) as the starting material. After the purification done by silica gel 
column chromatography with EtOAc/petroleum ether = 1/4 (Rf = 0.25) 
as eluents, the desired product was obtained in 45% yield (12 mg, 0.03 mmol) as a pale 
yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.79 (d, J = 7.5 Hz, 1H), 7.29 – 7.18 (m, 4H), 7.16 
(d, J = 7.5 Hz, 1H), 7.08 (t, J = 7.5 Hz, 1H), 6.81 (d, J = 7.5 Hz, 1H), 5.12 (s, 1H), 4.84 (s, 
2H), 4.67 (dd, J = 9.4, 6.1 Hz, 1H), 4.56 (d, J = 9.4 Hz, 1H), 3.18 (s, 3H), 2.96 (d, J = 6.1 
Hz, 1H), 1.80 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 170.74, 168.02, 144.43, 142.84, 
140.81, 134.83, 130.24, 127.38, 127.04, 126.57, 125.43, 122.72, 122.48, 121.71, 112.00, 
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107.36, 102.12, 75.29, 53.42, 53.39, 25.93, 20.71. HRMS (ESI): Calcd for (M + Na)
+
 
[C22H20O2NClNa]
+
: 388.1075, found: 388.1084. 
 
(E)-3-(3-(4-bromophenyl)-4-(prop-1-en-2-yl)dihydrofuran-2(3H)-ylidene)-1-methyl 
indolin-2-one (134k) was prepared according to the general procedure 
for the gold catalyzed O-migration reaction, by using 130l (37 mg, 0.09 
mmol) as the starting material. After the purification done by silica gel 
column chromatography with EtOAc/petroleum ether = 1/4 (Rf = 0.40) 
as eluents, the desired product was obtained in 72% yield (27 mg, 0.07 mmol) as a pale 
yellow oil. 
1
H NMR (400 MHz, CDCl3) δ 7.78 (d, J = 7.5 Hz, 1H), 7.43 (d, J = 8.3 Hz, 2H), 
7.21 (t, J = 7.5 Hz, 1H), 7.14 (d, J = 8.3 Hz, 2H), 7.07 (t, J = 7.5 Hz, 1H), 6.81 (d, J = 7.5 
Hz, 1H), 5.09 (s, 1H), 4.83 (s, 2H), 4.67 (dd, J = 9.3, 6.2 Hz, 1H), 4.57 (d, J = 9.3 Hz, 1H), 
3.18 (s, 3H), 2.95 (d, J = 6.2 Hz, 1H), 1.80 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 171.13, 
168.02, 144.46, 140.75, 139.96, 132.11, 128.79, 126.53, 122.65, 122.48, 121.71, 121.02, 
111.97, 107.37, 101.96, 75.36, 53.37, 53.28, 25.91, 20.67. HRMS (ESI): Calcd for (M + 
Na)
+
 [C22H20O2NBrNa]
+
: 432.0570, found: 432.0577. 
 
(E)-1-methyl-3-(4-(prop-1-en-2-yl)-3-(thiophen-3-yl)dihydrofuran-2(3H)-ylidene) 
indolin-2-one (134l) was prepared according to the general procedure for 
the gold catalyzed O-migration reaction, by using 130l (35 mg, 0.10 
mmol) as the starting material. After the purification done by silica gel 
column chromatography with EtOAc/petroleum ether = 1/6 (Rf = 0.39) as 
eluents, the desired product was obtained in 67% yield (23 mg, 0.07 mmol) as a yellow oil. 
1
H NMR (400 MHz, CDCl3) δ 7.77 (d, J = 7.6 Hz, 1H), 7.28 (dd, J = 4.9, 3.0 Hz, 1H), 7.22 
(t, J = 7.6 Hz, 1H), 7.15 – 7.04 (m, 3H), 6.85 (d, J = 7.6 Hz, 1H), 5.25 (s, 1H), 4.83 (s, 2H), 
4.75 (dd, J = 9.4, 6.0 Hz, 1H), 4.61 (d, J = 9.4 Hz, 1H), 3.24 (s, 3H), 3.06 (d, J = 6.0 Hz, 
1H), 1.80 (s, 3H).
 13
C NMR (101 MHz, CDCl3) δ 173.24, 168.74, 144.33, 140.06, 139.64, 
127.04, 126.41, 122.64, 122.21, 121.20, 111.86, 107.72, 101.41, 77.36, 76.15, 52.14, 49.22, 
26.28, 20.89. HRMS (ESI): Calcd for (M + H)
+
 [C20H20O2NS]
+
: 338.1209, found: 338.1219. 
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(E)-1-methyl-3-(4-(prop-1-en-2-yl)-3-propyldihydrofuran-2(3H)-ylidene)indolin-2-one 
(134m) was prepared according to the general procedure for the gold 
catalyzed O-migration reaction with 10 mol% catalyst loading, by using 
130m (18 mg, 0.06 mmol) as the starting material. After the purification 
done by silica gel column chromatography with EtOAc/petroleum ether = 
1/7 (Rf = 0.29) as eluents, the desired product was obtained in 50% yield (9 mg, 0.03 mmol) 
as a yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.68 (d, J = 7.6 Hz, 1H), 7.17 (td, J = 7.6, 0.9 
Hz, 1H), 7.03 (t, J = 7.6 Hz, 1H), 6.82 (d, J = 7.6 Hz, 1H), 4.75 (s, 1H), 4.72 (s, 1H), 4.63 
(dd, J = 9.4, 6.2 Hz, 1H), 4.52 (d, J = 9.4 Hz, 1H), 3.85 (dd, J = 10.3, 3.2 Hz, 1H), 3.28 (s, 
3H), 2.88 (d, J = 6.2 Hz, 1H), 1.90 – 1.80 (m, 1H), 1.70 (s, 2H), 1.61 – 1.55 (m, 1H), 1.55 – 
1.45 (m, 1H), 1.01 (t, J = 7.3 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 176.05, 168.58, 
145.38, 140.26, 125.83, 123.03, 122.27, 121.57, 110.98, 107.17, 100.16, 75.90, 48.47, 48.15, 
34.61, 25.92, 21.45, 20.60, 13.95. HRMS (ESI): Calcd for (M + H)
+
 [C19H24O2N]
+
: 
298.1802, found: 298.1805. 
 
(E)-3-(3-isopentyl-4-(prop-1-en-2-yl)dihydrofuran-2(3H)-ylidene)-1-methylindolin-2-on
e (134n) was prepared according to the general procedure for the gold 
catalyzed O-migration reaction, by using 130n (35 mg, 0.11 mmol) as 
the starting material. After the purification done by silica gel column 
chromatography with EtOAc/petroleum ether = 1/7 (Rf = 0.31) as 
eluents, the desired product was obtained in 36% yield (12 mg, 0.04 mmol) as a yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.45 (dd, J = 7.6, 0.7 Hz, 1H), 7.31 (td, J = 7.6, 1.2 Hz, 1H), 
7.09 (td, J = 7.6, 0.7 Hz, 1H), 6.79 (d, J = 7.8 Hz, 1H), 5.34 (t, J = 7.2 Hz, 1H), 4.31 (dd, J = 
10.5, 7.2 Hz, 1H), 4.24 (dd, J = 10.5, 7.2 Hz, 1H), 3.18 (s, 3H), 2.24 (td, J = 7.4, 1.6 Hz, 
2H), 1.69 (s, 3H), 1.67 – 1.61 (m, 2H), 1.41 (td, J = 7.4 Hz, 2H), 0.85 (dd, J = 6.6, 2.3 Hz, 
7H).
13
C NMR (126 MHz, CDCl3) δ 172.42, 143.29, 137.98, 130.23, 128.68, 124.84, 123.38, 
120.62, 108.58, 89.47, 74.84, 73.90, 62.15, 37.33, 27.44, 26.45, 25.91, 22.22, 18.13, 17.12. 
HRMS (ESI): Calcd for (M + Na)
+
 [C21H27O2NNa]
+
: 348.1934, found: 348.1945. 
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(E)-1,5-dimethyl-3-(3-phenyl-4-(prop-1-en-2-yl)dihydrofuran-2(3H)-ylidene)indolin-2-o
ne (134o) was prepared according to the general procedure for the 
gold catalyzed O-migration reaction, by using 130o (24 mg, 0.07 
mmol) as the starting material. After the purification done by silica 
gel column chromatography with EtOAc/petroleum ether = 1/5 (Rf = 
0.27) as eluents, the desired product was obtained in 76% yield (18 mg, 0.05 mmol) as a 
brown oil. 
1
H NMR (400 MHz, CDCl3) δ 7.66 (s, 1H), 7.35 – 7.23 (m, 5H), 7.03 (dd, J = 
7.8, 0.8 Hz, 1H), 6.72 (d, J = 7.9 Hz, 1H), 5.18 (s, 1H), 4.86 (s, 1H), 4.84 (s, 1H), 4.72 (dd, J 
= 9.6, 6.0 Hz, 1H), 4.60 (dd, J = 9.5, 1.0 Hz, 1H), 3.18 (s, 3H), 3.00 (d, J = 6.0 Hz, 1H), 2.43 
(s, 3H), 1.84 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 171.64, 168.10, 144.86, 140.89, 
138.54, 130.97, 128.99, 127.02, 126.65, 123.33, 122.68, 111.63, 106.97, 101.86, 75.29, 
53.76, 53.43, 25.93, 21.42, 20.79. HRMS (ESI): Calcd for (M + H)
+
 [C23H24O2N]
+
: 
346.1802, found: 346.1812. 
 
(E)-5-methoxy-1-methyl-3-(3-phenyl-4-(prop-1-en-2-yl)dihydrofuran-2(3H)-ylidene) 
indolin-2-one (134p) was prepared according to the general 
procedure for the gold catalyzed O-migration reaction, by using 130p 
(27 mg, 0.07 mmol) as the starting material. After the purification 
done by silica gel column chromatography with EtOAc/petroleum 
ether = 1/4 (Rf = 0.27) as eluents, the desired product was obtained in 66% yield (18 mg, 
0.05 mmol) as a yellow oil. 
1
H NMR (300 MHz, CDCl3) δ 7.44 (d, J = 2.5 Hz, 1H), 7.37 – 
7.16 (m, 5H), 6.76 (dd, J = 8.4, 2.5 Hz, 1H), 6.68 (d, J = 8.4 Hz, 1H), 5.15 (s, 1H), 4.83 (s, 
1H), 4.81 (s, 1H), 4.70 (dd, J = 9.5, 6.0 Hz, 1H), 4.57 (d, J = 9.5 Hz, 1H), 3.86 (s, 3H), 3.14 
(s, 3H), 2.98 (d, J = 6.0 Hz, 1H), 1.80 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 172.10, 167.96, 
155.49, 144.80, 140.82, 134.85, 129.01, 127.06, 127.02, 123.59, 111.67, 111.35, 109.61, 
107.39, 102.12, 75.44, 56.17, 53.81, 53.39, 25.97, 20.77. HRMS (ESI): Calcd for (M + Na)
+
 
[C23H23O3NNa]
+
: 384.1570, found: 384.1579. 
 
(E)-1,5,7-trimethyl-3-(3-phenyl-4-(prop-1-en-2-yl)dihydrofuran-2(3H)-ylidene) 
indolin-2-one (134q) was prepared according to the general 
procedure for the gold catalyzed O-migration reaction, by using 130q 
(33 mg, 0.09 mmol) as the starting material. After the purification 
done by silica gel column chromatography with EtOAc/petroleum 
ether = 1/4 (Rf = 0.25) as eluents, the desired product was obtained in 58% yield (19 mg, 
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0.05 mmol) as a pale yellow solid. mp: 183 °C 
1
H NMR (500 MHz, CDCl3) δ 7.54 (s, 1H), 
7.30 (t, J = 7.4 Hz, 2H), 7.26 – 7.17 (m, 3H), 6.75 (s, 1H), 5.18 (s, 1H), 4.83 (s, 1H), 4.81 (s, 
1H), 4.68 (dd, J = 9.4, 6.1 Hz, 1H), 4.56 (d, J = 9.4 Hz, 1H), 3.43 (s, 3H), 2.96 (d, J = 6.1 
Hz, 1H), 2.52 (s, 3H), 2.35 (s, 3H), 1.80 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 171.42, 
168.67, 144.93, 141.01, 136.37, 130.86, 130.66, 128.97, 127.02, 126.98, 123.31, 121.40, 
118.58, 111.60, 101.88, 75.27, 53.89, 53.44, 29.15, 21.08, 20.78, 19.09. HRMS (ESI): Calcd 
for (M + Na)
+
 [C24H25O2NNa]
+
: 382.1778, found: 382.1783. 
 
(E)-6-bromo-1-methyl-3-(3-phenyl-4-(prop-1-en-2-yl)dihydrofuran-2(3H)- 
ylidene)indolin-2-one (134r) was prepared according to the general 
procedure for the gold catalyzed O-migration reaction, by using 130r 
(27 mg, 0.07 mmol) as the starting material. After the purification 
done by silica gel column chromatography with EtOAc/petroleum 
ether = 1/5 (Rf = 0.54) as eluents, the desired product was obtained in 69% yield (19 mg, 
0.05 mmol) as a brown oil. 
1
H NMR (300 MHz, CDCl3) δ 7.59 (d, J = 8.0 Hz, 1H), 7.40 – 
7.17 (m, 6H), 6.90 (d, J = 1.7 Hz, 1H), 5.08 (s, 1H), 4.79 (s, 2H), 4.68 (dd, J = 9.5, 6.0 Hz, 
1H), 4.55 (dd, J = 9.5, 1.1 Hz, 1H), 3.11 (s, 3H), 2.95 (d, J = 6.0 Hz, 1H), 1.77 (s, 3H). 
13
C 
NMR (75 MHz, CDCl3) δ 172.76, 167.84, 144.64, 141.78, 140.50, 129.07, 127.19, 126.99, 
124.31, 123.56, 121.55, 119.61, 111.77, 110.62, 101.02, 75.69, 54.00, 53.34, 25.99, 20.76. 
HRMS (ESI): Calcd for (M + H)
+
 [C22H21O2NBr]
+
: 410.0750, found: 410.1757. 
 
(E)-5-fluoro-1-methyl-3-(3-phenyl-4-(prop-1-en-2-yl)dihydrofuran-2(3H)-ylidene)indoli
n-2-one (134s) was prepared according to the general procedure for 
the gold catalyzed O-migration reaction, by using 130s (31 mg, 0.09 
mmol) as the starting material. After the purification done by silica 
gel column chromatography with EtOAc/petroleum ether = 1/4 (Rf = 
0.33) as eluents, the desired product was obtained in 62% yield (19 mg, 0.05 mmol) as a 
yellow oil. 
1
H NMR (400 MHz, CDCl3) δ 7.53 (dd, J = 8.9, 2.6 Hz, 1H), 7.39 – 7.28 (m, 
2H), 7.28 – 7.19 (m, 3H), 6.89 (td, J = 8.9, 2.6 Hz, 1H), 6.68 (dd, J = 8.9, 4.2 Hz, 1H), 5.14 
(s, 1H), 4.83 (s, 2H), 4.72 (dd, J = 9.5, 6.1 Hz, 1H), 4.60 (dd, J = 9.5, 1.0 Hz, 1H), 3.16 (s, 
3H), 2.99 (d, J = 6.1 Hz, 1H), 1.81 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 173.01, 167.86, 
158.99 (d, J = 236.7 Hz), 144.62, 140.51, 136.69, 129.07, 127.17, 126.98, 123.64 (d, J = 
10.0 Hz), 112.22 (d, J = 24.0 Hz), 111.75, 101.68, 110.13 (d, J = 26.0 Hz), 107.31 (d, J = 8.5 
130 
 
Hz), 75.73, 53.94, 53.33, 26.03, 20.76. HRMS (ESI): Calcd for (M + H)
+
 [C22H21O2NF]
+
: 
350.1551, found: 350.1558. 
 
(E)-5-chloro-1-methyl-3-(3-phenyl-4-(prop-1-en-2-yl)dihydrofuran-2(3H)-ylidene) 
indolin-2-one (134t) was prepared according to the general procedure 
for the gold catalyzed O-migration reaction, by using 130t (31 mg, 
0.08 mmol) as the starting material. After the purification done by 
silica gel column chromatography with EtOAc/petroleum ether = 1/5 
(Rf = 0.29) as eluents, the desired product was obtained in 65% yield (20 mg, 0.05 mmol) as 
a yellow oil. 
1
H NMR (400 MHz, CDCl3) δ 7.78 (d, J = 2.1 Hz, 1H), 7.38 – 7.29 (m, 2H), 
7.28 – 7.21 (m, 3H), 7.17 (dd, J = 8.3, 2.1 Hz, 1H), 6.71 (d, J = 8.3 Hz, 1H), 5.14 (s, 1H), 
4.84 (s, 2H), 4.74 (dd, J = 9.5, 6.0 Hz, 1H), 4.62 (dd, J = 9.5, 1.1 Hz, 1H), 3.16 (s, 3H), 3.00 
(d, J = 6.0 Hz, 1H), 1.82 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 173.24, 167.67, 144.59, 
140.44, 139.07, 129.08, 127.20, 126.98, 126.92, 125.84, 123.99, 122.56, 111.79, 107.99, 
101.05, 75.80, 54.02, 53.31, 26.01, 20.76. HRMS (ESI): Calcd for (M + H)
+
 
[C22H21O2NCl]
+
: 366.1255, found: 366.1267. 
 
(E)-1-methyl-3-(3-phenyl-4-(prop-1-en-2-yl)dihydrofuran-2(3H)-ylidene)-5-(trifluorom
ethoxy)indolin-2-one (134u) was prepared according to the general 
procedure for the gold catalyzed O-migration reaction, by using 130u 
(28 mg, 0.07 mmol) as the starting material. After the purification 
done by silica gel column chromatography with EtOAc/petroleum 
ether = 1/4 (Rf = 0.38) as eluents, the desired product was obtained in 74% yield (21 mg, 
0.05 mmol) as a brown oil. 
1
H NMR (300 MHz, CDCl3) δ 7.66 (d, J = 1.5 Hz, 1H), 7.39 – 
7.28 (m, 2H), 7.28 – 7.17 (m, 3H), 7.06 (dd, J = 8.4, 1.3 Hz, 1H), 6.74 (d, J = 8.4 Hz, 1H), 
5.14 (s, 1H), 4.84 (s, 2H), 4.75 (dd, J = 9.6, 6.1 Hz, 1H), 4.62 (dd, J = 9.6, 1.1 Hz, 1H), 3.17 
(s, 3H), 3.00 (d, J = 5.9 Hz, 1H), 1.81 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 173.57, 167.89, 
144.55, 144.27, 140.42, 139.12, 129.10, 127.23, 127.00, 124.68 (d, J = 317.8 Hz), 123.58, 
119.13, 116.20, 111.83, 107.28, 101.21, 75.94, 54.07, 53.30, 26.04, 20.77. HRMS (ESI): 
Calcd for (M + H)
+
 [C23H21O3NF3]
+
: 416.1468, found: 416.1460. 
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(E)-1-methyl-5-nitro-3-(3-phenyl-4-(prop-1-en-2-yl)dihydrofuran-2(3H)-ylidene) 
indolin-2-one (134v) was prepared according to the general 
procedure for the gold catalyzed O-migration reaction, by using 130v 
(28 mg, 0.07 mmol) as the starting material. After the purification 
done by silica gel column chromatography with EtOAc/petroleum 
ether = 1/4 (Rf = 0.18) as eluents, the desired product was obtained in 64% yield (18 mg, 
0.05 mmol) as a yellow oil. 
1
H NMR (400 MHz, CDCl3) δ 8.66 (d, J = 2.3 Hz, 1H), 8.20 
(dd, J = 8.3, 2.3 Hz, 1H), 7.43 – 7.31 (m, 2H), 7.31 - 7.18 (m, 3H), 6.86 (d, J = 8.6 Hz, 1H), 
5.15 (s, 1H), 4.98 – 4.78 (m, 3H), 4.74 (dd, J = 9.6, 1.0 Hz, 1H), 3.26 (s, 3H), 3.06 (d, J = 
5.8 Hz, 1H), 1.84 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 175.30, 168.02, 145.37, 144.31, 
142.88, 139.93, 129.19, 127.42, 126.96, 123.20, 122.86, 117.89, 112.00, 106.54, 100.04, 
76.56, 54.48, 53.16, 26.32, 20.73. HRMS (ESI): Calcd for (M + H)
+
 [C22H20O4N2]
+
: 
377.1496, found: 377.1503. 
 
(E)-1-benzyl-3-(3-phenyl-4-(prop-1-en-2-yl)dihydrofuran-2(3H)-ylidene)indolin-2-one 
(134w) was prepared according to the general procedure for the gold 
catalyzed O-migration reaction, by using 130w (25 mg, 0.06 mmol) as the 
starting material. After the purification done by silica gel column 
chromatography with EtOAc/petroleum ether = 1/4 (Rf = 0.61) as eluents, 
the desired product was obtained in 96% yield (24 mg, 0.06 mmol) as a yellow oil. 
1
H NMR 
(500 MHz, CDCl3) δ 7.83 (dd, J = 7.2, 1.1 Hz, 1H), 7.37 – 7.16 (m, 10H), 7.14 – 7.00 (m, 
2H), 6.71 (d, J = 7.2 Hz, 1H), 5.20 (s, 1H), 5.00 (d, J = 15.9 Hz, 1H), 4.87 (s, 1H), 4.86 (s, 
1H), 4.80 (d, J = 15.9 Hz, 1H), 4.73 (dd, J = 9.5, 6.0 Hz, 1H), 4.61 (dd, J = 9.5, 1.2 Hz, 1H), 
3.02 (d, J = 6.0 Hz, 1H), 1.85 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 172.87, 168.26, 
144.68, 140.73, 139.67, 136.75, 129.02, 128.70, 128.41, 127.36, 127.31, 127.11, 127.05, 
126.28, 122.84, 122.69, 121.88, 111.79, 108.44, 101.64, 75.62, 54.09, 53.55, 43.59, 20.84. 
HRMS (ESI): Calcd for (M + H)
+
 [C28H26O2N]
+
: 408.1958, found: 408.1958. 
 
(E)-1-(4-methoxybenzyl)-3-(3-phenyl-4-(prop-1-en-2-yl)dihydrofuran-2(3H)- 
ylidene)indolin-2-one (134x) was prepared according to the general 
procedure for the gold catalyzed O-migration reaction, by using 130x (33 
mg, 0.08 mmol) as the starting material. After the purification done by 
silica gel column chromatography with EtOAc/petroleum ether = 1/4 (Rf 
132 
 
= 0.30) as eluents, the desired product was obtained in 83% yield (27 mg, 0.06 mmol) as a 
brown oil. 
1
H NMR (400 MHz, CDCl3) δ 7.82 (dd, J = 7.5, 0.9 Hz, 1H), 7.43 – 7.20 (m, 
5H), 7.16 (d, J = 8.6 Hz, 2H), 7.13 – 6.98 (m, 2H), 6.79 (d, J = 8.6 Hz, 2H), 6.71 (d, J = 7.5 
Hz, 1H), 5.20 (s, 1H), 4.94 (d, J = 15.6 Hz, 1H), 4.87 (s, 1H), 4.85 (s, 1H), 4.77 – 4.67 (m, 
2H), 4.59 (dd, J = 9.5, 1.0 Hz, 1H), 3.75 (s, 3H), 3.01 (d, J = 5.8 Hz, 1H), 1.84 (s, 3H). 
13
C 
NMR (101 MHz, CDCl3) δ 172.24, 167.95, 158.84, 144.73, 140.83, 139.82, 129.03, 128.99, 
128.68, 127.03, 127.01, 126.20, 122.84, 122.61, 121.59, 114.04, 111.72, 108.25, 101.63, 
75.42, 55.33, 53.91, 53.51, 42.89, 20.85. HRMS (ESI): Calcd for (M + H)
+
 [C29H28O3N]
+
: 
438.2064, found: 438.2065. 
 
(E)-1-(methoxymethyl)-3-(3-phenyl-4-(prop-1-en-2-yl)dihydrofuran-2(3H)-  
ylidene)indolin-2-one (134y) was prepared according to the general 
procedure for the gold catalyzed O-migration reaction, by using 130y (39 
mg, 0.11 mmol) as the starting material. After the purification done by 
silica gel column chromatography with EtOAc/petroleum ether = 1/7 (Rf 
= 0.37) as eluents, the desired product was obtained in 97% yield (38 mg, 0.10 mmol) as a 
brown oil. 
1
H NMR (500 MHz, CDCl3) δ 7.83 (d, J = 6.9 Hz, 1H), 7.35 – 7.17 (m, 6H), 7.11 
(td, J = 7.7, 0.9 Hz, 1H), 7.01 (d, J = 7.7 Hz, 1H), 5.15 (d, J = 10.9 Hz, 1H), 5.14 (s, 1H), 
5.04 (d, J = 10.9 Hz, 1H), 4.85 (s, 1H), 4.84 (s, 1H), 4.71 (dd, J = 9.5, 5.7 Hz, 1H), 4.59 (dd, 
J = 9.5, 1.2 Hz, 1H), 3.25 (s, 3H), 3.00 (d, J = 5.7 Hz, 1H), 1.82 (s, 3H). 
13
C NMR (126 
MHz, CDCl3) δ 172.76, 168.38, 144.69, 140.66, 139.08, 129.00, 128.38, 127.08, 126.99, 
126.47, 122.72, 122.25, 111.75, 108.64, 101.50, 75.58, 71.13, 56.16, 54.04, 53.51, 20.78. 
HRMS (ESI): Calcd for (M + Na)
+
 [C23H23O3NNa]
+
: 384.1570, found: 384.1584. 
 
(E)-3-(3-phenyl-4-(prop-1-en-2-yl)dihydrofuran-2(3H)-ylidene)-1-((2-(trimethylsilyl) 
ethoxy)methyl)indolin-2-one (134z) was prepared according to the 
general procedure for the gold catalyzed O-migration reaction, by using 
130z (22 mg, 0.05 mmol) as the starting material. After the purification 
done by silica gel column chromatography with EtOAc/petroleum ether = 
1/10 (Rf = 0.42) as eluents, the desired product was obtained in 51% yield (11 mg, 0.03 
mmol) as a yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.89 (d, J = 7.6 Hz, 1H), 7.43 – 7.35 
(m, 2H), 7.33 (d, J = 8.9 Hz, 2H), 7.29 (d, J = 5.9 Hz, 1H), 7.27 (d, J = 7.6 Hz, 1H), 7.17 (t, 
J = 7.6 Hz, 1H), 7.10 (d, J = 7.6 Hz, 1H), 5.24 (d, J = 11.0 Hz, 1H), 5.23 (s, 1H), 5.16 (d, J = 
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11.0 Hz, 1H), 4.92 (s, 1H), 4.91 (d, J = 1.1 Hz, 1H), 4.78 (dd, J = 9.4, 6.2 Hz, 1H), 4.66 (d, J 
= 9.4 Hz, 1H), 3.60 – 3.48 (m, 2H), 3.08 (d, J = 6.2 Hz, 1H), 1.89 (s, 3H), 0.92 (dd, J = 8.2, 
8.0 Hz, 2H), -0.03 (s, 9H). 
13
C NMR (126 MHz, CDCl3) δ 172.57, 168.23, 144.76, 140.68, 
139.27, 128.99, 127.07, 127.02, 126.43, 122.73, 122.65, 122.11, 111.73, 108.81, 101.57, 
75.54, 69.14, 65.74, 53.93, 53.48, 20.76, 17.93, -1.35. HRMS (ESI): Calcd for (M + Na)
+
 
[C27H33O3NSiNa]
+
: 470.2122, found: 470.2137. 
 
(E)-1-methyl-3-(4-(prop-1-en-2-yl)-3-(propan-2-ylidene)dihydrofuran-2(3H)- 
ylidene)indolin-2-one (138) was prepared according to the general 
procedure for the gold catalyzed O-migration reaction, by using 137 (22 
mg, 0.07 mmol) as the starting material. After the purification done by 
silica gel column chromatography with EtOAc/petroleum ether = 1/7 (Rf 
= 0.33) as eluents, the desired product was obtained in 46% yield (10 mg, 0.03 mmol) as a 
yellow solid. mp: 147 °C 
1
H NMR (500 MHz, CDCl3) δ 7.76 (d, J = 7.6 Hz, 1H), 7.16 (t, J 
= 7.6 Hz, 1H), 7.00 (t, J = 7.6 Hz, 1H), 6.81 (d, J = 7.6 Hz, 1H), 4.83 (s, 1H), 4.76 (s, 1H), 
4.46 – 4.36 (m, 2H), 3.66 (d, J = 6.0 Hz, 1H), 3.28 (s, 3H), 2.01 (s, 3H), 1.99 (s, 3H), 1.71 (s, 
3H). 
13
C NMR (126 MHz, CDCl3) δ 166.39, 165.35, 148.00, 143.07, 140.21, 127.86, 125.77, 
124.22, 122.78, 121.16, 113.01, 106.90, 102.99, 73.62, 49.52, 26.07, 24.84, 23.76, 20.28. 
HRMS (ESI): Calcd for (M + H)
+
 [C19H22O2N]
+
: 296.1645, found: 296.1649. 
 
(E)-3-(3-phenyl-4-(prop-1-en-2-yl)dihydrofuran-2(3H)-ylidene)indolin-2-one (134aa) 
was prepared according to the general procedure for the gold catalyzed 
O-migration reaction, by using 133aa (33 mg, 0.01 mmol) as the starting 
material. After the purification done by silica gel column chromatography 
with EtOAc/petroleum ether = 1/2 (Rf = 0.23) as eluents, the desired 
product was obtained in 95% yield (31 mg, 0.10 mmol) as a yellow oil. 
1
H NMR (500 MHz, 
CDCl3) δ 7.89 (s, 1H), 7.77 (d, J = 7.6 Hz, 1H), 7.35 – 7.27 (m, 2H), 7.28 – 7.18 (m, 3H), 
7.12 (td, J = 7.6, 1.0 Hz, 1H), 7.04 (td, J = 7.6, 0.6 Hz, 1H), 6.77 (d, J = 7.6 Hz, 1H), 5.12 (s, 
1H), 4.84 (s, 1H), 4.83 (s, 1H), 4.71 (dd, J = 9.5, 6.0 Hz, 1H), 4.58 (dd, J = 9.5, 1.0 Hz, 1H), 
3.00 (d, J = 6.0 Hz, 1H), 1.81 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 172.78, 169.50, 
144.73, 140.69, 137.85, 128.93, 127.13, 127.09, 126.33, 123.59, 122.87, 121.65, 111.80, 
108.96, 101.88, 75.65, 53.87, 53.44, 20.71. HRMS (ESI): Calcd for (M + Na)
+
 
[C21H19O2NNa]
+
: 340.1308, found: 340.1312. 
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5.4.4 Gold catalyzed O-migration reaction with deuterated CD3OD as nucleophile 
 
At 0 °C, to a THF (0.4 ml) solution of 130 (0.08 mmol) and d-MeOH (53 µL, 0.75 mmol) 
was added a solution of cat II (3 mg, 4 µmol) in THF (0.4 mL). The reaction mixture was 
stirred at room temperature overnight. Afterwards, the reaction mixture was passed through a 
short pad of silica gel (Et2O as the eluent). The resulting solution was concentrated under 
reduced pressure, followed by silica gel column chromatography (EtOAc/petroleum ether = 
1:4 as eluents) to obtain compounds 159 in 12% yield (3 mg, 0.01 mmol, D-40%) as a 
yellow oil and 160 in 47% yield (13 mg, 0.04 mmol, D-50%) as a yellow oil. 
 
(E)-1-methyl-3-(3-phenyl-4-(prop-1-en-2-yl)dihydrofuran-2(3H)-ylidene)indolin-2-one 
(159)
 1
H NMR (300 MHz, cdcl3) δ 7.79 (d, J = 7.4 Hz, 1H), 7.36 – 
7.13 (m, 6H), 7.06 (t, J = 7.6 Hz, 1H), 6.80 (d, J = 7.8 Hz, 1H), 
5.15 (s, 0:6H), 4.83 (s, 1H), 4.81 (s, 1H), 4.69 (dd, J = 9.4, 6.1 Hz, 
1H), 4.56 (d, J = 9.4 Hz, 1H), 3.17 (s, 3H), 2.98 (d, J = 6.1 Hz, 
1H), 1.80 (s, 3H).  
 
(E)-3-((4-(2-(methoxy-d3)propan-2-yl)-3-phenyldihydrofuran-2(3H)-ylidene)-1-methyli
ndolin-2-one (160) 
1
H NMR (300 MHz, CDCl3) δ 7.75 (d, J = 
7.5 Hz, 1H), 7.34 – 7.12 (m, 6H), 7.04 (t, J = 7.5 Hz, 1H), 6.77 
(d, J = 7.5 Hz, 1H), 5.10 (s, 0.5H), 4.73 (dd, J = 9.9, 1.7 Hz, 
1H), 4.64 (dd, J = 9.9, 6.8 Hz, 1H), 3.15 (s, 3H), 2.51 (d, J = 6.8 
Hz, 1H), 1.26 (s, 3H), 1.09 (s, 3H). 
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5.4.5  Gold(I) catalyzed single cleavage rearrangement of crotylated 1,6-enyne (161) 
 
At 0 °C, to a DCM (0.6 ml) solution of 1,6-enyne (0.1 mmol) was added a solution of cat III 
(5.9 mg, 5 µmol) in DCM (0.4 ml). After warming to room temperature, the reaction mixture 
was stirred overnight and then passed through a short pad of silica gel (Et2O as the eluent). 
The resulting solution was concentrated under reduced pressure, followed by silica gel 
column chromatography (EtOAc/petroleum ether as eluents) to obtain the desired product. 
 
(E)-3'-ethylidene-1-methyl-4'-phenyl-3',6'-dihydrospiro[indoline-3,2'-pyran]-2-one 
(165a) was prepared according to the general procedure for the gold 
catalyzed C-migration reaction, by using 161a (30 mg, 0.09 mmol, 82% 
(E)-isomer) as the starting material. After the purification done by silica gel 
column chromatography with EtOAc/petroleum ether = 1/7 (Rf = 0.20) as 
eluents, the desired product was obtained in 60% yield (18 mg, 0.06 mmol) as a yellow oil. 
The recrystallization was performed from DCM and petroleum ether. mp: 131.0 °C 
1
H 
NMR (500 MHz, CDCl3) δ 7.45 (d, J = 7.6 Hz, 1H), 7.40 (td, J = 7.6, 1.1 Hz, 1H), 7.38 – 
7.33 (m, 2H), 7.33 – 7.28 (m, 1H), 7.25 (dd, J = 8.1, 1.3 Hz, 2H), 7.09 (td, J = 7.6, 1.1 Hz, 
1H), 6.95 (d, J = 7.6 Hz, 1H), 6.11 (s, 1H), 5.49 (q, J = 7.3Hz, 1H), 4.87 (dd, J = 17.8, 2.9 
Hz, 1H), 4.65 (dd, J = 17.8, 3.1 Hz, 1H), 3.30 (s, 3H), 1.19 (d, J = 7.3 Hz, 3H). 
13
C NMR 
(126 MHz, CDCl3) δ 174.34, 143.80, 141.86, 136.54, 130.84, 129.76, 129.40, 128.48, 
128.39, 127.23, 127.17, 125.95, 124.84, 122.96, 108.73, 79.61, 63.77, 26.35, 16.34. HRMS 
(ESI): Calcd for (M + Na)
+
 [C21H19O2NNa]
+
: 340.1308, found: 340.1321. 
 
(E)-3'-ethylidene-1-methyl-4'-(p-tolyl)-3',6'-dihydrospiro[indoline-3,2'-pyran]-2-one 
(165b) was prepared according to the general procedure for the gold 
catalyzed C-migration reaction, by using 161c (40 mg, 0.12 mmol, 77% 
(E)-isomer) as the starting material. After the purification done by silica 
gel column chromatography with EtOAc/petroleum ether = 1/5 (Rf = 
0.35) as eluents, the desired product was obtained in 60% yield (24 mg, 0.07 mmol) as a 
yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.40 (d, J = 7.5 Hz, 1H), 7.35 (t, J = 7.7 Hz, 1H), 
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7.12 (d, J = 8.1 Hz, 2H), 7.09 (d, J = 8.1 Hz, 2H), 7.03 (t, J = 7.5 Hz, 1H), 6.89 (d, J = 7.5 
Hz, 1H), 6.04 (s, 1H), 5.44 (q, J = 7.3 Hz, 1H), 4.80 (dd, J = 17.7, 3.0 Hz, 1H), 4.59 (dd, J = 
17.7, 3.0 Hz, 1H), 3.26 (s, 3H), 2.35 (s, 3H), 1.16 (d, J = 7.3 Hz, 3H). 
13
C NMR (126 MHz, 
CDCl3) δ 174.45, 143.84, 139.01, 136.96, 136.57, 131.02, 129.75, 129.56, 129.21, 127.91, 
127.15, 125.91, 124.87, 122.99, 108.76, 79.74, 63.86, 26.42, 21.29, 16.45. HRMS (ESI): 
Calcd for (M + Na)
+
 [C22H21O2NNa]
+
: 354.1465, found: 354.1480. 
 
(E)-3'-ethylidene-1-methyl-4'-(m-tolyl)-3',6'-dihydrospiro[indoline-3,2'-pyran]-2-one 
(165c) was prepared according to the general procedure for the gold 
catalyzed C-migration reaction, by using 161c (41 mg, 0.12 mmol, 84% 
(E)-isomer) as the starting material. After the purification done by silica 
gel column chromatography with EtOAc/petroleum ether = 1/5 (Rf = 
0.43) as eluents, the desired product was obtained in 66% yield (27 mg, 0.08 mmol) as a 
yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.40 (d, J = 7.5 Hz, 1H), 7.35 (td, J = 7.5, 1.2 Hz, 
1H), 7.19 (t, J = 7.5 Hz, 1H), 7.08 (d, J = 7.5 Hz, 1H), 7.04 (td, J = 7.5, 0.9 Hz, 1H), 7.02 (s, 
1H), 6.99 (d, J = 7.5 Hz, 1H), 6.90 (d, J = 7.5 Hz, 1H), 6.07 – 6.01 (m, 1H), 5.43 (q, J = 7.3 
Hz, 1H), 4.81 (dd, J = 17.8, 3.0 Hz, 1H), 4.59 (dd, J = 17.8, 3.2 Hz, 1H), 3.26 (s, 3H), 2.33 
(s, 3H), 1.14 (d, J = 7.3 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 174.40, 143.86, 141.86, 
138.11, 136.66, 130.87, 129.78, 129.47, 128.39, 128.17, 127.97, 127.91, 125.98, 124.92, 
124.46, 123.01, 108.77, 79.67, 63.83, 26.42, 21.55, 16.43. HRMS (ESI): Calcd for (M + 
Na)
+
 [C22H21O2NNa]
+
: 354.1465, found: 354.1455. HRMS (ESI): Calcd for (M + Na)
+
 
[C22H21O2NNa]
+
: 354.1465, found: 354.1455. 
 
(E)-3'-ethylidene-4'-(2-methoxyphenyl)-1-methyl-3',6'-dihydrospiro[indoline-3,2'-pyran
]-2-one (165e) was prepared according to the general procedure for the 
gold catalyzed C-migration reaction, by using 161e (31 mg, 0.09 mmol, 
81% (E)-isomer) as the starting material. After the purification done by 
silica gel column chromatography with EtOAc/petroleum ether = 1/5 (Rf 
= 0.15) as eluents, the desired product was obtained in 29% yield (9 mg, 0.03 mmol) as a 
yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.57 (d, J = 7.5 Hz, 1H), 7.34 (td, J = 7.7, 1.3 Hz, 
1H), 7.30 – 7.23 (m, 1H), 7.14 (d, J = 7.5 Hz, 1H), 7.06 (td, J = 7.5, 1.0 Hz, 1H), 6.93 (td, J 
= 7.5, 1.0 Hz, 1H), 6.88 (d, J = 7.7 Hz, 1H), 6.83 (d, J = 8.2 Hz, 1H), 5.94 (s, 1H), 5.26 (q, J 
= 7.4 Hz, 1H), 4.80 (dd, J = 17.9, 2.6 Hz, 1H), 4.59 (dd, J = 17.9, 2.8 Hz, 1H), 3.65 (s, 3H), 
3.25 (s, 3H), 1.06 (d, J = 7.4 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 174.58, 157.02, 
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143.83, 130.17, 129.62, 129.55, 128.72, 128.48, 125.56, 124.42, 122.60, 120.83, 108.57, 
93.35, 63.49, 55.41, 26.41, 14.48. HRMS (ESI): Calcd for (M + H)
+
 [C22H20O3N]
+
: 
348.1594, found: 348.1595. 
 
(E)-3'-ethylidene-4'-(4-methoxyphenyl)-1-methyl-3',6'-dihydrospiro[indoline-3,2'-pyran
]-2-one (165f) was prepared according to the general procedure for the 
gold catalyzed C-migration reaction, by using 161f (51 mg, 0.15 mmol, 
82% (E)-isomer) as the starting material. After the purification done by 
silica gel column chromatography with EtOAc/petroleum ether = 1/5 
(Rf = 0.27) as eluents, the desired product was obtained in 59% yield 
(30 mg, 0.09 mmol) as an orange oil. 
1
H NMR (500 MHz, CDCl3) δ 7.39 (d, J = 7.5 Hz, 
1H), 7.34 (td, J = 7.8, 1.0 Hz, 1H), 7.22 (t, J = 7.9 Hz, 1H), 7.04 (td, J = 7.5, 1.0 Hz, 1H), 
6.89 (d, J = 7.8 Hz, 1H), 6.85 – 6.77 (m, 2H), 6.77 – 6.73 (m, 1H), 6.10 – 6.04 (m, 1H), 5.43 
(q, J = 7.3 Hz, 1H), 4.81 (dd, J = 17.8, 3.0 Hz, 1H), 4.59 (dd, J = 17.8, 3.2 Hz, 1H), 3.77 (s, 
3H), 3.25 (s, 3H), 1.18 (d, J = 7.3 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 174.35, 159.82, 
143.84, 143.36, 136.44, 130.79, 129.79, 129.50, 129.42, 128.40, 126.09, 124.88, 122.99, 
119.91, 113.06, 112.56, 108.76, 79.62, 63.76, 55.37, 26.39, 16.34. HRMS (ESI): Calcd for 
(M + Na)
+
 [C22H21O3NNa]
+
: 370.1414, found: 370.1407. 
 
(E)-3'-ethylidene-4'-(4-fluorophenyl)-1-methyl-3',6'-dihydrospiro[indoline-3,2'-pyran]-
2-one (165g) was prepared according to the general procedure for the 
gold catalyzed C-migration reaction, by using 161g (49 mg, 0.15 mmol, 
78% (E)-isomer) as the starting material. After the purification done by 
silica gel column chromatography with EtOAc/petroleum ether = 1/7 (Rf 
= 0.18) as eluents, the desired product was obtained in 51% yield (25 mg, 0.07 mmol) as a 
yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.41 – 7.31 (m, 1H), 7.17 (dd, J = 8.7, 5.5 Hz, 
1H), 7.05 (t, J = 7.5 Hz, 1H), 7.00 (t, J = 8.7 Hz, 1H), 6.89 (d, J = 7.5 Hz, 1H), 6.03 (s, 1H), 
5.42 (q, J = 7.5 Hz, 1H), 4.81 (dd, J = 17.8, 3.0 Hz, 1H), 4.59 (dd, J = 17.8, 3.0 Hz, 1H), 
3.25 (s, 3H), 1.14 (d, J = 7.5 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 174.34, 162.26 (d, J = 
246.1 Hz), 143.91, 137.96, 135.56, 130.94, 129.90, 129.35, 128.85 (d, J = 7.8 Hz), 128.60, 
126.16, 124.91, 123.05, 115.44 (d, J = 21.4 Hz), 108.81, 79.61, 63.79, 26.41, 16.40. HRMS 
(ESI): Calcd for (M + Na)
+
 [C21H18O2NFNa]
+
: 358.1214, found: 358.1223. 
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(E)-4'-(3-chlorophenyl)-3'-ethylidene-1-methyl-3',6'-dihydrospiro[indoline-3,2'-pyran]-
2-one (165h) was prepared according to the general procedure for the 
gold catalyzed C-migration reaction, by using 161i (48 mg, 0.14 mmol, 
80% (E)-isomer) as the starting material. After the purification done by 
silica gel column chromatography with EtOAc/petroleum ether = 1/7 (Rf 
= 0.19) as eluents, the desired product was obtained in 31% yield (15 mg, 0.04 mmol) as a 
brown oil. 
1
H NMR (500 MHz, CDCl3) δ 7.39 – 7.33 (m, 2H), 7.25 – 7.23 (m, 2H), 7.20 (s, 
1H), 7.11 – 7.08 (m, 1H), 7.07 (td, J = 7.6, 0.9 Hz, 1H), 6.90 (d, J = 7.6 Hz, 1H), 6.08 (s, 
1H), 5.44 (q, J = 7.3 Hz, 1H), 4.83 (dd, J = 18.0, 2.9 Hz, 1H), 4.60 (dd, J = 18.0, 3.0 Hz, 
1H), 3.25 (s, 3H), 1.16 (d, J = 7.3 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 174.23, 143.94, 
143.73, 135.26, 134.46, 130.48, 129.98, 129.84, 129.46, 129.17, 127.36, 126.42, 125.55, 
124.97, 123.11, 108.84, 79.47, 63.79, 26.43, 16.59.HRMS (ESI): Calcd for (M + Na)
+
 
[C21H18O2NClNa]
+
: 374.0918, found: 374.0929. 
 
(E)-4'-(4-bromophenyl)-3'-ethylidene-1-methyl-3',6'-dihydrospiro[indoline-3,2'-pyran]-
2-one (165j) was prepared according to the general procedure for the 
gold catalyzed C-migration reaction, by using 161k (44 mg, 0.11 
mmol, 76% (E)-isomer) as the starting material. After the purification 
done by silica gel column chromatography with EtOAc/petroleum 
ether = 1/5 (Rf = 0.25) as eluents, the desired product was obtained in 28% yield (12 mg, 
0.03 mmol) as an orange oil. 
1
H NMR (500 MHz, CDCl3) δ 7.44 (d, J = 8.5 Hz, 2H), 7.40 – 
7.31 (m, 2H), 7.13 – 7.02 (m, 3H), 6.91 (d, J = 7.8 Hz, 1H), 6.11 – 6.03 (m, 1H), 5.43 (q, J = 
7.2 Hz, 1H), 4.80 (dd, J = 17.9, 2.9 Hz, 1H), 4.59 (dd, J = 17.9, 3.1 Hz, 1H), 3.26 (s, 3H), 
1.16 (d, J = 7.2 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 174.98, 143.95, 140.98, 135.76, 
131.98, 130.74, 130.25, 129.59, 129.30, 129.16, 126.67, 125.15, 123.56, 121.52, 109.26, 
79.98, 77.65, 77.40, 77.14, 64.04, 26.78, 16.84. HRMS (ESI): Calcd for (M + Na)
+
 
[C21H18O2NBrNa]
+
: 418.0413, found: 418.0418. 
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(E)-3'-ethylidene-1-methyl-4'-(thiophen-2-yl)-3',6'-dihydrospiro[indoline-3,2'-pyran]-2-
one (165k) was prepared according to the general procedure for the gold 
catalyzed C-migration reaction, by using 161m (44 mg, 0.14 mmol, 83% 
(E)-isomer) as the starting material. After the purification done by silica gel 
column chromatography with EtOAc/petroleum ether = 1/5 (Rf = 0.33) as 
eluents, the desired product was obtained in 45% yield (20 mg, 0.06 mmol) as a dark brown 
oil. 
1
H NMR (300 MHz, CDCl3) δ 7.46 – 7.30 (m, 2H), 7.26 – 7.22 (m, 1H), 7.10 – 6.98 (m, 
2H), 6.93 (d, J = 5.0 Hz, 1H), 6.89 (d, J = 7.8 Hz, 1H), 6.12 (s, 1H), 5.43 (q, J = 7.2 Hz, 1H), 
4.79 (dd, J = 17.7, 3.0 Hz, 1H), 4.56 (dd, J = 17.7, 3.0 Hz, 1H), 3.25 (s, 3H), 1.24 (d, J = 7.2 
Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ 174 .38, 143.78, 142.66, 131.55, 131.10, 129.82, 
129.42, 127.80, 127.50, 126.09, 125.52, 124.86, 123.04, 121.07, 108.78, 79.63, 63.71, 26.42, 
15.89. HRMS (ESI): Calcd for (M + Na)
+
 [C19H17O2NSNa]
+
: 346.0872, found: 346.0884. 
 
(E)-3'-ethylidene-1-methyl-4'-(prop-1-en-2-yl)-3',6'-dihydrospiro[indoline-3,2'-pyran]-2
-one (165l) was prepared according to the general procedure for the gold 
catalyzed C-migration reaction, by using 161n (51 mg, 0.18 mmol, 79% 
(E)-isomer) as the starting material. After the purification done by silica 
gel column chromatography with EtOAc/petroleum ether = 1/5 (Rf = 0.43) 
as eluents, the desired product was obtained in 25% yield (13 mg, 0.05 mmol) as a yellow 
oil. 
1
H NMR (500 MHz, CDCl3) δ 7.37 – 7.28 (m, 2H), 7.03 (t, J = 8.0 Hz, 1H), 6.84 (d, J = 
8.2 Hz, 1H), 6.10 – 6.03 (m, 1H), 5.38 (q, J = 7.1 Hz, 1H), 4.93 (s, 2H), 4.67 (dd, J = 17.0, 
3.3 Hz, 1H), 4.45 (dd, J = 17.0, 3.5 Hz, 1H), 3.21 (s, 3H), 1.88 (s, 3H), 1.70 (d, J = 7.3 Hz, 
3H). 
13
C NMR (126 MHz, CDCl3) δ 174.81, 145.12, 143.72, 138.42, 130.27, 129.71, 
129.68, 126.26, 125.56, 124.91, 122.91, 113.81, 108.67, 79.95, 63.52, 26.37, 21.37, 15.70. 
HRMS (ESI): Calcd for (M + H)
+
 [C18H20O2N]
+
: 282.1489, found: 282.1499. 
 
(E)-4'-cyclopropyl-3'-ethylidene-1-methyl-3',6'-dihydrospiro[indoline-3,2'-pyran]-2-one 
(165m) was prepared according to the general procedure for the gold 
catalyzed C-migration reaction, by using 161o (51 mg, 0.18 mmol, 78% 
(E)-isomer) as the starting material. After the purification done by silica 
gel column chromatography with EtOAc/petroleum ether = 1/5 (Rf = 0.30) 
as eluents, the desired product was obtained in 75% yield (38 mg, 0.14 mmol) as a brown oil. 
1
H NMR (500 MHz, CDCl3) δ 7.31 (td, J = 7.7, 1.2 Hz, 1H), 7.28 – 7.23 (m, 1H), 7.03 (td, J 
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= 7.7, 0.9 Hz, 1H), 6.84 (d, J = 7.7 Hz, 1H), 5.78 (s, 1H), 5.27 (q, J = 7.5 Hz, 1H), 4.65 (d, J 
= 17.6 Hz, 1H), 4.39 (d, J = 17.6 Hz, 1H), 3.19 (s, 3H), 2.01 (d, J = 7.5 Hz, 3H), 1.76 – 1.67 
(m, 1H), 0.84 – 0.71 (m, 2H), 0.67 – 0.56 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 174.62, 
143.89, 135.65, 132.08, 129.98, 129.68, 124.80, 124.16, 123.74, 122.88, 108.57, 79.98, 
63.20, 26.26, 17.06, 15.46, 8.30, 7.54. HRMS (ESI): Calcd for (M + H)
+
 [C18H20O2N]
+
: 
282.1489, found: 282.1496. 
 
(E)-3'-ethylidene-1-methyl-4'-propyl-3',6'-dihydrospiro[indoline-3,2'-pyran]-2-one 
(165n) was prepared according to the general procedure for the gold 
catalyzed C-migration reaction, by using 161p (50 mg, 0.18 mmol, 81% 
(E)-isomer) as the starting material. After the purification done by silica 
gel column chromatography with EtOAc/petroleum ether = 1/5 (Rf = 0.35) 
as eluents, the desired product was obtained in 48% yield (24 mg, 0.08 mmol) as a yellow 
solid. mp: 96 °C 
1
H NMR (600 MHz, CDCl3) δ 7.34 – 7.28 (m, 4H), 7.03 (t, J = 7.5 Hz, 
1H), 6.83 (s, 1H), 5.82 (s, 1H), 5.21 (q, J = 7.5 Hz, 1H), 4.66 (d, J = 17.8 Hz, 1H), 4.40 (d, J 
= 17.8 Hz, 1H), 3.20 (s, 3H), 2.45 (tq, J = 15.5, 7.6 Hz, 3H), 1.82 (d, J = 7.5 Hz, 3H), 1.55 – 
1.45 (m, 2H), 0.97 (t, J = 7.6 Hz, 3H).
 13
C NMR (151 MHz, CDCl3) δ 174.70, 143.88, 
135.03, 131.56, 130.02, 129.66, 125.27, 124.95, 123.30, 122.83, 108.57, 80.19, 63.17, 38.30, 
26.29, 22.23, 15.45, 14.06. HRMS (ESI): Calcd for (M + H)
+
 [C18H22O2N]
+
: 284.1645, 
found: 284.1635. 
 
(E)-3'-ethylidene-1,5-dimethyl-4'-phenyl-3',6'-dihydrospiro[indoline-3,2'-pyran]-2-one 
(165o) was prepared according to the general procedure for the gold 
catalyzed C-migration reaction, by using 161q (28 mg, 0.08 mmol, 
80% (E)-isomer) as the starting material. After the purification done by 
silica gel column chromatography with EtOAc/petroleum ether = 1/4 
(Rf = 0.43) as eluents, the desired product was obtained in 71% yield (20 mg, 0.06 mmol) as 
a yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.35 – 7.26 (m, 3H), 7.24 – 7.19 (m, 3H), 7.15 
(d, J = 8.6 Hz, 1H), 6.78 (d, J = 7.9 Hz, 1H), 6.06 (s, 1H), 5.41 (q, J = 7.3 Hz, 1H), 4.82 (dd, 
J = 17.7, 2.9 Hz, 1H), 4.60 (dd, J = 17.7, 3.0 Hz, 1H), 3.23 (s, 3H), 2.31 (s, 3H), 1.13 (d, J = 
7.3 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 174.45, 142.05, 141.52, 136.55, 132.60, 130.98, 
130.02, 129.57, 128.51, 128.49, 127.37, 127.16, 125.99, 125.69, 108.49, 79.85, 63.77, 26.42, 
21.31, 16.38. HRMS (ESI): Calcd for (M + H)
+
 [C21H22O2N]
+
: 332.1645, found: 332.1637. 
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(E)-3'-ethylidene-5-methoxy-1-methyl-4'-phenyl-3',6'-dihydrospiro[indoline-3,2'-pyran]
-2-one (165p) was prepared according to the general procedure for the 
gold catalyzed C-migration reaction, by using 161r (45 mg, 0.13 
mmol, 83% (E)-isomer) as the starting material. After the purification 
done by silica gel column chromatography with EtOAc/petroleum 
ether = 1/4 (Rf = 0.35) as eluents, the desired product was obtained in 51% yield (23 mg, 
0.07 mmol) as a dark red oil. 
1
H NMR (300 MHz, CDCl3) δ 7.42 – 7.27 (m, 3H), 7.25 – 7.16 
(m, 2H), 7.03 (d, J = 2.5 Hz, 1H), 6.88 (dd, J = 8.5, 2.5 Hz, 1H), 6.80 (d, J = 8.5 Hz, 1H), 
6.06 (s, 1H), 5.44 (q, J = 7.4 Hz, 1H), 4.82 (dd, J = 17.8, 3.1 Hz, 1H), 4.60 (dd, J = 17.8, 3.1 
Hz, 1H), 3.74 (s, 3H), 3.23 (s, 3H), 1.13 (d, J = 7.4 Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ 
174.17, 156.23, 141.87, 137.26, 136.55, 130.77, 130.60, 128.52, 128.38, 127.30, 127.21, 
126.23, 113.87, 112.41, 109.08, 79.93, 63.78, 55.99, 26.50, 16.42. HRMS (ESI): Calcd for 
(M + Na)
+
 [C22H21O3NNa]
+
: 370.1414, found: 370.1426. 
 
(E)-3'-ethylidene-1,5,7-trimethyl-4'-phenyl-3',6'-dihydrospiro[indoline-3,2'-pyran]-2-on
e (165q) was prepared according to the general procedure for the gold 
catalyzed C-migration reaction, by using 161s (40 mg, 0.12 mmol, 
80% (E)-isomer) as the starting material. After the purification done by 
silica gel column chromatography with EtOAc/petroleum ether = 1/7 
(Rf = 0.30) as eluents, the desired product was obtained in 75% yield (30 mg, 0.09 mmol) as 
an orange oil. 
1
H NMR (500 MHz, CDCl3) δ 7.36 – 7.16 (m, 5H), 7.04 (s, 1H), 6.89 (s, 1H), 
6.06 (s, 1H), 5.35 (q, J = 7.2 Hz, 1H), 4.83 (dd, J = 17.5, 2.9 Hz, 1H), 4.57 (dd, J = 17.5, 3.2 
Hz, 1H), 3.50 (s, 3H), 2.55 (s, 3H), 2.25 (s, 3H), 1.12 (d, J = 7.2 Hz, 3H). 
13
C NMR (126 
MHz, CDCl3) δ 175.37, 142.10, 139.12, 136.47, 134.02, 132.47, 131.31, 130.43, 128.62, 
128.47, 127.37, 127.09, 126.03, 123.64, 119.97, 79.15, 63.59, 29.76, 20.95, 19.16, 16.38. 
HRMS (ESI): Calcd for (M + Na)
+
 [C23H23O2NNa]
+
: 368.1621, found: 368.1607. 
 
(E)-3'-ethylidene-5-fluoro-1-methyl-4'-phenyl-3',6'-dihydrospiro[indoline-3,2'-pyran]-2
-one (165r) was prepared according to the general procedure for the gold 
catalyzed C-migration reaction, by using 161t (41 mg, 0.12 mmol, 77% 
(E)-isomer) as the starting material. After the purification done by silica 
gel column chromatography with EtOAc/petroleum ether = 1/5 (Rf = 
0.35) as eluents, the desired product was obtained in 51% yield (21 mg, 0.06 mmol) as an 
orange oil. 
1
H NMR (300 MHz, CDCl3) δ 7.37 – 7.20 (m, 3H), 7.18 – 7.09 (m, 3H), 7.02 (td, 
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J = 8.7, 2.6 Hz, 1H), 6.78 (dd, J = 8.7, 4.1 Hz, 1H), 6.03 (s, 1H), 5.41 (q, J = 7.3 Hz, 1H), 
4.78 (dd, J = 17.9, 3.0 Hz, 1H), 4.55 (dd, J = 17.9, 3.0 Hz, 1H), 3.21 (s, 3H), 1.10 (d, J = 7.3 
Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ 174.14, 159.38 (d, J = 241.3 Hz), 141.61, 139.75, 
136.49, 130.86 (d, J = 7.7 Hz), 130.43, 128.60, 128.28, 127.36, 127.23, 126.53, 115.94 (d, J 
= 23.5 Hz), 113.04 (d, J = 25.3 Hz), 109.27 (d, J = 8.0 Hz), 79.69, 63.84, 26.58, 16.45. 
HRMS (ESI): Calcd for (M + Na)
+
 [C21H18O2NFNa]
+
: 358.1214, found: 358.1225. 
 
(E)-5-chloro-3'-ethylidene-1-methyl-4'-phenyl-3',6'-dihydrospiro[indoline-3,2'-pyran]-2
-one (165s) was prepared according to the general procedure for the 
gold catalyzed C-migration reaction, by using 161u (40 mg, 0.11 mmol, 
77% (E)-isomer) as the starting material. After the purification done by 
silica gel column chromatography with EtOAc/petroleum ether = 1/5 
(Rf = 0.34) as eluents, the desired product was obtained in 50% yield (20 mg, 0.06 mmol) as 
an orange oil. 
1
H NMR (300 MHz, CDCl3) δ 7.41 – 7.27 (m, 5H), 7.21 (d, J = 1.8 Hz, 1H), 
7.19 (s, 1H), 6.82 (d, J = 8.2 Hz, 1H), 6.07 (d, J = 1.1 Hz, 1H), 5.42 (q, J = 7.3 Hz, 1H), 4.82 
(dd, J = 17.8, 3.1 Hz, 1H), 4.59 (dd, J = 17.8, 3.1 Hz, 1H), 3.24 (s, 3H), 1.14 (d, J = 7.3 Hz, 
3H).
13
C NMR (75 MHz, CDCl3) δ 174.00, 142.40, 141.65, 136.42, 131.03, 130.38, 129.69, 
128.60, 128.41, 128.33, 127.35, 127.29, 126.58, 125.27, 109.73, 79.58, 63.83, 26.54, 16.44. 
HRMS (ESI): Calcd for (M + H)
+ 
[C21H19O2NCl]
+
: 352.1099, found: 352.1107. 
 
(E)-6-bromo-3'-ethylidene-1-methyl-4'-phenyl-3',6'-dihydrospiro[indoline-3,2'-pyran]-2
-one (165t) was prepared according to the general procedure for the 
gold catalyzed C-migration reaction, by using 161v (43 mg, 0.11 mmol, 
76% (E)-isomer) as the starting material. After the purification done by 
silica gel column chromatography with EtOAc/petroleum ether = 1/8 
(Rf = 0.28) as eluents, the desired product was obtained in 58% yield (25 mg, 0.06 mmol) as 
an orange oil. 
1
H NMR (600 MHz, CDCl3) δ 7.35 – 7.22 (m, 4H), 7.21 – 7.16 (m, 3H), 7.05 
(d, J = 1.7 Hz, 1H), 6.08 – 6.03 (m, 1H), 5.42 (q, J = 7.1 Hz, 1H), 4.80 (dd, J = 17.8, 3.1 Hz, 
1H), 4.57 (dd, J = 17.8, 3.1 Hz, 1H), 3.24 (s, 3H), 1.14 (d, J = 7.1 Hz, 3H). 
13
C NMR (151 
MHz, CDCl3) δ 174.18, 145.20, 141.64, 136.52, 130.51, 128.60, 128.39, 128.36, 127.36, 
127.21, 126.34, 126.15, 125.78, 123.57, 112.35, 79.33, 63.86, 26.54, 16.43. HRMS (ESI): 
Calcd for (M + H)
+
 [C21H19O2NBr]
+
: 396.0594, found: 396.0600. 
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(E)-3'-ethylidene-1-methyl-4'-phenyl-5-(trifluoromethoxy)-3',6'-dihydrospiro 
[indoline-3,2'-pyran]-2-one (165u) was prepared according to the 
general procedure for the gold catalyzed C-migration reaction, by 
using 161w (49 mg, 0.12 mmol, 80% (E)-isomer) as the starting 
material. After the purification done by silica gel column 
chromatography with EtOAc/petroleum ether = 1/7 (Rf = 0.20) as eluents, the desired 
product was obtained in 65% yield (32 mg, 0.08 mmol) as a brown oil. 
1
H NMR (500 MHz, 
CDCl3) δ 7.39 – 7.27 (m, 4H), 7.24 (d, J = 8.5 Hz, 1H), 7.18 (d, J = 6.8 Hz, 2H), 6.88 (d, J = 
8.5 Hz, 1H), 6.09 (s, 1H), 5.43 (q, J = 7.2 Hz, 1H), 4.82 (dd, J = 17.7, 2.8 Hz, 1H), 4.58 (dd, 
J = 17.7, 3.0 Hz, 1H), 3.27 (s, 3H), 1.15 (d, J = 7.3 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 
174.26, 144.95, 142.52, 141.54, 136.64, 130.95, 130.50, 128.63, 128.39, 127.42, 127.21, 
126.59, 122.92, 120.67 (d, J = 256.9 Hz), 119.08, 109.17, 79.59, 63.86, 26.60, 16.38. HRMS 
(ESI): Calcd for (M + H)
+
 [C22H19O3NF3]
+
: 402.1312, found: 402.1323. 
 
 (E)-1-benzyl-3'-ethylidene-4'-phenyl-3',6'-dihydrospiro[indoline-3,2'-pyran]-2-one 
(165v) was prepared according to the general procedure for the gold 
catalyzed C-migration reaction, by using 161x (42 mg, 0.11 mmol, 76% 
(E)-isomer) as the starting material. After the purification done by silica gel 
column chromatography with EtOAc/petroleum ether = 1/8 (Rf = 0.31) as 
eluents, the desired product was obtained in 45% yield (19 mg, 0.05 mmol) as a yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.41 (d, J = 6.8 Hz, 1H), 7.38 – 7.30 (m, 6H), 7.30 – 7.27 (m, 
2H), 7.25 – 7.19 (m, 3H), 7.01 (td, J = 7.6, 0.8 Hz, 1H), 6.76 (d, J = 7.6 Hz, 1H), 6.10 (s, 
1H), 5.48 (q, J = 7.1 Hz, 1H), 5.05 (d, J = 15.8 Hz, 1H), 4.89 (d, J = 15.8 Hz, 1H), 4.86 (dd, 
J = 17.7, 3.0 Hz, 1H), 4.63 (dd, J = 17.7, 3.1 Hz, 1H), 1.16 (d, J = 7.3 Hz, 3H). 
13
C NMR 
(126 MHz, CDCl3) δ 174.59, 142.95, 141.90, 136.64, 135.82, 131.13, 129.68, 129.60, 
128.96, 128.58, 128.55, 127.75, 127.35, 127.31, 127.25, 126.06, 124.97, 123.04, 109.83, 
79.75, 63.85, 43.87, 16.48. HRMS (ESI): Calcd for (M + H)
+
 [C27H24O2N]
+
: 394.1802, 
found: 394.1810. 
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(E)-3'-ethylidene-1-(4-methoxybenzyl)-4'-phenyl-3',6'-dihydrospiro[indoline-3,2'-pyran
]-2-one (165w) was prepared according to the general procedure for the 
gold catalyzed C-migration reaction, by using 161y (24 mg, 0.06 mmol, 
73% (E)-isomer) as the starting material. After the purification done by 
silica gel column chromatography with EtOAc/petroleum ether = 1/7 (Rf = 
0.35) as eluents, the desired product was obtained in 42% yield (10 mg, 0.02 mmol) as a 
yellow oil. 
1
H NMR (600 MHz, CDCl3) δ 7.39 (dd, J = 7.6, 0.9 Hz, 1H), 7.35 – 7.19 (m, 
8H), 7.00 (td, J = 7.6, 0.9 Hz, 1H), 6.90 – 6.83 (m, 2H), 6.79 (d, J = 7.8 Hz, 1H), 6.09 (td, J 
= 3.1, 1.4 Hz, 1H), 5.47 (q, J = 7.0 Hz, 1H), 4.98 (d, J = 15.4 Hz, 1H), 4.85 (dd, J = 17.7, 3.2 
Hz, 1H), 4.83 (d, J = 15.4 Hz, 1H), 4.62 (dd, J = 17.7, 3.2 Hz, 1H), 3.78 (s, 3H), 1.15 (d, J = 
7.0 Hz, 3H). 
13
C NMR (151 MHz, CDCl3) δ 174.52, 159.22, 142.96, 141.91, 136.65, 131.09, 
129.65, 129.59, 128.76, 128.56, 127.87, 127.31, 127.25, 126.02, 124.92, 122.98, 114.36, 
109.86, 79.72, 63.86, 55.42, 43.36, 16.51. HRMS (ESI): Calcd for (M + Na)
+
 
[C28H25O3NNa]
+
: 446.1727, found: 446.1734. 
 
(E)-3'-ethylidene-1-(methoxymethyl)-4'-phenyl-3',6'-dihydrospiro[indoline-3,2'-pyran]-
2-one (165x) was prepared according to the general procedure for the gold 
catalyzed C-migration reaction, by using 161z (31 mg, 0.09 mmol, 77% 
(E)-isomer) as the starting material. After the purification done by silica 
gel column chromatography with EtOAc/petroleum ether = 1/7 (Rf = 0.33) 
as eluents, the desired product was obtained in 29% yield (9 mg, 0.03 mmol) as a brown oil. 
1
H NMR (500 MHz, CDCl3) δ 7.41 (d, J = 7.5 Hz, 1H), 7.36 (t, J = 7.8 Hz, 1H), 7.34 – 7.26 
(m, 3H), 7.24 – 7.17 (m, 2H), 7.09 (t, J = 8.6 Hz, 2H), 6.09 (s, 1H), 5.43 (q, J = 7.3 Hz, 1H), 
5.23 (d, J = 10.9 Hz, 1H), 5.14 (d, J = 10.9 Hz, 1H), 4.82 (dd, J = 17.7, 3.0 Hz, 1H), 4.61 
(dd, J = 17.7, 3.1 Hz, 1H), 3.38 (s, 3H), 1.14 (d, J = 7.3 Hz, 3H). 
13
C NMR (126 MHz, 
CDCl3) δ 142.36, 142.08, 130.21, 128.82, 127.53, 126.55, 125.43, 123.81, 110.51, 71.87, 
64.08, 56.72, 16.72. HRMS (ESI): Calcd for (M + Na)
+
 [C22H21O3NNa]
+
: 370.1414, found: 
370.1405. 
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(E)-3'-ethylidene-4'-phenyl-1-((2-(trimethylsilyl)ethoxy)methyl)-3',6'-dihydrospiro 
[indoline -3,2'-pyran]-2-one (165y) was prepared according to the general 
procedure for the gold catalyzed C-migration reaction, by using 161aa (33 
mg, 0.08 mmol, 82% (E)-isomer) as the starting material. After the 
purification done by silica gel column chromatography with 
EtOAc/petroleum ether = 1/10 (Rf = 0.33) as eluents, the desired product was obtained in 
70% yield (23 mg, 0.05 mmol) as a pale yellow solid. mp: 117 °C 
1
H NMR (500 MHz, 
CDCl3) δ 7.40 (d, J = 7.5 Hz, 1H), 7.36 (td, J = 7.8, 1.2 Hz, 1H), 7.34 – 7.26 (m, 3H), 7.23 – 
7.18 (m, 2H), 7.12 (d, J = 7.8 Hz, 1H), 7.09 (td, J = 7.6, 0.9 Hz, 1H), 6.13 – 6.04 (m, 1H), 
5.41 (q, J = 7.3 Hz, 1H), 5.28 (d, J = 11.1 Hz, 1H), 5.13 (d, J = 11.1 Hz, 1H), 4.82 (dd, J = 
17.7, 3.0 Hz, 1H), 4.61 (dd, J = 17.7, 3.1 Hz, 1H), 3.66 – 3.57 (m, 2H), 1.13 (d, J = 7.3 Hz, 
2H), 1.01 – 0.91 (m, 2H), -0.02 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 174.86, 142.32, 
141.89, 136.41, 131.09, 129.93, 129.08, 128.61, 128.55, 127.29, 127.24, 126.26, 125.16, 
123.45, 110.37, 109.73, 79.98, 69.62, 66.17, 63.83, 17.96, 16.45, -1.32. HRMS (ESI): Calcd 
for (M + Na)
+
 [C26H31O3NNaSi]
+
: 456.1965, found: 456.1953. 
 
5.4.6  Gold(I) catalyzed acyl-migration reaction of crotylated 1,6-enyne (161) 
 
At 0 °C, to a DCM (0.5 ml) solution of 1,6-enyne (0.1 mmol) was added a solution of cat IIa 
(4.5 mg, 5 µmol) in DCM (0.5 ml). After warming to room temperature, the reaction mixture 
was stirred overnight. After TLC showed full conversion of the starting material, the mixture 
was passed through a short pad of silica gel (Et2O as the eluent). The resulting solution was 
concentrated under reduced pressure, followed by silica gel column chromatography 
(EtOAc/petroleum ether as the eluent) to obtain the desired product. 
 
1,3-dimethyl-1a-phenyl-1a,3,9,9a-tetrahydrocyclopropa[4,5]pyrano[3,2-c]quinolin-2(1H
)-one (166a) was prepared according to the general procedure for the 
gold catalyzed carbonyl-migration reaction, by using 161a (30 mg, 0.09 
mmol, 82% (E)-isomer) as the starting material. After the purification 
done by silica gel column chromatography EtOAc/petroleum ether = 
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1/5 (Rf = 0.24) as eluents, the desired product was obtained in 67% yield (20 mg, 0.06 mmol) 
as a brown oil. The recrystallization was performed from DCM and petroleum ether. mp 
196.8-197.3 °C 
1
H NMR (500 MHz, CDCl3) δ 7.94 (dd, J = 8.0, 1.5 Hz, 1H), 7.68 (d, J = 
7.8 Hz, 2H), 7.51 – 7.45 (m, 1H), 7.27 (t, J = 7.8 Hz, 2H), 7.22 (d, J = 8.4 Hz, 1H), 7.21 – 
7.15 (m, 2H), 5.05 (dd, J = 11.9, 7.9 Hz, 1H), 3.93 (dd, J = 11.9, 7.9 Hz, 1H), 3.57 (s, 3H), 
1.61 – 1.54 (m, 1H), 1.30 – 1.23 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 162.29, 158.12, 
140.01, 138.71, 132.63, 130.44, 127.53, 126.50, 123.53, 121.50, 116.44, 115.72, 113.80, 
71.77, 31.49, 29.26, 26.70, 26.50, 16.50. HRMS (ESI): Calcd for (M + Na)
+
 
[C21H19O2NNa]
+
: 340.1308, found: 340.1320. 
 
1,3-dimethyl-1a-(m-tolyl)-1a,3,9,9a-tetrahydrocyclopropa[4,5]pyrano[3,2-c]quinolin-2(
1H)-one (166b) was prepared according to the general procedure for 
the gold catalyzed carbonyl-migration reaction, by using 161c (45 mg, 
0.14 mmol, 84% (E)-isomer) as the starting material. After the 
purification done by silica gel column chromatography 
EtOAc/petroleum ether = 1/5 (Rf = 0.30) as eluents, the desired product was obtained in 31% 
yield (14 mg, 0.04 mmol) as a yellow solid. mp: 135 °C 
1
H NMR (500 MHz, CDCl3) δ 7.97 
(dd, J = 8.0, 1.3 Hz, 1H), 7.58 (d, J = 7.7 Hz, 1H), 7.55 – 7.47 (m, 1H), 7.42 (s, 1H), 7.28 – 
7.16 (m, 3H), 7.02 (d, J = 7.7 Hz, 1H), 5.08 (dd, J = 11.9, 7.9 Hz, 1H), 3.95 (dd, J = 11.9, 
6.0 Hz, 1H), 3.60 (s, 3H), 2.33 (s, 3H), 1.63 – 1.53 (m, 1H), 1.30 – 1.26 (m, 4H). 13C NMR 
(126 MHz, CDCl3) δ 162.33, 158.15, 139.97, 138.79, 137.05, 133.10, 130.45, 129.97, 
127.36, 127.31, 123.58, 121.52, 116.55, 115.97, 113.84, 71.88, 60.53, 31.57, 29.35, 26.62, 
21.59, 16.56. HRMS (ESI): Calcd for (M + H)
+
 [C22H22O2N]
+
: 332.1645, found: 332.1636. 
 
1,3-dimethyl-1a-(p-tolyl)-1a,3,9,9a-tetrahydrocyclopropa[4,5]pyrano[3,2-c]quinolin-2(1
H)-one (166c) was prepared according to the general procedure for the 
gold catalyzed carbonyl-migration reaction, by using 161d (33 mg, 0.10 
mmol, 77% (E)-isomer) as the starting material. After the purification 
done by silica gel column chromatography EtOAc/petroleum ether = 
1/5 (Rf = 0.30) as eluents, the desired product was obtained in 39% yield (13 mg, 0.04 mmol) 
as a pale orange solid. mp: 177 °C 
1
H NMR (500 MHz, CDCl3) δ 7.94 (d, J = 7.9 Hz, 1H), 
7.56 (d, J = 8.1 Hz, 2H), 7.52 – 7.45 (m, 1H), 7.24 (d, J = 7.9 Hz, 1H), 7.19 (t, J = 7.9 Hz, 
1H), 7.07 (d, J = 8.1 Hz, 2H), 5.04 (dd, J = 11.9, 7.9 Hz, 1H), 3.92 (dd, J = 11.9, 6.0 Hz, 
1H), 3.57 (s, 3H), 2.29 (s, 3H), 1.59 – 1.50 (m, 1H), 1.30 – 1.22 (m, 4H). 13C NMR (126 
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MHz, CDCl3) δ 162.63, 158.29, 139.01, 137.26, 136.31, 132.75, 130.68, 128.59, 123.82, 
121.77, 116.79, 116.19, 114.08, 72.06, 31.79, 29.58, 26.83, 26.59, 21.53, 16.75. HRMS 
(ESI): Calcd for (M + Na)
+
 [C22H21O2NNa]
+
: 354.1645, found: 354.1454. 
 
1a-(4-fluorophenyl)-1,3-dimethyl-1a,3,9,9a-tetrahydrocyclopropa[4,5]pyrano[3,2- 
c]quinolin-2(1H)-one (166d) was prepared according to the general procedure for the gold 
catalyzed carbonyl-migration reaction, by using 161g (29 mg, 0.09 
mmol, 78% (E)-isomer) as the starting material. After the purification 
done by silica gel column chromatography EtOAc/petroleum ether = 
1/7 (Rf = 0.25) as eluents, the desired product was obtained in 63% 
yield (18 mg, 0.05 mmol) as a pale orange oil. 
1
H NMR (500 MHz, CDCl3) δ 7.94 (dd, J = 
8.0, 1.3 Hz, 1H), 7.67 – 7.59 (m, 2H), 7.54 – 7.45 (m, 1H), 7.28 – 7.15 (m, 2H), 6.94 (t, J = 
8.8 Hz, 2H), 5.04 (dd, J = 11.9, 7.8 Hz, 1H), 3.93 (dd, J = 11.9, 5.9 Hz, 1H), 3.58 (s, 3H), 
1.58 – 1.48 (m, 1H), 1.23 (s, 4H).13C NMR (126 MHz, CDCl3) δ 162.35, 161.68 (d, J = 
245.0 Hz), 158.15, 138.78, 135.64 (d, J = 3.2 Hz), 134.19 (d, J = 8.0 Hz), 130.60, 123.62, 
121.65, 116.45, 115.50, 114.39 (d, J = 21.2 Hz), 113.92, 71.67, 31.55, 29.34, 26.61, 26.03, 
16.46. HRMS (ESI): Calcd for (M + Na)
+
 [C21H18O2NFNa]
+
: 358.1214, found: 358.1223. 
 
1a-(3-chlorophenyl)-1,3-dimethyl-1a,3,9,9a-tetrahydrocyclopropa[4,5]pyrano[3,2- 
c]quinolin-2(1H)-one (166e) was prepared according to the general 
procedure for the gold catalyzed carbonyl-migration reaction, by using 
161i (27 mg, 0.08 mmol, 80% (E)-isomer) as the starting material. 
After the purification done by silica gel column chromatography with 
EtOAc/petroleum ether = 1/7 (Rf = 0.25) as eluents, the desired product was obtained in 52% 
yield (16 mg, 0.05 mmol) as an orange oil. 
1
H NMR (500 MHz, CDCl3) δ 7.94 (dd, J = 8.0, 
1.5 Hz, 1H), 7.65 (d, J = 7.7 Hz, 1H), 7.56 (t, J = 1.5 Hz, 1H), 7.54 – 7.47 (m, 1H), 7.25 (d, J 
= 8.0 Hz, 1H), 7.20 (t, J = 7.7 Hz, 2H), 7.18 – 7.13 (m, 1H), 5.03 (dd, J = 11.9, 7.8 Hz, 1H), 
3.94 (dd, J = 11.9, 5.9 Hz, 1H), 3.58 (s, 3H), 1.62 – 1.50 (m, 1H), 1.25 (s, 4H). 13C NMR 
(126 MHz, CDCl3) δ 162.25, 158.26, 142.13, 138.85, 133.26, 132.41, 131.20, 130.69, 
128.64, 126.84, 123.66, 121.67, 116.40, 115.03, 113.92, 71.42, 31.57, 29.35, 26.61, 26.50, 
16.52. HRMS (ESI): Calcd for (M + H)
+
 [C21H19O2NCl]
+
: 352.1099, found: 352.1113. 
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1a-(4-bromophenyl)-1,3-dimethyl-1a,3,9,9a-tetrahydrocyclopropa[4,5]pyrano[3,2- 
c]quinolin-2(1H)-one (166f) was prepared according to the general 
procedure for the gold catalyzed carbonyl-migration reaction, by using 
161k (30 mg, 0.08 mmol, 76% (E)-isomer) as the starting material. 
After the purification done by silica gel column chromatography 
EtOAc/petroleum ether = 1/5 (Rf = 0.25) as eluents, the desired product was obtained in 50% 
yield (15 mg, 0.04 mmol) as a brown oil. 
1
H NMR (500 MHz, CDCl3) δ 7.94 (dd, J = 8.0, 
1.3 Hz, 1H), 7.54 (d, J = 8.5 Hz, 2H), 7.53 – 7.48 (m, 1H), 7.38 (d, J = 8.5 Hz, 2H), 7.28 – 
7.24 (m, 1H), 7.23 – 7.17 (m, 1H), 5.03 (dd, J = 11.9, 7.8 Hz, 1H), 3.94 (dd, J = 11.9, 5.9 
Hz, 1H), 3.58 (s, 3H), 1.56 – 1.46 (m, 1H), 1.24 (s, 4H). 13C NMR (126 MHz, CDCl3) δ 
162.55, 158.44, 139.34, 139.03, 134.66, 130.98, 130.92, 123.88, 121.93, 120.93, 116.65, 
115.33, 114.19, 71.72, 31.73, 29.59, 26.81, 26.48, 16.73. HRMS (ESI): Calcd for (M + H)
+
 
[C21H19O2NNBr]
+
: 396.0594, found: 396.0588. 
 
1,3-dimethyl-1a-(thiophen-3-yl)-1a,3,9,9a-tetrahydrocyclopropa[4,5]pyrano  
[3,2-c]quinolin-2(1H)-one (166g) was prepared according to the 
general procedure for the gold catalyzed carbonyl-migration reaction, 
by using 161m (51 mg, 0.16 mmol, 83% (E)-isomer) as the starting 
material. After the purification done by silica gel column 
chromatography with EtOAc/petroleum ether = 1/7 (Rf = 0.16) as eluents, the desired 
product was obtained in 59% yield (30 mg, 0.09 mmol) as a yellow oil. 
1
H NMR (300 MHz, 
CDCl3) δ 7.92 (d, J = 8.0 Hz, 1H), 7.50 (t, J = 7.8 Hz, 1H), 7.42 (d, J = 2.9 Hz, 1H), 7.35 (d, 
J = 4.9 Hz, 1H), 7.29 – 7.10 (m, 4H), 5.04 (dd, J = 11.9, 8.0 Hz, 1H), 3.88 (dd, J = 11.9, 6.1 
Hz, 1H), 3.61 (s, 3H), 1.63 (t, J = 6.7 Hz, 1H), 1.20 (s, 4H). 
13
C NMR (75 MHz, CDCl3) δ 
162.40, 158.21, 140.10, 138.69, 131.47, 130.52, 125.63, 123.51, 123.42, 121.61, 116.47, 
115.22, 113.89, 71.97, 31.90, 29.34, 26.14, 21.87, 15.85. HRMS (ESI): Calcd for (M + H)
+
 
[C19H18O2NS]
+
: 324.1053, found: 324.1062. 
 
1,3,6-trimethyl-1a-phenyl-1a,3,9,9a-tetrahydrocyclopropa[4,5]pyrano[3,2-c]quinolin-2(
1H)-one (166h) was prepared according to the general procedure for 
the gold catalyzed carbonyl-migration reaction, by using 161q (32 
mg, 0.10 mmol, 80% (E)-isomer) as the starting material. After the 
purification done by silica gel column chromatography 
EtOAc/petroleum ether = 1/4 (Rf = 0.28) as eluents, the desired product was obtained in 38% 
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yield (12 mg, 0.04 mmol) as a pale orange solid. mp: 215 °C (decomposed) 
1
H NMR (500 
MHz, CDCl3) δ 7.74 (s, 1H), 7.67 (d, J = 7.0 Hz, 2H), 7.30 (dd, J = 8.6, 1.6 Hz, 1H), 7.28 – 
7.23 (m, 2H), 7.17 (t, J = 7.4 Hz, 1H), 7.14 (d, J = 8.6 Hz, 1H), 5.05 (dd, J = 11.9, 7.9 Hz, 
1H), 3.91 (dd, J = 11.9, 6.1 Hz, 1H), 3.55 (s, 3H), 2.41 (s, 3H), 1.61 – 1.51 (m, 1H), 1.26 (s, 
4H). 
13
C NMR (126 MHz, CDCl3) δ 162.23, 158.05, 140.14, 136.85, 132.67, 131.67, 131.09, 
127.56, 126.51, 123.29, 116.35, 115.82, 113.83, 71.87, 31.51, 29.31, 26.79, 26.57, 20.88, 
16.54. HRMS (ESI): Calcd for (M + H)
+
 [C22H22O2N]
+
: 332.1645, found: 332.1637. 
 
1,3,4,6-tetramethyl-1a-phenyl-1a,3,9,9a-tetrahydrocyclopropa[4,5]pyrano[3,2-c] 
quinolin-2(1H)-one (166i) was prepared according to the general 
procedure for the gold catalyzed carbonyl-migration reaction, by 
using 161s (40 mg, 0.12 mmol, 80% (E)-isomer) as the starting 
material. After the purification done by silica gel column 
chromatography EtOAc/petroleum ether = 1/4 (Rf = 0.20) as eluents, the desired product was 
obtained in 40% yield (16 mg, 0.05 mmol) as an orange solid. mp: 153 °C 
1
H NMR (500 
MHz, CDCl3) δ 7.66 (d, J = 7.9 Hz, 2H), 7.58 (s, 1H), 7.30 – 7.19 (m, 2H), 7.19 – 7.14 (m, 
1H), 7.08 (s, 1H), 5.05 (dd, J = 11.9, 8.0 Hz, 1H), 3.89 (dd, J = 11.9, 6.1 Hz, 1H), 3.65 (s, 
3H), 2.54 (s, 3H), 2.35 (s, 3H), 1.61 – 1.50 (m, 1H), 1.23 (s, 4H). 13C NMR (126 MHz, 
CDCl3) δ 164.13, 158.16, 139.88, 135.85, 132.41, 131.32, 127.51, 126.39, 124.74, 120.93, 
118.41, 109.99, 71.82, 71.48, 36.33, 31.17, 26.58, 25.74, 23.43, 20.50, 16.31. HRMS (ESI): 
Calcd for (M + Na)
+
 [C23H23O2NNa]
+
: 368.1621, found: 368.1623. 
 
6-methoxy-1,3-dimethyl-1a-phenyl-1a,3,9,9a-tetrahydrocyclopropa[4,5]pyrano[3,2-c] 
quinolin-2(1H)-one (166j) was prepared according to the general 
procedure for the gold catalyzed carbonyl-migration reaction, by 
using 161r (52 mg, 0.15 mmol, 83% (E)-isomer) as the starting 
material. After the purification done by silica gel column 
chromatography with EtOAc/petroleum ether = 1/5 (Rf = 0.29) as eluents, the desired product 
was obtained in 40% yield (21 mg, 0.06 mmol) as a brown oil. 
1
H NMR (500 MHz, CDCl3) 
δ 7.67 (d, J = 7.8 Hz, 2H), 7.39 (d, J = 2.9 Hz, 1H), 7.31 – 7.22 (m, 3H), 7.22 – 7.12 (m, 
2H), 7.11 (dd, J = 9.1, 2.9 Hz, 1H), 5.06 (dd, J = 11.9, 7.9 Hz, 1H), 3.92 (dd, J = 11.9, 6.1 
Hz, 1H), 3.87 (s, 3H), 3.56 (s, 3H), 1.63 – 1.51 (m, 1H), 1.26 (s, 4H). 13C NMR (126 MHz, 
CDCl3) δ 162.14, 157.94, 154.84, 140.30, 133.70, 132.93, 127.83, 126.80, 119.74, 117.32, 
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116.55, 115.57, 105.38, 72.21, 56.10, 31.81, 29.68, 27.15, 26.85, 16.78. HRMS (ESI): Calcd 
for (M + H)
+
 [C22H22O3N]
+
: 348.1594, found: 348.1605. 
 
6-fluoro-1,3-dimethyl-1a-phenyl-1a,3,9,9a-tetrahydrocyclopropa[4,5]pyrano  
[3,2-c]quinolin-2(1H)-one (166k) was prepared according to the 
general procedure for the gold catalyzed carbonyl-migration reaction, 
by using 161t (44 mg, 0.13 mmol, 77% (E)-isomer) as the starting 
material. After the purification done by silica gel column 
chromatography with EtOAc/petroleum ether = 1/7 (Rf = 0.14) as eluents, the desired 
product was obtained in 48% yield (21 mg, 0.06 mmol) as a yellow oil. 
1
H NMR (300 MHz, 
CDCl3) δ 7.63 (d, J = 7.2 Hz, 2H), 7.57 (dd, J = 8.9, 1.8 Hz, 1H), 7.31 – 7.07 (m, 5H), 5.01 
(dd, J = 11.9, 7.8 Hz, 1H), 3.91 (dd, J = 11.9, 5.9 Hz, 1H), 3.52 (s, 3H), 1.59 – 1.49 (m, 1H), 
1.22 (s, 4H). 
13
C NMR (75 MHz, CDCl3) δ 161.96, 159.43, 156.72 (d, J = 73.4 Hz), 139.73, 
135.26, 132.66, 127.61, 126.65, 118.13 (d, J = 23.9 Hz), 117.42 (d, J = 8.4 Hz), 116.71, 
115.43 (d, J = 8.0 Hz), 109.08 (d, J = 24.1 Hz), 71.81, 31.61, 29.56, 26.75, 26.52, 16.50. 
HRMS (ESI): Calcd for (M + H)
+
 [C21H19O2NF]
+
: 336.1394, found: 336.1404. 
 
6-chloro-1,3-dimethyl-1a-phenyl-1a,3,9,9a-tetrahydrocyclopropa[4,5]pyrano  
[3,2-c]quinolin-2(1H)-one (166l) was prepared according to the 
general procedure for the gold catalyzed carbonyl-migration 
reaction, by using 161u (44 mg, 0.13 mmol, 77% (E)-isomer) as the 
starting material. After the purification done by silica gel column 
chromatography with EtOAc/petroleum ether = 1/7 (Rf = 0.17) as eluents, the desired 
product was obtained in 50% yield (22 mg, 0.06 mmol) as a brown oil. 
1
H NMR (500 MHz, 
CDCl3) δ 7.92 (d, J = 2.4 Hz, 1H), 7.66 (d, J = 7.2 Hz, 2H), 7.43 (dd, J = 8.9, 2.4 Hz, 1H), 
7.33 – 7.23 (m, 2H), 7.23 – 7.12 (m, 2H), 5.05 (dd, J = 11.9, 7.8 Hz, 1H), 3.96 (dd, J = 11.9, 
5.8 Hz, 1H), 3.55 (s, 3H), 1.65 – 1.51 (m, 1H), 1.27 (s, 4H). 13C NMR (75 MHz, CDCl3) δ 
161.99, 157.03, 139.67, 137.21, 132.65, 130.41, 127.62, 127.31, 126.68, 123.09, 117.56, 
116.66, 115.32, 71.79, 31.62, 29.47, 26.71, 26.50, 16.49. HRMS (ESI): Calcd for (M + H)
+
 
[C21H19O2NCl]
+
: 352.1099, found: 352.1112. 
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5-bromo-1,3-dimethyl-1a-phenyl-1a,3,9,9a-tetrahydrocyclopropa[4,5]pyrano  
[3,2-c]quinolin-2(1H)-one (166m) was prepared according to the 
general procedure for the gold catalyzed carbonyl-migration 
reaction, by using 161v (51 mg, 0.13 mmol, 76% (E)-isomer) as the 
starting material. After the purification done by silica gel column 
chromatography with EtOAc/petroleum ether = 1/7 (Rf = 0.30) as eluents, the desired product 
was obtained in 47% yield (24 mg, 0.06 mmol) as a red oil. 
1
H NMR (300 MHz, CDCl3) δ 
7.75 (d, J = 8.5 Hz, 1H), 7.62 (d, J = 7.2 Hz, 2H), 7.36 (s, 1H), 7.34 – 7.19 (m, 4H), 7.17 (d, 
J = 7.2 Hz, 1H), 5.01 (dd, J = 11.9, 7.8 Hz, 1H), 3.91 (dd, J = 11.9, 5.9 Hz, 1H), 3.50 (s, 
3H), 1.53 (t, J = 6.4 Hz, 1H), 1.22 (s, 4H). 
13
C NMR (75 MHz, CDCl3) δ 162.11, 157.70, 
139.70, 139.59, 132.63, 127.61, 126.66, 124.99, 124.84, 124.75, 116.79, 115.95, 115.31, 
71.74, 31.54, 29.41, 26.64, 26.46, 16.49. HRMS (ESI): Calcd for (M + H)
+
 [C21H19O2NBr]
+
: 
396.0594, found: 396.0602. 
 
1,3-dimethyl-1a-phenyl-6-(trifluoromethoxy)-1a,3,9,9a-tetrahydrocyclopropa 
[4,5]pyrano[3,2-c]quinolin-2(1H)-one (166n) was prepared 
according to the general procedure for the gold catalyzed 
carbonyl-migration reaction, by using 161w (34 mg, 0.08 mmol, 
80% (E)-isomer) as the starting material. After the purification done 
by silica gel column chromatography with EtOAc/petroleum ether = 1/7 (Rf = 0.24) as 
eluents, the desired product was obtained in 44% yield (15 mg, 0.04 mmol) as an orange oil. 
1
H NMR (500 MHz, CDCl3) δ 7.79 (s, 1H), 7.65 (d, J = 7.2 Hz, 2H), 7.34 (dd, J = 9.1, 2.0 
Hz, 1H), 7.32 – 7.16 (m, 5H), 5.05 (dd, J = 11.9, 7.8 Hz, 1H), 3.97 (dd, J = 11.9, 5.8 Hz, 
1H), 3.57 (s, 3H), 1.26 (s, 5H). 
13
C NMR (126 MHz, CDCl3) δ 162.04, 157.10, 143.65, 
139.63, 137.25, 132.67, 127.64, 126.73, 123.58, 120.73 (d, J = 257.0 Hz), 117.24, 116.85, 
115.89, 115.25, 71.75, 31.71, 29.58, 26.79, 26.60, 16.49. HRMS (ESI): Calcd for (M + H)
+
 
[C22H19O3NF3]
+
: 402.1312, found: 402.1323. 
 
3-benzyl-1-methyl-1a-phenyl-1a,3,9,9a-tetrahydrocyclopropa[4,5]pyrano[3,2-c] 
quinolin-2(1H)-one (166o) was prepared according to the general 
procedure for the gold catalyzed carbonyl-migration reaction, by using 
161x (46 mg, 0.12 mmol, 76% (E)-isomer) as the starting material. 
After the purification done by silica gel column chromatography with 
EtOAc/petroleum ether = 1/7 (Rf = 0.40) as eluents, the desired product was obtained in 52% 
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yield (24 mg, 0.06 mmol) as a brown oil. 
1
H NMR (500 MHz, DMSO) δ 7.88 (dd, J = 8.0, 
1.5 Hz, 1H), 7.59 (d, J = 7.0 Hz, 2H), 7.47 – 7.42 (m, 1H), 7.32 – 7.12 (m, 9H), 7.05 (d, J = 
7.3 Hz, 2H), 5.47 (bs, 1H), 5.27 (bs, 1H), 5.14 (dd, J = 11.9, 8.0 Hz, 1H), 3.99 (dd, J = 12.0, 
6.1 Hz, 1H), 1.66 – 1.59 (m, 1H), 1.33 – 1.26 (m, 1H), 1.14 (d, J = 6.3 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) δ 162.65, 158.66, 140.22, 138.47, 137.22, 132.90, 130.72, 129.00, 
127.82, 127.30, 126.80, 123.92, 121.88, 116.94, 115.84, 114.99, 72.17, 45.97, 31.83, 27.11, 
26.61, 16.79. HRMS (ESI): Calcd for (M + H)
+
 [C27H24O2N]
+
: 394.1802, found: 394.1809. 
 
3-(4-methoxybenzyl)-1-methyl-1a-phenyl-1a,3,9,9a-tetrahydrocyclopropa[4,5] 
pyrano[3,2-c]quinolin-2(1H)-one (166p) was prepared according to 
the general procedure for the gold catalyzed carbonyl-migration 
reaction, by using 161y (23 mg, 0.05 mmol, 73% (E)-isomer) as the 
starting material. After the purification done by silica gel column 
chromatography with EtOAc/petroleum ether = 1/7 (Rf = 0.28) as eluents, the desired 
product was obtained in 43% yield (10 mg, 0.02 mmol) as a red oil. 
1
H NMR (500 MHz, 
CDCl3) δ 7.94 (d, J = 7.9 Hz, 1H), 7.69 (d, J = 7.6 Hz, 2H), 7.34 (m, 1H), 7.28 – 7.25 (m, 
2H), 7.20 – 7.12 (m, 3H), 6.99 (d, J = 8.2 Hz, 2H), 6.74 (d, J = 8.2 Hz, 2H), 5.49 (bs, 1H), 
5.19 (bs, 1H), 5.09 (dd, J = 11.9, 8.0 Hz, 1H), 3.96 (dd, J = 11.9, 6.1 Hz, 1H), 3.72 (s, 3H), 
1.62 – 1.58 (m, 1H), 1.34 – 1.27 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 162.63, 158.94, 
158.62, 140.23, 138.46, 132.90, 130.66, 129.32, 128.15, 127.81, 126.77, 123.89, 121.82, 
116.94, 115.88, 114.97, 114.43, 72.20, 55.60, 45.40, 31.81, 27.12, 26.60, 16.79. HRMS 
(ESI): Calcd for (M + Na)
+
 [C28H25O3NNa]
+
: 446.1727, found: 446.1734. 
 
5.4.7  Gold(I) catalyzed O-migration reaction of crotylated 1,6-enyne (161) 
 
To a DCE (0.5 ml) solution of 1,6-enyne (161, 0.5 mmol) and MeOH (41 µL, 1 mmol) in a 
pressure tube equipped with a stirring bar was added a solution of cat II (3.9 mg, 5 µmol) in 
DCE (0.5 mL) and the mixture was stirred at 60
 
°C overnight until TLC showed full 
conversion of the starting material. After cooling to room temperature, the reaction mixture 
was passed through a short pad of silica gel (Et2O as the eluent). The resulting solution was 
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concentrated under reduced pressure, followed by silica gel column chromatography 
(EtOAc/petroleum ether as eluents) to obtain the desired product. 
 
(E)-3-(4-(1-methoxyethyl)-3-phenyldihydrofuran-2(3H)-ylidene)-1-methylindolin-2-one 
(167a) was prepared from according to the general procedure for the gold 
catalyzed O-migration reaction with MeOH as nucleophile, by using 161a 
(30 mg, 0.09 mmol, 82% (E)-isomer) as the starting material. After the 
purification done by silica gel column chromatography with 
EtOAc/petroleum ether = 1/3 (Rf = 0.20) as eluents, the desired product was obtained in 73% 
yield (24 mg, 0.07 mmol) as a yellow oil. The recrystallization was performed from DCM 
and petroleum ether. mp: 127.9-129.6 °C 
1
H NMR (500 MHz, CDCl3) δ 7.79 (d, J = 7.6 Hz, 
1H), 7.35 – 7.23 (m, 5H), 7.22 (d, J = 7.6 Hz, 1H), 7.18 (dd, J = 7.6, 1.2 Hz, 1H), 7.06 (td, J 
= 7.6, 0.9 Hz, 1H), 6.79 (d, J = 7.6 Hz, 1H), 5.06 (s, 1H), 4.73 (dd, J = 9.5, 1.5 Hz, 1H), 4.60 
(dd, J = 9.5, 6.5 Hz, 1H), 3.36 – 3.26 (m, 4H), 3.17 (s, 3H), 2.44 (t, J = 6.5 Hz, 1H), 1.28 (d, 
J = 6.1 Hz, 3H).
13
C NMR (126 MHz, CDCl3) δ 172.58, 168.06, 141.13, 140.61, 128.96, 
127.08, 126.92, 126.16, 122.81, 122.53, 121.55, 107.17, 101.20, 76.98, 73.23, 56.74, 52.93, 
51.21, 25.88, 16.63.HRMS (ESI): Calcd for (M + H)
+
 [C22H24O3N]
+
: 350.1751, found: 
350.1763. 
 
(E)-3-(4-(1-methoxyethyl)-3-(p-tolyl)dihydrofuran-2(3H)-ylidene)-1-methylindolin-2-on
e (167b) was prepared from according to the general procedure for the 
gold catalyzed O-migration reaction with MeOH as nucleophile, by 
using 161d (33 mg, 0.10 mmol, 77% (E)-isomer) as the starting 
material. After the purification done by silica gel column 
chromatography with EtOAc/petroleum ether = 1/4 (Rf = 0.30) as 
eluents, the desired product was obtained in 64% yield (23 mg, 0.06 mmol) as an orange oil. 
1
H NMR (500 MHz, CDCl3) δ 7.79 (d, J = 7.7 Hz, 1H), 7.19 (t, J = 7.7 Hz, 1H), 7.15 (d, J = 
8.0 Hz, 2H), 7.10 (d, J = 8.0 Hz, 2H), 7.06 (t, J = 7.7 Hz, 1H), 6.79 (d, J = 7.7 Hz, 1H), 5.02 
(s, 1H), 4.72 (d, J = 9.5 Hz, 1H), 4.60 (dd, J = 9.5, 6.5 Hz, 1H), 3.33 (s, 3H), 3.32 – 3.28 (m, 
1H), 3.17 (s, 3H), 2.42 (t, J = 6.3 Hz, 1H), 2.29 (s, 3H), 1.28 (d, J = 6.1 Hz, 3H). 
13
C NMR 
(126 MHz, CDCl3) δ 172.85, 168.07, 140.59, 138.11, 136.47, 129.66, 126.94, 126.09, 
122.86, 122.49, 121.52, 107.14, 101.09, 73.25, 56.72, 53.04, 50.88, 25.90, 21.18, 16.66. 
HRMS (ESI): Calcd for (M + Na)
+
 [C23H25O3NNa]
+
: 386.1727, found: 386.1726. 
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(E)-3-(4-(1-methoxyethyl)-3-(m-tolyl)dihydrofuran-2(3H)-ylidene)-1-methylindolin-2-o
ne (167c) was prepared from according to the general procedure for the 
gold catalyzed O-migration reaction with MeOH as nucleophile, by 
using 161c (51 mg, 0.15 mmol, 84% (E)-isomer) as the starting 
material. After the purification done by silica gel column 
chromatography with EtOAc/petroleum ether = 1/4 (Rf = 0.30) as eluents, the desired product 
was obtained in 72% yield (40 mg, 0.11 mmol) as a pale yellow solid. mp: 136 °C 
1
H NMR 
(500 MHz, CDCl3) δ 7.81 (d, J = 7.5 Hz, 1H), 7.24 – 7.13 (m, 2H), 7.12 – 6.98 (m, 5H), 6.80 
(d, J = 7.7 Hz, 1H), 5.04 (s, 1H), 4.73 (d, J = 9.5 Hz, 1H), 4.59 (dd, J = 9.5, 6.5 Hz, 1H), 
3.34 (d, J = 2.4 Hz, 3H), 3.32 – 3.27 (m, 1H), 3.18 (s, 3H), 2.42 (t, J = 6.5 Hz, 1H), 2.32 (s, 
3H), 1.29 (d, J = 6.1 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 172.94, 168.36, 141.26, 
140.87, 138.81, 129.07, 128.06, 127.92, 126.38, 124.39, 123.13, 122.80, 121.80, 107.43, 
101.45, 77.24, 73.42, 57.00, 53.31, 51.44, 26.16, 21.96, 16.92. HRMS (ESI): Calcd for (M + 
Na)
+
 [C23H25O3NNa]
+
: 386.1727, found: 386.1721. 
 
(E)-3-(4-(1-methoxyethyl)-3-(o-tolyl)dihydrofuran-2(3H)-ylidene)-1-methylindolin-2-on
e (167d) was prepared from according to the general procedure for the 
gold catalyzed O-migration reaction with MeOH as nucleophile, by 
using 161b (33 mg, 0.10 mmol, 79% (E)-isomer) as the starting 
material. After the purification done by silica gel column 
chromatography with EtOAc/petroleum ether = 1/3 (Rf = 0.33) as eluents, the desired product 
was obtained in 41% yield (15 mg, 0.04 mmol) as a yellow solid. mp: 184 °C 
1
H NMR (500 
MHz, CDCl3) δ 7.81 (d, J = 7.5 Hz, 1H), 7.25 – 7.17 (m, 2H), 7.12 (td, J = 7.5, 1.3 Hz, 1H), 
7.07 (td, J = 7.5, 1.0 Hz, 1H), 7.03 (t, J = 7.5 Hz, 1H), 6.88 (d, J = 7.5 Hz, 1H), 6.79 (d, J = 
7.5 Hz, 1H), 5.23 (s, 1H), 4.72 (dd, J = 9.4, 1.1 Hz, 1H), 4.59 (dd, J = 9.4, 6.2 Hz, 1H), 3.39 
– 3.32 (m, 1H), 3.33 (s, 3H), 3.17 (s, 3H), 2.61 (s, 3H), 2.29 (t, J = 6.2 Hz, 1H), 1.27 (d, J = 
6.2 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 173.70, 168.10, 140.33, 138.97, 135.99, 130.83, 
126.93, 126.13, 125.92, 125.32, 122.74, 122.30, 121.43, 109.99, 107.04, 72.86, 56.73, 51.25, 
47.92, 25.80, 20.25, 16.34. HRMS (ESI): Calcd for (M + Na)
+
 [C23H25O3NNa]
+
: 386.1727, 
found: 386.1723. 
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(E)-3-(4-(1-methoxyethyl)-3-(4-methoxyphenyl)dihydrofuran-2(3H)-ylidene)-1- 
methylindolin-2-one (167e) was prepared from according to the 
general procedure for the gold catalyzed O-migration reaction with 
MeOH as nucleophile, by using 161f (47 mg, 0.12 mmol, 82% 
(E)-isomer) as the starting material. After the purification done by 
silica gel column chromatography with EtOAc/petroleum ether = 1/4 (Rf = 0.15) as eluents, 
the desired product was obtained in 72% yield (34 mg, 0.09 mmol) as a pale yellow solid. 
mp: 130 °C 
1
H NMR (500 MHz, CDCl3) δ 7.78 (d, J = 7.4 Hz, 1H), 7.25 – 7.16 (m, 2H), 
7.06 (t, J = 7.6 Hz, 1H), 6.88 – 6.71 (m, 5H), 5.04 (s, 1H), 4.71 (d, J = 9.5 Hz, 1H), 4.59 (dd, 
J = 9.5, 6.3 Hz, 1H), 3.77 (s, 3H), 3.33 (s, 3H), 3.33 – 3.26 (m, 1H), 3.18 (s, 3H), 2.44 (t, J = 
6.3 Hz, 1H), 1.28 (d, J = 6.3 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 173.70, 168.10, 
140.33, 138.97, 135.99, 130.83, 126.93, 126.13, 125.92, 125.32, 122.74, 122.30, 121.43, 
109.99, 107.04, 77.26, 72.86, 56.73, 51.25, 47.92, 25.80, 20.25, 16.34. HRMS (ESI): Calcd 
for (M + Na)
+
 [C23H25O4NNa]
+
: 402.1676, found: 402.1671. 
 
(E)-3-(3-(4-fluorophenyl)-4-(1-methoxyethyl)dihydrofuran-2(3H)-ylidene)-1- 
methylindolin-2-one (167f) was prepared according to the general 
procedure for the gold catalyzed O-migration reaction with MeOH as 
nucleophile, by using 161g (36 mg, 0.11 mmol, 78% (E)-isomer) as the 
starting material. After the purification done by silica gel column 
chromatography with EtOAc/petroleum ether = 1/4 (Rf = 0.14) as eluents, the desired product 
was obtained in 58% yield (23 mg, 0.06 mmol) as a yellow oil. 
1
H NMR (500 MHz, CDCl3) 
δ 7.78 (d, J = 7.6 Hz, 1H), 7.25 – 7.14 (m, 3H), 7.06 (td, J = 7.6, 0.8 Hz, 1H), 6.98 (t, J = 8.7 
Hz, 2H), 6.80 (d, J = 7.6 Hz, 1H), 5.03 (s, 1H), 4.72 (dd, J = 9.5, 1.5 Hz, 1H), 4.59 (dd, J = 
9.5, 6.4 Hz, 1H), 3.37 – 3.30 (m, 4H), 3.18 (s, 3H), 2.42 (t, J = 6.4 Hz, 1H), 1.27 (d, J = 6.1 
Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 172.25, 168.03, 161.77 (d, J = 245.1 Hz), 140.63, 
136.96, 128.63 (d, J = 8.0 Hz), 126.30, 122.67, 122.57, 121.63, 115.81 (d, J = 21.4 Hz), 
107.25, 101.25, 76.91, 73.21, 56.73, 52.91, 50.42, 25.90, 16.53. HRMS (ESI): Calcd for (M 
+ H)
+
 [C22H23O3NF]
+
: 368.1657, found: 368.1669. 
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(E)-3-(3-(2,4-difluorophenyl)-4-(1-methoxyethyl)dihydrofuran-2(3H)-ylidene)-1-methyli
ndolin-2-one (167g) was prepared from according to the general 
procedure for the gold catalyzed O-migration reaction with MeOH as 
nucleophile, by using 161h (30 mg, 0.08 mmol, 78% (E)-isomer) as 
the starting material. After the purification done by silica gel column 
chromatography with EtOAc/petroleum ether = 1/4 (Rf = 0.25) as 
eluents, the desired product was obtained in 55% yield (18 mg, 0.05 mmol) as an orange oil. 
1
H NMR (500 MHz, CDCl3) δ 7.78 (d, J = 7.6 Hz, 1H), 7.20 (t, J = 7.6 Hz, 1H), 7.07 (t, J = 
7.6 Hz, 1H), 7.06 – 6.97 (m, 1H), 6.89 – 6.81 (m, 1H), 6.80 (d, J = 7.6 Hz, 1H), 6.73 (t, J = 
8.3 Hz, 1H), 5.13 (s, 1H), 4.78 (dd, J = 9.4, 1.7 Hz, 1H), 4.54 (dd, J = 9.4, 6.3 Hz, 1H), 3.33 
(s, 3H), 3.34 – 3.27 (m, 1H), 3.17 (s, 3H), 2.37 (t, J = 6.3 Hz, 1H), 1.30 (d, J = 6.1 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 171.34, 168.19, 162.38 (d, J = 248.2 Hz), 159.82 (d, J = 12.0 
Hz), 140.97, 126.67, 128.85 (dd, J = 9.5, 5.4 Hz), 124.44 (dd, J = 14.6, 3.9 Hz), 122.90, 
122.77, 121.93, 111.54 (dd, J = 21.2, 3.7 Hz), 107.55, 104.68 (t, J = 25.6 Hz), 101.67, 77.02, 
73.55, 57.04, 52.41, 45.52, 26.16, 16.97. HRMS (ESI): Calcd for (M + H)
+
 [C22H22O3NF2]
+
: 
386.1562, found: 386.1562. 
 
(E)-3-(3-(2-chlorophenyl)-4-(1-methoxyethyl)dihydrofuran-2(3H)-ylidene)-1-methyl 
indolin-2-one (167h) was prepared from according to the general 
procedure for the gold catalyzed O-migration reaction with MeOH as 
nucleophile, by using 161j (32 mg, 0.09 mmol, 78% (E)-isomer) as the 
starting material. After the purification done by silica gel column 
chromatography with EtOAc/petroleum ether = 1/3 (Rf = 0.38) as 
eluents, the desired product was obtained in 86% yield (30 mg, 0.08 mmol) as a red oil. 
1
H 
NMR (500 MHz, Chloroform-d) δ 7.82 (d, J = 7.7 Hz, 1H), 7.45 (dd, J = 7.7, 1.4 Hz, 1H), 
7.21 (td, J = 7.7, 1.4 Hz, 1H), 7.17 (td, J = 7.7, 1.7 Hz, 1H), 7.15 – 7.05 (m, 2H), 7.00 (dd, J 
= 7.7, 1.7 Hz, 1H), 6.81 (d, J = 7.7 Hz, 1H), 5.40 (s, 1H), 4.81 (dd, J = 9.4, 1.5 Hz, 1H), 4.50 
(dd, J = 9.4, 6.2 Hz, 1H), 3.47 (qd, J = 6.2, 6.2 Hz, 1H), 3.34 (s, 2H), 3.18 (s, 3H), 2.35 (t, J 
= 6.2 Hz, 1H), 1.35 (d, J = 6.2 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 171.83, 167.93, 
138.28, 133.76, 130.09, 128.24, 127.10, 126.96, 126.13, 122.51, 122.44, 121.47, 107.09, 
77.15, 72.46, 56.86, 51.47, 49.52, 25.79, 16.96. 
13
C NMR (126 MHz, CDCl3) δ 171.83, 
167.93, 140.53, 138.28, 133.76, 130.09, 128.24, 127.10, 126.96, 126.13, 122.51, 122.44, 
121.47, 108.22, 107.09, 77.15, 72.46, 56.86, 51.47, 49.52, 25.79, 16.96. HRMS (ESI): Calcd 
for (M + H)
+
 [C22H23O3NCl]
+
: 384.1361, found: 384.1366. 
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(E)-3-(3-(3-chlorophenyl)-4-(1-methoxyethyl)dihydrofuran-2(3H)-ylidene)-1- 
methylindolin-2-one (167i) was prepared according to the general 
procedure for the gold catalyzed O-migration reaction with MeOH as 
nucleophile, by using 161i (34 mg, 0.10 mmol, 80% (E)-isomer) as the 
starting material. After the purification done by silica gel column 
chromatography with EtOAc/petroleum ether = 1/4 (Rf = 0.15) as eluents, the desired product 
was obtained in 67% yield (25 mg, 0.07 mmol) as a brown oil. 
1
H NMR (500 MHz, CDCl3) 
δ 7.78 (d, J = 7.6 Hz, 1H), 7.25 – 7.12 (m, 5H), 7.07 (td, J = 7.6, 0.9 Hz, 1H), 6.80 (d, J = 
7.6 Hz, 1H), 5.03 (s, 1H), 4.71 (dd, J = 9.6, 1.6 Hz, 1H), 4.58 (dd, J = 9.6, 6.5 Hz, 1H), 3.33 
(s, 4H), 3.18 (s, 3H), 2.43 (t, J = 6.5 Hz, 1H), 1.26 (d, J = 6.1 Hz, 3H). 
13
C NMR (126 MHz, 
CDCl3) δ 171.40, 168.01, 143.18, 140.70, 134.75, 130.18, 127.24, 127.05, 126.39, 125.49, 
122.66, 122.59, 121.66, 107.29, 101.48, 76.86, 73.09, 56.75, 52.79, 50.81, 25.91, 16.49. 
HRMS (ESI): Calcd for (M + H)
+
 [C22H23O3NCl]
+
: 384.1361, found: 384.1378. 
 
(E)-3-(3-(4-bromophenyl)-4-(1-methoxyethyl)dihydrofuran-2(3H)-ylidene)-1-methyl 
indolin-2-one (167j) was prepared according to the general procedure 
for the gold catalyzed O-migration reaction with MeOH as nucleophile, 
by using 161k (41 mg, 0.10 mmol, 76% (E)-isomer) as the starting 
material. After the purification done by silica gel column 
chromatography with EtOAc/petroleum ether = 1/4 (Rf = 0.17) as eluents, the desired product 
was obtained in 75% yield (33 mg, 0.08 mmol) as an orange oil. 
1
H NMR (500 MHz, 
CDCl3) δ 7.77 (d, J = 7.5 Hz, 1H), 7.41 (d, J = 8.4 Hz, 2H), 7.20 (td, J = 7.5, 0.9 Hz, 1H), 
7.13 (d, J = 8.4 Hz, 2H), 7.06 (t, J = 7.5 Hz, 1H), 6.80 (d, J = 7.5 Hz, 1H), 4.99 (s, 1H), 4.71 
(dd, J = 9.6, 1.5 Hz, 1H), 4.57 (dd, J = 9.5, 6.5 Hz, 1H), 3.36 – 3.30 (m, 4H), 3.17 (s, 3H), 
2.41 (t, J = 6.5 Hz, 1H), 1.26 (d, J = 6.1 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 171.77, 
167.99, 140.66, 140.30, 132.06, 128.85, 126.37, 122.60, 121.65, 120.85, 107.28, 101.35, 
76.88, 73.20, 56.74, 52.76, 50.63, 25.91, 16.49. HRMS (ESI): Calcd for (M + H)
+
 
[C22H23O3NBr]
+
: 428.0856, found: 428.0865. 
 
  
158 
 
(E)-3-(4-(1-methoxyethyl)-3-(2-(trifluoromethyl)phenyl)dihydrofuran-2(3H)-ylidene)-1-
methylindolin-2-one (167k) was prepared from according to the 
general procedure for the gold catalyzed O-migration reaction with 
MeOH as nucleophile, by using 161l (40 mg, 0.10 mmol, 72% 
(E)-isomer) as the starting material. After the purification done by 
silica gel column chromatography with EtOAc/petroleum ether = 1/4 
(Rf = 0.38) as eluents, the desired product was obtained in 30% yield (13 mg, 0.03 mmol) as 
a pale yellow solid. mp: 146 °C 
1
H NMR (500 MHz, CDCl3) δ 7.83 (d, J = 7.4 Hz, 1H), 
7.74 (d, J = 7.4 Hz, 1H), 7.37 (t, J = 7.4 Hz, 1H), 7.32 (t, J = 7.4 Hz, 1H), 7.20 (td, J = 7.7, 
1.1 Hz, 1H), 7.12 – 7.04 (m, 2H), 6.80 (d, J = 7.4 Hz, 1H), 5.46 (s, 1H), 4.82 (d, J = 9.4 Hz, 
1H), 4.49 (dd, J = 9.4, 6.0 Hz, 1H), 3.53 (p, J = 6.0 Hz, 1H), 3.28 (s, 3H), 3.17 (s, 3H), 2.38 
– 2.33 (m, 1H), 1.22 (d, J = 6.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 172.26, 168.11, 
140.77, 132.32, 128.08 (d, J = 30.0 Hz), 127.49, 127.27 (d, J = 6.3 Hz), 127.21, 126.26, 
122.83, 122.68, 121.60, 107.21, 100.92, 77.82, 71.82, 57.33, 52.12, 49.59, 25.96, 16.90. 
HRMS (ESI): Calcd for (M + Na)
+
 [C23H22O3NF3Na]
+
: 440.1444, found: 440.1444. 
 
(E)-3-(4-(1-methoxyethyl)-3-(thiophen-3-yl)dihydrofuran-2(3H)-ylidene)-1- 
methylindolin-2-one (167l) was prepared according to the general 
procedure for the gold catalyzed O-migration reaction with MeOH as 
nucleophile, by using 161m (44 mg, 0.14 mmol, 83% (E)-isomer) as the 
starting material. After the purification done by silica gel column 
chromatography with EtOAc/petroleum ether = 1/4 (Rf = 0.10) as eluents, the desired product 
was obtained in 77% yield (37 mg, 0.10 mmol) as a red oil. 
1
H NMR (500 MHz, CDCl3) δ 
7.74 (d, J = 7.5 Hz, 1H), 7.26 – 7.24 (m, 1H), 7.18 (td, J = 7.5, 1.2 Hz, 1H), 7.13 – 6.99 (m, 
3H), 6.79 (d, J = 7.5 Hz, 1H), 5.16 (s, 1H), 4.73 (dd, J = 9.4, 1.1 Hz, 1H), 4.60 (dd, J = 9.4, 
6.3 Hz, 1H), 3.31 (s, 3H), 3.29 – 3.23 (m, 1H), 3.21 (s, 3H), 2.50 (t, J = 6.3 Hz, 1H), 1.25 (d, 
J = 6.1 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 172.29, 168.14, 140.51, 140.13, 127.08, 
126.19, 126.16, 122.79, 122.52, 121.57, 120.95, 107.17, 100.93, 76.72, 73.50, 56.73, 51.74, 
46.38, 25.91, 16.65. HRMS (ESI): Calcd for (M + H)
+
 [C20H22O3NS]
+
: 356.1315, found: 
356.1326. 
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(E)-3-(4-(1-methoxyethyl)-3-phenyldihydrofuran-2(3H)-ylidene)-1,5-dimethylindolin-2-
one (167m) was prepared from according to the general procedure for 
the gold catalyzed O-migration reaction with MeOH as nucleophile, by 
using 161q (42 mg, 0.13 mmol, 80% (E)-isomer) as the starting 
material. After the purification done by silica gel column 
chromatography with EtOAc/petroleum ether = 1/4 (Rf = 0.20) as eluents, the desired product 
was obtained in 67% yield (31 mg, 0.09 mmol) as a pale yellow solid. mp: 173 °C 
1
H NMR 
(500 MHz, CDCl3) δ 7.64 (s, 1H), 7.33 – 7.23 (m, 4H), 7.21 (t, J = 7.1 Hz, 1H), 7.00 (d, J = 
7.8 Hz, 1H), 6.68 (d, J = 7.8 Hz, 1H), 5.07 (s, 1H), 4.74 (d, J = 9.5 Hz, 1H), 4.60 (dd, J = 
9.5, 6.8 Hz, 1H), 3.34 (s, 3H), 3.35 – 3.27 (m, 1H), 3.15 (s, 2H), 2.44 (t, J = 6.8 Hz, 1H), 
2.40 (s, 3H), 1.29 (d, J = 6.1 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 172.19, 168.09, 
141.18, 138.47, 130.91, 128.93, 127.06, 126.88, 126.51, 123.29, 122.80, 106.89, 101.32, 
76.99, 73.10, 56.73, 52.93, 51.14, 25.90, 21.39, 16.63. HRMS (ESI): Calcd for (M + Na)
+
 
[C23H23O2NNa]
+
: 368.1621, found: 368.1607. 
 
(E ) -3- (4- (1-methoxyethyl ) -3 -phenyld ihydrofuran -2(3H)-yl idene) -1 ,5 ,7 - 
trimethylindolin-2-one (167n) was prepared according to the general 
procedure for the gold catalyzed O-migration reaction with MeOH as 
nucleophile, by using 161s (40 mg, 0.12 mmol, 80% (E)-isomer) as the 
starting material. After the purification done by silica gel column 
chromatography with EtOAc/petroleum ether = 1/4 (Rf = 0.18) as eluents, the desired product 
was obtained in 78% yield (34 mg, 0.09 mmol) as a brown oil. 
1
H NMR (500 MHz, CDCl3) 
δ 7.54 (s, 1H), 7.34 – 7.15 (m, 5H), 6.74 (s, 1H), 5.09 (s, 1H), 4.73 (dd, J = 9.5, 1.3 Hz, 1H), 
4.58 (dd, J = 9.5, 6.4 Hz, 1H), 3.43 (s, 3H), 3.34 (s, 3H), 3.30 (dd, J = 7.3, 6.3 Hz, 1H), 2.52 
(s, 3H), 2.42 (dd, J = 7.3, 6.4 Hz, 1H), 2.34 (s, 3H), 1.29 (d, J = 6.3 Hz, 3H). 
13
C NMR (126 
MHz, CDCl3) δ 171.96, 168.64, 141.24, 136.27, 130.78, 130.51, 128.91, 127.04, 126.83, 
123.38, 121.33, 118.47, 101.30, 77.00, 73.04, 56.72, 52.89, 51.23, 29.12, 21.06, 19.08, 
16.63. HRMS (ESI): Calcd for (M + H)
+
 [C24H28O3N]
+
: 378.2064, found: 378.2075. 
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(E)-5-methoxy-3-(4-(1-methoxyethyl)-3-phenyldihydrofuran-2(3H)-ylidene)-1- 
methylindolin-2-one (167o) was prepared according to the general 
procedure for the gold catalyzed O-migration reaction with MeOH 
as nucleophile, by using 161r (47 mg, 0.14 mmol, 83% (E)-isomer) 
as the starting material. After the purification done by silica gel 
column chromatography with EtOAc/petroleum ether = 1/3 (Rf = 0.22) as eluents, the desired 
product was obtained in 64% yield (33 mg, 0.09 mmol) as a brown oil. 
1
H NMR (500 MHz, 
CDCl3) δ 7.44 (d, J = 2.5 Hz, 1H), 7.43 – 7.41 (m, 1H), 7.33 – 7.23 (m, 4H), 7.23 – 7.18 (m, 
1H), 6.75 (dd, J = 8.4, 2.5 Hz, 1H), 6.68 (d, J = 8.4 Hz, 1H), 5.06 (s, 1H), 4.73 (dd, J = 9.5, 
1.5 Hz, 1H), 4.60 (dd, J = 9.5, 6.3 Hz, 1H), 3.86 (s, 3H), 3.34 (s, 3H), 3.31 (dd, J = 7.4, 6.1 
Hz, 1H), 3.14 (s, 3H), 2.44 (dd, J = 7.4, 6.3 Hz, 1H), 1.28 (d, J = 6.1 Hz, 3H). 
13
C NMR 
(126 MHz, CDCl3) δ 172.65, 167.94, 155.49, 141.12, 134.78, 128.95, 127.06, 126.91, 
123.69, 111.37, 109.52, 107.31, 101.58, 76.95, 73.27, 56.73, 56.18, 52.89, 51.18, 25.96, 
16.62. HRMS (ESI): Calcd for (M + H)
+
 [C23H26O4N]
+
: 380.1856, found: 380.1867. 
 
(E)-5-fluoro-3-(4-(1-methoxyethyl)-3-phenyldihydrofuran-2(3H)-ylidene)-1- 
methylindolin-2-one (167p) was prepared according to the general 
procedure for the gold catalyzed O-migration reaction with MeOH as 
nucleophile, by using 161t (39 mg, 0.12 mmol, 77% (E)-isomer) as 
the starting material. After the purification done by silica gel column 
chromatography with EtOAc/petroleum ether = 1/3 (Rf = 0.30) as eluents, the desired product 
was obtained in 63% yield (27 mg, 0.07 mmol) as a brown oil. 
1
H NMR (500 MHz, CDCl3) 
δ 7.52 (dd, J = 8.6, 2.6 Hz, 1H), 7.35 – 7.16 (m, 5H), 6.92 – 6.82 (m, 1H), 6.67 (dd, J = 8.6, 
4.2 Hz, 1H), 5.04 (s, 1H), 4.75 (dd, J = 9.6, 1.6 Hz, 1H), 4.63 (dd, J = 9.6, 6.4 Hz, 1H), 3.34 
(s, 4H), 3.15 (s, 3H), 2.50 – 2.41 (m, 1H), 1.27 (d, J = 6.1 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 173.69, 167.87, 159.01 (d, J = 236.5 Hz), 140.91, 136.63, 129.02, 127.05, 127.03, 
123.83 (d, J = 9.9 Hz), 112.04 (d, J = 24.0 Hz), 110.10 (d, J = 26.1 Hz), 107.20 (d, J = 8.6 
Hz), 101.08, 76.99, 73.56, 56.76, 52.83, 51.44, 26.01, 16.58. HRMS (ESI): Calcd for (M + 
H)
+
 [C22H24O3N]
+
: 350.1751, found: 350.1757. 
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(E)-5-chloro-3-(4-(1-methoxyethyl)-3-phenyldihydrofuran-2(3H)-ylidene)-1- 
methylindolin-2-one (167q) was prepared according to the general 
procedure for the gold catalyzed O-migration reaction with MeOH as 
nucleophile, by using 161u (37 mg, 0.11 mmol, 77% (E)-isomer) as 
the starting material. After the purification done by silica gel column 
chromatography with EtOAc/petroleum ether = 1/3 (Rf = 0.28) as eluents, the desired product 
was obtained in 62% yield (25 mg, 0.07 mmol) as a yellow oil. 
1
H NMR (500 MHz, CDCl3) 
δ 7.77 (d, J = 2.0 Hz, 1H), 7.34 – 7.16 (m, 5H), 7.14 (dd, J = 8.2, 2.0 Hz, 1H), 6.68 (d, J = 
8.2 Hz, 1H), 5.03 (s, 1H), 4.76 (dd, J = 9.6, 1.5 Hz, 1H), 4.64 (dd, J = 9.6, 6.4 Hz, 1H), 3.36 
– 3.29 (m, 4H), 3.15 (s, 3H), 2.46 (t, J = 6.4 Hz, 1H), 1.27 (d, J = 6.1 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) δ 174.19, 167.94, 141.10, 139.26, 129.29, 127.30, 127.15, 125.93, 
124.43, 122.80, 108.15, 100.69, 77.26, 77.17, 73.89, 57.04, 53.05, 51.79, 26.25, 16.82. 
HRMS (ESI): Calcd for (M + H)
+
 [C22H23O3NCl]
+
: 384.1361, found: 384.1379. 
 
(E)-6-bromo-3-(4-(1-methoxyethyl)-3-phenyldihydrofuran-2(3H)-ylidene)-1- 
methylindolin-2-one (167r) was prepared according to the general 
procedure for the gold catalyzed O-migration reaction with MeOH as 
nucleophile, by using 161v (42 mg, 0.11 mmol, 76% (E)-isomer) as 
the starting material. After the purification done by silica gel column 
chromatography with EtOAc/petroleum ether = 1/3 (Rf = 0.33) as eluents, the desired product 
was obtained in 70% yield (32 mg, 0.07 mmol) as a yellow oil. 
1
H NMR (500 MHz, CDCl3) 
δ 7.62 (d, J = 7.9 Hz, 1H), 7.40 – 7.19 (m, 6H), 7.17 (d, J = 7.9 Hz, 1H), 6.92 (s, 1H), 5.01 
(s, 1H), 4.73 (d, J = 9.5 Hz, 1H), 4.68 – 4.57 (m, 1H), 3.33 (s, 4H), 3.14 (s, 3H), 2.45 (s, 1H), 
1.27 (d, J = 5.7 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 173.70, 168.08, 141.97, 141.14, 
129.28, 127.35, 127.31, 124.51, 123.79, 121.98, 119.68, 110.79, 100.67, 77.24, 73.78, 57.02, 
53.10, 51.76, 26.23, 16.85. HRMS (ESI): Calcd for (M + H)
+
 [C22H23O3NBr]
+
: 428.0856, 
found: 428.0866. 
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(E)-3-(4-(1-methoxyethyl)-3-phenyldihydrofuran-2(3H)-ylidene)-1-methyl-5-(trifluoro
methoxy)indolin-2-one (167s) was prepared according to the 
general procedure for the gold catalyzed O-migration reaction with 
MeOH as nucleophile, by using 161w (35 mg, 0.09 mmol, 80% 
(E)-isomer) as the starting material. After the purification done by 
silica gel column chromatography with EtOAc/petroleum ether = 1/4 (Rf = 0.11) as eluents, 
the desired product was obtained in 71% yield (27 mg, 0.06 mmol) as a yellow oil. 
1
H NMR 
(500 MHz, CDCl3) δ 7.65 (s, 1H), 7.35 – 7.29 (m, 2H), 7.28 – 7.15 (m, 3H), 7.05 (d, J = 8.4 
Hz, 1H), 6.73 (d, J = 8.4 Hz, 1H), 5.04 (s, 1H), 4.77 (dd, J = 9.6, 1.6 Hz, 1H), 4.65 (dd, J = 
9.6, 6.5 Hz, 1H), 3.34 (s, 4H), 3.16 (s, 3H), 2.46 (t, J = 6.5 Hz, 1H), 1.27 (d, J = 6.1 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 174.27, 167.88, 144.29, 140.82, 139.03, 129.05, 127.06, 
123.76, 120.91 (d, J = 255.9 Hz), 118.92, 116.15, 107.17, 100.61, 76.97, 73.80, 56.77, 52.80, 
51.60, 32.77, 26.04, 16.57. HRMS (ESI): Calcd for (M + H)
+
 [C23H23O4NF3]
+
: 434.1574, 
found: 434.1573. 
 
(E)-1-benzyl-3-(4-(1-methoxyethyl)-3-phenyldihydrofuran-2(3H)-ylidene) 
indolin-2-one (167t) was prepared according to the general procedure 
for the gold catalyzed O-migration reaction with MeOH as nucleophile, 
by using 161x (39 mg, 0.10 mmol, 76% (E)-isomer) as the starting 
material. After the purification done by silica gel column 
chromatography with EtOAc/petroleum ether = 1/4 (Rf = 0.29) as eluents, the desired product 
was obtained in 69% yield (29 mg, 0.07 mmol) as a yellow oil. 
1
H NMR (500 MHz, CDCl3) 
δ 7.81 (d, J = 6.4 Hz, 1H), 7.37 – 7.13 (m, 11H), 7.12 – 7.05 (m, 1H), 7.05 – 7.00 (m, 1H), 
6.68 (d, J = 7.4 Hz, 1H), 5.10 (s, 1H), 5.01 (d, J = 15.8 Hz, 1H), 4.81 – 4.74 (m, 2H), 4.63 
(dd, J = 9.5, 6.6 Hz, 1H), 3.36 (s, 4H), 2.47 (t, J = 6.6 Hz, 1H), 1.31 (d, J = 6.1 Hz, 3H). 
13
C 
NMR (126 MHz, CDCl3) δ 172.95, 167.98, 141.13, 139.75, 137.01, 128.95, 128.65, 127.33, 
127.27, 127.10, 126.92, 126.09, 122.96, 122.60, 121.62, 108.20, 101.07, 76.91, 73.35, 56.74, 
53.03, 51.30, 43.43, 16.72. HRMS (ESI): Calcd for (M + H)
+
 [C26H28O3N]
+
: 426.2064, 
found: 426.2076. 
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(E)-1-(4-methoxybenzyl)-3-(4-(1-methoxyethyl)-3-phenyldihydrofuran-2(3H)-ylidene)in
dolin-2-one (167u) was prepared from according to the general 
procedure for the gold catalyzed O-migration reaction with MeOH as 
nucleophile, by using 161y (25 mg, 0.06 mmol, 73% (E)-isomer) as the 
starting material. After the purification done by silica gel column 
chromatography with EtOAc/petroleum ether = 1/3 (Rf = 0.28) as eluents, the desired product 
was obtained in 60% yield (16 mg, 0.04 mmol) as a brown oil. 
1
H NMR (500 MHz, CDCl3) 
δ 7.79 (d, J = 7.5 Hz, 1H), 7.36 – 7.25 (m, 4H), 7.25 – 7.20 (m, 1H), 7.14 (d, J = 8.6 Hz, 
2H), 7.07 (td, J = 7.5, 1.2 Hz, 1H), 7.02 (t, J = 7.5 Hz, 1H), 6.77 (d, J = 8.6 Hz, 2H), 6.69 (d, 
J = 7.6 Hz, 1H), 5.09 (s, 1H), 4.94 (d, J = 15.6 Hz, 1H), 4.75 (dd, J = 9.6, 1.5 Hz, 1H), 4.70 
(d, J = 15.6 Hz, 1H), 4.61 (dd, J = 9.6, 6.6 Hz, 1H), 3.74 (s, 3H), 3.36 (s, 4H), 2.46 (t, J = 6.6 
Hz, 1H), 1.31 (d, J = 6.1 Hz, 3H).
13
C NMR (126 MHz, CDCl3) δ 173.09, 168.20, 159.15, 
141.40, 140.04, 129.42, 129.21, 128.95, 127.37, 127.17, 126.33, 123.23, 122.85, 121.82, 
114.34, 108.46, 101.40, 77.16, 73.57, 57.00, 55.62, 53.30, 51.52, 43.14, 16.99. HRMS 
(ESI): Calcd for (M + H)
+
 [C29H30O4N]
+
: 456.2169, found: 456.2179. 
 
(E)-3-(4-(1-methoxyethyl)-3-phenyldihydrofuran-2(3H)-ylidene)-1-(methoxymethyl) 
indolin -2-one (167v) was prepared from according to the general 
procedure for the gold catalyzed O-migration reaction with MeOH as 
nucleophile, by using 161z (27 mg, 0.08 mmol, 77% (E)-isomer) as the 
starting material. After the purification done by silica gel column 
chromatography with EtOAc/petroleum ether = 1/5 (Rf = 0.20) as eluents, the desired product 
was obtained in 71% yield (21 mg, 0.06 mmol) as a yellow solid. mp: 107 °C 
1
H NMR (500 
MHz, CDCl3) δ 7.82 (d, J = 7.6 Hz, 1H), 7.33 – 7.16 (m, 6H), 7.10 (t, J = 7.6 Hz, 1H), 7.00 
(d, J = 7.6 Hz, 1H), 5.15 (d, J = 10.9 Hz, 1H), 5.05 (s, 1H), 5.03 (d, J = 10.9 Hz, 1H), 4.75 
(dd, J = 9.5, 1.5 Hz, 1H), 4.62 (dd, J = 9.5, 6.7 Hz, 1H), 3.34 (s, 3H), 3.41 – 3.29 (m, 1H), 
3.24 (s, 3H), 2.46 (t, J = 6.7 Hz, 1H), 1.29 (d, J = 6.1 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) 
δ 173.45, 168.35, 140.96, 138.97, 128.95, 127.05, 126.95, 126.32, 122.84, 122.67, 122.21, 
108.57, 100.87, 76.92, 73.43, 71.10, 56.74, 56.13, 52.92, 51.41, 16.64. HRMS (ESI): Calcd 
for (M + Na)
+
 [C23H25O4NNa]
+
: 402.1676, found: 402.1669. 
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(E)-3-(-4-(-1-ethoxyethyl)-3-phenyldihydrofuran-2(3H)-ylidene)-1-methylindolin-2-one 
(167w) was prepared from according to the general procedure for the gold 
catalyzed O-migration reaction with MeOH as nucleophile, by using 161a 
(30 mg, 0.09 mmol, 82% (E)-isomer) as the starting material. After the 
purification done by silica gel column chromatography with 
Et2O/petroleum ether = 1/2 (Rf = 0.25) as eluents, the desired product was obtained in 76% 
yield (26 mg, 0.07 mmol) as a yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.79 (d, J = 7.5 Hz, 
1H), 7.29 (t, J = 7.5 Hz, 2H), 7.27 – 7.22 (m, 2H), 7.21 (d, J = 7.5 Hz, 1H), 7.18 (d, J = 7.5 
Hz, 1H), 7.06 (t, J = 7.5 Hz, 1H), 6.79 (d, J = 7.5 Hz, 1H), 5.06 (s, 1H), 4.74 (d, J = 9.5 Hz, 
1H), 4.59 (dd, J = 9.4, 6.5 Hz, 1H), 3.66 – 3.57 (m, 1H), 3.43 – 3.32 (m, 2H), 3.17 (s, 3H), 
2.43 (t, J = 6.5 Hz, 1H), 1.29 (d, J = 6.1 Hz, 3H), 1.15 (t, J = 7.0 Hz, 3H). 
13
C NMR (126 
MHz, CDCl3) δ 172.70, 168.07, 141.01, 140.54, 128.95, 127.06, 126.91, 126.12, 122.78, 
122.48, 121.55, 107.17, 101.16, 75.23, 73.31, 64.51, 52.98, 51.23, 25.89, 17.47, 15.55. 
HRMS (ESI): Calcd for (M + H) 
+
 [C23H26O3N] 
+
:364.1907, found:364.1902. 
 
5.4.8  Compounds isolated from the condition screening 
(E)-3-(-4-(-1-hydroxyethyl)-3-phenyldihydrofuran-2(3H)-ylidene)-1-methylindolin-2-on
e (167OH) 
1
H NMR (500 MHz, CDCl3) δ 7.78 (d, J = 7.5 Hz, 1H), 7.34 – 
7.23 (m, 4H), 7.23 – 7.14 (m, 2H), 7.06 (t, J = 7.5 Hz, 1H), 6.76 (d, J = 
7.5 Hz, 1H), 5.07 (s, 1H), 4.81 (d, J = 9.6 Hz, 1H), 4.62 (dd, J = 9.6, 6.3 
Hz, 1H), 3.89 (qd, J = 6.3 Hz, 6.3 Hz, 1H), 3.12 (s, 3H), 2.40 (dd, J = 6.3 
Hz, 1H), 1.35 (d, J = 6.3 Hz, 3H), 1.25 (s, 1H). 
13
C NMR (126 MHz, CDCl3) δ 172.52, 
168.14, 140.97, 140.49, 129.00, 127.04, 127.00, 126.20, 122.70, 122.53, 121.66, 107.26, 
101.20, 72.92, 68.34, 54.15, 51.51, 25.88, 21.70. HRMS (ESI): Calcd for (M + H) 
+
 
[C21H22O3N] 
+
: 336.1594, found: 336.1589. 
 
1-(-5-((E)-1-methyl-2-oxoindolin-3-ylidene)-4-phenyltetrahydrofuran-3-yl)ethyl 
acetate (167OAc/epi-167OAc = 4/3) 
1
H NMR (500 
MHz, CDCl3) δ 7.79 (d, J = 7.3 Hz, 1H, 4OAc), 7.77 
(d, J = 7.2 Hz, 1H, epi-4OAc), 7.35 – 7.18 (m, 6H, 
4OAc and epi-4OAc), 7.10 - 7.05 (m, 1H, 4OAc and 
epi-4OAc), 6.82 (d, J = 7.7 Hz, 1H, 4OAc), 6.79 (d, J 
= 7.7 Hz, 1H, epi-4OAc), 5.19 - 5.18 (m, 1H, 4OAc and epi-4OAc), 5.04 (qd, J = 6.3, 6.3 
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Hz, 1H, 4OAc), 4.76 (dd, J = 8.7, 8.7 Hz, 1H, epi-4OAc), 4.69 - 4.55 (m, 2H, 4OAc and 
epi-4OAc), 3.20 (s, 3H, 4OAc), 3.18 (s, 3H, epi-4OAc), 3.00 – 2.93 (m, 1H, epi-4OAc), 
2.67 (t, J = 6.3 Hz, 1H, 4OAc), 2.04 (s, 3H, 4OAc), 1.91 (s, 3H, epi-4OAc), 1.34 - 1.27 
(m, 3H, 4OAc and epi-4OAc). HRMS (ESI): Calcd for (M + H) 
+
 [C23H24O4N] 
+
: 
378.1700, found: 378.1700. 
 
1,3-dimethyl-1a-phenyl-1a,3,9,9a-tetrahydrocyclopropa[4,5]pyrano[3,2-c] 
quinolin-2(1H)-one (epi-166) 
1
H NMR (500 MHz, CDCl3) δ 7.91 
(dd, J = 8.0, 1.4 Hz, 1H), 7.51 – 7.45 (m, 1H), 7.33 (d, J = 7.0 Hz, 
2H), 7.23 (d, J = 8.4 Hz, 1H), 7.19 – 7.14 (m, 3H), 7.08 (t, J = 7.3 
Hz, 1H), 4.87 (dd, J = 12.3, 8.5 Hz, 1H), 4.02 (dd, J = 12.3, 5.3 Hz, 
1H), 3.51 (s, 3H), 2.14 (dq, J = 8.1, 6.4 Hz, 1H), 1.58 – 1.51 (m, 
1H), 1.02 (d, J = 6.4 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 162.26, 158.39, 144.56, 
139.18, 130.65, 128.92, 128.09, 126.20, 123.64, 121.60, 116.10, 113.99, 109.62, 65.15, 
29.40, 25.93, 22.60, 21.62, 8.96. HRMS (ESI): Calcd for (M + H) 
+
 [C21H20O2N] 
+
: 
318.1489, found: 318.1489.
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5.4.9  Gold(I) catalyzed cycloisomerizations to 1,6-enyens with different olefins (172) 
 
At 0 °C, to a mixture of 1,6-enyne (172, 0.1 mmol) and corresponding gold catalyst (5 µmol) 
was added dry DCM (1.0 ml)* under Ar(g) atmosphere. After warming to room temperature, 
the reaction mixture was stirred overnight and then passed through a short pad of silica gel 
(Et2O as the eluent). The resulting solution was concentrated under reduced pressure, 
followed by silica gel column chromatography (EtOAc/petroleum ether as eluents,) to obtain 
the desired product. 
*In the formation of 173f, dry Et2O was applied as the solvent. 
 
(E)-1-methyl-4'-phenyl-3'-propylidene-3',6'-dihydrospiro[indoline-3,2'-pyran]-2-one 
(2b) was prepared according to the general procedure, by using 172b (39 
mg, 0.12 mmol) and cat III (7 mg, 5.88 µmol). After silica gel column 
chromatography with EtOAc/petroleum ether = 1/5 (Rf = 0.25) as eluents, 
the desired product was obtained in 88% yield (34 mg, 0.11 mmol) as an 
orange solid. mp: 104 °C 
1
H NMR (600 MHz, CDCl3) δ 7.41 (d, J = 7.5 Hz, 1H), 7.37 (t, J 
= 7.7 Hz, 1H), 7.34 – 7.25 (m, 3H), 7.21 (d, J = 7.5 Hz, 2H), 7.05 (t, J = 7.5 Hz, 1H), 6.91 
(d, J = 7.5 Hz, 1H), 6.04 (s, 1H), 5.28 (t, J = 7.3 Hz, 1H), 4.82 (d, J = 17.4 Hz, 1H), 4.60 (d, 
J = 17.4 Hz, 1H), 3.27 (s, 3H), 1.54 – 1.39 (m, 2H), 0.68 (t, J = 7.3 Hz, 3H). 13C NMR (151 
MHz, CDCl3) δ 174.29, 143.88, 142.17, 136.68, 133.60, 129.81, 129.36, 129.30, 128.46, 
128.42, 127.25, 127.18, 124.91, 123.00, 108.81, 79.53, 63.84, 26.45, 23.48, 13.58. HRMS 
(ESI): Calcd for (M + Na)
+
 [C22H21O2NNa]
+
: 354.1465, found: 354.1461. 
 
 
 
  
167 
 
1-ethyl-3-methyl-1a-phenyl-1a,3,9,9a-tetrahydrocyclopropa[4,5]pyrano[3,2-c] 
quinolin-2(1H)-one (174b) was prepared according to the general 
procedure, by using 172b (40 mg, 0.12 mmol) and cat IIa (4 mg, 4.83 
µmol). After silica gel column chromatography with EtOAc/petroleum 
ether = 1/5 (Rf = 0.28) as eluents, the desi1red product was obtained in 
40% yield (16 mg, 0.05 mmol) as a yellow solid. mp: 186 °C
 1
H NMR (600 MHz, CDCl3) δ 
7.95 (d, J = 7.8 Hz, 1H), 7.69 (d, J = 7.8 Hz, 2H), 7.50 (t, J = 7.8 Hz, 1H), 7.29 – 7.23 (m, 
3H), 7.21 (t, J = 7.6 Hz, 1H), 7.18 (t, J = 7.6 Hz, 1H), 5.08 (dd, J = 11.8, 7.9 Hz, 1H), 3.93 
(dd, J = 11.8, 6.1 Hz, 1H), 3.59 (s, 3H), 2.04 – 1.97 (m, 1H), 1.59 (dd, J = 12.4, 6.1 Hz, 1H), 
1.21 – 1.13 (m, 1H), 1.07 (t, J = 7.1 Hz, 3H), 1.06 – 0.95 (m, 1H). 13C NMR (151 MHz, 
CDCl3) δ 162.37, 158.11, 140.46, 138.75, 132.49, 130.50, 127.59, 126.55, 123.59, 121.57, 
116.50, 115.73, 113.88, 71.97, 39.44, 29.33, 27.12, 25.31, 24.54, 14.09. HRMS (ESI): Calcd 
for (M + Na)
+
 [C22H21O2NNa]
+
: 354.1465, found: 354.1462. 
 
1-ethyl-3-methyl-1a-phenyl-1a,3,9,9a-tetrahydrocyclopropa[4,5]pyrano[3,2-c] 
quinolin-2(1H)-one (174c) was prepared according to the general 
procedure, by using 172c (30 mg, 0.09 mmol) and cat III (5 mg, 4.53 
µmol). After silica gel column chromatography with EtOAc/petroleum 
ether = 1/7 (Rf = 0.25) as eluents, the desired product was obtained in 
63% yield (19 mg, 0.06 mmol) as an orange solid. mp: 190 °C 
1
H NMR (500 MHz, CDCl3) 
δ 8.00 (dd, J = 8.0, 1.4 Hz, 1H), 7.55 (t, J = 8.6 Hz, 1H), 7.43 (d, J = 7.1 Hz, 2H), 7.30 (d, J 
= 8.4 Hz, 1H), 7.29 – 7.22 (m, 3H), 7.17 (t, J = 7.3 Hz, 1H), 4.96 (dd, J = 12.3, 8.5 Hz, 1H), 
4.08 (dd, J = 12.3, 5.5 Hz, 1H), 3.58 (s, 3H), 2.05 (dd, J = 15.3, 7.3 Hz, 1H), 1.71 – 1.61 (m, 
1H), 1.59 – 1.48 (m, 1H), 1.35 (td, J = 14.5, 7.3 Hz, 1H), 1.08 (t, J = 7.4 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) δ 162.09, 158.03, 144.68, 139.12, 130.59, 129.22, 127.99, 126.15, 
123.62, 121.51, 116.01, 113.91, 109.97, 65.39, 30.63, 29.36, 25.99, 21.36, 17.79, 13.73. 
HRMS (ESI): Calcd for (M + Na)
+
 [C22H21O2NNa]
+
: 354.1465, found: 354.1454. 
 
 
 
 
  
168 
 
3-methyl-1,1a-diphenyl-1a,3,9,9a-tetrahydrocyclopropa[4,5]pyrano[3,2-c]quinolin-2(1H
)-one (174d) was prepared according to the general procedure, by using 
172d (30 mg, 0.08 mmol) and cat I (4 mg, 4.0 µmol). After silica gel 
column chromatography with EtOAc/petroleum ether = 1/4 (Rf = 0.35) as 
eluents, the desired product was obtained in 40% yield (12 mg, 0.03 
mmol) as a pale yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.99 (dd, J = 8.0, 1.2 Hz, 1H), 
7.53 (t, J = 8.0 Hz, 1H), 7.31 – 7.26 (m, 3H), 7.23 (t, J = 7.6 Hz, 1H), 7.20 – 7.13 (m, 3H), 
7.08 – 7.04 (m, 3H), 6.99 – 6.94 (m, 2H), 5.15 (dd, J = 11.9, 7.4 Hz, 1H), 4.14 (dd, J = 11.9, 
5.4 Hz, 1H), 3.59 (s, 3H), 2.51 (d, J = 5.6 Hz, 1H), 2.50 – 2.45 (m, 1H). 13C NMR (126 
MHz, CDCl3) δ 162.09, 158.12, 138.89, 138.47, 137.61, 132.79, 130.71, 128.27, 127.90, 
127.14, 126.49, 126.30, 123.59, 121.66, 116.30, 115.39, 113.93, 70.90, 41.77, 30.43, 29.37, 
25.72. HRMS (ESI): Calcd for (M + H)
+
 [C26H22O2N]
+
: 380.1645, found: 380.1643. 
 
3-methyl-1a-phenyl-1a,3,9,9a-tetrahydrocyclopropa[4,5]pyrano[3,2-c]quinolin-2(1H)-o
ne (174e) was prepared according to the general procedure, by using 172e 
(9 mg, 0.03 mmol) and cat IIa (1.3 mg, 1.5 µmol). After silica gel column 
chromatography with EtOAc/petroleum ether = 1/4 (Rf = 0.18) as eluents, 
the desired product was obtained in 56% yield (5 mg, 0.02 mmol) as an 
orange soild. mp: 153 °C 
1
H NMR (500 MHz, CDCl3) δ 7.98 (dd, J = 8.0, 1.3 Hz, 1H), 7.54 
(t, J = 8.0 Hz, 1H), 7.36 (d, J = 7.3 Hz, 2H), 7.31 (d, J = 8.5 Hz, 1H), 7.28 – 7.21 (m, 3H), 
7.16 (t, J = 7.3 Hz, 1H), 4.96 (dd, J = 11.8, 7.2 Hz, 1H), 3.99 (dd, J = 11.8, 5.2 Hz, 1H), 3.60 
(s, 3H), 2.07 (dd, J = 8.0, 5.2 Hz, 1H), 1.67 – 1.59 (m, 1H), 0.96 (t, J = 5.2 Hz, 1H). 13C 
NMR (75 MHz, CDCl3) δ 162.28, 158.00, 143.43, 138.90, 130.62, 128.41, 128.13, 126.20, 
123.57, 121.63, 116.18, 113.94, 113.59, 70.57, 29.31, 22.74, 21.56, 20.40. HRMS (ESI): 
Calcd for (M + Na)
+
 [C20H17O2NNa]
+
: 326.1152, found: 326.1145. 
 
1,5'-dimethyl-3'-methylene-4'-phenyl-3',6'-dihydrospiro[indoline-3,2'-pyran]-2-one 
(173f) was prepared according to the general procedure, by using 172f (50 
mg, 0.16 mmol), cat IIa (7 mg, 7.9 µmol), and dry Et2O (1.6 ml) as the 
solvent. After silica gel column chromatography with EtOAc/petroleum 
ether = 1/7 (Rf = 0.50) as eluents, the desired product was obtained in 46% 
yield (23 mg, 0.07 mmol) as a pale yellow oil. The recrystallization was performed from 
DCM and petroleum ether. mp: 95 °C 
1
H NMR (500 MHz, CDCl3) δ 7.40 – 7.32 (m, 4H), 
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7.29 (t, J = 7.5 Hz, 1H), 7.18 (d, J = 7.0 Hz, 2H), 7.10 (t, J = 7.5 Hz, 1H), 6.87 (d, J = 7.5 
Hz, 1H), 4.82 (d, J = 17.1 Hz, 1H), 4.52 (s, 1H), 4.48 (s, 1H), 4.41 (d, J = 17.1 Hz, 1H), 3.22 
(s, 3H), 1.61 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 174.11, 144.23, 140.53, 137.94, 
132.54, 131.76, 130.15, 130.09, 129.46, 128.35, 127.09, 125.00, 123.22, 112.48, 108.65, 
78.76, 66.39, 26.29, 16.58. HRMS (ESI): Calcd for (M + Na)
+
 [C21H19O2NNa]
+
: 340.1308, 
found: 340.1308. 
 
1-methyl-4'-phenyl-5'-(prop-1-en-2-yl)-5',6'-dihydrospiro[indoline-3,2'-pyran]-2-one 
(132) was prepared according to the general procedure, by using 130 (30 mg, 
0.09 mmol) and cat III (5 mg, 5.4 µmol). After silica gel column 
chromatography with toluene/DCM as eluents, in gradient manner,* the 
desired product was obtained in 33% yield (10 mg, 0.03 mmol) as a pale 
yellow oil. The recrystallization was performed from DCM and petroleum ether. mp: 150 °C 
1
H NMR (500 MHz, CDCl3) δ 7.43 – 7.22 (m, 8H), 7.08 (t, J = 7.1 Hz, 1H), 6.84 (dd, J = 
8.2, 0.5 Hz, 1H), 5.96 (s, 1H), 5.05 (dd, J = 11.4, 3.4 Hz, 1H), 5.03 (s, 1H), 5.01 (s, 1H), 4.05 
(dd, J = 11.4, 0.9 Hz, 1H), 3.32 (d, J = 3.4 Hz, 1H), 3.19 (s, 3H), 1.97 (s, 3H). 
13
C NMR 
(126 MHz, CDCl3) δ 175.92, 144.82, 143.86, 139.78, 139.05, 130.27, 129.61, 128.46, 
127.99, 125.91, 125.02, 123.38, 122.20, 114.46, 108.59, 77.73, 65.42, 43.56, 26.31, 22.31. 
HRMS (ESI): Calcd for (M + Na)
+
 [C22H21O2NNa]
+
: 354.1465, found: 354.1475. *In the 
solvent of EtOAc/ petroleum ether, the compound 132 and 134 present the same Rf value. 
 
(E)-1-methyl-3-(3-phenyl-4-(prop-1-en-2-yl)dihydrofuran-2(3H)-ylidene)indolin-2-one 
(134) 
[101]
 was prepared according to the general procedure, by using 130 (50 
mg, 0.15 mmol) and cat IIa (6 mg, 7.5 µmol). After silica gel column 
chromatography with EtOAc/petroleum ether = 1/7 (Rf = 0.26) as eluents, 
the desired product was obtained in 51% yield (25 mg, 0.08 mmol) as a pale 
yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.79 (d, J = 7.4 Hz, 1H), 7.36 – 7.13 (m, 6H), 7.06 
(t, J = 7.6 Hz, 1H), 6.78 (d, J = 7.8 Hz, 1H), 5.15 (s, 1H), 4.83 (s, 1H), 4.81 (s, 1H), 4.69 (dd, 
J = 9.4, 6.1 Hz, 1H), 4.56 (d, J = 9.4 Hz, 1H), 3.16 (s, 3H), 2.97 (d, J = 6.1 Hz, 1H), 1.80 (s, 
3H). 
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5.4.10 Gold(I) catalyzed cycloisomerizations with allyl moiety and nucleophile 
variations 
To a mixture of 1,6-enyne (172, 0.15 mmol), gold(I) catalyst (II), and corresponding 
nucleophile, i.e. dry MeOH (61 µL, 1.51 mmol), or N-oxide 10 [4053-38-7] (27 mg, 0.17 
mmol), in a pressure tube with a stirring bar was added dry DCE (1.5 mL). The mixture was 
stirred at 60 °C overnight until TLC showed full conversion of the starting material. After 
cooling to room temperature, the reaction mixture was passed through a short pad of silica 
gel (Et2O as the eluent). The resulting solution was concentrated under reduced pressure, 
followed by silica gel column chromatography (EtOAc/petroleum ether as eluents) to obtain 
the desired product. 
 
 
(E)-3-(4-(1-methoxypropyl)-3-phenyldihydrofuran-2(3H)-ylidene)-1-methylindolin-2-on
e (175b) was prepared according to the general procedure, by using 172b 
(40 mg, 0.12 mmol) and MeOH (48 µL, 1.21 mmol) as the nucleophile. 
After silica gel column chromatography with EtOAc/petroleum ether = 1/3 
(Rf = 0.33) as eluents, the desired product was obtained in 50% yield (22 
mg, 0.06 mmol) as an orange solid. mp: 108 °C 
1
H NMR (500 MHz, 
CDCl3) δ 7.79 (d, J = 7.0 Hz, 1H), 7.35 – 7.15 (m, 6H), 7.06 (td, J = 7.7, 0.8 Hz, 1H), 6.79 
(d, J = 7.7 Hz, 1H), 5.04 (s, 1H), 4.70 (dd, J = 9.5, 1.4 Hz, 1H), 4.61 (dd, J = 9.5, 6.2 Hz, 
1H), 3.35 (s, 3H), 3.17 (s, 3H), 3.16 – 3.13 (m, 1H), 2.54 (t, J = 6.8 Hz, 1H), 1.78 – 1.61 (m, 
2H), 0.95 (t, J = 7.4 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) δ 172.69, 168.07, 141.05, 
140.53, 128.99, 127.06, 126.95, 126.14, 122.75, 122.50, 121.57, 107.19, 101.10, 82.10, 
73.22, 57.90, 51.34, 49.69, 25.90, 23.26, 8.94. HRMS (ESI): Calcd for (M + Na)
+
 
[C23H25O3NNa]
+
: 386.1727, found: 386.1725. 
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(E)-3-(4-(1-methoxypropyl)-3-phenyldihydrofuran-2(3H)-ylidene)-1-methylindolin-2-on
e (175c) was prepared according to the general procedure, by using 172c 
(49 mg, 0.15 mmol) and MeOH (64 µL, 1.48 mmol) as the nucleophile. 
After silica gel column chromatography with EtOAc/petroleum ether = 1/7 
(Rf = 0.27) as eluents, the desired product was obtained in 20% yield (11 
mg, 0.03 mmol) as a brown oil. 
1
H NMR (500 MHz, CDCl3) δ 7.77 (d, J = 
7.1 Hz, 1H), 7.34 – 7.15 (m, 6H), 7.06 (td, J = 7.7, 0.7 Hz, 1H), 6.79 (d, J = 7.7 Hz, 1H), 
5.11 (s, 1H), 4.63 (dd, J = 9.7, 6.4 Hz, 1H), 4.56 (dd, J = 9.7, 1.1 Hz, 1H), 3.36 (s, 3H), 3.17 
(s, 4H), 2.64 (t, J = 6.4 Hz, 1H), 1.60 – 1.43 (m, 2H), 0.92 (t, J = 7.4 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) δ 172.85, 168.03, 141.41, 140.57, 128.97, 127.11, 126.87, 126.14, 
122.79, 122.44, 121.53, 107.20, 101.15, 83.12, 73.57, 58.13, 50.44, 49.27, 25.90, 23.22, 
9.83. HRMS (ESI): Calcd for (M + H)
+
 [C23H26O3N]
+
: 364.1907, found: 364.1904. 
 
(E)-3-(4-(methoxy(phenyl)methyl)-3-phenyldihydrofuran-2(3H)-ylidene)-1-methyl 
indolin-2-one (175d) was prepared according to the general procedure, by 
using 172d (18 mg, 0.05 mmol) and MeOH (19 µL, 0.47 mmol) as the 
nucleophile. After silica gel column chromatography with 
EtOAc/petroleum ether = 1/3 (Rf = 0.27) as eluents, the desired product 
was obtained in 56% yield (11 mg, 0.03 mmol) as a brown solid. mp: 143 
°C 
1
H NMR (500 MHz, CDCl3) δ 7.82 (d, J = 7.3 Hz, 1H), 7.44 (t, J = 7.3 Hz, 2H), 7.41 – 
7.35 (m, 1H), 7.33 (d, J = 7.0 Hz, 2H), 7.23 – 7.12 (m, 4H), 7.08 (td, J = 7.6, 0.8 Hz, 1H), 
6.85 (d, J = 7.0 Hz, 2H), 6.80 (d, J = 7.7 Hz, 1H), 4.95 (dd, J = 9.6, 1.0 Hz, 1H), 4.82 (s, 
1H), 4.61 (dd, J = 9.6, 5.9 Hz, 1H), 3.99 (d, J = 9.6 Hz, 1H), 3.19 (s, 3H), 3.15 (s, 3H), 2.68 
(dd, J = 9.6, 5.9 Hz, 1H). 
13
C NMR (75 MHz, CDCl3) δ 172.01, 167.79, 140.69, 140.65, 
139.23, 129.07, 128.81, 128.71, 128.57, 128.49, 128.20, 127.75, 126.81, 126.25, 122.70, 
122.55, 121.55, 107.18, 101.57, 83.93, 73.49, 57.04, 54.11, 50.93, 25.94. HRMS (ESI): 
Calcd for (M + H)
+
 [C27H26O3N]
+
: 412.1907, found: 412.1905. 
 
  
172 
 
(E)-3-(4-(2-methoxypropan-2-yl)-3-phenyldihydrofuran-2(3H)-ylidene)-1-methyl 
indolin-2-one (175g) was prepared according to the general procedure, by 
using 130 (50 mg, 0.15 mmol) and MeOH (61 µL, 1.51 mmol) as the 
nucleophile. After silica gel column chromatography with 
EtOAc/petroleum ether = 1/5 (Rf = 0.18) as eluents, the desired product 
was obtained in 66% yield (36 mg, 0.10 mmol) as an orange solid. mp: 
201 °C
 1
H NMR (500 MHz, CDCl3) δ 7.76 (d, J = 7.0 Hz, 1H), 7.31 – 7.15 (m, 6H), 7.05 
(td, J = 7.6, 0.8 Hz, 1H), 6.78 (d, J = 7.6 Hz, 1H), 5.11 (s, 1H), 4.73 (dd, J = 9.9, 1.6 Hz, 
1H), 4.64 (dd, J = 9.9, 6.9 Hz, 1H), 3.18 (s, 3H), 3.16 (s, 3H), 2.53 (d, J = 6.9 Hz, 1H), 1.27 
(s, 3H), 1.10 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 173.43, 167.99, 141.88, 140.47, 
128.95, 126.99, 126.81, 126.05, 122.82, 122.38, 121.52, 107.18, 100.64, 75.48, 73.25, 55.74, 
50.56, 49.42, 25.88, 22.05, 21.39. HRMS (ESI): Calcd for (M + Na)
+
 [C23H25O3NNa]
+
: 
386.1727, found: 386.1724. 
 
(E)-4-benzoyl-1-methyl-3-(pent-2-en-1-yloxy)quinolin-2(1H)-one (176) was prepared 
according to the general procedure, by using 172b (15 mg, 0.05 mmol) 
and N-oxide 10 (8 mg, 0.17 mmol), as the nucleophile. After silica gel 
column chromatography with EtOAc/petroleum ether = 1/4 (Rf = 0.37) 
as eluents, the desired product was obtained in 70% yield (11 mg, 0.03 
mmol) as a brown oil. 
1
H NMR (700 MHz, CDCl3) δ 7.92 (d, J = 7.2 Hz, 2H), 7.61 (t, J = 
7.4 Hz, 1H), 7.53 – 7.43 (m, 3H), 7.41 (d, J = 8.5 Hz, 1H), 7.28 – 7.24 (m, 1H), 7.15 (t, J = 
8.0 Hz, 1H), 5.61 (dt, J = 15.3, 6.6 Hz, 1H), 5.36 (dt, J = 15.3, 6.6 Hz, 1H), 4.62 (dd, J = 6.6, 
0.4 Hz, 2H), 3.82 (s, 3H), 1.92 (qd, J = 7.3, 6.6 Hz, 2H), 0.87 (t, J = 7.3 Hz, 3H). 
13
C NMR 
(176 MHz, CDCl3) δ 194.58, 159.11, 143.57, 138.00, 137.35, 136.72, 134.68, 134.34, 
129.72, 129.34, 128.95, 126.06, 124.15, 123.06, 118.52, 114.53, 73.56, 30.13, 25.28, 13.16. 
HRMS (ESI): Calcd for (M + Na)
+
 [C22H21O3NNa]
+
: 370.1414, found: 370.1415. 
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5.5 Investigations toward gold(I) catalyzed chirality transfer experiments 
5.5.1 Preparation of optically enriched 1,6- enyne substrates 130* and 172b* 
 
To a solution of Zn(OTf)2 (451 mg, 1.24 mmol) and chiral ligand (483 mg, 1.37 mmol) in 
phenyl acetylene (2.04 ml, 18.62 mmol) was added trientylamine (0.26 ml, 1.86 mmol) 
under N2 atmosphere at room temperature.  After the resulting mixture was stirred for 2h,  
the 1-methylisatin (139, 1000 mg, 6.21 mmol) was introduced to the reaction mixture in one 
portion. After stirring for overnight at 70 °C, the mixture was diluted with DCM and washed 
with 0.5M HCl(aq) for three times. The organic phase was washed with brine, water, and 
dried over MgSO4 (s). After removal of solvent, the crude product was purified by silica gel 
column chromatography with EtOAc/petroleum ether = 1/2 (Rf = 0.34) as eluents, to obtain 
the desire product in 93% yield (114a*, 1519 mg, 5.77 mmol) as pale yellow solid.
[69]
 The 
allylation step was employed the general procedure D for the preparation of starting material 
(Section 5.3) to obtain the corresponding optically enrich 1,6-enynes (130* or 172b*).  
 
5.5.2 Chirality transfer reaction with oxindole based prenylated 1,6-enyne (130*) 
 
The transformations toward compound 134* were performed according to the synthesis of 
134. The enantiomeric excess values were determined by the HPLC analysis. 
 
1-methyl-3-((3-methylbut-2-en-1-yl)oxy)-3-(phenylethynyl)indolin-2-one (130*) yield: 
93%; major enantiomer: tR = 42.0 min; minor enantiomer: tR = 45.7 min; ee: 73% 
(eluents: ihexane/ethanol = 90/10, flow rate: 0.5 ml/min, column: chiralpak IC) 
 
(E)-1-methyl-3-((3R,4R)-3-phenyl-4-(prop-1-en-2-yl)dihydrofuran-2(3H)-ylidene) 
indolin-2-one (134*) yield: 73%; major enantiomer: tR = 24.0 min; minor enantiomer: tR = 
174 
 
34.0 min; ee: 36% (eluents: ihexane/ipropanol = 97/3, flow rate: 0.5 ml/min, column: 
chiralpak IC) 
 
5.5.3 Chirality transfer reaction with oxindole based crotylated 1,6-enyne (172b*) 
  
The transformations toward compounds (2b*, 3b*, and 4b*) were performed according to 
the synthesis of 2b, 3b, and 4b. The enantiomeric excess values were determined by the 
HPLC analysis.  
 
(E)-1-methyl-3-(pent-2-en-1-yloxy)-3-(phenylethynyl)indolin-2-one (172b*) yield: 88%; 
major enantiomer: tR = 15.6 min; minor enantiomer: tR = 18.7 min; ee: 36% (eluents: 
ihexane/ethanol = 95/5, flow rate: 0.5 ml/min, column: chiralpak IA) 
 
(E)-1-methyl-4'-phenyl-3'-propylidene-3',6'-dihydrospiro[indoline-3,2'-pyran]-2-one 
(173b*) yield: 37%; major enantiomer: tR = 18.5 min; minor enantiomer: tR = 22.7 min; ee: 
36% (eluents: ihexane/ethanol = 95/5, flow rate: 0.5 ml/min, column: chiralpak IA) 
 
1-ethyl-3-methyl-1a-phenyl-1a,3,9,9a-tetrahydrocyclopropa[4,5]pyrano[3,2-c] quinolin 
-2(1H)-one (174b*) yield: 67%; major enantiomer: tR = 21.9 min; minor enantiomer: tR = 
20.1 min; ee: 29.85% (eluents: ihexane/ethanol = 95/5, flow rate: 0.5 ml/min, column: 
chiralpak IA) 
 
(E)-3-(4-(1-methoxypropyl)-3-phenyldihydrofuran-2(3H)-ylidene)-1-methylindolin-2-on
e (175b*) major enantiomer: tR = 18.2 min; minor enantiomer: tR = 15.2 min; ee: 14% 
(eluents: ihexane/ethanol = 95/5, flow rate: 0.5 ml/min, column: chiralpak IA) 
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5.6 Formation of bicyclic [3.2.1] system by gold(I) catalyzed acyl group migration 
5.6.1 Preparation of camphorquinon derived 1,6-enyne substrate (198 and 199) 
 
 
Synthesis of propargyl alcohol (S10 and S11) At -78 °C, to a solution of phenyl acetylene 
(0.25 ml, 2.26 mmol) in THF (9 ml) was slowly added 
2.5 M nBuLi in hexanes (0.87 ml, 2.17 mmol) and the 
mixture was stirred for 1 h at the same temperature. To 
the reaction mixture was added the THF solution (9ml) of 
camphorquinon [10334-26-6] (S9, 300 mg, 1.80 mmol) in dropwise manner. After stirring 
for 2 h at same temperature, the reaction was quenched with NH4Cl(sat) and extracted with 
EtOAc (30 ml) for three times. The combined organic layers were washed with brine and 
dried over MgSO4(s). After concentration under reduced pressure, the crude product was 
purified by flash column chromatography with EtOAc/petroleum ether = 1/10 (Rf = 0.52) as 
eluents, the desired products were obtained in 95% yield (461 g, 1.72 mmol, S10:S11 = 1:1 
by 
1
H NMR) as a pale yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.45 – 7.39 (m, 4H), 7.37 – 
7.26 (m, 6H), 3.06 (s, 1H), 2.99 (s, 1H), 2.34 (d, J = 5.2 Hz, 1H), 2.30 – 2.22 (m, 2H), 2.22 – 
2.15 (m, 1H), 2.03 – 1.91 (m, 2H), 1.85 – 1.75 (m, 1H), 1.75 – 1.57 (m, 3H), 1.12 (s, 3H), 
1.12 (s, 3H), 1.08 (s, 3H), 1.02 (s, 3H), 1.01 (s, 3H), 0.98 (s, 3H). HRMS (ESI): Calcd for 
(M + H)
+
 [C18H21O2N]
+
: 269.1536, found: 269.1534. 
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Synthesis of camphorquinon derived 1,6-enyne substrate (198 and 199) 
To a solution of the mixture of propargyl alcohol S10 and S11 (406 mg, 1.51 mmol) in DMF 
(15 ml) at 0 °C was added NaH 60% wt (79 mg, 1.97 mmol) in one portion and the mixture 
was stirred at same temperature for 1 h. To the resulting mixture was added dropwise the 
respective crotyl bromide (0.20 ml, 1.97 mmol). The mixture was warmed to room 
temperature and stirred overnight. The reaction was quenched with NH4Cl(sat) and the 
mixture was diluted with EtOAc (60 ml). After extraction, the organic layer was washed 
with H2O (150 ml) three times and once with brine, dried over MgSO4(s), filtered, and 
concentrated under reduced pressure to provide the crude product. The product was purified 
by flash column chromatography with the combination of petroleum ether/DCM (Rf = 0.3 in 
n-pentane) as gradient eluent to separate 199 26% yield (first fraction, E:Z = 3:1, 132 mg, 
0.41 mmol) as a pale yellow oil and 198 in 41% yield (second fraction, E:Z = 6:1, 208 mg, 
0.62 mmol) as a pale yellow oil. 
 
(3S)-3-(((E)-but-2-en-1-yl)oxy)-1,7,7-trimethyl-3-(phenylethynyl)bicyclo[2.2.1]heptan 
-2-one (198) According to the major (E)-isomer: 
1
H NMR (500 MHz, 
CDCl3) δ 7.48 – 7.41 (m, 2H), 7.31 (dt, J = 3.0, 2.0 Hz, 3H), 5.77 – 5.65 
(m, 1H), 5.62 – 5.54 (m, 1H), 4.36 (dd, J = 11.3, 6.1 Hz, 1H), 4.30 (dd, J 
= 11.3, 6.3 Hz, 1H), 2.28 (d, J = 4.6 Hz, 1H), 2.17 (ddd, J = 13.2, 8.9, 
4.0 Hz, 1H), 2.01 – 1.90 (m, 1H), 1.68 (dd, J = 6.5, 1.2 Hz, 3H), 1.67 – 1.56 (m, 2H), 1.08 (s, 
3H), 1.00 (s, 3H), 0.97 (s, 3H). HRMS (ESI): Calcd for (M + H)
+
 [C22H26O2Na]
+
: 
345.1825, found: 345.1818. 
 
(3S)-3-(((E)-but-2-en-1-yl)oxy)-4,7,7-trimethyl-3-(phenylethynyl)bicyclo[2.2.1]heptan 
-2-one (199) According to the major (E)-isomer: 
1
H NMR (500 MHz, 
CDCl3) δ 7.50 – 7.41 (m, 2H), 7.36 – 7.27 (m, 3H), 5.73 – 5.63 (m, 1H), 
5.60 – 5.50 (m, 1H), 4.48 – 4.36 (m, 2H), 2.34 – 2.24 (m, 2H), 1.98 – 
1.88 (m, 1H), 1.79 – 1.70 (m, 1H), 1.69 (dd, J = 6.4, 1.3 Hz, 3H), 1.61 – 
1.52 (m, 1H), 1.14 (s, 3H), 1.10 (s, 3H), 0.98 (s, 3H). HRMS (ESI): Calcd for (M + Na)
+
 
[C22H26O2Na]
+
: 345.1825, found: 345.1818.
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5.6.2 Gold(I) catalyzed  bicyclic [3.2.1] system formation (201 and 203) 
 
At 0 °C, to a mixture of 1,6-enyne (16 mg, 0.05 mmol) and gold catalyst (III) with 
corresponding catalyst loading in a pressure tube equipped with a stirring bar was added dry 
DCE (0.5 ml) under Ar(g) atmosphere. At 60 °C, the reaction mixture was stirred overnight 
and then passed through a short pad of silica gel (Et2O as eluents,). The resulting solution 
was concentrated under reduced pressure, followed by silica gel column chromatography to 
obtain the desired product. 
 
(1R,1aR,4S,7S,8bS)-1,7,9,9-tetramethyl-8b-phenyl-1,1a,2,4,5,6,7,8b-octahydro-8H-4,7-
methanocyclohepta[b]cyclopropa[d]pyran-8-one (201) was prepared 
according to the general procedure, by using 198 and gold catalyst III (5 
mol%, 3 mg, 2.48 mol). After silica gel column chromatography with 
EtOAc/petroleum ether = 1/20 (Rf = 0.32) as eluents, the desired product 
was obtained in 56% yield (9 mg, 0.03 mmol) as a white solid. mp: 131 °C optical rotation:
 20D  = 34.8 (c 1.00, DCM) 
1
H NMR (500 MHz, CDCl3) δ 7.51 (d, J = 7.3 Hz, 2H), 7.23 (t, 
J = 7.3 Hz, 2H), 7.13 (t, J = 7.3 Hz, 1H), 4.90 (dd, J = 12.0, 8.0 Hz, 1H), 3.69 (dd, J = 12.0, 
5.7 Hz, 1H), 2.36 (d, J = 6.3 Hz, 1H), 2.18 – 2.09 (m, 1H), 1.75 (ddd, J = 13.8, 10.2, 3.6 Hz, 
1H), 1.59 – 1.52 (m, 1H), 1.39 (ddd, J = 13.0, 9.5, 3.6 Hz, 1H), 1.25 (dt, J = 8.0, 5.7 Hz, 
1H), 1.13 (d, J = 6.3 Hz, 3H), 0.94 (s, 3H), 0.91 – 0.85 (m, 1H), 0.83 (s, 3H), 0.66 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 201.47, 175.34, 140.37, 132.20, 127.53, 126.12, 115.42, 
72.84, 57.68, 52.74, 46.64, 33.88, 31.42, 27.33, 25.36, 24.65, 23.65, 18.46, 16.37, 13.71. 
HRMS (ESI): Calcd for (M + H)
+
 [C22H27O2]
+
: 323.2006, found: 323.2004. 
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(1S,1aS,4S,7S,8bR)-1,4,9,9-tetramethyl-8b-phenyl-1,1a,2,4,5,6,7,8b-octahydro-8H-4,7-m
ethanocyclohepta[b]cyclopropa[d]pyran-8-one (203) was prepared 
according to the general procedure, by using 199 and cat III (10 mol%, 6 
mg, 4.96 mol). After silica gel column chromatography with 
EtOAc/petroleum ether = 1/10 (Rf = 0.35) as eluents, the desired product 
was obtained in 63% yield (10 mg, 0.03 mmol) as a white solid. mp: 147 °C optical 
rotation:  20D  = -14.3 (c 1.00, DCM) 
1
H NMR (500 MHz, CDCl3) δ 7.52 (d, J = 7.3 Hz, 
2H), 7.22 (t, J = 7.3 Hz, 2H), 7.13 (t, J = 7.3 Hz, 1H), 4.97 (dd, J = 12.0, 8.2 Hz, 1H), 3.54 
(dd, J = 12.0, 6.4 Hz, 1H), 2.30 (d, J = 7.4 Hz, 1H), 2.14 – 2.05 (m, 1H), 1.83 (ddd, J = 13.1, 
10.1, 5.0 Hz, 1H), 1.54 (ddd, J = 13.1, 9.5, 3.6 Hz, 1H), 1.38 (ddd, J = 14.1, 9.5, 5.0 Hz, 1H), 
1.32 – 1.27 (m, 1H), 1.12 (s, 3H), 1.11 (d, J = 6.3 Hz, 3H), 0.90 – 0.85 (m, 1H), 0.79 (s, 3H), 
0.63 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 200.48, 177.85, 140.13, 132.20, 127.53, 
126.23, 116.35, 74.26, 61.37, 51.60, 46.90, 36.16, 31.09, 25.69, 25.13, 24.42, 23.15, 18.26, 
16.23, 12.63. HRMS (ESI): Calcd for (M + H)
+
 [C22H27O2]
+
: 323.2006, found: 323.2002. 
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5.7 X-ray crystallographic analysis (performed by C.G., L.K, K. L., and C.S.) 
5.7.1  Crystal data and structure refinement for 120 
  
Identification code  CCDC# 1577276 
Empirical formula  C21H21NO3  
Formula weight  335.39  
Temperature/K  100.0  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  12.2227(15)  
b/Å  11.6138(11)  
c/Å  13.0593(16)  
α/°  90  
β/°  111.996(4)  
γ/°  90  
Volume/Å
3
  1718.9(3)  
Z  4  
ρcalcg/cm
3
  1.296  
μ/mm-1  0.087  
F(000)  712.0  
Crystal size/mm
3
  0.63 × 0.47 × 0.37  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.86 to 55.998  
Index ranges  -16 ≤ h ≤ 16, -14 ≤ k ≤ 15, -17 ≤ l ≤ 17  
Reflections collected  24344  
Independent reflections  4149 [Rint = 0.0364, Rsigma = 0.0254]  
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Data/restraints/parameters  4149/0/237  
Goodness-of-fit on F
2
  1.069  
Final R indexes [I>=2σ (I)]  R1 = 0.0399, wR2 = 0.0933  
Final R indexes [all data]  R1 = 0.0498, wR2 = 0.0980  
Largest diff. peak/hole / e Å
-3
  0.41/-0.21  
 
5.7.2  Crystal data and structure refinement for 121 
  
Identification code  CCDC# 1577691 
Empirical formula  C20H17NO3  
Formula weight  319.35  
Temperature/K  100.0  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  10.3530(8)  
b/Å  12.2650(9)  
c/Å  12.1885(9)  
α/°  90  
β/°  98.562(3)  
γ/°  90  
Volume/Å
3
  1530.4(2)  
Z  4  
ρcalcg/cm
3
  1.386  
μ/mm-1  0.093  
F(000)  672.0  
Crystal size/mm
3
  0.399 × 0.295 × 0.19  
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Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  6.504 to 82.346  
Index ranges  -19 ≤ h ≤ 19, -22 ≤ k ≤ 22, -22 ≤ l ≤ 22  
Reflections collected  131617  
Independent reflections  10178 [Rint = 0.0413, Rsigma = 0.0191]  
Data/restraints/parameters  10178/0/218  
Goodness-of-fit on F
2
  1.080  
Final R indexes [I>=2σ (I)]  R1 = 0.0433, wR2 = 0.1186  
Final R indexes [all data]  R1 = 0.0525, wR2 = 0.1242  
Largest diff. peak/hole / e Å
-3
  0.73/-0.28  
 
5.7.3  Crystal data and structure refinement for 131 
  
Identification code  CCDC# 1577690 
Empirical formula  C22H22NO2  
Formula weight  332.40  
Temperature/K  100.0  
Crystal system  orthorhombic  
Space group  Pbca  
a/Å  8.5705(3)  
b/Å  15.3132(6)  
c/Å  26.7732(11)  
α/°  90  
β/°  90  
γ/°  90  
Volume/Å
3
  3513.8(2)  
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Z  8  
ρcalcg/cm
3
  1.257  
μ/mm-1  0.631  
F(000)  1416.0  
Crystal size/mm
3
  0.426 × 0.217 × 0.147  
Radiation  CuKα (λ = 1.54178)  
2Θ range for data collection/°  6.602 to 149.344  
Index ranges  -10 ≤ h ≤ 10, -15 ≤ k ≤ 19, -33 ≤ l ≤ 33  
Reflections collected  46513  
Independent reflections  3590 [Rint = 0.0281, Rsigma = 0.0127]  
Data/restraints/parameters  3590/0/229  
Goodness-of-fit on F
2
  1.047  
Final R indexes [I>=2σ (I)]  R1 = 0.0454, wR2 = 0.1268  
Final R indexes [all data]  R1 = 0.0474, wR2 = 0.1287  
Largest diff. peak/hole / e Å
-3
  0.59/-0.68  
 
5.7.4  Crystal data and structure refinement for 132 
  
Identification code  CCDC# 1577715 
Empirical formula  C22H21NO2  
Formula weight  331.40  
Temperature/K  173(2)  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  13.2924(7)  
b/Å  10.9029(5)  
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c/Å  12.0252(6)  
α/°  90  
β/°  94.289(5)  
γ/°  90  
Volume/Å
3
  1737.88(15)  
Z  4  
ρcalcg/cm
3
  1.267  
μ/mm-1  0.081  
F(000)  704.0  
Crystal size/mm
3
  ? × ? × ?  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.838 to 51.996  
Index ranges  -9 ≤ h ≤ 16, -13 ≤ k ≤ 13, -14 ≤ l ≤ 14  
Reflections collected  11976  
Independent reflections  3411 [Rint = 0.0209, Rsigma = 0.0202]  
Data/restraints/parameters  3411/0/228  
Goodness-of-fit on F
2
  1.035  
Final R indexes [I>=2σ (I)]  R1 = 0.0372, wR2 = 0.0919  
Final R indexes [all data]  R1 = 0.0452, wR2 = 0.0975  
Largest diff. peak/hole / e Å
-3
  0.20/-0.19  
 
5.7.5  Crystal data and structure refinement for 133 
  
Identification code  CCDC# 1577705 
Empirical formula  C22H21NO2  
Formula weight  331.40  
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Temperature/K  173.15  
Crystal system  triclinic  
Space group  P-1  
a/Å  7.4182(5)  
b/Å  9.4457(7)  
c/Å  12.4918(8)  
α/°  82.200(6)  
β/°  86.582(5)  
γ/°  81.408(6)  
Volume/Å
3
  856.78(10)  
Z  2  
ρcalcg/cm
3
  1.285  
μ/mm-1  0.082  
F(000)  352.0  
Crystal size/mm
3
  0.3 × 0.19 × 0.116  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.398 to 51.99  
Index ranges  -9 ≤ h ≤ 9, -11 ≤ k ≤ 11, -15 ≤ l ≤ 15  
Reflections collected  11871  
Independent reflections  3381 [Rint = 0.0363, Rsigma = 0.0344]  
Data/restraints/parameters  3381/0/228  
Goodness-of-fit on F
2
  1.043  
Final R indexes [I>=2σ (I)]  R1 = 0.0399, wR2 = 0.0982  
Final R indexes [all data]  R1 = 0.0517, wR2 = 0.1061  
Largest diff. peak/hole / e Å
-3
  0.23/-0.22  
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5.7.6  Crystal data and structure refinement for 134 
 
Identification code  CCDC# 1448645  
Empirical formula  C22H21NO2  
Formula weight  331.40  
Temperature/K  173(2)  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  10.5511(7)  
b/Å  9.3096(5)  
c/Å  17.9883(10)  
α/°  90  
β/°  90.151(6)  
γ/°  90  
Volume/Å
3
  1766.93(19)  
Z  4  
ρcalcg/cm
3
  1.246  
μ/mm-1  0.079  
F(000)  704.0  
Crystal size/mm
3
  0.3 × 0.25 × 0.15  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.528 to 53.996  
Index ranges  -13 ≤ h ≤ 12, -11 ≤ k ≤ 11, -22 ≤ l ≤ 22  
Reflections collected  16629  
Independent reflections  3819 [Rint = 0.0392, Rsigma = 0.0338]  
Data/restraints/parameters  3819/0/228  
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Goodness-of-fit on F
2
  1.036  
Final R indexes [I>=2σ (I)]  R1 = 0.0436, wR2 = 0.0994  
Final R indexes [all data]  R1 = 0.0599, wR2 = 0.1088  
Largest diff. peak/hole / e Å
-3
  0.21/-0.24  
 
5.7.7  Crystal data and structure refinement for 135 
  
Identification code  CCDC# 1577695 
Empirical formula  C22H21NO3  
Formula weight  347.40  
Temperature/K  173.15  
Crystal system  triclinic  
Space group  P-1  
a/Å  8.5820(5)  
b/Å  12.8508(6)  
c/Å  16.8775(8)  
α/°  94.396(4)  
β/°  104.686(4)  
γ/°  99.416(4)  
Volume/Å
3
  1762.60(16)  
Z  4  
ρcalcg/cm
3
  1.309  
μ/mm-1  0.087  
F(000)  736.0  
Crystal size/mm
3
  0.35 × 0.2 × 0.18  
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5.7.8  Crystal data and structure refinement for 165 
 
Identification code CCDC# 1448677 
Chemical formula C21H19NO2 
Formula weight 317.37 g/mol 
Temperature 100(2) K 
Wavelength 1.54178 Å 
Crystal size 0.042 x 0.227 x 0.279 mm 
Crystal system monoclinic 
Space group P 1 21/c 1 
Unit cell dimensions 
a = 12.8527(5) 
Å 
α = 90° 
 
b = 9.9453(4) Å β = 114.4410(10)° 
 
c = 13.9172(5) 
Å 
γ = 90° 
Volume 1619.54(11) Å
3
 
 
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.338 to 54  
Index ranges  -10 ≤ h ≤ 10, -16 ≤ k ≤ 16, -21 ≤ l ≤ 21  
Reflections collected  27169  
Independent reflections  7686 [Rint = 0.0451, Rsigma = 0.0393]  
Data/restraints/parameters  7686/2/481  
Goodness-of-fit on F
2
  1.016  
Final R indexes [I>=2σ (I)]  R1 = 0.0429, wR2 = 0.0988  
Final R indexes [all data]  R1 = 0.0639, wR2 = 0.1099  
Largest diff. peak/hole / e Å
-3
  0.23/-0.27  
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Z 4 
Density (calculated) 1.302 g/cm
3
 
Absorption coefficient 0.662 mm
-1
 
F(000) 672 
Diffractometer Bruker APEX-II CCD 
Theta range for data collection 3.78 to 65.31° 
Index ranges -15<=h<=15, -11<=k<=11, -16<=l<=16 
Reflections collected 13387 
Independent reflections 2757 [R(int) = 0.0417] 
Coverage of independent 
reflections 
99.5% 
Absorption correction none 
Max. and min. transmission 0.9730 and 0.8370 
Structure solution technique direct methods 
Structure solution program SHELXS-97 (Sheldrick 2008) 
Refinement method Full-matrix least-squares on F
2
 
Refinement program SHELXL-2014 (Sheldrick 2014) 
Function minimized Σ w(Fo
2
 - Fc
2
)
2
 
Data / restraints / parameters 2757 / 0 / 219 
Goodness-of-fit on F
2
 1.025 
Final R indices 
2323 data; 
I>2σ(I) 
R1 = 0.0481, wR2 = 0.1171 
 
all data R1 = 0.0585, wR2 = 0.1243 
Weighting scheme 
w=1/[σ2(Fo
2
)+(0.0686P)
2
+0.8411P] 
where P=(Fo
2
+2Fc
2
)/3 
Largest diff. peak and hole 0.258 and -0.290 eÅ
-3
 
R.M.S. deviation from mean 0.055 eÅ
-3
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5.7.9  Crystal data and structure refinement for 166 
 
Identification code  CCDC# 1448646 
Empirical formula  C21H19NO2  
Formula weight  317.37  
Temperature/K  173(2)  
Crystal system  monoclinic  
Space group  P21/n  
a/Å  13.3456(6)  
b/Å  7.5048(3)  
c/Å  16.0725(7)  
α/°  90  
β/°  99.871(4)  
γ/°  90  
Volume/Å
3
  1585.93(11)  
Z  4  
ρcalcg/cm
3
  1.329  
μ/mm-1  0.085  
F(000)  672.0  
Crystal size/mm
3
  ? × ? × ?  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  5.146 to 58.228  
Index ranges  -16 ≤ h ≤ 18, -10 ≤ k ≤ 10, -21 ≤ l ≤ 21  
Reflections collected  21487  
Independent reflections  3879 [Rint = 0.0357, Rsigma = 0.0290]  
Data/restraints/parameters  3879/0/219  
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Goodness-of-fit on F
2
  1.026  
Final R indexes [I>=2σ (I)]  R1 = 0.0444, wR2 = 0.1023  
Final R indexes [all data]  R1 = 0.0576, wR2 = 0.1093  
Largest diff. peak/hole / e Å
-3
  0.28/-0.25  
 
5.7.10  Crystal data and structure refinement for 167 
 
Identification code  CCDC# 1448652  
Empirical formula  C22H23NO3  
Formula weight  349.41  
Temperature/K  100.03  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  14.9063(10)  
b/Å  7.2965(4)  
c/Å  17.0837(11)  
α/°  90  
β/°  102.332(2)  
γ/°  90  
Volume/Å
3
  1815.2(2)  
Z  4  
ρcalcg/cm
3
  1.279  
μ/mm-1  0.085  
F(000)  744.0  
Crystal size/mm
3
  0.603 × 0.388 × 0.378  
Radiation  MoKα (λ = 0.71073)  
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2Θ range for data collection/°  4.882 to 55.796  
Index ranges  -19 ≤ h ≤ 19, -9 ≤ k ≤ 9, -22 ≤ l ≤ 22  
Reflections collected  35891  
Independent reflections  4339 [Rint = 0.0490, Rsigma = 0.0314]  
Data/restraints/parameters  4339/0/238  
Goodness-of-fit on F
2
  1.076  
Final R indexes [I>=2σ (I)]  R1 = 0.0466, wR2 = 0.1015  
Final R indexes [all data]  R1 = 0.0646, wR2 = 0.1102  
Largest diff. peak/hole / e Å
-3
  0.35/-0.27  
 
5.7.11  Crystal data and structure refinement for 173f 
 
Identification code  CCDC #1448387 
Empirical formula  C21H19NO2  
Formula weight  317.37  
Temperature/K  173(2)  
Crystal system  monoclinic  
Space group  P21/n  
a/Å  12.5601(10)  
b/Å  7.5169(5)  
c/Å  18.7897(15)  
α/°  90  
β/°  108.189(9)  
γ/°  90  
Volume/Å
3
  1685.4(2)  
Z  4  
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ρcalcg/cm
3
  1.251  
μ/mm-1  0.080  
F(000)  672.0  
Crystal size/mm
3
  ? × ? × ?  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  4.564 to 51.994  
Index ranges  -15 ≤ h ≤ 15, -9 ≤ k ≤ 9, -23 ≤ l ≤ 23  
Reflections collected  19281  
Independent reflections  3298 [Rint = 0.0500, Rsigma = 0.0401]  
Data/restraints/parameters  3298/0/294  
Goodness-of-fit on F
2
  1.013  
Final R indexes [I>=2σ (I)]  R1 = 0.0431, wR2 = 0.0986  
Final R indexes [all data]  R1 = 0.0743, wR2 = 0.1151  
Largest diff. peak/hole / e Å
-3
  0.16/-0.18  
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7 Appendix 
7.1 List of abbreviations 
Ac acetyl 
ACN acetonitrile 
Ad adamantyl 
Ar aryl 
BCC basal cell carcinoma 
BIOS biology-oriented synthesis 
Bn benzyl 
BODIPY borondipyrromethene 
Calcd calculated 
Cat. catalyst 
CB2 cannabinoid receptor type 2 
Cbz carboxybenzyl 
COMAS Compound Management and Screening Center 
cond. condition 
COX cyclooxygenase 
CtD complexity to diversity synthesis 
DAPI 4’-6-diamidino-2-phenylindole 
DCE 1,2-dichloroethane 
DCM dichloromethane 
df-oxindole (E)-3-(dihydrofuran-2(3H)-ylidene) indolin-2-one 
dia diastereomer 
DMSO dimethylsulfoxide 
DMF dimethylformamide 
DNP dictionary of natural product 
DOS diversity-oriented synthesis 
dr diastereomeric ratio 
DTS diverted total synthesis 
EC50 half maximal effective concentration 
EDG electron-donating group 
ee enantiomeric excess 
ent enantiomer 
eq equivalent 
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ESI electrospray ionization 
Et ethyl 
EWG electron-withdrawing group 
FDA Food and Drug Administration 
FOS function-oriented synthesis 
HH hedgehog 
HPLC high-performance liquid chromatography 
HRMS high resolution mass spectrometry 
HTS high throughput screening 
Hz Hertz 
IC50 half-maximal inhibitory concentration 
IMes 1,3-Bis(2,4,6-trimethylphenyl)-1,3-dihydro-2H-imidazol-2- 
 ylidene 
iPr iso-propyl 
IPr 1,3-bis(diisopropylphenyl)-imidazol-2-ylidene 
J coupling constants 
L ligand 
LD50 half-maximal lethal dose 
LDS ligand directed divergent scaffold synthesis 
LG leaving group 
M.-S. rear. Meyer-Schuster rearrangement 
Me methyl 
Mes 2,4,6-trimethylphenyl 
MOM methoxymethyl 
mp melting point 
n.a. no activity 
MS molecular sieves 
nBu normal butyl 
NHC N-heterocyclic carbene 
NMR nuclear magnetic resonance 
NP natural product 
Nu nucleophile 
PDB protein data bank 
Ph phenyl 
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PMB para-methoxy benzyl 
ppm,  parts per million 
PRPP 5-phosphoribosyl-1-pyrophosphate 
PRS privileged ring system  
PTCH Patched 
pTol para-tolyl 
qPCR quantitative polymerase chain reaction 
Rf retardation factor 
rt  room temperature  
SAR structure activity relationship 
SCNOP structural classification of natural product 
s.d. standard deviation 
SEM 2-(trimethylsilyl)ethoxymethyl 
SM  stating material 
SMO smoothened 
TBAF tetra-n-butylammonium fluoride 
TBS tert-butyl dimethylsilyl 
tBu tert-butyl 
TEA trimethylamine 
Tf trifluoromethanesulfonyl 
THF tetrahydrofuran 
TLC thin-layer chromatography 
TMS trimethylsilyl 
TOM (triisopropylsiloxy)methyl 
Ts para-tosyl 
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